0001725160-20-000034.txt : 20201109 0001725160-20-000034.hdr.sgml : 20201109 20201109070705 ACCESSION NUMBER: 0001725160-20-000034 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201109 DATE AS OF CHANGE: 20201109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001725160 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39263 FILM NUMBER: 201296058 BUSINESS ADDRESS: STREET 1: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (212) 433-3791 MAIL ADDRESS: STREET 1: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC DATE OF NAME CHANGE: 20200107 FORMER COMPANY: FORMER CONFORMED NAME: Zeno Pharma, LLC DATE OF NAME CHANGE: 20171212 10-Q 1 zntl-20200930.htm 10-Q zntl-20200930
0001725160FALSEQ312/31202000017251602020-01-012020-09-30xbrli:shares00017251602020-11-05iso4217:USD00017251602020-09-3000017251602019-12-310001725160us-gaap:CommonClassAMember2019-12-310001725160us-gaap:CommonClassAMember2020-09-300001725160us-gaap:CommonClassBMember2019-12-310001725160us-gaap:CommonClassBMember2020-09-30iso4217:USDxbrli:shares00017251602020-07-012020-09-3000017251602019-07-012019-09-3000017251602019-01-012019-09-300001725160us-gaap:CommonStockMember2020-07-012020-09-300001725160us-gaap:CommonStockMember2019-07-012019-09-300001725160us-gaap:CommonStockMember2020-01-012020-09-300001725160us-gaap:CommonStockMember2019-01-012019-09-300001725160us-gaap:CommonClassAMember2020-07-012020-09-300001725160us-gaap:CommonClassAMember2019-07-012019-09-300001725160us-gaap:CommonClassAMember2020-01-012020-09-300001725160us-gaap:CommonClassAMember2019-01-012019-09-3000017251602018-12-3100017251602019-09-300001725160us-gaap:CommonStockMember2020-06-300001725160us-gaap:AdditionalPaidInCapitalMember2020-06-300001725160us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001725160us-gaap:RetainedEarningsMember2020-06-300001725160us-gaap:NoncontrollingInterestMember2020-06-3000017251602020-06-300001725160us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001725160us-gaap:CommonStockMember2020-07-012020-09-300001725160us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001725160us-gaap:NoncontrollingInterestMember2020-07-012020-09-300001725160us-gaap:RetainedEarningsMember2020-07-012020-09-300001725160us-gaap:CommonStockMember2020-09-300001725160us-gaap:AdditionalPaidInCapitalMember2020-09-300001725160us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001725160us-gaap:RetainedEarningsMember2020-09-300001725160us-gaap:NoncontrollingInterestMember2020-09-300001725160us-gaap:ConvertiblePreferredStockMember2019-12-310001725160us-gaap:CommonStockMemberus-gaap:CommonClassAMember2019-12-310001725160us-gaap:CommonStockMemberus-gaap:CommonClassBMember2019-12-310001725160us-gaap:CommonStockMember2019-12-310001725160us-gaap:AdditionalPaidInCapitalMember2019-12-310001725160us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001725160us-gaap:RetainedEarningsMember2019-12-310001725160us-gaap:NoncontrollingInterestMember2019-12-310001725160us-gaap:SeriesCPreferredStockMember2020-09-300001725160us-gaap:SeriesCPreferredStockMember2019-09-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassBMember2020-01-012020-09-300001725160us-gaap:IPOMemberus-gaap:CommonStockMember2020-01-012020-09-300001725160us-gaap:IPOMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001725160us-gaap:IPOMember2020-01-012020-09-300001725160us-gaap:NoncontrollingInterestMember2020-01-012020-09-300001725160us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001725160us-gaap:ConvertiblePreferredStockMember2020-01-012020-09-300001725160us-gaap:CommonStockMember2020-01-012020-09-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-01-012020-09-300001725160us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300001725160us-gaap:RetainedEarningsMember2020-01-012020-09-300001725160us-gaap:ConvertiblePreferredStockMember2020-09-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassAMember2020-09-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassBMember2020-09-300001725160us-gaap:ConvertiblePreferredStockMember2019-06-300001725160us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-06-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassAMember2019-06-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassBMember2019-06-300001725160us-gaap:RetainedEarningsMember2019-06-300001725160us-gaap:NoncontrollingInterestMember2019-06-3000017251602019-06-300001725160us-gaap:ConvertiblePreferredStockMember2019-07-012019-09-300001725160us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassBMember2019-07-012019-09-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassAMember2019-07-012019-09-300001725160us-gaap:NoncontrollingInterestMember2019-07-012019-09-300001725160us-gaap:RetainedEarningsMember2019-07-012019-09-300001725160us-gaap:ConvertiblePreferredStockMember2019-09-300001725160us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-09-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassAMember2019-09-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassBMember2019-09-300001725160us-gaap:RetainedEarningsMember2019-09-300001725160us-gaap:NoncontrollingInterestMember2019-09-300001725160us-gaap:ConvertiblePreferredStockMember2018-12-310001725160us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2018-12-310001725160us-gaap:CommonStockMemberus-gaap:CommonClassAMember2018-12-310001725160us-gaap:CommonStockMemberus-gaap:CommonClassBMember2018-12-310001725160us-gaap:RetainedEarningsMember2018-12-310001725160us-gaap:NoncontrollingInterestMember2018-12-310001725160us-gaap:ConvertiblePreferredStockMember2019-01-012019-09-300001725160us-gaap:ConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-09-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassBMember2019-01-012019-09-300001725160us-gaap:CommonStockMemberus-gaap:CommonClassAMember2019-01-012019-09-300001725160us-gaap:NoncontrollingInterestMember2019-01-012019-09-300001725160us-gaap:RetainedEarningsMember2019-01-012019-09-30xbrli:pure00017251602017-12-212017-12-210001725160us-gaap:IPOMember2020-04-020001725160us-gaap:CommonStockMemberus-gaap:IPOMember2020-04-022020-04-020001725160us-gaap:RestrictedStockMemberus-gaap:IPOMember2020-04-022020-04-020001725160us-gaap:CommonStockMemberus-gaap:IPOMember2020-04-072020-04-070001725160us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2020-04-072020-04-070001725160us-gaap:CommonStockMemberus-gaap:IPOMember2020-04-0700017251602020-04-072020-04-0700017251602020-05-192020-05-190001725160us-gaap:SeriesAPreferredStockMember2020-05-192020-05-190001725160zntl:ZenteraTherapeuticsLtdMember2020-09-30zntl:executive0001725160zntl:ZenteraStockPlanMember2020-05-190001725160us-gaap:RestrictedStockMemberzntl:ZenteraStockPlanMember2020-05-192020-05-190001725160zntl:FollowOnOfferingMemberus-gaap:CommonStockMember2020-08-032020-08-030001725160us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2020-08-032020-08-030001725160zntl:FollowOnOfferingMemberus-gaap:CommonStockMember2020-08-030001725160zntl:FollowOnOfferingMember2020-08-032020-08-030001725160zntl:KalyraPharmaceuticalsIncMember2017-12-212017-12-210001725160zntl:KalyraPharmaceuticalsIncMember2017-12-210001725160us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2020-09-300001725160us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2019-12-310001725160us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2020-01-012020-09-300001725160us-gaap:CommercialPaperMember2020-09-300001725160us-gaap:CorporateDebtSecuritiesMember2020-09-300001725160us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-300001725160us-gaap:USTreasurySecuritiesMember2020-09-30zntl:security0001725160us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-09-300001725160us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-09-300001725160us-gaap:MoneyMarketFundsMember2020-09-300001725160us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2019-12-310001725160us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2019-12-310001725160us-gaap:MoneyMarketFundsMember2019-12-310001725160us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-09-300001725160us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-300001725160us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-300001725160us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-12-310001725160us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310001725160us-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310001725160us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-09-300001725160us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2020-09-300001725160us-gaap:USTreasurySecuritiesMember2020-09-300001725160us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-12-310001725160us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2019-12-310001725160us-gaap:USTreasurySecuritiesMember2019-12-310001725160us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2020-09-300001725160us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-09-300001725160us-gaap:CorporateDebtSecuritiesMember2020-09-300001725160us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310001725160us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310001725160us-gaap:CorporateDebtSecuritiesMember2019-12-310001725160us-gaap:FairValueInputsLevel1Member2020-09-300001725160us-gaap:FairValueInputsLevel2Member2020-09-300001725160us-gaap:FairValueInputsLevel1Member2019-12-310001725160us-gaap:FairValueInputsLevel2Member2019-12-310001725160us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2020-09-300001725160us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2020-09-300001725160us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2019-12-310001725160us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2019-12-310001725160us-gaap:CommercialPaperMember2019-12-310001725160us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-09-300001725160us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-09-300001725160us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2019-12-310001725160us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2019-12-310001725160us-gaap:CorporateDebtSecuritiesMember2019-12-310001725160us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-300001725160us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-300001725160us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310001725160us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310001725160us-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310001725160us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2020-09-300001725160us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2020-09-300001725160us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2019-12-310001725160us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2019-12-310001725160us-gaap:USTreasurySecuritiesMember2019-12-310001725160zntl:ComputerAndOfficeEquipmentMember2020-09-300001725160zntl:ComputerAndOfficeEquipmentMember2019-12-310001725160zntl:LaboratoryEquipmentMember2020-09-300001725160zntl:LaboratoryEquipmentMember2019-12-310001725160us-gaap:LeaseholdImprovementsMember2020-09-300001725160us-gaap:LeaseholdImprovementsMember2019-12-310001725160us-gaap:ConstructionInProgressMember2020-09-300001725160us-gaap:ConstructionInProgressMember2019-12-310001725160us-gaap:SeriesAPreferredStockMember2015-09-012015-09-300001725160us-gaap:SeriesAPreferredStockMember2015-09-300001725160us-gaap:SeriesAPreferredStockMember2016-03-310001725160us-gaap:SeriesAPreferredStockMember2016-02-012016-03-310001725160us-gaap:SeriesBPreferredStockMember2017-12-310001725160us-gaap:SeriesBPreferredStockMember2017-12-012017-12-310001725160us-gaap:SeriesBPreferredStockMember2018-08-310001725160us-gaap:SeriesBPreferredStockMember2018-01-012018-08-310001725160us-gaap:SeriesCPreferredStockMember2019-09-012019-09-300001725160us-gaap:SeriesCPreferredStockMember2020-02-290001725160us-gaap:SeriesCPreferredStockMember2020-02-012020-02-290001725160us-gaap:SeriesAPreferredStockMember2019-12-310001725160us-gaap:SeriesBPreferredStockMember2019-12-310001725160us-gaap:SeriesCPreferredStockMember2019-12-3100017251602020-01-012020-04-020001725160us-gaap:SeriesAPreferredStockMember2020-09-300001725160us-gaap:SeriesBPreferredStockMember2020-09-300001725160us-gaap:SeriesAPreferredStockMember2017-12-310001725160us-gaap:CommonClassAMember2017-12-310001725160us-gaap:CommonClassBMember2017-12-3100017251602017-12-310001725160us-gaap:CommonClassAMember2019-09-300001725160us-gaap:CommonClassAMember2019-01-012019-12-310001725160us-gaap:CommonClassBMember2017-12-012017-12-310001725160us-gaap:CommonClassBMember2019-09-300001725160zntl:CorporateConversionMemberus-gaap:CommonStockMember2020-04-022020-04-0200017251602020-04-020001725160us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2020-04-070001725160us-gaap:IPOMember2020-04-072020-04-070001725160us-gaap:CommonClassBMemberzntl:A2017ProfitInterestPlanMember2017-12-210001725160us-gaap:CommonStockMemberzntl:A2020IncentiveAwardPlanMember2020-04-300001725160srt:MaximumMemberzntl:A2020IncentiveAwardPlanMemberus-gaap:CommonClassBMember2020-04-300001725160us-gaap:CommonStockMemberzntl:A2020IncentiveAwardPlanMember2020-04-012020-04-300001725160us-gaap:CommonClassBMember2020-01-012020-09-300001725160us-gaap:RestrictedStockMember2020-04-012020-04-3000017251602020-04-012020-04-300001725160us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001725160us-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300001725160us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001725160us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300001725160us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001725160us-gaap:GeneralAndAdministrativeExpenseMember2019-07-012019-09-300001725160us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001725160us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-09-300001725160zntl:ZenteraStockPlanMember2020-07-012020-09-300001725160zntl:ZenteraStockPlanMember2020-01-012020-09-300001725160zntl:ZenteraStockPlanMember2019-01-012019-09-300001725160zntl:ZenteraStockPlanMember2019-07-012019-09-300001725160zntl:ProfitInterestAwardsMember2020-07-012020-09-300001725160zntl:ProfitInterestAwardsMember2019-07-012019-09-300001725160zntl:ProfitInterestAwardsMember2020-01-012020-09-300001725160zntl:ProfitInterestAwardsMember2019-01-012019-09-300001725160us-gaap:EmployeeStockOptionMember2020-07-012020-09-300001725160us-gaap:EmployeeStockOptionMember2019-07-012019-09-300001725160us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001725160us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001725160zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember2020-07-012020-09-300001725160zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember2019-07-012019-09-300001725160zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember2020-01-012020-09-300001725160zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember2019-01-012019-09-300001725160zntl:ProfitInterestAwardsMember2020-09-300001725160zntl:ProfitInterestAwardsMember2019-09-300001725160srt:MinimumMemberzntl:ProfitInterestAwardsMember2019-01-012019-09-300001725160srt:MaximumMemberzntl:ProfitInterestAwardsMember2019-01-012019-09-300001725160us-gaap:CommonClassBMember2019-01-012019-09-300001725160srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-07-012020-09-300001725160srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-07-012020-09-300001725160srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-09-300001725160srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-09-300001725160us-gaap:EmployeeStockOptionMember2020-09-300001725160us-gaap:RestrictedStockMember2020-09-300001725160us-gaap:RestrictedStockMember2020-01-012020-09-300001725160us-gaap:RestrictedStockUnitsRSUMember2020-09-300001725160us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001725160zntl:RestrictedStockAwardMember2020-09-300001725160srt:ScenarioForecastMemberzntl:RealEstate107YearLeaseTermMember2020-12-310001725160srt:ScenarioForecastMemberzntl:RealEstate12YearLeaseTermMember2020-12-310001725160us-gaap:ConvertiblePreferredStockMember2020-01-012020-09-300001725160us-gaap:ConvertiblePreferredStockMember2019-01-012019-09-300001725160zntl:ClassBCommonIncentiveUnitsMember2020-01-012020-09-300001725160zntl:ClassBCommonIncentiveUnitsMember2019-01-012019-09-300001725160us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001725160us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001725160us-gaap:RestrictedStockMember2020-01-012020-09-300001725160us-gaap:RestrictedStockMember2019-01-012019-09-300001725160us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001725160us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300001725160zntl:KalyraPharmaceuticalsIncMemberus-gaap:SeriesBPreferredStockMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2017-12-210001725160zntl:KalyraPharmaceuticalsIncMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2017-12-210001725160zntl:KalyraPharmaceuticalsIncMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2017-12-212017-12-210001725160zntl:KalyraPharmaceuticalsIncMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2019-01-012019-09-300001725160zntl:MasterServicesAgreementMembersrt:AffiliatedEntityMember2019-07-012019-09-300001725160zntl:MasterServicesAgreementMembersrt:AffiliatedEntityMember2020-07-012020-09-300001725160zntl:MasterServicesAgreementMembersrt:AffiliatedEntityMember2020-01-012020-09-300001725160zntl:MasterServicesAgreementMembersrt:AffiliatedEntityMember2019-01-012019-09-300001725160srt:AffiliatedEntityMemberzntl:IntercompanyServicesAgreementMember2019-07-012019-09-300001725160srt:AffiliatedEntityMemberzntl:IntercompanyServicesAgreementMember2020-07-012020-09-300001725160srt:AffiliatedEntityMemberzntl:IntercompanyServicesAgreementMember2020-01-012020-09-300001725160srt:AffiliatedEntityMemberzntl:IntercompanyServicesAgreementMember2019-01-012019-09-300001725160srt:AffiliatedEntityMemberzntl:IntercompanyServicesAgreementMember2020-09-300001725160srt:AffiliatedEntityMemberzntl:IntercompanyServicesAgreementMember2019-09-300001725160us-gaap:CapitalAdditionsMember2020-06-012020-06-01


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
or
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________________ to ___________________
Commission File Number: 001-39263
Zentalis Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware82-3607803
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
530 Seventh Avenue,
Suite 2201
New York,
 New York
10018
(Address of principal executive offices)(Zip Code)
(212) 433-3791
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock,
$0.001 par value per share
ZNTLThe Nasdaq Global Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes ☒  No ☐   
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer  Accelerated filer
Non-accelerated Filer
  Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  ☒
As of November 5, 2020, the registrant had 40,613,857 shares of common stock, $0.001 par value per share, outstanding.


Table of Contents
Page
PART I.
Item 1.
Item 2.
Item 3.
Item 4.
PART II.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
i


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Quarterly Report, including without limitation statements regarding our future results of operations and financial position, the anticipated impact of the novel coronavirus (“COVID-19”) pandemic on our business, business strategy, prospective products and product candidates, clinical trial timelines and expected timing for the release of data, research and development costs, future revenue, timing and likelihood of success, potential collaboration opportunities, and plans and objectives of management are forward-looking statements.
The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of known and unknown risks, uncertainties, assumptions and other important factors, including those described under the sections in this Quarterly Report entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

SUMMARY RISK FACTORS
Our business is subject to numerous risks and uncertainties, including those described in Part II, Item
1A. “Risk Factors” in this Quarterly Report on Form 10-Q. You should carefully consider these risks and
uncertainties when investing in our ordinary shares. The principal risks and uncertainties affecting our business include the following:

We have a limited operating history, have not completed any clinical trials, and have no products
approved for commercial sale, which may make it difficult for you to evaluate our current business
and predict our future success and viability.

We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.

We will require substantial additional capital to finance our operations. If we are unable to raise
such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate
one or more of our research and drug development programs or future commercialization efforts.

We are substantially dependent on the success of our lead product candidate, ZN-c5, which is
currently in clinical trials. If we are unable to complete development of, obtain approval for and
commercialize ZN-c5 in a timely manner, our business will be harmed.

The outcome of preclinical testing and early clinical trials may not be predictive of the success of
later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.

We may face additional risks associated with the development of ZN-c5, ZN-c3, ZN-d5, ZN-e4 and
potentially other product candidates in combination with other therapies.

The clinical trial and regulatory approval processes are lengthy, time consuming and inherently
unpredictable, and we may incur additional costs or experience delays in completing, or ultimately
be unable to complete, the development and commercialization of our product candidates.

The competition for qualified personnel is particularly intense in our industry. If we are unable to retain or hire key personnel, we may not be able to sustain or grow our business.

We face significant competition, and if our competitors develop and market technologies or products
more rapidly than we do or that are more effective, safer or less expensive than the product
ii


candidates we develop, our commercial opportunities will be negatively impacted.

Our success depends on our ability to protect our licensed-in intellectual property and our
proprietary technologies. If we are unable to adequately protect our licensed-in intellectual property and our proprietary technologies, or obtain and maintain issued patents which are sufficient to protect our product candidates, others could compete against us more directly, which would negatively impact our business.

Our existing collaborations are important to our business and future licenses may also be important
to us, and if we are unable to maintain any of these collaborations, or if these arrangements are not successful, our business could be adversely affected.

We rely, and expect to continue to rely, on third parties, including independent clinical investigators
and CROs, to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.

Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.

The outbreak of the novel strain of coronavirus disease, COVID-19, had adversely impacted and we
expect will continue to adversely impact our business, including our preclinical studies and clinical trials.
iii


BASIS OF PRESENTATION
As used in this Quarterly Report on Form 10-Q, unless the context otherwise requires, references to “we,” “us,” “our,” the “Company,” “Zentalis” and similar references refer: (1) following the consummation of our statutory conversion to a Delaware corporation on April 2, 2020 in connection with our initial public offering, to Zentalis Pharmaceuticals, Inc., and (2) prior to the completion of such conversion, to Zentalis Pharmaceuticals, LLC. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations”—“Corporate Conversion” in this Quarterly Report on Form 10-Q for further information.
iv


PART I—FINANCIAL INFORMATION
3


Item 1. Financial Statements.
Zentalis Pharmaceuticals, Inc. (Successor to Zentalis Pharmaceuticals, LLC)
FINANCIAL STATEMENTS
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except unit and share amounts)
September 30,December 31,
 20202019
ASSETS
Current assets
Cash and cash equivalents$92,552 $67,246 
Marketable securities, available-for-sale274,884  
Accounts receivable from government grants, net122 140 
Prepaid expenses and other current assets5,178 1,505 
Total current assets372,736 68,891 
Property and equipment, net471 501 
Operating lease right-of-use assets1,925 2,335 
Prepaid expenses and other assets4,245 2,134 
Deferred financing costs 841 
Goodwill3,736 3,736 
In-process research and development8,800 8,800 
Restricted cash1,320 243 
Total assets$393,233 $87,481 
LIABILITIES, CONVERTIBLE PREFERRED UNITS AND EQUITY/(DEFICIT)
Current liabilities
Accounts payable$5,437 $4,289 
Accrued expenses18,469 10,608 
Total current liabilities23,906 14,897 
Deferred tax liability2,463 2,463 
Other long-term liabilities1,031 1,700 
Total liabilities27,400 19,060 
Commitments and contingencies
Convertible preferred units; Redemption value of $146,944,000 at December 31, 2019
 141,706 
EQUITY (DEFICIT)
Class A common units; 20,000,000 units authorized; 5,601,478 units issued and outstanding at December 31, 2019
 709 
Class B common units, 3,458,522 units authorized; 2,670,668 units issued and outstanding at December 31, 2019
 2,178 
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2020
  
Common stock, $0.001 par value; 250,000,000 shares authorized; 40,614,453 shares issued and outstanding at September 30, 2020
41  
Additional paid-in capital
501,522  
Accumulated other comprehensive income23  
Accumulated deficit(160,531)(82,993)
Total stockholders’ equity/members’ (deficit)341,055 (80,106)
Noncontrolling interests24,778 6,821 
Total equity (deficit)365,833 (73,285)
Total liabilities, convertible preferred units and equity (deficit)$393,233 $87,481 

See notes to condensed consolidated financial statements.


4


Zentalis Pharmaceuticals, Inc. (Successor to Zentalis Pharmaceuticals, LLC)
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except per unit and per share amounts)
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2020 201920202019
Operating Expenses 
Research and development$24,670 $10,739 $55,380 $26,517 
General and administrative10,097 1,844 23,162 5,423 
Total operating expenses34,767 12,583 78,542 31,940 
Operating loss(34,767)(12,583)(78,542)(31,940)
Other Income (Expense)
Investment and other income, net120 12 368 123 
Net loss before income taxes(34,647)(12,571)(78,174)(31,817)
Income tax expense18 1 18 15 
Net loss(34,665)(12,572)(78,192)(31,832)
Net loss attributable to noncontrolling interests(110)(228)(654)(675)
Net loss attributable to Zentalis $(34,555)$(12,344)$(77,538)$(31,157)
Net loss per common share outstanding, basic and diluted
$(0.91)$ $(3.21)$ 
Net loss per Class A common unit outstanding, basic and diluted
$ $(2.20)$ $(5.56)
Common shares/units used in computing net loss per share/Class A common unit, basic and diluted
37,959 5,601 24,143 5,601 

See notes to condensed consolidated financial statements.
5


Zentalis Pharmaceuticals, Inc. (Successor to Zentalis Pharmaceuticals, LLC)
Condensed Consolidated Statements of Comprehensive Loss
(Unaudited)
(In thousands)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Net loss(34,665)(12,572)(78,192)(31,832)
Other comprehensive income:
Unrealized gain on marketable securities
19  23  
Total comprehensive loss$(34,646)$(12,572)$(78,169)$(31,832)
Comprehensive loss attributable to noncontrolling interests
(110)(228)(654)(675)
Comprehensive loss attributable to Zentalis
$(34,536)$(12,344)$(77,515)$(31,157)

See notes to condensed consolidated financial statements.
6


Zentalis Pharmaceuticals, Inc. (Successor to Zentalis Pharmaceuticals, LLC)
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
 Nine Months Ended
September 30,
 20202019
Operating Activities: 
Consolidated net loss$(78,192)$(31,832)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization127 70 
Share-based compensation15,259 405 
Amortization of premiums on marketable securities, net224  
Changes in operating assets and liabilities:
Accounts receivable18 867 
Prepaid expenses and other assets(5,784)(833)
Accounts payable and accrued liabilities9,049 5,155 
Operating lease right-of-use assets and liabilities, net(169)216 
Net cash used in operating activities(59,468)(25,952)
Investing activities:
Purchases of marketable securities(304,085) 
Proceeds from maturities of marketable securities29,000  
Purchases of property and equipment(97)(316)
Net cash used in investing activities(275,182)(316)
Financing Activities:
Proceeds from issuance of common stock in initial public offering, net172,482  
Contributions from noncontrolling interest owners, net18,424  
Proceeds from the issuance of Series C convertible preferred units, net14,228 81,883 
Proceeds from issuance of common stock, net155,899  
Net cash provided by financing activities361,033 81,883 
Net increase in cash, cash equivalents and restricted cash26,383 55,615 
Cash, cash equivalents and restricted cash at beginning of period67,489 25,154 
Cash, cash equivalents and restricted cash at end of period$93,872 $80,769 
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities$ $1,412 
Costs incurred in connection with equity offering included in accounts payable and accrued liabilities$594 $ 
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Consolidated Statements of Cash Flows for the periods presented:
7


September 30,
20202019
Cash and cash equivalents$92,552 $80,526 
Restricted cash, non-current1,320 243 
Total cash, cash equivalents and restricted cash reported in the Consolidated Statement of Cash Flows
$93,872 $80,769 
See notes to condensed consolidated financial statements.
8


Zentalis Pharmaceuticals, Inc. (Successor to Zentalis Pharmaceuticals, LLC)
Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members’/Stockholders’ Equity/(Deficit)
(In thousands)

Three Months Ended September 30, 2020
Zentalis Stockholders
Common
Additional
Paid-In
Capital
Accumulated Other Comprehensive IncomeAccumulated
Deficit
Noncontrolling
Interests
Total
Equity
(Deficit)
SharesAmount
Balance at June 30, 202035,878 $36 $339,160 $4 $(125,976)$24,701 $237,925 
Share-based compensation expense
— — 7,249 — — — 7,249 
Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs4,744 5 155,300 — — — 155,305 
Cancellation of restricted stock awards(7)— — — — — — 
Other comprehensive income
— — — 19 — — 19 
Net loss attributable to noncontrolling interest— — (187)— — 77 (110)
Net loss attributable to Zentalis
— — — — (34,555)— (34,555)
Balance at September 30, 202040,615 $41 $501,522 $23 $(160,531)$24,778 $365,833 

9


Nine Months Ended September 30, 2020
Zentalis Members/Stockholders
 Convertible
Preferred Units
Convertible
Preferred Units
Class A
Common Units
 
Class B
Common Units
 CommonAdditional
Paid-In
Capital
Accumulated Other Comprehensive IncomeAccumulated
Deficit
Noncontrolling
Interests
Total
Equity
(Deficit)
 UnitsAmountUnitsAmountUnitsAmountUnitsAmount SharesAmount
Balance at December 31, 20199,950 $141,706 — $— 5,601 $709 2,671 $2,178  $ $ $ $(82,993)$6,821 $(73,285)
Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs
867 14,228 — — — — — — — — — — — — — 
Cancellation of profit interest awards, net
— — — — — — (64)— — — — — — — — 
Issuance of common stock in connection with an initial public offering, net of underwriting discounts, commissions and offering costs — — — — — — — — 10,589 11 172,354 — — — 172,365 
Contributions from noncontrolling interest owners— — — — — — — — — — — — — 18,424 18,424 
Share-based compensation expense
— — — — — — — 329 — — 14,930 — — — 15,259 
Conversion of convertible preferred units to common stock
(10,817)(155,934)— — — — — — 15,011 15 155,919 — — — 155,934 
Conversion of common and incentive units to common and restricted stock— — — — (5,601)(709)(2,607)(2,507)10,278 10 3,206 — — — — 
Issuance of common stock in connection with an equity offering, net of underwriting discounts, commissions and offering costs— — — — — — — — 4,744 5 155,300 — — — 155,305 
Cancellation of restricted stock awards— — — — — — — — (7)— — — — — — 
Other comprehensive income
— — — — — — — — — — — 23 — — 23 
Net loss attributable to noncontrolling interest— — — — — — — — — — (187)— — (467)(654)
Net loss attributable to Zentalis
— — — — — — — — — — — — (77,538)— (77,538)
Balance at September 30, 2020 $ — $—  $  $$ 40,615 $41 $501,522 $23 $(160,531)$24,778 $365,833 










10




Three Months Ended September 30, 2019
Zentalis Members
Convertible
Preferred Units
Convertible
Preferred Units
Class A
Common Units
 
Class B
Common Units
Accumulated
Deficit
Noncontrolling
Interests
Total
Equity
(Deficit)
UnitsAmountUnitsAmountUnitsAmountUnitsAmount
Balance at June 30, 2019 $ 5,103 $59,830 5,594 $676 1,669 $1,844 $(56,143)$7,089 $13,296 
Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs
4,847 81,883 — — — — — — — —  
Reclassification of convertible preferred units for contingent liquidation features not within the Company's control
5,103 59,830 (5,103)(59,830)— — — — — — (59,830)
Issuance of profit interest awards, net
— — — — — — 278 — — — — 
Share-based compensation expense
— — — — — 2 — 153 — — 155 
Net loss attributable to noncontrolling interest— — — — — — — — — (228)(228)
Net loss attributable to Zentalis
— — — — — — — — (12,344)— (12,344)
Balance at September 30, 20199,950 $141,713  $ 5,594 $678 1,947 $1,997 $(68,487)$6,861 $(58,951)







11


Nine Months Ended September 30, 2019
Zentalis Members
 Convertible
Preferred Units
Convertible
Preferred Units
Class A
Common Units
Class B
Common Units
 Accumulated
Deficit
Noncontrolling
Interests
Total
Equity
(Deficit)
 UnitsAmountUnitsAmountUnitsAmountUnitsAmount
Balance at December 31, 2018 $ 5,103 $59,830 5,594 $672 1,612 $1,598 $(37,330)$7,536 $32,306 
Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs
4,847 81,883 — — — — — — — —  
Reclassification of convertible preferred units for contingent liquidation features not within the Company's control
5,103 59,830 (5,103)(59,830)— — — — — — (59,830)
Issuance of profit interest awards, net
— — — — — — 335 — — — — 
Share-based compensation expense
— — — — — 6 — 399 — — 405 
Net loss attributable to noncontrolling interest— — — — — — — — — (675)(675)
Net loss attributable to Zentalis
— — — — — — — — (31,157)— (31,157)
Balance at September 30, 20199,950 $141,713  $ 5,594 $678 1,947 $1,997 $(68,487)$6,861 $(58,951)

See notes to condensed consolidated financial statements.
12


Zentalis Pharmaceuticals, Inc. (Successor to Zentalis Pharmaceuticals, LLC)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Organization and Business
Organization
Zentalis Pharmaceuticals, Inc. (successor to Zentalis Pharmaceuticals, LLC) (“Zentalis”, “We” or the “Company”) is a clinical-stage pharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. To date, all of the Company’s revenue has been generated in the United States. All of the Company’s tangible assets are held in the United States.
The Company was formed and incorporated in the state of Delaware as Zeno Pharmaceuticals, Inc. on December 23, 2014. Effective November 21, 2017, Zeno Pharma, LLC was formed by the shareholders of Zeno Pharmaceuticals, Inc. On December 21, 2017, Zeno Pharmaceuticals, Inc. became a wholly owned subsidiary of Zeno Pharma, LLC. In connection with this restructuring, the rights and preferences of the Preferred Stock of Zeno Pharmaceuticals, Inc. were exchanged for preferred units with similar rights and preferences of Zeno Pharma, LLC. As part of the restructuring, the employees, consultants and board members of Zeno Pharmaceuticals, Inc. exchanged their equity grants in Zeno Pharmaceuticals, Inc. stock for Class B common units in Zeno Pharma, LLC. Additionally, existing common stockholders of Zeno Pharmaceuticals, Inc. exchanged their common stock for Class A common units in Zeno Pharma, LLC. All exchanges were made on a one-for-one basis. The restructuring was accounted for as a common control transaction. In December 2019, the Company was renamed to Zentalis Pharmaceuticals, LLC.
Immediately prior to the effectiveness of the registration statement pertaining to the Company’s initial public offering (“IPO”) on April 2, 2020, the Company converted from a Delaware limited liability company into a Delaware corporation, and changed its name to Zentalis Pharmaceuticals, Inc. Pursuant to the statutory corporate conversion, all of the outstanding units of Zentalis Pharmaceuticals, LLC converted into shares of common stock of Zentalis Pharmaceuticals, Inc. based upon the value of Zentalis Pharmaceuticals, Inc. at the time of the IPO with a value implied by the price of the shares of common stock sold in the IPO. Based on the IPO price of $18.00 per share, the outstanding units converted into 25,288,854 shares of common stock (including 1,160,277 shares of restricted common stock).
On April 7, 2020, the Company completed the IPO in which the Company issued and sold 10,557,000 shares of common stock (including 1,377,000 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a public offering price of $18.00 per share. The Company’s aggregate gross proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $190.0 million before fees and expenses of $17.6 million.
On May 19, 2020, the Company announced the closing of a Series A financing of Zentera Therapeutics, Ltd. (“Zentera”), a majority owned biopharmaceutical company with headquarters in Shanghai, China. Contributions from noncontrolling interest members totaled $20.0 million before issuing costs of $1.6 million. The Company holds 60.2% equity interest in Zentera for purposes of the development and commercialization of ZN-c5, ZN-d5 and ZN-c3 for the treatment or preventions of disease, other than for pain, in the People’s Republic of China, Macau, Hong Kong and Taiwan. Two of our executives entered into restricted stock purchase agreements with Zentera. The associated shares vest over four years.

On August 3, 2020, the Company completed a follow-on offering in which the Company issued and sold 4,743,750 shares of common stock (including 618,750 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a public offering price of $35.00 per share. The
13


Company’s aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $166.0 million before fees and expenses of $10.8 million.
Liquidity
Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after the date that the interim unaudited condensed consolidated financial statements for the quarter ended September 30, 2020 are issued.
2. Interim Unaudited Financial Statements
Basis of Presentation
The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company’s audited financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2019 included in the Company’s final prospectus for its IPO, filed pursuant to Rule 424(b) under the Securities Exchange Act of 1933, as amended, with the SEC on April 6, 2020. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments.
The condensed consolidated financial statements include the accounts of our wholly owned subsidiaries, majority-owned or controlled companies, and variable interest entity (“VIE”), Kalyra Pharmaceuticals, Inc. (“Kalyra”), for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.
Noncontrolling Interest
The shares third parties own in Kalyra and Zentera represent an interest in their respective equity we do not control. We reflect the noncontrolling interest attributable to other owners in a separate line in our condensed consolidated statement of operations and a separate line within stockholders’ equity in our condensed consolidated balance sheet. In addition, we record a noncontrolling interest adjustment to account for equity based compensation in Zentera. This adjustment is a reclassification within stockholders’ equity from additional paid-in capital to noncontrolling interest equal to the amount of equity based compensation expense Zentera had recognized.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.
Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.
14


Marketable Securities
Marketable securities are investments with original maturities of more than ninety days from the date of purchase that we have the ability to liquidate to fund current operations. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term investments on the accompanying condensed consolidated balance sheets Marketable securities are considered available-for-sale and are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders’ deficit. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of operations. We assess whether our available-for-sale debt securities in an unrealized loss position have credit-related losses and record such losses, and any subsequent improvements as interest income, through an allowance account. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of operations.
15


Adoption and Pending Adoption of Recent Accounting Pronouncements
The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
Standard  Description  Effective Date  Effect on the Financial
Statements or Other
Significant Matters
In March 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial InstrumentsThis guidance makes improvements to financial instruments guidance, including the current expected credit losses guidance.January 1, 2020We have adopted the new guidance as of January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321)This standard clarifies the interaction between accounting standards related to equity securities (ASC 321), equity method investments (ASC 323), and certain derivatives (ASC 815). January 1, 2021We currently do not hold equity securities, have equity method investments or derivatives. We do not believe the adoption will have a material impact on our consolidated financial position or results of operations.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. In November 2018 and April and May of 2019, the FASB issued additional guidance related to Topic 326.The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income.January 1, 2020We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes.The new guidance is intended to simplify aspects of the accounting for income taxes, including the elimination of certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, among other changes.January 1, 2020We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
3. Business Combinations
Kalyra Pharmaceuticals, Inc.
On December 21, 2017, we acquired $4.5 million of Kalyra’s Series B Preferred Stock representing a 25% equity interest in Kalyra for purposes of entering the analgesics therapeutic research space. The acquisition price was paid entirely in cash.
16


In accordance with the authoritative guidance, we concluded that Kalyra is a business consisting of inputs, employees, intellectual property and processes capable of producing outputs. Additionally, we have concluded that Kalyra is a variable interest entity, we are the primary beneficiary and have the power to direct the activities that most significantly affect Kalyra’s economic performance through common management and our board representation. Prior to the change of control, Zentalis and Kalyra transacted for the delivery of research and development services and support. The financial position and results of operations of Kalyra have been included in our consolidated financial statements from the date of the initial investment.
Pursuant with authoritative guidance, we have recorded the identifiable assets, liabilities and noncontrolling interests in the VIE at their fair value upon initial consolidation. The identified goodwill is comprised of the workforce and expected synergies from combining the entities. Total assets and liabilities of Kalyra as of September 30, 2020 and December 31, 2019 are as follows (in thousands):
September 30,December 31,
 20202019
Cash and cash equivalents$417 $712 
Other current assets31 21 
In-process research and development8,800 8,800 
Goodwill3,736 3,736 
Other long-term assets14 14 
Accounts payable and accrued expenses87 391 
Deferred tax liability2,463 2,463 
Noncontrolling interests$6,635 $6,821 
The liabilities recognized as a result of consolidating Kalyra do not represent additional claims on our general assets. Pursuant to the authoritative guidance, the equity interest in Kalyra not owned by Zentalis is reported as a noncontrolling interest on our consolidated balance sheets.
The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):
September 30,
 2020
Noncontrolling interest at beginning of period$6,821 
Net loss attributable to noncontrolling interest(186)
Noncontrolling interest at end of period$6,635 
4. Fair Value Measurement
Available-for-sale marketable securities consisted of the following (in thousands):
17


September 30, 2020
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Commercial paper $125,748 $9 $(7)$125,750 
Corporate debt securities
31,840 5 (3)31,842 
US government agencies
77,523 22 (5)77,540 
US Treasury securities39,750 3 (1)39,752 
$274,861 $39 $(16)$274,884 
As of September 30, 2020, 19 of our available-for-sale debt securities with a fair market value of $85.3 million were in a gross unrealized loss position of sixteen thousand. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, our intent to sell or the likelihood that we would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of September 30, 2020, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.
Contractual maturities of available-for-sale debt securities are as follows (in thousands):

September 30, 2020
Estimated Fair Value
Due within one year$239,291 
After one but within five years35,593 
$274,884 

The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
18


September 30, 2020December 31, 2019
Level 1Level 2Total estimated fair valueLevel 1Level 2Total estimated fair value
Cash equivalents:
Money market funds
$29,924 $ $29,924 $62,961 $ $62,961 
US government agencies
 2,631 2,631    
US Treasury securities
9,999  9,999    
Corporate debt securities
 14,999 14,999    
Total cash equivalents:
39,923 17,630 57,553 62,961  62,961 
Available-for-sale marketable securities:
Commercial paper
 125,750 125,750    
Corporate debt securities
 31,842 31,842    
US government agencies
 77,540 77,540    
US Treasury securities
39,752  39,752    
Total available-for-sale marketable securities:
39,752 235,132 274,884    
Total assets measured at fair value
$79,675 $252,762 $332,437 $62,961 $ $62,961 

There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the nine months ended September 30, 2020. We had no instruments that were classified within Level 3 as of September 30, 2020 or December 31, 2019.
5. Prepaid Expenses and Other Assets
Prepaid expenses and other assets consisted of the following (in thousands):
September 30,December 31,
 20202019
Prepaid insurance
$1,761 $150 
Prepaid software licenses and maintenance
320 238 
Prepaid research and development expenses
5,735 2,985 
Interest receivable511  
Upfront lease payment810  
Other prepaid expenses
286 266 
Total prepaid expenses and other current assets
9,423 3,639 
Less long-term portion
4,245 2,134 
Total prepaid expenses and other assets, current
$5,178 $1,505 
19


6. Property and Equipment, net
Property and equipment, net consisted of the following (in thousands):
September 30,December 31,
 20202019
Computer and office equipment
$291 $243 
Lab equipment
360 401 
Leasehold improvements
43 24 
Construction in progress
6  
Subtotal
700 668 
Accumulated depreciation and amortization
(229)(167)
Property and equipment, net
$471 $501 
Depreciation and amortization expense for the three months ended September 30, 2020 and 2019 was approximately fifty-one thousand and twenty-five thousand, respectively. Depreciation and amortization expense for the nine months ended September 30, 2020 and 2019 was approximately one hundred twenty-seven thousand and seventy thousand, respectively.
7. Accrued Expenses
Accrued expenses consist of the following (in thousands):
September 30,December 31,
20202019
Accrued research and development expenses
$10,618 $5,465 
Accrued employee expenses
4,390 2,977 
Accrued general and administrative expenses
2,571 1,356 
Lease liability
871 781 
Other
19 29 
Total accrued expenses
$18,469 $10,608 
8. Convertible Preferred Units
Series A Convertible Preferred Units
In September 2015, Zeno Pharmaceuticals, Inc. entered into a Series A Preferred Stock Purchase Agreement (the “Series A Preferred Agreement”). Under the terms of the Series A Preferred Agreement, Zeno Pharmaceuticals, Inc. issued 1,293,104 shares of Series A convertible preferred stock at $11.60 per share for gross proceeds of $15.0 million. The net proceeds of this financing were $14.9 million after issuance costs of $0.1 million. In February and March 2016, Zeno Pharmaceuticals, Inc. issued an aggregate of 286,205 additional shares of Series A convertible preferred stock at $11.60 per share for additional gross proceeds of $3.3 million. The issuance costs of this additional financing were approximately thirty-nine thousand dollars. All Series A convertible preferred stock issued and outstanding by Zeno Pharmaceuticals, Inc. was converted into Series A convertible preferred units of Zentalis Pharmaceuticals, LLC in conjunction with the corporate restructuring and merger.
Series B Convertible Preferred Units
In December 2017, Zentalis Pharmaceuticals, LLC entered into a Series B Preferred Unit Purchase Agreement (the “Series B Preferred Agreement”). Under the terms of the Series B Preferred Agreement, Zentalis
20


Pharmaceuticals, LLC issued 2,735,320 Series B preferred units at $12.43 per unit for gross proceeds of $34.0 million. The net proceeds of this financing were $32.1 million after issuance costs of $1.9 million. In January and August 2018, Zentalis Pharmaceuticals, LLC issued an aggregate of 788,419 additional shares of Series B preferred units at $12.43 per unit for additional gross proceeds of $9.8 million. The net proceeds of this additional financing were $9.5 million after issuance costs of $0.3 million.
Series C Preferred Unit Issuance
In September 2019, Zentalis Pharmaceuticals, LLC entered into a Series C Preferred Unit Purchase Agreement (the “Series C Preferred Agreement”). Under the terms of the Series C Preferred Agreement, Zentalis Pharmaceuticals, LLC issued 4,847,106 units of Series C convertible preferred units at $17.50 per unit for gross proceeds of $84.8 million. The net proceeds of this financing were $81.9 million after issuance costs of $2.9 million. In February 2020, Zentalis Pharmaceuticals, LLC issued 867,194 additional units of Series C preferred units under the Series C Preferred Agreement. The units were issued for $17.50 per unit for gross proceeds of $15.2 million. The net proceeds of this financing were $14.2 million after issuance costs of $1.0 million.
There were no authorized, issued, and outstanding shares of convertible preferred units at September 30, 2020. As of December 31, 2019, the authorized, issued, and outstanding units of convertible preferred units were as follows (in thousands, except unit amounts):
December 31, 2019
SeriesUnits
Authorized
Units Issued
and
Outstanding
Liquidation
Value
Carrying
Value
Series A convertible preferred units
1,579,309 1,579,309 $18,320 $18,226 
Series B convertible preferred units
3,523,739 3,523,739 43,800 41,604 
Series C convertible preferred units
5,714,300 4,847,106 84,824 81,876 
Total
10,817,348 9,950,154 $146,944 $141,706 
During 2019, we reclassified the convertible preferred units from members’ equity to temporary equity because, in conjunction with the Series C convertible preferred units issuance, all units were now deemed to contain contingent liquidation features that are not solely within our control. During the year ended December 31, 2019 and prior to the conversion of convertible preferred units into common stock in conjunction with our IPO on April 2, 2020, we did not adjust the carrying values of the convertible preferred units to the deemed redemption values of such units since a liquidation event was not probable.

Dividends
Dividends are payable if and when declared by the Board of Directors. No dividends have been declared prior to the conversion of convertible preferred units into common stock in conjunction with our IPO on April 2, 2020.
Conversion
Each Series A preferred unit, Series B preferred unit and Series C preferred unit was convertible at the option of the holder thereof, at any time after the issuance of such unit, into Class A common units at a conversion price equal to the original purchase price (subject to anti-dilution adjustments, discussed below) which was $11.60, $12.43 and $17.50 per unit, respectively. The convertible preferred units automatically converted at the then applicable conversion rate upon the closing of a firm commitment underwritten public offering of shares of a successor corporations’ common stock, at a public offering price per share of equal to or greater than the Series C original purchase price (as adjusted for any stock splits, stock dividends, combinations or other similar recapitalization) resulting in aggregate gross cash proceeds of at least $75.0 million (a “Qualified IPO”). Additionally, the convertible preferred units would have automatically converted into common stock, at the then applicable conversion rate, upon written consent of a majority of the then outstanding Series A, Series B and Series C convertible preferred units
21


(voting as a separate class on an as converted to Common Unit basis). In conjunction with our IPO on April 2, 2020, which constituted a Qualified IPO, all convertible preferred units were converted into common stock.
Anti-dilution protection
The holders of the convertible preferred unit had proportional anti-dilution protection for unit splits, unit dividends and similar recapitalizations. Subject to certain exclusions, anti-dilution price protection for additional sales of securities by us for consideration per unit less than the applicable conversion price per unit of any series of convertible preferred stock, was on a broad-based weighted average basis.
Protective rights
The holders of the convertible preferred units had certain protective rights, including, without limitation, regarding the authorization, alteration, redemption, or sale of Class B common units; commencement of a liquidation or deemed liquidation event; entrance into a joint venture or partnership; any incurrence of indebtedness; certain transactions that exceed a certain dollar threshold; changes to our governing documents; or the declaration of any dividends. Such actions were required to be approved by a majority of the then outstanding Series A, Series B and Series C convertible preferred unit holders (voting as a single class and on an as-converted basis), as specified in the amended and restated LLC agreement. An increase or decrease in the authorized number of Directors constituting the Board or the creation of a membership interest or equity security senior to or pari passu with Series C convertible preferred units was required to be approved by a majority of the then outstanding Series C convertible preferred Units (voting as a separate class on an as converted basis).
Redemption
The Series A, Series B and Series C convertible preferred units were not redeemable except in the event of certain effected deemed liquidation events. As of immediately prior to our IPO on April 2, 2020 and December 31, 2019, we had classified convertible preferred units as temporary equity in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of our control, including liquidation, sale or transfer of control of the Company. We did not adjust the carrying value of the convertible preferred units to the deemed redemption values of such units since a liquidation event was not probable.
Liquidation preference
In the event of the dissolution, liquidation, merger or winding up of the Company, the holders of Series C convertible preferred units were entitled to receive, on a pro rata basis in respect of each such Series C convertible preferred unit, a preference amount of $17.50 per Series C convertible unit (as adjusted for any unit splits, dividends, combinations, recapitalizations or the like).
Subsequent to the payment of the Series C convertible preferred unit preferences, Series A and Series B convertible preferred units were entitled to receive, on a pro rata basis in respect of each convertible preferred unit in proportion to the relative preference amount of each preferred unit, a preference amount of $11.60 and $12.43 per unit of Series A and Series B convertible preferred units (as adjusted for any units splits, dividend, combinations, recapitalizations of the like), respectively.
Subsequent to the payment of the Series C, Series A and Series B convertible preferred unit preferences, Series A, Series B and Series C convertible preferred units were entitled to receive, on an as converted to common unit pro rata basis, an amount equal to distributions made to Class A common units prior to all unit classes sharing in distributions on a pro rata basis. Thereafter, Series A, Series B and Series C convertible preferred units and Series A and Series B common units were entitled to receive the remaining assets of the Company available for distribution to its unit holders pro rata based on the number of common units held by each holder, treating for these purposes as if all units had been converted to common.
22


Voting Rights
The holders of all units other than Class B common units that were unvested were to vote together as a single class. Each holder of Series A, Series B and Series C convertible preferred units were entitled to the number of votes calculated on an as converted to Class A common unit basis.
9. Equity and Share-based Compensation
In November 2017, Zentalis Pharmaceuticals, LLC was formed in the state of Delaware. In conjunction with a corporate restructuring, Zeno Pharmaceuticals, Inc., a Delaware Corporation formed in 2014, was acquired by the Company pursuant to a merger agreement and became a wholly owned subsidiary of the Company. Per the terms of the merger agreement, each share of Zeno Pharmaceuticals, Inc. common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive one Class A common unit and each share of Zeno Pharmaceuticals, Inc. Series A preferred stock issued and outstanding immediately prior to the effective date of the merger converted into the right to receive one Series A preferred unit. As of the effective time of the merger agreement, all outstanding options to purchase shares of Zeno Pharmaceuticals, Inc. common stock were cancelled and replaced with profit interest awards in the LLC.
In connection with the December 2017 corporate restructuring, we amended and restated the LLC agreement, and as amended, the capital units of the Company consisted of 1,638,000 authorized Series A preferred units, 3,621,000 authorized Series B preferred units, 15,000,000 authorized Class A common units and 872,620 authorized Class B common units.
Class A Common Units
In conjunction with the corporate restructuring in December 2017, 5,187,554 shares of common stock issued and outstanding and 406,831 shares of common stock subject to future vesting provisions of Zeno Pharmaceuticals, Inc. were converted into an equal number of Class A common units of Zentalis Pharmaceuticals, LLC. During the three months ended September 30, 2020 and 2019, we did not issue any Class A common units. As of September 30, 2020 and 2019, zero and 9,572 Class A common units were subject to future vesting conditions, respectively. During the year ended December 31, 2019, 7,093 Class A common units were issued and 9,572 Class A common units were subject to future vesting conditions. In September 2019, the number of authorized Class A common units was increased to 20,000,000.
Class B Common Units
In conjunction with the corporate restructuring in December 2017, 703,000 options exercisable into Zeno Pharmaceuticals, Inc. common stock were converted into an equal number of Class B common units of Zentalis Pharmaceuticals, LLC. In September 2019, the number of authorized Class B common units was increased to 3,458,522.
IPO and Follow-on Offering
On April 2, 2020 and immediately prior to the effectiveness of the Company’s IPO, Zentalis Pharmaceuticals, LLC converted from a Delaware limited liability company into a Delaware corporation pursuant to a statutory conversion, and changed its name to Zentalis Pharmaceuticals, Inc. In order to consummate the corporate conversion, a certificate of conversion was filed with the Secretary of State of the State of Delaware. All of the outstanding units of Zentalis Pharmaceuticals, LLC converted into shares of common stock of Zentalis Pharmaceuticals, Inc. based upon the value of Zentalis Pharmaceuticals, Inc. at the time of the IPO with a value implied by the price of the shares of common stock sold in the IPO. No cash or fractional shares of common stock were issued in connection with the corporate conversion. Based on the IPO price of $18.00 per share of common stock, all of the outstanding units converted into an aggregate of 25,288,854 shares of common stock (including 1,160,277 shares of restricted common stock).
23


In connection with the completion of the IPO, the board and stockholders approved the certificate of incorporation to provide for 250,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share.
On April 7, 2020, the Company completed an IPO in which the Company issued and sold 10,557,000 shares of common stock (including 1,377,000 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a price of $18.00 per share. The Company’s aggregate gross proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $190.0 million before fees and expenses of $17.6 million.
On August 3, 2020, the Company completed a follow-on offering in which the Company issued and sold 4,743,750 shares of common stock (including 618,750 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a public offering price of $35.00 per share. The Company’s aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $166.0 million before fees and expenses of $10.8 million.
Share-based Compensation
In the Company’s 2017 Profit Interest Plan (the Plan) as approved and adopted by the Board of Directors on December 21, 2017, the Company was authorized to issue up to 3,458,522 shares of Class B common units, subject to restrictions as described in the Plan. The Plan was terminated in April 2020. In April 2020, the Company’s board of directors adopted, and the Company’s stockholders approved the 2020 Incentive Award Plan (the 2020 Plan), which became effective upon the corporate conversion. The number of common shares initially available for issuance under the 2020 Plan is the sum of (1) 5,600,000 shares of common stock; plus (2) any shares forfeited from the unvested restricted shares of our common stock issued upon conversion of unvested Class B common units (up to 1,250,000 shares); plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ending December 31, 2021 and continuing to, and including, the fiscal year ending December 31, 2030, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by our board of directors.
During the nine months ended September 30, 2020, the Company granted 70,000 Class B common units to employees and directors under the Plan. The weighted average fair value of incentive units granted in the nine months ended September 30, 2020 was $3.06 per unit. In April 2020, each outstanding Class B common unit was converted into a number of shares of common stock and restricted common stock based upon the IPO price. The restricted common stock issued in respect of Class B common units continues to be subject to vesting in accordance with the vesting schedule that was applicable to such Class B common units. The Company granted 1,160,277 shares of restricted common stock to employees, consultants and directors as part of the conversion. In conjunction with the IPO, the Company also granted 1,970,671 stock options, with a weighted average of $11.97 per share, to purchase shares of common stock to employees and directors who were holders of Class B common units at the time of the incentive unit conversion and in new employee grants. The weighted average fair value of the 2,794,546 stock options granted to employees and directors in the nine months ended September 30, 2020 was $15.11 per share.
Total share-based compensation expense related to share based awards was comprised of the following (in thousands):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Research and development expense
$2,180 $95 $4,606 $224 
General and administrative expense
5,069 60 10,653 181 
Total share-based compensation expense
$7,249 $155 $15,259 $405 
24


Total share-based compensation expense includes $187 and $187 of share-based compensation expense for Zentera employees for the three and nine months ended September 30, 2020, respectively, compared to $0 for the same periods in 2019.
Share-based compensation expense by type of share-based award (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Profit interest award units
$ $155 $329 $405 
Stock options
2,212  3,814  
RSAs and RSUs
5,037  11,116  
$7,249 $155 $15,259 $405 

The fair value of the Class B common unit awards was estimated using an option pricing model with the following assumptions:
Nine Months Ended
September 30,
20202019
Members’ equity value (in thousands)$271,207$197,041
Threshold amounts (in thousands)$309,824$143,800
Risk free rate1.5%1.5%
Volatility75.0%75.0%
Time to liquidity (in years)1.1
1.1 - 1.8
Lack of marketability discount26.5%
18.8% - 26.4%
Grant date fair value$3.06
$1.88 - $3.06
The Black-Scholes-Merton option pricing model (“Black-Scholes model) is used to estimate the fair value of each Class B common unit award on the date of grant. The members’ equity value was based on a recent enterprise valuation analysis performed. The threshold amounts are based on the discretion of the Board of Directors at the time of grant. The expected life of the Class B common unit awards granted during the period presented was determined based on an expected liquidation event under the plan. We applied the risk-free interest rate based on the U.S. Treasury yield in effect at the time of the grant consistent with the life of the award. The expected volatility was based on a peer group in the industry in which the Company does business consistent with the expected time to liquidity. The dividend yield was set at zero as the underlying security does not and is not expected to pay a dividend. The Finnerty model and the Asian Protective Put Model methods were used to estimate the discount for lack of marketability inherent to the awards.
The Class B common units issued have been classified as equity awards, and share-based compensation expense is based on the grant date fair value of the award. During the nine months ended September 30, 2020 and 2019, we issued 70,000 and 91,000 Class B common units, respectively. As of September 30, 2020 and December 31, 2019, zero and approximately 1.7 million unvested Class B common units were outstanding, respectively.
The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes model. Due to the Company’s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected
25


companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company uses the “simplified method” for estimating the expected term of employee options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero. The fair value of the stock options granted during the three and nine months ended September 30, 2020 was determined with the following assumptions:
Three Months Ended
September 30, 2020
Nine Months Ended
September 30, 2020
Expected volatility
76.6% - 78.2%
76.6% - 78.2%
Average expected term (in years)
5.7 - 6.0
5.7 - 6.0
Risk-free interest rate
0.4%
0.4% - 0.5%
Expected dividend yield
%%

Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):
September 30, 2020
Unrecognized
Expense
Remaining
Weighted-Average Recognition Period
(years)
Stock options$38,247 3.54
RSAs$2,492 2.43
RSUs$17,563 1.15

During the nine months ended September 30, 2020, we did not issue any shares of common stock in connection with the exercises of stock options. For the nine months ended September 30, 2020, 309,010 shares of common stock issued in conjunction with certain RSAs fully vested. Stock options, unvested RSAs, and unvested RSUs totaling approximately 2.8 million shares, 0.8 million shares, and 1.1 million shares of our common stock, respectively, were outstanding as of September 30, 2020.
10. Commitments and Contingencies
Legal Contingencies
From time to time, we may be involved in various disputes, including lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any of these claims could subject us to costly legal expenses. While we do generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, or our policy limits may be inadequate to fully satisfy any damage awards or settlement. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings.
26


Leases
Our commitments include payments related to operating leases. Approximate annual future minimum operating lease payments as of September 30, 2020 are as follows (in thousands):
YearOperating Leases
2020$256 
20211,044 
2022661 
2023187 
Total minimum lease payments:
2,148 
Less: imputed interest(246)
Total operating lease liabilities
1,902 
The weighted-average remaining lease term of our operating leases is approximately 2.0 years. As of September 30, 2020, we had entered into an additional lease for real estate that had not yet commenced with total minimum lease payments of approximately $86.5 million. This lease is expected to commence in the fourth quarter of 2021 and has a lease term of 10.7 years. Zentera, our majority-owned subsidiary, had also entered into a separate lease for real estate that had not commenced as of September 30, 2020 with total minimum lease payments of approximately $0.1 million. This lease is expected to commence in the fourth quarter of 2020 and has a lease term of 1.2 years.
11. Net Loss Per Common Share/Class A Common Unit
Basic and diluted net loss per common share/Class A common unit were calculated as follows (in thousands except per share and per unit amounts):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Numerator:
Net loss attributable to Zentalis
$(34,555)$(12,344)$(77,538)$(31,157)
Denominator:
Weighted average number of common shares/Class A common units outstanding, basic and diluted
37,959 5,601 24,143 5,601 
Net loss per common share
$(0.91)$ $(3.21)$ 
Net loss per Class A common unit
$ $(2.20)$ $(5.56)
Our potential and dilutive securities, which include outstanding stock options, unvested RSAs, unvested RSUs and preferred units, have been excluded from the computation of diluted net loss per common share/Class A common unit as the effect would be anti-dilutive. We considered the impact of presenting a separate earnings per unit calculation for Class B common units. However, as earnings and losses are only allocable to Class B common units after the applicable threshold has been met, and such thresholds have not been met for earnings per unit purposes, no losses were allocated to Class B common units.
27


The following common stock/Class A common unit equivalents have been excluded from the calculations of diluted net loss per common share/Class A common unit because their inclusion would be antidilutive (in thousands).
 September 30,
 20202019
Preferred units, as if converted to Class A common units
 9,950 
Incentive units—Class B common units
 1,947 
Outstanding stock options
2,783  
Unvested RSAs
845  
Unvested RSUs
1,102  
4,730 11,897 
12. Related Party Disclosures
On December 21, 2017, we acquired 17,307,692 shares of Series B preferred stock of Kalyra for a per share price of twenty-six cents ($0.26) or approximately $4.5 million. The management team and stockholders of Kalyra are also stockholders of the Company.
Prior to the investment, we entered into a license agreement and a master services agreement with Kalyra. The license agreement was signed and commenced on December 31, 2014 for the exclusive rights to develop and commercialize products derived from Kalyra’s technology in the initial area of oncology. The license agreement and all rights were subsequently sold from Kalyra to Recurium IP Holdings, LLC (“Recurium IP”), an entity with common ownership to Kalyra prior to the Zentalis investment. Under the agreement, we have agreed to make payments to Recurium IP based on specific milestones and based on Recurium Equity, LLC’s equity ownership stake in us, as determined in accordance with terms of the license agreement, at the time the milestone is earned. Recurium Equity, LLC (“Recurium Equity”) is also an entity with common ownership to Kalyra prior to the Zentalis investment. In addition, the Company shall pay low to mid-single digit percentage royalties on net product sales to Recurium IP and sublicense fees on any consideration paid to us by a sublicensor. The royalty payments are also based on Recurium Equity’s then equity ownership in us, as determined in accordance with the terms of the license agreement. The license agreement will terminate upon the later of the last expiration of the patent rights or 15 years from the date of commencement.
The Master Services Agreement was entered into in January 2015 and states that Kalyra may provide research and development services to us and that we shall reimburse such expenses on a time and materials basis based on the initial statements of work. For each of the three months ended September 30, 2020 and 2019, we did not incur any expense with Kalyra. For the nine months ended September 30, 2020 and 2019, we incurred approximately zero and zero dollars of expense with Kalyra, respectively, that was eliminated in consolidation for research and development services provided. As of September 30, 2020 and 2019, there was no balance due to Kalyra.
We entered into an Intercompany Services Agreement with Kalyra in January 2018 which states that we may provide research and development services to Kalyra and that Kalyra shall reimburse such expenses on a time and materials basis. For each of the three months ended September 30, 2020 and 2019, we provided $0.1 million of research and development services to Kalyra that we eliminated in consolidation. For the nine months ended September 30, 2020 and 2019, we provided $0.3 million and $0.4 million of research and development services to Kalyra that was eliminated in consolidation, respectively. As of September 30, 2020 and 2019, $0.1 million and $0.4 million was due from Kalyra and eliminated in consolidation, respectively.
On June 1, 2020, we entered into an equipment purchase and sale agreement with Kalyra to purchase $0.4 million of equipment and related tangible assets to be used in our operations. As of September 30, 2020, there was no balance due to Kalyra for the transaction.
28



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of financial condition and operating results should be read together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and the related notes included in our final prospectus, dated July 29, 2020, filed with the Securities and Exchange Commission, or SEC, pursuant to Rule 424(b)(4) relating to our registration statement on Form S-1 (Registration No. 333-240115), as amended (the “Follow-On Prospectus”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. As a result of many important factors, such as those set forth in the “Risk Factors” section of this Quarterly Report on Form 10-Q, our actual results may differ materially from those anticipated in these forward-looking statements. For convenience of presentation some of the numbers have been rounded in the text below.
Overview
We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. We use our highly efficient drug discovery engine, which we refer to as our “Integrated Discovery Engine,” to identify targets and develop small molecule new chemical entities, or NCEs, with properties that we believe could result in potentially differentiated product profiles. Our discovery engine combines our extensive experience and capabilities across cancer biology and medicinal chemistry. We believe our product candidates are differentiated from current programs targeting similar pathways and have the potential to significantly impact the lives of patients with cancer.
We are developing a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Our lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. We have designed ZN-c5 to have high potency and selectivity, as well as favorable tolerability and pharmacokinetic, or PK, properties. We intend to initiate the Phase 2 monotherapy and combination (with palbociclib) portions of this Phase 1/2 trial in the first half of 2021. In addition, we plan to initiate a Phase 1b open label, multi-center trial evaluating ZN-c5 in combination with abemaciclib (marketed as Verzenio ® by Lilly) in patients with ER+/HER2- advanced or metastatic breast cancer in the second half of 2020 as part of a clinical research collaboration with Lilly. Abemaciclib is a CDK 4/6 inhibitor FDA approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative, or HR+/HER2-, advanced or metastatic breast cancer in combination with fulvestrant, aromatase inhibitors or as a single agent in certain patients with disease progression following treatment with prior endocrine therapy or chemotherapy regimens. We also intend to initiate, subject to feedback from the FDA, a Phase 2/3 clinical trial evaluating ZN-c5 in earlier stage breast cancer patients in 2021 and to initiate a Phase 1b clinical trial evaluating ZN-c5 in combination with ZN-d5, our BCL-2 inhibitor product candidate, in patients with ER+/HER2- breast cancer in 2021. Our other product candidates include ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, currently in a Phase 1/2 clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, or BCL-2, initially in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of epidermal growth factor receptor, or EGFR, currently in a Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer, or NSCLC. We expect to report initial results from the Phase 1 portion of the ongoing trials of each of ZN-c3 and ZN-e4 in 2021, and to initiate a Phase 1 clinical trial of ZN-d5 in patients with acute myeloid leukemia, or AML, or B-cell lymphoma in the first half of 2021. In addition, we plan to initiate a Phase 1b clinical trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer in the second half of 2020 and a Phase 2 trial evaluating ZN-c3 as monotherapy in patients with uterine serous carcinoma, or USC, in 2021. USC comprises 10%, and has the highest mortality rate, of all endometrial cancers, with approximately 6,000 new cases and 4,500 deaths in the United States per year. We continue to actively evaluate other potential combinations for the future clinical development of ZN-c3, and intend to initiate two additional Phase 1 clinical trials evaluating ZN-c3 in combination with chemotherapy and PARP inhibitors in ovarian cancer and other targeted indications in 2021. In addition, we intend to initiate a Phase 1b clinical trial evaluating ZN-d5 in combination with ZN-c5, our oral SERD product
29


candidate in patients with ER+/HER2- breast cancer in 2021. We currently own worldwide development and commercialization rights to each of our product candidates, other than in select Asian countries (including China) for each of ZN-c5, ZN-c3 and ZN-d5, for which we have out-licensed these rights to our majority-owned joint venture, Zentera Therapeutics (Cayman), Ltd., or Zentera, and for ZN-e4 for which we have out-licensed these rights to SciClone Pharmaceuticals International (Cayman) Development Ltd. Zentera intends to submit an IND in China for each of ZN-c5, ZN-c3 and ZN-d5 in 2021.

We are also currently advancing multiple small molecule programs in preclinical development for other cancer indications, including select solid tumors and hematological malignancies. We are now in lead optimization for our fifth product candidate and plan to submit an investigational new drug application, or IND, to the FDA in 2021.

Since our inception, our operations have been limited to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing research and development of our product pipeline. We do not have any products approved for commercial sale and have not generated any revenues from product sales. On April 7, 2020, we completed our initial public offering, or IPO, and issued and sold approximately 10.6 million shares of our common stock at a public offering price of $18.00 per share, including approximately 1.4 million shares in connection with the full exercise of the underwriters’ option to purchase additional shares, resulting in net proceeds of approximately $172.4 million, after deducting underwriting discounts and commissions and offering expenses. On August 3, 2020, pursuant to our registration statement on Form S-1 (Registration No. 333-240115), as amended, filed with the SEC on July 27, 2020, we completed a follow-on offering of our common stock and issued and sold approximately 4.7 million shares of our common stock at a public offering price of $35.00 per share, including approximately 0.6 million shares in connection with the full exercise of the underwriters’ option to purchase additional shares, resulting in net proceeds of approximately $155.2 million, after deducting underwriting discounts and commissions and offering expenses.

We had cash, cash equivalents and marketable securities of $367.4 million as of September 30, 2020. We believe that our existing cash, cash equivalents and marketable securities as of September 30, 2020 will enable us to fund our operating expenses and capital expenditure requirements into 2023. We have based these estimates on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect.
Since inception, we have incurred significant operating losses. Our net losses were $46.4 million for the year ended December 31, 2019, and $78.2 million and $31.8 million for the nine months ended September 30, 2020 and September 30, 2019, respectively. Our net losses were $34.7 million and $12.6 million for the three months ended September 30, 2020 and September 30, 2019, respectively. We had an accumulated deficit of $160.5 million as of September 30, 2020. We expect to continue to incur significant expenses and operating losses for the foreseeable future.
We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capabilities to support product sales, marketing and distribution activities, either alone or in collaboration with others. Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company.
As a result, we will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all. If we are unable to secure adequate additional funding as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions.
Corporate Conversion
30


In connection with our IPO, we converted from a Delaware limited liability company into a Delaware corporation pursuant to a statutory conversion, and changed our name from Zentalis Pharmaceuticals, LLC to Zentalis Pharmaceuticals, Inc. We refer to all transactions related to our conversion to a corporation as the Corporate Conversion. As a result of the Corporate Conversion, all holders of units of Zentalis Pharmaceuticals, LLC became holders of shares of common stock of Zentalis Pharmaceuticals, Inc.
In connection with the Corporate Conversion, our outstanding Series A convertible preferred units, Series B convertible preferred units, Series C convertible preferred units, Class A common units and Class B common units, or Units, converted into an aggregate of 25,288,854 shares of our common stock (including 1,160,277 shares of restricted common stock) based on the IPO price of $18.00 per share of common stock.
Impact of COVID-19 Pandemic
We continue to monitor how the COVID-19 pandemic is affecting our employees, business, preclinical studies and clinical trials. In response to the spread of COVID-19, we have closed our executive offices with our administrative employees continuing their work outside of our offices and limited the number of staff in any given research and development laboratory. Disruptions caused by the COVID-19 pandemic have resulted in difficulties including delays in initiating new trial sites and certain supply chain activities, suspension of enrollment at some of our existing trial sites, and the incurrence of additional costs as a result of preclinical study and clinical trial delays and adjustments. Limited operations at our laboratory facilities have also resulted in delays in our research-stage programs. As a result, we expect that the COVID-19 pandemic will continue to impact our business, results of operations, clinical development timelines and financial condition. At this time, there is significant uncertainty relating to the trajectory of the COVID-19 pandemic and impact of related responses. The impact of COVID-19 on our future results will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, the continued impact on financial markets and the global economy, and the effectiveness of the global response to contain and treat the disease. See “Risk Factors— The outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and we expect will continue to adversely impact our business, including our preclinical studies and clinical trials.” in Part II, Item 1A. of this Quarterly Report on Form 10-Q.
License Agreements and Strategic Collaboration Agreements
Recurium IP Holdings, LLC
In December 2014, and as amended and restated effective as of December 2017 and September 2019 and as amended in May 2020, we entered into a license agreement, or the Recurium Agreement, with Recurium IP Holdings, LLC, or Recurium IP, under which we were granted an exclusive worldwide license to certain intellectual property rights owned or controlled by Recurium IP to develop and commercialize pharmaceutical products for the treatment or prevention of disease, other than for pain. In connection with the May 2020 amendment, we clarified certain aspects of the sublicensing payment provisions. We have the right to sublicense our rights under the Recurium Agreement, subject to certain conditions. We are required to use commercially reasonable efforts to develop and commercialize at least one product that comprises or contains a licensed compound and to execute certain development activities.

Our payment obligations under the Recurium Agreement are based on the percentage ownership interest Recurium Equity, LLC, an affiliated company of Recurium IP, has in us, as determined in accordance with the terms of the Recurium Agreement. Under the terms of the Recurium Agreement, we are obligated to make development and regulatory milestone payments, pay royalties for net sales and make sublicensing payments with respect to certain licensed products directed to one of ten specific biological targets, including ZN-c5, ZN-c3 and ZN-e4. We are obligated to make development and regulatory milestone payments for such licensed products of up to $44.5 million if Recurium Equity, LLC has less than 10% ownership percentage of us, or up to $21.5 million if the ownership percentage is 10% or more but no more than 15%. If the percentage of ownership interest Recurium Equity, LLC has in us is greater than 15% then no development and regulatory milestone payments will be due. In addition, we
31


are obligated to make milestone payments up to $150,000 for certain licensed products used in animals. We are also obligated to pay royalties on sales of such licensed products at a mid- to high-single digit percentage if Recurium Equity, LLC’s ownership percentage in us is less than 10%, at a mid-single digit percentage if such ownership percentage is 10% or more but no more than 15%, and at a low-single digit percentage if such ownership percentage is above 15%. In addition, if we choose to sublicense or assign to any third parties our rights under the Recurium Agreement with respect to such licensed products, we must pay to Recurium IP 20% of sublicensing income received in connection with such transaction if Recurium Equity, LLC has less than 10% ownership percentage of us, or a percentage of 10% if the ownership percentage is 10% or more but no more than 15%. If the percentage of ownership interest Recurium Equity, LLC has in us is greater than 15% then no sublicensing payments will be due. As of September 30, 2020, Recurium Equity, LLC’s ownership interest in us, as determined in accordance with the terms of the Recurium Agreement was 10.2%, requiring potential payment of aggregate development and regulatory milestone payments of $21.5 million and royalties of mid-single digit percentage on sales of the relevant licensed products.
Mayo Foundation for Medical Education and Research
In February 2016, and as amended in April 2017 and December 2017, we entered into an option agreement, or the Mayo Agreement, with Mayo Foundation for Medical Education and Research under which we were granted an exclusive option to obtain a nonexclusive worldwide license to know-how and an exclusive worldwide license related to patent rights created by Mayo under the Mayo Agreement. We have the right to sublicense our rights under the Mayo Agreement, subject to certain conditions. We are required to use commercially reasonable efforts to develop and commercialize licensed products. Under the terms of the Mayo Agreement, we are obligated to pay royalties on sales for each licensed product at a low-single digit percentage as well as grants of equity interests to be negotiated on a case-by-case basis. In addition, in consideration for the grant of know-how we provided grants of common stock on the first anniversary and Class A common units on the second and third anniversaries following entry into the Mayo Agreement. As of September 30, 2020, we have granted equity securities which amount to 15,435 shares of common stock under the Mayo Agreement. The Mayo Agreement will expire on the date of the last to expire of the Mayo patent rights or, if no Mayo patent rights arise, on February 11, 2021. As of the date of this filing, no Mayo patent rights have been created under the Mayo Agreement. The Mayo Agreement may be terminated in its entirety or in part by Mayo in the event of an uncured material breach by us, in the event that we bring suit against Mayo, except for an uncured material breach of the Mayo Agreement by Mayo, or in the event we are subject to specified bankruptcy, insolvency or similar circumstances.
SciClone Pharmaceuticals International (Cayman) Development Ltd.
In December 2014, and as amended in December 2016 and December 2017, we entered into a collaboration and license agreement, or the SciClone Agreement, with SciClone Pharmaceuticals International (Cayman) Development Ltd., or SciClone, under which we granted an exclusive license certain intellectual property rights in the People’s Republic of China (including the territories of Macao and Hong Kong), South Korea, Taiwan and Vietnam, or the SciClone Territory, for SciClone to develop and commercialize a licensed product for the treatment or prevention of oncologic diseases and an exclusive option to obtain a similar license for up to two additional licensed products. Under the SciClone Agreement, SciClone is responsible for clinical development activities required in order to obtain regulatory approval in the SciClone Territory. SciClone paid to us a one-time upfront payment of $1.0 million upon entering into the SciClone Agreement, and $4.0 million in aggregate milestone payments. No additional development or commercial milestones or reimbursement for research and development expenses are payable under the SciClone Agreement, as amended. We are entitled to receive a mid-single digit royalty on net sales of licensed products in the SciClone Territory, which royalty is subject to certain reductions in the event that SciClone is unable to achieve certain gross margins or if generic products are sold or if technology covering a licensed product is licensed from a third party. We have also agreed to pay SciClone tiered royalties pursuant to the terms of the SciClone Agreement, the applicable rate of which are determined based on whether a compound is developed to a successful dual IND submission and the costs incurred by SciClone for the development of such product candidate. Following the December 2016 amendment to the SciClone Agreement, SciClone retains the exclusive license to develop and commercialize our EGFR inhibitor product candidate, ZN-e4, in the SciClone Territory, and the exclusive option to obtain an exclusive license to develop up to two specified compounds under the SciClone
32


Agreement for which we submit an IND by providing notice and paying $5 million to us. SciClone’s and our royalty obligations will expire on a licensed product-by-licensed product and country-by-country basis on the later of fifteen years from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product in such country.
Pfizer Clinical Trial Collaboration and Supply Agreement
In May 2018, we entered into a clinical trial collaboration and supply agreement with Pfizer, Inc. to evaluate the safety, tolerability and efficacy of ZN-c5 in combination with their CDK4/6 inhibitor, palbociclib, in our ongoing Phase 1/2 clinical trial of ZN-c5. Pursuant to this agreement, we will be responsible for the conduct and cost of the relevant studies, under the supervision of a joint development committee made up of our representatives and representatives of Pfizer that meets quarterly. Pfizer will supply palbociclib for use in the trial, at no cost to us.
Eli Lilly and Company Clinical Trial Collaboration and Supply Agreement
In July 2020, we entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company, or Lilly, to evaluate the safety, tolerability and efficacy of ZN-c5 in combination with their CDK4/6 inhibitor, abemaciclib, in a Phase 1b open label multi-center clinical trial that we intend to initiate in the second half of 2020. Pursuant to this agreement, we will be responsible for the conduct and cost of the relevant studies. Lilly is obligated to supply abemaciclib for use in the trial, at no cost to us. We are required to provide to Lilly clinical data and other reports at major decision points during the trial and no later than 60 days following completion of the planned Phase 1b clinical trial.

This agreement does not grant any right of first negotiation to participate in future clinical trials, and each of the parties retains all rights and ability to evaluate their respective compounds in any clinical studies, either as monotherapy or in combination with any other product or compound, in any therapeutic area.

The agreement with Lilly will expire upon completion of all obligations of the parties thereunder or upon termination by either party. We and Lilly each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations or if either party decides to discontinue development of its own compound for medical, scientific, legal or other reasons or if a regulatory authority takes any action preventing that party from supplying its compound for the study. Lilly also has the right to terminate this agreement if it notifies us in writing that it reasonably and in good faith believes that abemaciclib is being used in an unsafe manner, and we fail to incorporate changes to address such issue, and the issue is unable to be resolved following elevation to appropriate parties.

Zentera Therapeutics
In May 2020, each of our subsidiaries Zeno Alpha, Inc., K-Group Alpha, Inc. and K-Group Beta, Inc. entered into a collaboration and license agreement with our majority-owned joint venture, Zentera Therapeutics (Cayman), Ltd., or Zentera (the “Zentera Sublicenses”), pursuant to which we collaborate with Zentera on the development and commercialization of ZN-c5, ZN-d5 and ZN-c3, respectively, whether alone or in a licensed product (“Collaboration Products”), in each case for the treatment or preventions of disease, other than for pain (the “Zentera Field”), in the People’s Republic of China, Macau, Hong Kong and Taiwan (the “Zentera Collaboration Territory”). Under each Zentera Sublicense, Zentera will lead development, and upon regulatory approval, the commercialization, of the Collaboration Products in the Zentera Collaboration Territory. On May 19, 2020, Zentera issued an aggregate of 60.2% of its issued shares of common stock to Zeno Alpha, Inc., K-Group Alpha, Inc., K-Group Beta, Inc., Zeno Management, Inc. and Zeno Beta, Inc. Anthony Y. Sun, M.D., our President and Chief Executive Officer, serves as Chief Executive Officer and a member of the board of directors of Zentera, and Kevin D. Bunker, Ph.D., our Chief Operating Officer, serves as a member of the board of directors of Zentera.
Under each Zentera Sublicense, we granted Zentera an exclusive, royalty-bearing license under certain of our technology, including technology licensed from Recurium under the Recurium Agreement, to develop and commercialize the Collaboration Products in the Zentera Field and in the Zentera Collaboration Territory, subject to certain rights that we retain, and upon a successful manufacturing transfer, a non-exclusive license under certain of
33


our manufacturing technology to manufacture Collaboration Products in the Zentera Field and in the Zentera Collaboration Territory. Zentera has the right to sublicense its rights under the Zentera Sublicenses subject to certain conditions.
Under the terms of the Zentera Sublicenses, Zentera is responsible for the costs of developing the Collaboration Products in the Zentera Collaboration Territory, and we are responsible for the costs of developing the Collaboration Products outside the Zentera Collaboration Territory, provided that Zentera will reimburse us for a portion of its costs for global data management, pharmacovigilance, safety database management, and chemistry, manufacturing and controls activities with respect to each Collaboration Product. Under the Zentera Sublicenses, we will be eligible to receive future development and regulatory milestones based upon Recurium Equity LLC’s aggregate direct or indirect ownership percentage of the furthest down-stream sublicensee which is an affiliate of Zeno Management, Inc. of the applicable Collaboration Product (such ownership percentage, the “Recurium Equity Percentage”). At the Recurium Equity Percentages of less than 10%, and 10% but no more than 15%, we will be eligible to receive development and regulatory milestones of up to $4.45 million and $2.15 million per Collaboration Product, respectively. If the Recurium Equity Percentage is greater than 15%, then no development and regulatory milestone payments will be due. Zentera will pay us royalties on net sales of Collaboration Products in the Zentera Collaboration Territory at a mid- to high-single digit percentage if the Recurium Equity Percentage is less than 10%, at a mid-single digit percentage if the Recurium Equity Percentage is 10% or more but no more than 15%, and at a low-single digit percentage if the Recurium Equity Percentage is above 15%, in each subject to certain reductions. In addition, if Zentera or its affiliate chooses to sublicense or assign to any third parties its rights under the Zentera Sublicenses with respect to any Collaboration Product, Zentera must pay to us 20% of sublicensing income received by Zentera or its affiliates in connection with such transaction if the Recurium Equity Percentage is less than 10%, or a percentage of 10% if the Recurium Equity Percentage is 10% or more but no more than 15%. If the Recurium Equity Percentage is greater than 15% then no sublicensing payments will be due. As of September 30, 2020 the Recurium Equity Percentage, as determined in accordance with the terms of the Recurium Agreement, was 10.2%.
Zentera’s royalty obligations will expire on a Collaboration Product-by-Collaboration Product and region-by-region basis upon the later of the date on which such product is no longer covered by a valid claim of a licensed patent and the 15th anniversary of the first commercial sale of such product in such region.
Components of Our Results of Operations
Revenue
To date, we have not generated any revenue, and we do not expect to generate any revenue in the foreseeable future from product sales. We have generated, and may in the future generate, revenue from payments received under our collaboration agreements, which includes payments of upfront fees, license fees, milestone-based payments and reimbursements for research and development efforts.
Research and Development Expenses
salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;
expenses incurred under agreements with third parties, including contract research organizations, or CROs, and other third parties that conduct research, preclinical activities and clinical trials on our behalf as well as contract manufacturing organizations, or CMOs, that manufacture drug material for use in our preclinical studies and clinical trials;
costs of outside consultants, including their fees, stock-based compensation and related travel expenses;
the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;
34


license payments made for intellectual property used in research and development activities; and
allocated expenses for rent and maintenance of facilities and other operating costs.
We expense research and development costs as incurred. Reimbursed research and development costs under government grant arrangements are recorded as a reduction to research and development expenses and are recognized in the period in which the related costs are incurred.
We track external development costs by product candidate or development program, but we do not allocate personnel costs, license payments made under our licensing arrangements or other internal costs to specific development programs or product candidates. These costs are included in unallocated research and development expenses in the table below.
The following table summarizes our research and development expenses by product candidate or development program (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
ZN-c5$7,455 $2,473 $18,328 $5,627 
ZN-c33,697 1,675 7,858 4,170 
ZN-d52,305 1,575 4,984 3,549 
ZN-e4959 1,082 1,986 3,298 
Unallocated research and development expenses
10,254 3,934 22,224 9,873 
Total research and development expenses
$24,670 $10,739 $55,380 $26,517 
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase substantially for the foreseeable future and will comprise a larger percentage of our total expenses as we complete our ongoing clinical trials, initiate new clinical trials, continue to discover and develop additional product candidates and prepare regulatory filings for any product candidates that successfully complete clinical development.
The successful development of our product candidates is highly uncertain. At this time, we cannot determine with certainty the duration and costs of our existing and future clinical trials of our product candidates or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of our product candidates and any other product candidate we may develop in the future will depend on a variety of factors, including:
per patient trial costs;
the number of patients who enroll in each trial;
the number of trials required for approval;
the number of sites included in the trials;
the countries in which the trials are conducted;
the length of time required to enroll eligible patients;
35


the drop-out or discontinuation rates of patients;
any delays in clinical trials as a result of the COVID-19 pandemic;
potential additional safety monitoring requested by regulatory agencies;
the duration of patient participation in the trials and follow-up;
the phase of development of the product candidate; and
the efficacy and safety profile of the product candidate.
uncertainties in clinical trial design and patient enrollment rates;
the actual probability of success for our product candidates, including the safety and efficacy, early clinical data, competition, manufacturing capability and commercial viability;
significant and changing government regulation and regulatory guidance;
the timing and receipt of any marketing approvals; and
the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.
A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.
We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support increased research and development activities relating to ZN-c3, ZN-c5, ZN-d5, ZN-e4, and any other product candidate we may develop. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements; director and officer insurance costs; and investor and public relations costs.
Interest Income
Interest income consists of interest earned on cash, cash equivalents and available-for-sale marketable securities. We expect our interest income to increase due to the net proceeds from our IPO and August 2020 follow-on offering.
36


Income Taxes
Since our inception in December 2014, our corporate subsidiaries have generated cumulative federal and state net operating loss for which we have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within their respective carryforward periods.
Net Loss Attributable to Noncontrolling Interest
Since December 21, 2017, the date of our initial investment in Kalyra Pharmaceuticals, Inc., or Kalyra, we have consolidated the financial results of our affiliate, Kalyra. Although we do not have a controlling interest in Kalyra, we determined that Kalyra was a variable interest entity, of which we were the primary beneficiary. For more information on the treatment of Kalyra as a variable interest entity, please see Note 3 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
On May 19, 2020, our majority-owned subsidiary, Zentera, closed a Series A financing resulting in net proceeds of approximately $18.4 million after deducting offering costs. We have a controlling interest in Zentera and have consolidated the financial results of Zentera into our consolidated financial statements.
Results of Operations
Comparison of Three Months Ended September 30, 2020 to Three Months Ended September 30, 2019
The following table summarizes our results of operations for the periods indicated, together with the changes in those items in dollars:
 Three Months Ended September 30, Change
 2020 2019
 (in thousands)
Operating expenses
Research and development$24,670 $10,739 $13,931 
General and administrative 10,097 1,844 8,253 
Total operating expenses 34,767 12,583 22,184 
Loss from operations (34,767)(12,583)(22,184)
Investment and other income, net 120 12 108 
Net loss before income taxes (34,647)(12,571)(22,076)
Income tax expense 18 17 
Net loss (34,665)(12,572)(22,093)
Net loss attributable to noncontrolling interest (110)(228)118 
Net loss attributable to Zentalis$(34,555)$(12,344)$(22,211)
Revenue
We did not generate any revenue for the three months ended September 30, 2020 and September 30, 2019.
37


Research and Development Expenses
Research and development expenses for the three months ended September 30, 2020 were $24.7 million, compared to $10.7 million for the three months ended September 30, 2019. The increase of $13.9 million was primarily due to increases in external research and development expenses related to our lead product candidates, as we advanced our Phase 1/2 clinical trials for ZN-c5, ZN-c3 and ZN-d5. In addition, in the three months ended September 30, 2020, we conducted additional preclinical studies, incurred additional manufacturing costs, and incurred increased costs for study and lab materials. Unallocated research and development expenses increased by $6.3 million primarily due to $4.5 million of additional employee related costs, of which $2.1 million was driven by non-cash stock-based compensation from incentive grants and increased headcount to support our platform development and $1.4 million of facilities and other allocated overhead expenses.
General and Administrative Expenses
General and administrative expenses for the three months ended September 30, 2020 were $10.1 million, compared to $1.8 million during the three months ended September 30, 2019. This increase of $8.3 million was primarily attributable to an increase of $6.5 million in employee-related costs of which $5.0 million was driven by non-cash stock-based compensation from incentive grants issued during the quarter and increased headcount to support our growth. Professional service fees for legal, accounting and consulting services increased $1.1 million to support the increased operations of the organization, and insurance costs increased by $0.7 million related to operating as a public company.
Investment and Other Income, Net
Investment and other income was $0.1 million for the three months ended September 30, 2020, compared to a nominal amount for the three months ended September 30, 2019. The increase was the result of interest earned on higher invested cash and marketable securities balances.
Comparison of Nine Months Ended September 30, 2020 to Nine Months Ended September 30, 2019
The following table summarizes our results of operations for the periods indicated, together with the changes in those items in dollars:
Nine Months Ended September 30,Change
20202019
(in thousands)
Operating expenses
Research and development$55,380 $26,517 $28,863 
General and administrative23,162 5,423 17,739 
Total operating expenses78,542 31,940 46,602 
Loss from operations(78,542)(31,940)(46,602)
Investment and other income, net368 123 245 
Net loss before income taxes(78,174)(31,817)(46,357)
Income tax expense18 15 
Net loss(78,192)(31,832)(46,360)
Net loss attributable to noncontrolling interest(654)(675)21 
Net loss attributable to Zentalis$(77,538)$(31,157)$(46,381)
Revenue
We did not generate any revenue for the nine months ended September 30, 2020 and September 30, 2019.
38


Research and Development Expenses
Research and development expenses for the nine months ended September 30, 2020 were $55.4 million, compared to $26.5 million for the nine months ended September 30, 2019. The increase of $28.9 million was primarily due to increases in external research and development expenses related to our lead product candidates, as we advanced our Phase 1/2 clinical trials for ZN-c5 and ZN-c3. In addition, in the nine months ended September 30, 2020, we conducted additional preclinical studies, incurred additional manufacturing costs, and incurred increased costs for study and lab materials. Unallocated research and development expenses increased by $12.4 million primarily due to $9.5 million of additional employee related costs, of which $3.8 million was driven by non-cash stock-based compensation from incentive grants and increased headcount to support our platform development and $2.1 million of facilities and other allocated overhead expenses.
General and Administrative Expenses
General and administrative expenses for the nine months ended September 30, 2020 were $23.2 million, compared to $5.4 million during the nine months ended September 30, 2019. This increase of $17.7 million was primarily attributable to an increase of $12.8 million in employee-related costs of which $10.1 million was driven by non-cash stock-based compensation from incentive grants and increased headcount to support our growth. Professional service fees for legal, accounting and consulting services increased $3.6 million to support the increased operations of the organization, insurance costs increased by $1.3 million related to operating as a public company.
Investment and Other Income, Net
Investment and other income was $0.4 million for the nine months ended September 30, 2020, compared to $0.1 million for the nine months ended September 30, 2019. The increase was the result of interest earned on higher invested cash and marketable securities balances.
Liquidity and Capital Resources
Since our inception, our operations have been limited to organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and performing research and development of our product pipeline. We do not have any products approved for commercial sale and have not generated any revenues from product sales and we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our research programs and product candidates. We expect that our research and development and general and administrative costs will increase in connection with conducting additional preclinical studies and clinical trials for our current and future research programs and product candidates, contracting with CMOs to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations.
As a result, we will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all, particularly in light of the economic downturn and ongoing uncertainty related to the COVID-19 pandemic. The COVID-19 pandemic has and could continue to adversely affect the economies and financial markets of the global economy, resulting in an economic downturn that could also affect our operations, our ability to conduct our clinical trials, our ability to raise additional funds through public offerings and the volatility of our stock price and trading in our stock. Even after the COVID-19 pandemic has subsided, we expect we will continue to experience adverse impacts to our business as a result of any economic recession or depression that has occurred or may occur in the future. If we are unable to secure adequate additional funding as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions.
39


Because of the numerous risks and uncertainties associated with developing and commercializing therapeutics, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of equity securities. From inception through September 30, 2020, we raised a total of $162.1 million in gross proceeds from the sale of shares of our Series A, B and C convertible preferred units. On April 7, 2020, we completed our IPO and issued and sold approximately 10.6 million shares of our common stock, including approximately 1.4 million shares in connection with the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $18.00 per share, resulting in net proceeds of approximately $172.4 million, after deducting the underwriting discounts and commissions and estimated offering expenses.
On August 3, 2020, we completed a follow-on offering of our common stock and issued and sold approximately 4.7 million shares of our common stock, including approximately 0.6 million shares in connection with the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $35.00 per share, resulting in net proceeds of approximately $155.2 million, after deducting estimated underwriting discounts and commissions and offering expenses.
As of September 30, 2020, we had $92.6 million in unrestricted cash and cash equivalents, $274.9 million in marketable securities, and an accumulated deficit of $160.5 million. We had no indebtedness as of September 30, 2020.
Cash Flows
The following table summarizes our sources and uses of cash for the period presented:
 Nine Months Ended September 30,
 20202019
 (in thousands)
Net cash used in operating activities$(59,468)$(25,952)
Net cash used in investing activities(275,182)(316)
Net cash provided by financing activities361,033 81,883 
Net increase/(decrease) in cash and cash equivalents$26,383 $55,615 
Operating Activities
We have incurred losses since inception. Net cash used in operating activities for the nine months ended September 30, 2020 was $59.5 million, consisting primarily of our net loss of $78.2 million as we incurred expenses associated with research activities for our lead product candidates and incurred general and administrative expenses, partially offset by changes in operating assets and liabilities of $3.1 million and by non-cash adjustments of $15.6 million.
Net cash used in operating activities for the nine months ended September 30, 2019 was $26.0 million, consisting primarily of our net loss of $31.8 million as we incurred expenses associated with research activities for our lead product candidates and incurred general and administrative expenses, partially offset by changes in operating assets and liabilities of $5.4 million and non-cash adjustments of $0.5 million.
40


Investing Activities
Net cash used in investing activities for the nine months ended September 30, 2020 of $275.2 million was attributable to the net investment of excess cash of $275.1 million and the purchases of property and equipment of $0.1 million.
Net cash used in investing activities for the nine months ended September 30, 2019 was $0.3 million consisting of purchases of property and equipment.
Financing Activities
Net cash provided by financing activities in the nine months ended September 30, 2020 of $361.0 million relates to net proceeds from the completion of our initial public offering of $172.5 million, net proceeds from our follow-on offering of $155.9 million, net proceeds from the issuance of our Series C convertible preferred units of $14.2 million, and contributions from noncontrolling interest owners of $18.4 million.
Net cash provided by financing activities in the nine months ended September 30, 2019 of $81.9 million relates to net proceeds from the issuance of our Series C convertible preferred units.
Funding Requirements
Our operating expenses have increased substantially in 2019 and to date in 2020 and are expected to increase substantially in the future in connection with our ongoing activities.
Specifically, our expenses will increase as we:
advance the clinical development of ZN-c5, ZN-c3 and ZN-e4 for the treatment of oncology indications;
pursue the preclinical and clinical development of other current and future research programs and product candidates, including ZN-d5;
in-license or acquire the rights to other products, product candidates or technologies;
maintain, expand and protect our intellectual property portfolio;
hire additional personnel in research, manufacturing and regulatory and clinical development as well as management personnel;
seek regulatory approval for any product candidates that successfully complete clinical development; and
expand our operational, financial and management systems and increase personnel, including personnel to support our operations as a public company.
We believe that our existing cash, cash equivalents and marketable securities as of September 30, 2020, will enable us to fund our operating expenses and capital expenditure requirements into 2023. We have based these estimates
41


on assumptions that may prove to be imprecise, and we could utilize our available capital resources sooner than we expect.
Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drugs, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including:
the progress, costs and results of our clinical trials for our programs for ZN-c5, ZN-c3 and ZN-e4;
the progress, costs and results of additional research and preclinical studies in ZN-d5 and other research programs we initiate in the future;
the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs we advance them through preclinical and clinical development;
our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements;
the extent to which we in-license or acquire rights to other products, product candidates or technologies; and
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property-related claims.
In addition, the magnitude and duration of the COVID-19 pandemic and its impact on our liquidity and future funding requirements is uncertain as of the filing date of this Quarterly Report on Form 10-Q, as the pandemic continues to evolve globally. We have considered and will continue to consider the availability of relief provided by such legislative actions as the Families First Act and the CARES Act, and have opted to pursue certain, but not all measures including the deferral of employer payroll taxes, but not including Payroll Protection Plan loans. See “Impact of COVID-19 Pandemic” above and “Risk Factors— The outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and we expect will continue to adversely impact our business, including our preclinical studies and clinical trials.” in Part II, Item 1A. of this Quarterly Report on Form 10-Q for a further discussion of the potential impact of the COVID-19 pandemic on our business.
Further, our operating results may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.
Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaboration agreements, other third-party funding, strategic alliances, licensing arrangements and marketing and distribution arrangements.
We currently have no credit facility or committed sources of capital. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or
42


future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.
Contractual Obligations
The disclosure reported in “Contractual Obligations” in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Follow-On Prospectus contains a table summarizing our contractual obligations and commitments as of December 31, 2019. During the nine months ended September 30, 2020, there were no material changes to our principal contractual obligations, other than (1) the exclusion of certain laboratory space from our operating lease obligations as reported in our Follow-On Prospectus, and (2) certain other changes to our operating lease obligations relating to a new lease for approximately 117,929 square feet of office and laboratory space in San Diego, California, as disclosed in Note 10 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Critical Accounting Policies and Use of Estimates
There have been no significant changes to our critical accounting policies from our disclosure reported in “Critical Accounting Policies and Estimates” in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our final prospectus, dated April 2, 2020, filed with the SEC pursuant to Rule 424(b) relating to our registration statement on Form S-1 (Registration No. 333-236959), as amended, filed in connection with our IPO, except as described in Note 2 to the interim unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Emerging Growth Company Status
We are an “emerging growth company,” as defined in the JOBS Act, and we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with those standards. We have elected to take advantage of the extended transition period for complying with new or revised accounting standards; and as a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. The JOBS Act also exempts us from having to provide an auditor attestation of internal control over financial reporting under Sarbanes-Oxley Act Section 404(b).
We will remain an “emerging growth company” until the earliest to occur of: (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our IPO, or December 31, 2025, (b) in which we have total annual gross revenues of $1.07 billion or more, or (c) in which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our outstanding common stock held by non-affiliates exceeds $700 million as of last business day of our most recently completed second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years.
Recent Accounting Pronouncements
A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Off-Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not applicable.
43


Item 4. Controls and Procedures.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2020.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act that occurred during the quarter ended September 30, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

44


PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
We are not subject to any material legal proceedings.
Item 1A. Risk Factors.
You should carefully consider the risks and uncertainties described below and the other information in this Quarterly Report on Form 10-Q, including our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its potential impact on our business and the global economy. Our business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements.” Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below.
Risks Related to Our Financial Position and Need for Additional Capital
We have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.
We are a clinical stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We have no products approved for commercial sale and have not generated any revenue from product sales. To date, we have devoted substantially all of our resources and efforts to organizing and staffing our company, business planning, executing partnerships, raising capital, discovering, identifying and developing potential product candidates, securing related intellectual property rights and conducting preclinical studies and clinical trials of our product candidates, including the ongoing Phase 1/2 clinical trials of ZN-c5, ZN-c3 and ZN-e4. We have not yet demonstrated our ability to successfully complete any clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability than it could be if we had a longer operating history.
In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by clinical stage biopharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with a research focus to a company capable of supporting commercial activities. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer.
45


We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.
We have incurred net losses in each reporting period since our inception, have not generated any revenue from product sales to date and have financed our operations principally through private financings and our initial public offering, or IPO. We have incurred net losses of $46.4 million for the year ended December 31, 2019, and $78.2 million and $31.8 million for the nine months ended September 30, 2020 and September 30, 2019, respectively. As of September 30, 2020, we had an accumulated deficit of $160.5 million. Our losses have resulted principally from expenses incurred in research and development of our product candidates and from management and administrative costs and other expenses that we have incurred while building our business infrastructure. Three of our product candidates, ZN-c5, ZN-c3 and ZN-e4, are in clinical trials, and we intend to initiate a Phase 1 clinical trial of ZN-d5 in patients with AML or B-cell lymphoma in the first half of 2021. In addition, we plan to submit an IND to the FDA for our fifth product candidate in 2021. Our other programs are in preclinical research. As a result, we expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses as we discover, develop and market additional potential products.
We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval and commercialization of our product candidates. The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and our ability to achieve and maintain profitability.
Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives.
Our business depends entirely on the successful discovery, development and commercialization of our product candidates. We currently generate no revenues from sales of any products. We have no products approved for commercial sale and do not anticipate generating any revenue from product sales for the next several years, if ever. Our ability to generate revenue and achieve profitability depends significantly on our ability, or any future collaborator’s ability, to achieve a number of objectives, including:
successful and timely completion of preclinical and clinical development of our product candidates, including ZN-c5, ZN-c3, ZN-d5 and ZN-e4 and any other future product candidates, as well as the associated costs, including any unforeseen costs we have incurred and may continue to incur as a result of preclinical study or clinical trial delays due to the COVID-19 pandemic or other causes;
establishing and maintaining relationships with contract research organizations, or CROs, and clinical sites for the clinical development, both in the United States and internationally, of our product candidates, including ZN-c5, ZN-c3, ZN-d5 and ZN-e4 and any other future product candidates;
timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development;
making any required post-marketing approval commitments to applicable regulatory authorities;
developing an efficient and scalable manufacturing process for our product candidates, including obtaining finished products that are appropriately packaged for sale;
46


establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for product candidates that we develop, if approved;
successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether in-house or with one or more collaborators;
a continued acceptable safety profile following any marketing approval of our product candidates;
commercial acceptance of our product candidates by patients, the medical community and third-party payors;
identifying, assessing and developing new product candidates;
obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;
protecting our rights in our intellectual property portfolio;
defending against third-party interference or infringement claims, if any;
negotiating favorable terms in any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;
obtaining coverage and adequate reimbursement by hospitals, government and third-party payors for product candidates that we develop;
addressing any competing therapies and technological and market developments; and
attracting, hiring and retaining qualified personnel.
We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations.
47


We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.
Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we initiate and conduct clinical trials of, and seek marketing approval for, ZN-c5, ZN-c3, ZN-d5, ZN-e4 and our other product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. In addition, if we obtain marketing approval for any of our product candidates, including ZN-c5, ZN-c3, ZN-d5 and ZN-e4, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. We have also incurred, and expect to continue to incur, additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations.
As of September 30, 2020, we had cash, cash equivalents and marketable securities of $367.4 million. Based on current business plans, we believe that our existing cash, cash equivalents and marketable securities as of September 30, 2020 will be sufficient to fund our operating expenses and capital expenditures requirements into 2023, but will not be sufficient to fund all of the activities that are necessary to complete the development of our product candidates. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.
We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. Market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact our ability to access capital as and when needed. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts.
Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
We are substantially dependent on the success of our lead product candidate, ZN-c5, which is currently in clinical trials. If we are unable to complete development of, obtain approval for and commercialize ZN-c5 in a timely manner, our business will be harmed.
Our future success is dependent on our ability to timely complete clinical trials, obtain marketing approval for and successfully commercialize ZN-c5, our lead product candidate. We are investing significant efforts and financial resources in the research and development of ZN-c5. We are conducting a Phase 1/2 trial of ZN-c5 as monotherapy and in combination with palbociclib, a CDK4/6 inhibitor, in patients with ER+/HER2- advanced or metastatic breast cancer. ZN-c5 will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval from government regulators, substantial investment and significant marketing efforts before we can generate any revenues from product sales. We are not permitted to market or promote ZN-c5, or any other product candidate, before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.
48


The success of ZN-c5 will depend on several factors, including the following:
the successful and timely completion of our ongoing clinical trials of ZN-c5;
the initiation and successful patient enrollment and completion of additional clinical trials of ZN-c5 on a timely basis;
maintaining and establishing relationships with CROs and clinical sites for the clinical development of ZN-c5 both in the United States and internationally;
the frequency and severity of adverse events in the clinical trials;
the efficacy, safety and tolerability profiles that are satisfactory to the FDA, EMA or any comparable foreign regulatory authority for marketing approval;
the timely receipt of marketing approvals for ZN-c5 from applicable regulatory authorities;
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development of ZN-c5;
the maintenance of existing, or the establishment of new, scaled production arrangements with third-party manufacturers to obtain finished products that are appropriate for commercial sale of ZN-c5 if approved, including for supplies of drugs that we are testing in combination with ZN-c5;
obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;
the protection of our rights in our intellectual property portfolio;
the successful launch of commercial sales following any marketing approval;
a continued acceptable safety profile following any marketing approval;
commercial acceptance by patients, the medical community and third-party payors; and
our ability to compete with other therapies.
We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize ZN-c5, which would materially harm our business. If we do not receive marketing approvals for ZN-c5, we may not be able to continue our operations.
There is currently no FDA-approved oral SERD, and our development of ZN-c5 may never lead to a marketable product.
We are developing ZN-c5 as an oral SERD. There is currently no FDA-approved oral SERD. We have not received regulatory approval for ZN-c5 and cannot be certain that our approach will lead to the development of an approvable or marketable product, alone or in combination with other therapies. We may not succeed in demonstrating safety
49


and efficacy of ZN-c5 in our ongoing Phase 1/2 clinical trial or in larger-scale clinical trials. Advancing ZN-c5 as an oral SERD creates significant challenges for us, including:
obtaining marketing approval, as the FDA, EMA or other regulatory authorities have never approved an orally available SERD;
if ZN-c5 is approved, educating medical personnel regarding the potential efficacy and safety benefits, as well as the challenges, of incorporating our ZN-c5 into existing treatment regimens, including in combination with other treatments for breast cancer; and
establishing the sales and marketing capabilities upon obtaining any marketing approvals to gain market acceptance.
Our long-term prospects depend in part upon discovering, developing and commercializing additional product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.
Our future operating results are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize product candidates beyond those we currently have in clinical development. A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical testing or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate.
The success of other product candidates we may develop will depend on many factors, including the following:
generating sufficient data to support the initiation or continuation of clinical trials;
obtaining regulatory permission to initiate clinical trials;
contracting with the necessary parties to conduct clinical trials;
successful enrollment of patients in, and the completion of, clinical trials on a timely basis;
the timely manufacture of sufficient quantities of the product candidate for use in clinical trials; and
adverse events in the clinical trials.
Even if we successfully advance any other product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this “Risk Factors” section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our other product candidates.
50


The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.
We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities impose similar requirements. The time required to obtain approval by the FDA, EMA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA, EMA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.
Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, a U.S. federal government shutdown or budget sequestration, such as ones that occurred during 2013, 2018 and 2019, may result in significant reductions to the FDA’s budget, employees and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates.
Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following:
the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;
the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;
the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;
the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, or other submission or to obtain regulatory approval in the United States or elsewhere;
we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that a product candidate’s risk-benefit ratio for its proposed indication is acceptable;
the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and
51


the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.
This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects.
In addition, even if we obtain approval of our product candidates, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS. Regulatory authorities may not approve the price we intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could seriously harm our business.
The clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities or otherwise produce positive results.
Before obtaining marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.
In addition, we may rely in part on preclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing these third parties’ services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed, and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase.
We do not know whether our future clinical trials will begin on time or enroll patients on time, or whether our ongoing and/or future clinical trials will be completed on schedule or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:
the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;
obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design;
any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
obtaining approval from one or more institutional review boards, or IRBs;
52


IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;
changes to clinical trial protocol;
clinical sites deviating from trial protocol or dropping out of a trial;
manufacturing sufficient quantities of product candidate or obtaining sufficient quantities of combination therapies for use in clinical trials;
subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post- treatment follow-up;
subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;
lack of adequate funding to continue the clinical trial;
subjects experiencing severe or unexpected drug-related adverse effects;
occurrence of serious adverse events in trials of the same class of agents conducted by other companies;
selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;
a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;
any changes to our manufacturing process that may be necessary or desired;
third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements;
third-party contractors not performing data collection or analysis in a timely or accurate manner; or
third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.
53


In addition, disruptions caused by the COVID-19 pandemic have caused and we expect will continue to cause difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.
Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.
Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.
If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.
In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.
54


The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.
Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for their intended uses. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical studies and early-stage clinical trials does not mean that future clinical trials will be successful. We do not know whether ZN-c5, ZN-c3, ZN-d5 and ZN-e4 will perform in current or future clinical trials as ZN-c5, ZN-c3, ZN-d5 and ZN-e4 have performed in preclinical studies, or, with respect to ZN-c5, ZN-c3 and ZN-e4, ongoing clinical trials to date. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, EMA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials.
In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidate. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.
We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could seriously harm our business.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA, EMA or comparable foreign regulatory authority approval. We cannot guarantee that the FDA or foreign regulatory authorities will interpret trial results as we do, and more trials could be required before we are able to submit applications seeking approval of our product candidates. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential. Furthermore, the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA, EMA or comparable foreign regulatory authorities delaying, limiting or denying approval of our product candidates.
55


Interim, initial, “topline”, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.
From time to time, we may also disclose interim data from our preclinical studies and clinical trials. For example, we have reported interim data from our ongoing Phase 1/2 clinical trials of ZN-c5, ZN-c3 and ZN-e4, as of June 30, 2020, June 19, 2020 and February 5, 2020, respectively. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.
Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.
If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.
Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including:
the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;
the timing of market introduction of the product candidate as well as competitive products;
the clinical indications for which the product candidate is approved;
restrictions on the use of our product candidates, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required of alternative treatments and competitor products;
the potential and perceived advantages of product candidates over alternative treatments;
56


the cost of treatment in relation to alternative treatments;
the availability of coverage and adequate reimbursement, as well as pricing, by third-party payors, including government authorities;
the availability of the approved product candidate for use as a combination therapy;
relative convenience and ease of administration;
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
the effectiveness of sales and marketing efforts;
unfavorable publicity relating to our products or product candidates or similar approved products or product candidates in development by third parties; and
the approval of other new therapies for the same indications.
If any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted.
If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial’s conclusion as required by the FDA, EMA or other comparable foreign regulatory authorities. Additionally, certain clinical trials for future product candidates may be focused on indications with relatively small patient populations, which may further limit enrollment of eligible patients or may result in slower enrollment than we anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants.
Patient enrollment may also be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors’ product candidates. Patient enrollment for any of our clinical trials may be affected by other factors, including:
size and nature of the patient population;
severity of the disease under investigation;
availability and efficacy of approved drugs for the disease under investigation;
patient eligibility criteria for the trial in question as defined in the protocol;
perceived risks and benefits of the product candidate under study;
clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;
57


efforts to facilitate timely enrollment in clinical trials;
patient referral practices of physicians;
the ability to monitor patients adequately during and after treatment;
proximity and availability of clinical trial sites for prospective patients;
continued enrollment of prospective patients by clinical trial sites; and
the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials.
Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.
We intend to develop ZN-c5, ZN-c3, ZN-d5, ZN-e4 and potentially other product candidates in combination with other therapies, which exposes us to additional risks.
We intend to develop ZN-c5, ZN-c3, ZN-d5, ZN-e4 and likely other future product candidates in combination with one or more other approved or unapproved therapies to treat cancer or other diseases. For example, we are currently evaluating ZN-c5 in combination with certain approved agents, including palbociclib and abemaciclib.
Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or comparable foreign regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA, EMA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.
We also may choose to evaluate ZN-c5, ZN-c3, ZN-d5, ZN-e4 or any other future product candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA, EMA or comparable foreign regulatory authorities. We will not be able to market and sell ZN-c5, ZN-c3, ZN-d5, ZN-e4 or any product candidate we develop in combination with an unapproved cancer therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved cancer therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.
If the FDA, EMA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy.
If the market opportunity for any product candidate that we or our strategic partners develop is smaller than we believe, our revenue may be adversely affected and our business may suffer.
We intend to initially focus our product candidate development on treatments for various oncology indications. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based
58


on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business.
We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.
The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In addition, our products may need to compete with off-label drugs used by physicians to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our products.
In particular, there is intense competition in the fields of oncology we are pursuing. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new product candidates.
We have chosen to initially address well-validated biochemical targets, and therefore expect to face competition from existing products and products in development for each of our product candidates. There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Many of these current and potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA, EMA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before we do.
59


Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.
Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue.
60


Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.
Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA, EMA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA, EMA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management’s time and our resources and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics that we or our collaborators may develop.
Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.
There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare & Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS’s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor’s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
61


Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.
Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.
If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
Risks Related to Regulatory Approval and Other Legal Compliance Matters
We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize our product candidates.
Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. We cannot provide any assurance that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them.
62


We have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory authority. The time required to obtain approvals from the FDA and other regulatory authorities is unpredictable, and requires successful completion of extensive clinical trials which typically takes many years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can and often changes during drug development, which makes it difficult to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in FDA policy during the period of drug development, clinical trials and FDA regulatory review.
Any delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we developing and seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as part of approving a NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors.
We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval.
Our current or future product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.
As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our product candidates’ use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.
If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly.
63


Patients in our ongoing and planned clinical trials may in the future suffer significant adverse events or other side effects not observed in our preclinical studies or previous clinical trials. Some of our product candidates, may be used as chronic therapies or be used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if our product candidates are used in combination with other therapies, our product candidates may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate, but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients’ illnesses.
If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, EMA, other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects.
Further, if any of our product candidates obtains marketing approval, toxicities associated with such product candidates and not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage clinical trials.
The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
We may choose to conduct international clinical trials in the future. The acceptance of study data by the FDA, EMA or other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (1) the data are applicable to the United States population and United States medical practice; (2) the trials are performed by clinical investigators of recognized competence and pursuant to current GCP requirements; and (3) the FDA is able to validate the data through an on-site inspection or other appropriate mean. Additionally, the FDA’s clinical trial requirements, including the adequacy of the patient population studied and statistical powering, must be met. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of its applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction.
64


Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.
Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.
Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.
Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA, EMA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:
delays in or the rejection of product approvals;
restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;
restrictions on the products, manufacturers or manufacturing process;
warning or untitled letters;
civil and criminal penalties;
65


injunctions;
suspension or withdrawal of regulatory approvals;
product seizures, detentions or import bans;
voluntary or mandatory product recalls and publicity requirements;
total or partial suspension of production; and
imposition of restrictions on operations, including costly new manufacturing requirements.
The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.
The FDA’s and other regulatory authorities’ policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.
We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, the current U.S. administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA’s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.
The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.
66


If we are required by the FDA to obtain approval of a companion diagnostic test in connection with approval of any of our product candidates, and we do not obtain or face delays in obtaining FDA approval of a diagnostic device, we will not be able to commercialize such product candidate and our ability to generate revenue will be materially impaired.
If safe and effective use of any of our product candidates depends on an in vitro diagnostic that is not otherwise commercially available, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates if at all. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared for that indication. If a satisfactory companion diagnostic is not commercially available, we may be required to create or obtain one that would be subject to regulatory approval requirements. The process of obtaining or creating such diagnostic is time consuming and costly.
Companion diagnostics are developed in conjunction with clinical programs for the associated product and are subject to regulation as medical devices by the FDA and comparable regulatory authorities, and, to date, the FDA has required premarket approval of all companion diagnostics for cancer therapies. The approval of a companion diagnostic as part of the therapeutic product’s labeling limits the use of the therapeutic product to only those patients who express the specific genetic alteration that the companion diagnostic was developed to detect.
If the FDA, EMA or a comparable regulatory authority requires approval of a companion diagnostic for any of our product candidates, whether before or after it obtains marketing approval, we, and/or future collaborators, may encounter difficulties in developing and obtaining approval for such product candidate. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval or continued marketing of such product candidate.
We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial partners or negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our product candidate, if approved, on a timely or profitable basis, if at all.
Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the Securities and Exchange Commission, or the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
67


Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.
We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.
We may in the future seek an accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verity and describe the drug’s clinical benefit. If such post-approval studies fail to confirm the drug’s clinical benefit, the FDA may withdraw its approval of the drug.
Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other
68


form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.
We may face difficulties from changes to current regulations and future legislation.
Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.
For example, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was passed, which substantially changes the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have passed. On December 22, 2017, President Trump signed into law federal tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act, which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. In addition, the 2020 federal spending package permanently eliminates, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare Part D drug plans. In December 2018, CMS published a new final rule permitting further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Act. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March 2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review the case, although it is unclear when a decision will be made or how the Supreme Court will rule. In addition, there may be other efforts to challenge, repeal or replace the ACA. We are continuing to monitor any changes to the ACA that, in turn, may potentially impact our business in the future.
In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2030 unless additional congressional action is taken, with the exception of a temporary suspension from May 1, 2020 through December 31, 2020 implemented under the Coronavirus Aid, Relief, and Economic Security Act, which was signed into law on March 27, 2020. In addition, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations.
69


Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, at the federal level, the Trump administration released a “Blueprint” to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. On March 10, 2020, the Trump administration sent “principles” for drug pricing to Congress, calling for legislation that would among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Additionally, the Trump administration’s budget proposal for the fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. Although a number of these and other measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
Further, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Beilina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new product candidates that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its products available to eligible patients as a result of the Right to Try Act.
We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.
70


Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.
Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:
the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal
healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;
the federal false claims and civil monetary penalties laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians, as defined by such law, certain other healthcare providers starting in 2022 and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information reported is publicly available on a searchable website, with disclosure required annually; and
71


analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.
Some state laws require biotechnology companies to comply with the biotechnology industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Some state laws require biotechnology companies to report information on the pricing of certain drug products.
State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For instance, the collection and use of health data in the European Union is governed by the General Data Protection Regulation, or the GDPR, which extends the geographical scope of European Union data protection law to non-European Union entities under certain conditions, tightens existing European Union data protection principles, creates new obligations for companies and new rights for individuals. Failure to comply with the GDPR may result in substantial fines and other administrative penalties. The GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may be onerous and if our efforts to comply with GDPR or other applicable European Union laws and regulations are not successful, it could adversely affect our business in the European Union. Moreover, the United Kingdom leaving the EU could also lead to further legislative and regulatory changes. It remains unclear how the United Kingdom data protection laws or regulations will develop in the medium to longer term and how data transfer to the United Kingdom from the EU will be regulated, especially following the United Kingdom’s departure from the EU on January 31, 2020 without a deal. However, the United Kingdom has transposed the GDPR into domestic law with the Data Protection Act 2018, which remains in force following the United Kingdom’s departure from the EU. In addition, on June 28, 2018, the State of California enacted the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and in other states.
Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.
72


Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.
Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials.
In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.
73


Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.
Certain laws and regulations require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive.
Our business activities may be subject to the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.
If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, prospects, operating results and financial condition.
In addition, our products and activities may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell access to our products would likely adversely affect our business.
74


Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business
The outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and we expect will continue to adversely impact our business, including our preclinical studies and clinical trials.
In December 2019, a novel strain of the coronavirus disease, COVID-19, was identified in Wuhan, China. This virus continues to spread globally, including within the United States, and, in March 2020, the World Health Organization declared COVID-19 a pandemic. The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the spread of COVID-19, we have closed our executive offices with our administrative employees continuing their work outside of our offices and limited the number of staff in any given research and development laboratory. As a result of the COVID-19 pandemic, we have experienced and we expect to continue to experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:
continued delays or difficulties in enrolling patients in our clinical trials;
continued delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;
delays in receiving authorizations from regulatory authorities to initiate our planned clinical trials;
diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;
risk that participants enrolled in our clinical trials will contract COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;
risk that we are unable to enroll participants in our clinical trials in adequate numbers;
interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;
interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;
interruptions in preclinical studies due to restricted or limited operations at our laboratory facility;
delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;
75


changes in local regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;
limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;
interruption or delays to our sourced discovery and clinical activities; and
refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.
The COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.
Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.
To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts.
Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.
If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.
We currently do not have and have never had a marketing or sales team. In order to commercialize any product candidates, if approved, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks.
Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our
76


behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.
We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.
We have never commercialized a product candidate, and we currently have no sales force, marketing or distribution capabilities. To achieve commercial success for the product candidates, which we may license to others, we will rely on the assistance and guidance of those collaborators. For product candidates for which we retain commercialization rights, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party.
Factors that may affect our ability to commercialize our product candidates on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our product candidates and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may not generate revenues from them or be able to reach or sustain profitability.
In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.
As of September 30, 2020, we had 110 full-time employees, including 72 employees engaged in research and development. In order to successfully implement our development and commercialization plans and strategies, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:
identifying, recruiting, integrating, maintaining and motivating additional employees;
managing our internal development efforts effectively, including the clinical, FDA, EMA and other comparable foreign regulatory agencies’ review process for ZN-c5, ZN-c3, ZN-d5 and ZN-e4 and any other future product candidates, while complying with any contractual obligations to contractors and other third parties we may have; and
improving our operational, financial and management controls, reporting systems and procedures.
Our future financial performance and our ability to successfully develop and, if approved, commercialize, ZN-c5, ZN-c3, ZN-d5 and ZN-e4 and any other future product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. Furthermore, certain of our employees, including members of our management team, perform services on behalf of Kalyra Pharmaceuticals, Inc., a corporation that is 25% owned by us, pursuant to intercompany service agreements. As a result, such individuals do not allocate all of their time and resources to us and our other subsidiaries which,
77


coupled with the need to manage growth activities, could further limit their ability to devote a sufficient amount of attention to day-to-day activities of our business.
We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of ZN-c5, ZN-c3, ZN-d5 and ZN-e4 and any other future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.
If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize ZN-c5, ZN-c3, ZN-d5 and ZN-e4 and any other future product candidates and, accordingly, may not achieve our research, development and commercialization goals.
Our internal computer systems, or those of any of our CROs, manufacturers, other contractors, consultants, collaborators or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.
Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants, collaborators and third-party service providers, are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as HIPAA, Health Information Technology for Economic and Clinical Health Act and GDPR), it could result in a material disruption of our drug discovery and development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws.
Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention.
78


EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states.
We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the European Union, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures.
Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.
Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician’s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.
In addition, in most foreign countries, including the European Economic Area, or EEA, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected.
A portion of our manufacturing of our lead product candidates takes place in China through third-party manufacturers. A significant disruption in the operation of those manufacturers, a trade war or political unrest in China could materially adversely affect our business, financial condition and results of operations.
We currently contract manufacturing operations to third parties, and clinical quantities of our lead product candidates are manufactured by these third parties outside the United States, including in China, and we expect to continue to use such third-party manufacturers for such product candidates. Any disruption in production or inability of our manufacturers in China to produce adequate quantities to meet our needs, whether as a result of a natural disaster or other causes, could impair our ability to operate our business on a day-to-day basis and to continue our
79


development of our product candidates. Furthermore, since these manufacturers are located in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to tariffs on the chemical intermediates we use that are manufactured in China. Any of these matters could materially and adversely affect our business and results of operations. Any recall of the manufacturing lots or similar action regarding our product candidates used in clinical trials could delay the trials or detract from the integrity of the trial data and its potential use in future regulatory filings. In addition, manufacturing interruptions or failure to comply with regulatory requirements by any of these manufacturers could significantly delay clinical development of potential products and reduce third-party or clinical researcher interest and support of proposed trials. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in China. Future appreciation of the local currency could increase our costs. In addition, our labor costs could continue to rise as wage rates increase due to increased demand for skilled laborers and the availability of skilled labor declines in China.
Our operations are vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity and other events beyond our control, which could harm our business.
Our facility is located in a region which experiences severe weather from time to time. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major tornado, flood, fire, earthquake, power loss, terrorist activity or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.
Our ability to utilize our net operating loss carryforwards and certain other tax attributes of our corporate subsidiaries may be limited.
The net operating loss, or NOL, carryforwards of the Company and our corporate subsidiaries could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law. Under the Tax Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, signed into law on March 27, 2020, NOLs arising in tax years beginning after December 31, 2017, and before January 1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss, and NOLs arising in tax years beginning after December 31, 2020 may not be carried back. Moreover, under the Tax Act as modified by the CARES Act, federal NOLs of the Company and our corporate subsidiaries generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax years beginning after December 31, 2020 may be limited. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. In addition, a “Separate Return Limitation Year” (“SRLY”) generally encompasses all separate return years of a member (or predecessor in a transaction pursuant to Section 381 of the Internal Revenue Code of 1986, as amended, or the Code, or certain other transactions), including tax years in which it joins a consolidated return of another group. According to Treasury Regulation Section 1.1502-21, NOLs of a member that arises in a SRLY may be applied against consolidated taxable income only to the extent of the loss member’s cumulative contribution to the consolidated taxable income. As a result, this SRLY limitation may also increase the tax liability to the Company (by reducing the carryforward of certain NOLs that otherwise might be used to offset the amount of taxable gain), potentially decreasing the value of our common stock. As of December 31, 2019, our corporate subsidiaries had available NOL carryforwards of approximately $89.2 million for federal income tax purposes, of which $68.2 million were generated in and after 2018 and can be carried forward indefinitely. The remaining federal NOLs of $21.0 million, which were generated prior to 2018, will start to expire in 2033 if not utilized. We do not anticipate carrying back any NOLs of our corporate subsidiaries.
80


In addition, under Sections 382 and 383 of the Code, if a corporation undergoes an “ownership change” (generally defined as a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period), the corporation’s ability to use its pre-change NOLs and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine annual limitations, if any, that could result from such changes in the ownership. Our ability to utilize those NOLs could be limited by an “ownership change” as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations.
A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.
We plan to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:
differing regulatory requirements and reimbursement regimes in foreign countries;
unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
economic weakness, including inflation, or political instability in particular foreign economies and markets;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
foreign taxes, including withholding of payroll taxes;
foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;
difficulties staffing and managing foreign operations;
workforce uncertainty in countries where labor unrest is more common than in the United States;
potential liability under the FCPA or comparable foreign regulations;
challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
business interruptions resulting from geo-political actions, including war and terrorism.
These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.
81


Risks Related to Our Intellectual Property
Our success depends on our ability to protect our in-licensed intellectual property and our proprietary technologies.
Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our and our licensors’ ability to operate without infringing the proprietary rights of others. If we or our licensors are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We and our licensors generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our in-licensed patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our in-licensed patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around, invalidated or rendered unenforceable by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our and our licensors’ proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our or our licensors’ rights or permit us or our licensors to gain or keep any competitive advantage. These uncertainties and/or limitations in our and our licensors’ ability to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.
Although we license issued patents in the United States and foreign countries, we cannot be certain that the claims in our other in-licensed U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our in-licensed issued patents will not be found invalid or unenforceable if challenged.
The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our licensors or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:
the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
patent applications may not result in any patents being issued;
patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;
our competitors, many of whom have substantially greater resources than we or our licensors do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates;
there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and
82


countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.
The patent prosecution process is also expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our licensors may not identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license, including those from our licensors and from third parties. We also may require the cooperation of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.
In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, licensors, and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.
If we fail to comply with our obligations in the agreements under which we license intellectual property rights from our licensors and third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
We are a party to a number of license agreements under which we are granted rights to intellectual property that are important to our business and we may enter into additional license agreements in the future. For example, in September 2019, we entered into an exclusive license agreement with Recurium IP Holdings, LLC, or Recurium IP, to obtain an exclusive license to certain intellectual property rights to develop and commercialize ZN-e5, ZN-c3 and ZN-c4.
This and our other existing license agreements impose on us, and we expect that any future license agreements where we in-license intellectual property will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensors may have the right to terminate the licenses, in which event we would not be able to market products covered by the licenses.
83


We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:
the scope of rights granted under the license agreement and other interpretation-related issues;
whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;
our right to sublicense patents and other rights to third parties;
our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;
our right to transfer or assign the license; and
the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and its affiliates and sublicensees and by us and our partners and sublicensees.
If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.
In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, if we choose to sublicense or assign to any third parties our rights under our existing license agreement with Recurium with respect to any licensed product, we may be required to pay to Recurium a specified percentage of all revenue to be received in connection with such transaction.
If the scope of any patent protection our licensors obtain is not sufficiently broad, or if our licensors lose any of the patent protection we license, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.
The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the existence, issuance, scope, validity, enforceability and commercial value of our in-licensed patent rights are highly uncertain. Our pending and future in-licensed patent applications may not result in patents being issued that protect our product candidates or that effectively prevent others from commercializing competitive product candidates.
Moreover, the scope of claims in a patent application can be significantly reduced before any claims in a patent is issued, and claim scope can be reinterpreted after issuance. Even if patent applications we license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage.
84


Any patents that we license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner, which could materially adversely affect our business, financial condition, results of operations and prospects.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our licensed-in patents may not cover our product candidates or may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity of our in-licensed patents, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensors and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our in-licensed patents and patent applications or those of our licensors has been found. There is also no assurance that there is not prior art of which we or licensors are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or those of our licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our in-licensed patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Such loss of in-licensed patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.
The patent protection and patent prosecution for some of our product candidates may be dependent on our licensors and third parties.
We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our in-licensed patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our in-licensed patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.
As a licensee of third parties, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are
85


not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.
In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to us assuming control over patent prosecution.
Our technology acquired or licensed from various third parties, including our licensors, may be subject to retained rights. Our licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for use in fields other than the fields licensed to us or for use in noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.
If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our product candidate.
Some of our intellectual property has been discovered through government-funded programs and thus may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.
Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as “march-in rights”). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.
86


Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:
others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license;
we or our licensors might not have been the first to make the inventions covered by the issued patents or patent application that we own or license;
we or our licensors might not have been the first to file patent applications covering certain of our inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
it is possible that our licensors’ pending patent applications will not lead to issued patents;
issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;
our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
we may not develop additional proprietary technologies that are patentable; and
the patents of others may have an adverse effect on our business.
Should any of these events occur, it could significantly harm our business, results of operations and prospects.
Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.
Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.
87


As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:
result in costly litigation that may cause negative publicity;
divert the time and attention of our technical personnel and management;
cause development delays;
prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or unenforceable or not infringed in a court of law;
require us to develop non-infringing technology, which may not be possible on a cost-effective basis;
subject us to significant liability to third parties; or
require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.
Although no third party has asserted a claim of patent infringement against us as of the date of this Quarterly Report on Form 10-Q, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results.
Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.
88


We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. Further, our in-licensed issued patents could be found invalid or unenforceable if challenged in court.
Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we and/or our licensors may be required to file infringement claims, which can be expensive and time-consuming. Further, our licensors may need to file infringement claims, and our licensors may elect not file such claims. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our licensors or potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty or written description, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent intentionally withheld material information from the USPTO or made a misleading statement during prosecution.
If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business.
Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.
Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.
During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.
89


Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.
Derivation or interference proceedings provoked by third parties or brought by us or our licensors, or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our or our licensors’ patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our or our licensors’ defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.
Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.
In September 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a “first inventor to file” system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (1) file any patent application related to our product candidates or (2) invent any of the inventions claimed in our patents or patent applications.
The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.
Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or licensors’ patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.
90


Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.
For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our or our licensors’ ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensors’ ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.
We or our licensors may be subject to claims challenging the inventorship or ownership of our or our in-licensed patents and other intellectual property.
We may also be subject to claims that former employees or other third parties have an ownership interest in our in-licensed patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we or our licensors are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.
Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the term of a patent, and the protection it affords, is limited. Even if patents directed to our product candidates are obtained, once the patent term has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents directed to our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.
91


If we or our licensors do not obtain patent term extension for our product candidates, our business may be materially harmed.
Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch- Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we or our licensors may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we or our licensors are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.
We may not be able to protect our intellectual property rights throughout the world.
Although we have in-licensed issued patents and pending patent applications in the United States and certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our in-licensed inventions in all countries outside the United States or from selling or importing products made using our in-licensed inventions in and into the United States or other jurisdictions. Competitors may use our in-licensed technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our or our licensors patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our or our licensors’ patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our or our licensors’ patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our licensors’ patents at risk of being invalidated or interpreted narrowly and our or our licensors’ patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our licensors’ efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.
92


Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants, licensors and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.
Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we or our licensors do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.
We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.
As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.
93


Risks Related to Our Dependence on Third Parties
We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.
We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.
Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely.
Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.
The COVID-19 pandemic and government measures taken in response have also had a significant impact on our CROs, and we expect that they will face further disruption which may affect our ability to initiate and complete our preclinical studies and clinical trials.
94


If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.
We contract with third parties for the manufacture of our product candidates for preclinical studies and our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have long-term supply agreements. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. For example, the extent to which the COVID-19 pandemic impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain COVID-19 or treat its effects.
We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:
the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;
the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;
the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;
the breach by the third-party contractors of our agreements with them;
the failure of third-party contractors to comply with applicable regulatory requirements;
the failure of the third party to manufacture our product candidates according to our specifications;
the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;
95


clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and
the misappropriation of our proprietary information, including our trade secrets and know-how.
We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.
Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.
The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.
Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.
96



If we decide to establish collaborations in the future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.
Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may continue to seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.
We would face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.
In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators.
If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.
We have and in the future may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.
We have and may in the future seek third-party collaborators for the development and commercialization of one or more of our product candidates. Our likely collaborators for any future collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies.

We may have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators’ abilities and efforts to successfully perform the functions assigned to
97


them in these arrangements. Collaborations involving our product candidates could pose numerous risks to us, including the following:
collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected;
collaborators may deemphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators’ strategic focus, including as a result of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products;
collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings;
disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;
collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all; and
if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our drug development or commercialization program could be delayed, diminished or terminated.
98


Risks Related to Ownership of Our Common Stock

Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.
We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:
variations in the level of expense related to the ongoing development of our product candidates or future development programs;
results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future partners;
our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements;
any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved;
additions and departures of key personnel;
strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;
if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates;
regulatory developments affecting our product candidates or those of our competitors; and
changes in general market and economic conditions.
If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.
Current beneficial owners of 5% or more of our common stock and management own a significant percentage of our stock and are able to exert significant influence over matters subject to stockholder approval.
As of September 30, 2020, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially own approximately 59.8% of our outstanding common stock. As a result, these stockholders will be able to significantly influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.
99


Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Outstanding shares of our common stock may be freely sold in the public market at any time to the extent permitted by Rules 144 and 701 under the Securities Act, or to the extent that such shares have already been registered under the Securities Act and are held by non-affiliates of ours. Moreover, holders of a substantial number of shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also have registered all shares of common stock that we may issue under our equity compensation plans or that are issuable upon exercise of outstanding options. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.
Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.
We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. For example, in August 2020, we completed an underwritten public offering of our common stock. To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.
We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.
We are an “emerging growth company,” as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including:
being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;
not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;
not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;
reduced disclosure obligations regarding executive compensation; and
exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.
100


We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our IPO, or December 31, 2025, (b) in which we have total annual gross revenues of $1.07 billion or more, or (c) in which we are deemed to be a large accelerated filer under the rules of the SEC, which means the market value of our outstanding common stock held by non-affiliates exceeds $700 million as of last business day of our most recently completed second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years.
Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.
Even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company” if the market value of our voting and non-voting common shares held by non-affiliates is less than $250 million (or less than $700 million if our annual revenues during the most recently completed fiscal year are less than $100 million) as measured on the last business day of our second fiscal quarter. Similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations, such as an exemption from providing selected financial data and an ability to provide simplified executive compensation information and only two years of audited financial statements.
Provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.

Our certificate of incorporation and bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:
establish a classified board of directors so that not all members of our board are elected at one time;
permit only the board of directors to establish the number of directors and fill vacancies on the board;
provide that directors may only be removed “for cause” and only with the approval of two-thirds of our stockholders;
authorize the issuance of “blank check” preferred stock that our board could use to implement a stockholder rights plan (also known as a “poison pill”);
eliminate the ability of our stockholders to call special meetings of stockholders;
prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;
prohibit cumulative voting;
authorize our board of directors to amend the bylaws;
101


establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and
require a super-majority vote of stockholders to amend some provisions described above.
In addition, Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.
Any provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.
Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for:
any derivative action or proceeding brought on our behalf;
any action asserting a claim of breach of fiduciary duty;
any action asserting a claim against us arising under the DGCL, our certificate of incorporation or our bylaws; and
any action asserting a claim against us that is governed by the internal-affairs doctrine.
This exclusive-forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. If a court were to find this exclusive-forum provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. Nothing in our certificate of incorporation precludes stockholders that assert claims under the Securities Act or the Exchange Act from bringing such claims in state or federal court, subject to applicable law.
General Risk Factors

If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.

From time to time, we may evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:
increased operating expenses and cash requirements;
the assumption of additional indebtedness or contingent liabilities;
the issuance of our equity securities;
102


assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;
the diversion of our management’s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition;
retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;
risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and
our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.
The price of our stock may be volatile, and you could lose all or part of your investment.

The trading price of our common stock is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.
Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In addition to the factors discussed in this “Risk Factors” section, these factors include:
the timing and results of preclinical studies and clinical trials of our product candidates or those of our competitors;
the success of competitive products or announcements by potential competitors of their product development efforts;
regulatory actions with respect to our products or our competitors’ products;
actual or anticipated changes in our growth rate relative to our competitors;
regulatory or legal developments in the United States and other countries;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel;
announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
103


fluctuations in the valuation of companies perceived by investors to be comparable to us;
market conditions in the pharmaceutical and biotechnology sector;
changes in the structure of healthcare payment systems;
share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
announcement or expectation of additional financing efforts;
sales of our common stock by us, our insiders or our other stockholders;
expiration of market stand-off or lock-up agreements; and
general economic, industry and market conditions.
In addition, the trading prices for common stock of other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. The COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. The realization of any of the above risks or any of a broad range of other risks, including those described in this “Risk Factors” section, could have a dramatic and adverse impact on the market price of our common stock.
If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.

The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.
The requirements of being a public company may strain our resources, result in more litigation and divert management’s attention.

As a public company, we are and will continue to be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of Nasdaq and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control over financial reporting on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management’s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses.
In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in
104


many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We have invested and intend to continue to invest in resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.
These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers. By disclosing information in in filings required of us as a public company, our business and financial condition will continue to become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management’s resources and seriously harm our business.
If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.

Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.
We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. We could be an emerging growth company for up to five years from the date of our IPO. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.
We may be subject to securities litigation, which is expensive and could divert management attention.
The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.
We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock.

We have never declared or paid any cash dividends on our equity securities. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring
105


or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our common stock, which is not certain
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Use of Proceeds
On April 7, 2020, we completed our IPO and issued and sold 10,557,000 shares of our common stock (including 1,377,000 shares of our common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a price to the public of $18.00 per share.
As of September 30, 2020, net proceeds of approximately $172.4 million from our initial public offering have been invested in investment grade, interest-bearing instruments. There has been no material change in the expected use of the net proceeds from our initial public offering as described in our final prospectus, dated April 2, 2020, filed with the SEC pursuant to Rule 424(b) relating to our registration statement on Form S-1 (Registration No. 333-236959), as amended, filed in connection with our IPO.
Item 3. Defaults Upon Senior Securities.
Not applicable.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.

Exhibit
Number
DescriptionIncorporated by Reference
FormFile No.ExhibitFiling
Date
Filed/Furnished Herewith
2.110-Q001-392632.105/15/2020
2.210-Q001-392632.205/15/2020
3.1S-8333-2375934.104/07/2020
3.2S-8333-2375934.204/07/2020
10.1S-1/A333-24011510.2307/28/2020
106



Exhibit
Number
DescriptionIncorporated by Reference
FormFile No.ExhibitFiling
Date
Filed/Furnished Herewith
10.28-K001-3926310.110/02/2020
10.38-K001-3926310.210/02/2020
10.4
8-K001-3926310.310/02/2020
10.58-K001-3926310.410/02/2020
10.6*
10.7*
31.1*
31.2*
32.1**
32.2**
101.INS
Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document
*
101.SCHInline XBRL Taxonomy Extension Schema Document*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
107


*    Filed herewith.
**    Furnished herewith.

108


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Zentalis Pharmaceuticals, Inc.
Date: November 9, 2020
By:/s/ Anthony Y. Sun, M.D.
Anthony Y. Sun, M.D.
Chief Executive Officer, President and Chairman
Date: November 9, 2020
By:/s/ Melissa B. Epperly
Melissa B. Epperly
Chief Financial Officer
109
EX-10.6 2 employmentagreementgal.htm EX-10.6 Document
        
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company”) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the “Parent”), and Cam Gallagher (“Executive”), and shall be effective as of October 1, 2020 (the “Effective Date”).
WHEREAS, the Company and Executive are parties to that certain Amended and Restated Consulting Agreement effective as of February 25, 2020 (the “Prior Agreement”); and
WHEREAS, the Company desires to employ Executive, and Executive desires to commence employment with the Company, on the terms and conditions set forth in this Agreement.
NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties agree as follows:
1.Definitions. As used in this Agreement, the following terms shall have the following meanings:

        (a)    “Board” means the Board of Directors of the Company.

        (b)    “Cause” means any of the following:
(i)     Executive’s unauthorized use or disclosure of confidential information or trade secrets of the Company or its affiliates or any material breach of a written agreement between Executive and the Company or any affiliate, including without limitation a material breach of any employment, confidentiality, non-compete, non-solicit or similar agreement;
(ii)     Executive’s commission of, indictment for or the entry of a plea of guilty or nolo contendere by Executive to, a felony under the laws of the United States or any state thereof or any crime involving dishonesty or moral turpitude (or any similar crime in any jurisdiction outside the United States);
(iii)     Executive’s gross negligence or willful misconduct or Executive’s willful or repeated failure or refusal to substantially perform assigned duties;
(iv)    any act of fraud, embezzlement, material misappropriation or dishonesty committed by Executive against the Company or its affiliates; or
(v)     any acts, omissions or statements by Executive which the Company reasonably determines to be materially detrimental or damaging to the reputation, operations, prospects or business relations of the Company or its affiliates;
provided, however, that prior to the determination that “Cause” under clauses (i), (iii), (iv) or (v) of this Section 1(b) has occurred, the Company shall (A) provide to Executive in writing, in reasonable detail, the reasons for the determination that such “Cause” exists, (B) afford Executive a reasonable opportunity to remedy any such breach, (C) provide Executive an opportunity to be

|US-DOCS\117550217.3||


heard prior to the final decision to terminate Executive’s employment hereunder for such “Cause” and (D) make any decision that such “Cause” exists in good faith.
The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to discharge or dismiss Executive for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause.
(c)    “Change in Control” shall have the meaning ascribed to such term in the Zentalis Pharmaceuticals, Inc. 2020 Incentive Award Plan.

        (d)    “Code” means the Internal Revenue Code of 1986, as amended from time to time, and the Treasury Regulations and other interpretive guidance issued thereunder.
    (e)    “Good Reason” means the occurrence of any of the following events or conditions without Executive’s written consent:

(i)a change in Executive’s position or responsibilities that represents a substantial reduction in his position or responsibilities as in effect immediately prior thereto; the assignment to Executive of any duties or responsibilities that are materially inconsistent with such position or responsibilities; or any removal of Executive from or failure to reappoint or reelect Executive to any of such positions, except in connection with the termination of Executive’s services for Cause, as a result of his Permanent Disability or death, or by Executive other than for Good Reason; provided, however, that neither a change in Executive’s reporting relationship as a result of a Change in Control nor the fact that Executive’s reporting relationship is altered following a Change in Control because the Company or its successor is a wholly-owned subsidiary of another entity following such Change in Control shall alone constitute Good Reason;

            (ii)    a material reduction in Executive’s annual base salary;
            (iii)    the Company requiring Executive (without Executive’s consent) to be based at any place outside a fifty (50)-mile radius of his then-current place of employment with the Company prior to any such relocation, except for reasonably required travel on the Company’s business; or
            (iv)    any material breach by the Company or any affiliate of its obligations to Executive under any applicable employment or services agreement between Executive and the Company or such affiliate.
    Executive must provide written notice to the Company of the occurrence of any of the foregoing events or conditions without Executive’s written consent within sixty (60) days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30) days to cure such event or condition after receipt of written notice of such event from Executive. Executive’s Separation from Service by reason of resignation from employment with the Company for Good Reason must occur within thirty (30) days following the expiration of the foregoing thirty (30) day cure period.
    2    
|US-DOCS\117550217.3||


    (f)    “Involuntary Termination” means (i) Executive’s Separation from Service by reason of Executive’s discharge by the Company other than for Cause, or (ii) Executive’s Separation from Service by reason of Executive’s resignation of employment with the Company for Good Reason. Executive’s Separation from Service by reason of Executive’s death or discharge by the Company following Executive’s Permanent Disability shall not constitute an Involuntary Termination.
    (g)    Executive’s “Permanent Disability” shall be deemed to have occurred if Executive shall become physically or mentally incapacitated or disabled or otherwise unable fully to discharge his duties hereunder for a period of ninety (90) consecutive calendar days or for one hundred twenty (120) calendar days in any one hundred eighty (180) calendar-day period. The existence of Executive’s Permanent Disability shall be determined by the Company on the advice of a physician chosen by the Company and the Company reserves the right to have Executive examined by a physician chosen by the Company at the Company’s expense.
         (h)     “Separation from Service,” with respect to Executive, means Executive’s “separation from service,” as defined in Treasury Regulation Section 1.409A-1(h).    
        (i)    “Stock Awards” means all stock options, restricted stock and such other awards granted pursuant to the Company’s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof.
2.    Services to Be Rendered.
    (a)    Duties and Responsibilities. Executive shall serve as Executive Director of the Company. In the performance of such duties, Executive shall report directly to, and shall be subject to the direction of, the Chief Executive Officer of the Company (the “CEO”) and to such limits upon Executive’s authority as the CEO may from time to time impose. In the event of the CEO’s unavailability or incapacity, Executive shall report directly to the Board. Executive hereby consents to serve as an officer and/or director of the Company, Parent or any subsidiary or affiliate thereof without any additional salary or compensation, if so requested by the Board or the CEO. Executive shall be employed by the Company on a part-time basis. Executive shall work remotely from his home office, or such other locations as mutually agreed upon by the CEO and Consultant from time to time, but shall report to the CEO at the Company’s New York, New York offices from time to time as required by the CEO. Executive will be expected to travel to the Company’s locations as reasonably required in connection with his duties. Executive shall be subject to and comply with the policies and procedures generally applicable to senior executives of the Company to the extent the same are not inconsistent with any term of this Agreement.
    (b)    Exclusive Services. Executive shall at all times faithfully, industriously and to the best of his ability, experience and talent perform all of the duties that may be assigned to Executive hereunder and shall devote fifty percent (50%) of his productive time and efforts to the performance of such duties. Subject to the terms of the Proprietary Information and Inventions Agreement referred to in Section 5(b), this shall not preclude Executive from (i) serving on industry, trade, civic, or charitable boards or committees; (ii) managing personal, family and other investments; (iii) serving in an advisory capacity for any entity; or (iv) serving on the board of directors or other similar governance body of any entity; provided that such activities do not interfere with his duties to the Company, as determined in good faith by the CEO or the Board.
    (c)    Board Service. Executive shall continue to serve as a member of the Board.
    3    
|US-DOCS\117550217.3||


3.Compensation and Benefits. The Company shall pay or provide, as the case may be, to Executive the compensation and other benefits and rights set forth in this Section 3.
(a)Base Salary. The Company shall pay to Executive a base salary of $340,000 per year, payable in accordance with the Company’s usual pay practices (and in any event no less frequently than monthly). Executive’s base salary shall be subject to review annually by and at the sole discretion of the Board or its designee.
(b)Annual Bonus. Executive shall participate in any annual bonus plan that the Board or its designee may approve for the senior executives of the Company. In addition to Executive’s base salary, Executive may be eligible to earn, for each fiscal year of the Company ending during the term of Executive’s employment with the Company, an annual cash performance bonus under the Company’s bonus plan, as approved from time to time by the Board. Executive’s target bonus under any such annual bonus plan shall be forty percent (40%) of Executive’s base salary actually paid for the year to which such annual bonus relates (the “Target Bonus”). Executive’s actual annual bonus will be determined on the basis of Executive’s and/or the Company’s or its affiliates’ attainment of financial or other performance criteria established by the Board or its designee in accordance with the terms and conditions of such bonus plan. Except as otherwise provided in this Agreement, Executive must be employed by the Company on the date of payment of such annual bonus in order to be eligible to receive such annual bonus. Executive hereby acknowledges and agrees that nothing contained herein confers upon Executive any right to an annual bonus in any year, and that whether the Company pays Executive an annual bonus and the amount of any such annual bonus will be determined by the Company in its sole discretion.
(c)Benefits. Executive shall be entitled to participate in benefits under the Company’s benefit plans and arrangements, including, without limitation, any employee benefit plan or arrangement made available in the future by the Company to its senior executives, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and arrangements. The Company shall have the right to amend or delete any such benefit plan or arrangement made available by the Company to its senior executives and not otherwise specifically provided for herein.
(d)Expenses. The Company shall reimburse Executive for reasonable out-of-pocket business expenses incurred in connection with the performance of his duties hereunder, subject to such policies as the Company may from time to time establish, and Executive furnishing the Company with evidence in the form of receipts satisfactory to the Company substantiating the claimed expenditures.
(e)    Paid Time Off. Executive shall be entitled to such periods of paid time off (“PTO”) each year as provided from time to time under the Company’s PTO policy and as otherwise provided for senior executive officers; provided, however, that Executive shall be entitled to a minimum of twenty (20) days of PTO per year.
(f)Equity and Other Benefit Plans. Executive shall be entitled to participate in any equity or other employee benefit plan that is generally available to senior executive officers of the Company. Except as otherwise provided in this Agreement, Executive’s participation in and benefits under any such plan shall be on the terms and subject to the conditions specified in the governing document of the particular plan.
4.    Severance. Executive shall be entitled to receive benefits upon a Separation from Service only as set forth in this Section 4:
    4    
|US-DOCS\117550217.3||


(a)    At-Will Employment; Termination. The Company and Executive acknowledge that Executive’s employment is and shall continue to be at-will, as defined under applicable law, and that Executive’s employment with the Company may be terminated by either party at any time for any or no reason, with or without notice. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in this Agreement. Executive’s employment under this Agreement shall be terminated immediately on the death of Executive.
(b)    Severance Upon Involuntary Termination. Subject to Sections 4(d) and 9(o) and Executive’s continued compliance with Section 5, if Executive’s employment is Involuntarily Terminated, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive may otherwise be entitled under any severance plan or program of the Company, the benefits provided below:
    (i)    the Company shall pay to Executive his fully earned but unpaid base salary, when due, through the date of Executive’s Involuntary Termination at the rate then in effect, accrued and unused PTO, plus all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other Company group benefit plan to which Executive may be entitled pursuant to the terms of such plans or agreements at the time of Executive’s Involuntary Termination (the “Accrued Obligations”);
    (ii)    Executive shall be entitled to receive severance pay in an amount equal to (A) Executive’s monthly base salary as in effect immediately prior to the date of Executive’s Involuntary Termination, multiplied by (B) twelve (12), which amount shall be payable in a lump sum sixty (60) days following Executive’s Involuntary Termination;
(iii)    Executive shall be entitled to receive Executive’s Target Bonus for the year in which Executive’s Involuntary Termination occurs, prorated for the portion of the year that has expired prior to the date of Executive’s Involuntary Termination, which amount shall be payable in a lump sum sixty (60) days following Executive’s Involuntary Termination;
    (iv)     for the period beginning on the date of Executive’s Involuntary Termination and ending on the date which is twelve (12) full months following the date of Executive’s Involuntary Termination (or, if earlier, (A) the date on which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) expires or (B) the date Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment) (such period, the “COBRA Coverage Period”), if Executive and/or his eligible dependents who were covered under the Company’s health insurance plans as of the date of Executive’s Involuntary Termination elect to have COBRA coverage and are eligible for such coverage, the Company shall pay for or reimburse Executive on a monthly basis for an amount equal to (1) the monthly premium Executive and/or his covered dependents, as applicable, are required to pay for continuation coverage pursuant to COBRA for Executive and/or his eligible dependents, as applicable, who were covered under the Company’s health plans as of the date of Executive’s Involuntary Termination (calculated by reference to the premium as of the date of Executive’s Involuntary Termination) less (2) the amount Executive would have had to pay to receive group health coverage for Executive and/or his covered dependents, as applicable, based on the cost sharing levels in effect on the date of Executive’s Involuntary Termination. If any of the Company’s health benefits are self-funded as of the date of Executive’s Involuntary Termination, or if the Company cannot provide the foregoing benefits in a manner that is exempt from Section 409A (as defined below) or that is otherwise compliant with applicable law (including, without limitation, Section 2716 of the Public Health Service Act), instead of providing the payments or reimbursements as set forth above, the Company shall instead pay to
    5    
|US-DOCS\117550217.3||


Executive the foregoing monthly amount as a taxable monthly payment for the COBRA Coverage Period (or any remaining portion thereof). Executive shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums. Executive shall notify the Company immediately if Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment.
        (v)    (A) in the event of Executive’s Involuntary Termination within eighteen (18) months following a Change in Control, the Target Bonus payable pursuant to clause (iii) shall not be subject to proration, which amount shall be payable as provided in clause (iii) above, and (B) in the event of Executive’s Involuntary Termination at any time following a Change in Control, all of Executive’s Stock Awards will vest on an accelerated basis effective as of the date of Executive’s Involuntary Termination. The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award (and, for the avoidance of doubt, if any Stock Award is subject to more favorable vesting pursuant to any agreement or plan regarding such Stock Award, such more favorable provisions shall continue to apply and shall not be limited by this clause (v)).
(c)    Termination for Cause, Voluntary Resignation Without Good Reason, Death or Termination for Permanent Disability. In the event of Executive’s termination of employment as a result of Executive’s discharge by the Company for Cause, Executive’s resignation without Good Reason, Executive’s death or Executive’s termination of employment following Executive’s Permanent Disability, the Company shall not have any other or further obligations to Executive under this Agreement (including any financial obligations) except that Executive shall be entitled to receive the Accrued Obligations. The foregoing shall be in addition to, and not in lieu of, any and all other rights and remedies which may be available to the Company under the circumstances, whether at law or in equity.
(d)    Release. As a condition to Executive’s receipt of any post-termination benefits pursuant to Section 4(b) above, Executive (or, in the event of Executive’s incapacity as a result of his Permanent Disability, Executive’s legal representative) shall execute and not revoke a general release of all claims in favor of the Company and its affiliates (the “Release”) in the form attached hereto as Exhibit A. In the event the Release does not become effective within the fifty-five (55) day period following the date of Executive’s Involuntary Termination, Executive shall not be entitled to the aforesaid payments and benefits.
        (e)    Exclusive Remedy. Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive’s rights to salary, severance, benefits, bonuses and other amounts hereunder (if any) accruing after the termination of Executive’s employment shall cease upon such termination. In the event of Executive’s termination of employment with the Company, Executive’s sole remedy shall be to receive the payments and benefits described in this Section 4. In addition, Executive acknowledges and agrees that he is not entitled to any reimbursement by the Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to this Section 4, including, without limitation, any excise tax imposed by Section 4999 of the Code. Any payments made to Executive under this Section 4 shall be inclusive of any amounts or benefits to which Executive may be entitled pursuant to the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor regulations thereunder, or any similar state statute.
        (f)    No Mitigation. Except as otherwise provided in Section 4(b)(iv) above, Executive shall not be required to mitigate the amount of any payment provided for in this Section 4 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section 4 be reduced by any compensation earned
    6    
|US-DOCS\117550217.3||


by Executive as the result of employment by another employer or self-employment or by retirement benefits; provided, however, that loans, advances or other amounts owed by Executive to the Company may be offset by the Company against amounts payable to Executive under this Section 4.
(g)    Return of the Company’s Property. In the event of Executive’s termination of employment for any reason, the Company shall have the right, at its option, to require Executive to vacate his offices prior to or on the effective date of separation and to cease all activities on the Company’s behalf. Upon Executive’s termination of employment in any manner, as a condition to Executive’s receipt of any severance benefits described in this Agreement, Executive shall immediately surrender to the Company all lists, books and records of, or in connection with, the Company’s business, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. Executive shall deliver to the Company a signed statement certifying compliance with this Section 4(g) prior to the receipt of any severance benefits described in this Agreement.
5.    Certain Covenants.

1.Noncompetition. Except as may otherwise be approved by the Board, during the term of Executive’s employment, Executive shall not have any ownership interest (of record or beneficial) in, or have any interest as an employee, salesman, consultant, officer or director in, or otherwise aid or assist in any manner, any firm, corporation, partnership, proprietorship or other business that engages in any county, city or part thereof in the United States and/or any foreign country in a business which competes directly or indirectly (as determined by the Board) with the Company’s business in such county, city or part thereof, so long as the Company, or any successor in interest of the Company to the business and goodwill of the Company, remains engaged in such business in such county, city or part thereof or continues to solicit customers or potential customers therein; provided, however, that Executive may own, directly or indirectly, solely as an investment, securities of any entity which are traded on any national securities exchange if Executive (i) is not a controlling person of, or a member of a group which controls, such entity; or (ii) does not, directly or indirectly, own one percent (1%) or more of any class of securities of any such entity.
2.Confidential Information. Executive and the Company have entered into the Company’s standard proprietary information and inventions assignment agreement (the “Proprietary Information and Inventions Agreement”). Executive agrees to perform each and every obligation of Executive therein contained.
3.Solicitation of Employees. During the term of Executive’s employment or service and for one (1) year thereafter (the “Restricted Period”), Executive will not, either directly or through others, solicit or attempt to solicit any employee, independent contractor or consultant of the Company or its affiliates to terminate his relationship with the Company or its affiliates in order to become an employee, consultant or independent contractor to or for any other person or entity, or otherwise encourage or solicit any employee of the Company or its affiliates to leave the Company or such affiliates for any reason or to devote less than all of any
    7    
|US-DOCS\117550217.3||


such employee’s efforts to the affairs of the Company; provided that the foregoing shall not affect any responsibility Executive may have as an employee of the Company with respect to the bona fide hiring and firing of Company personnel.
4.Solicitation of Consultants. Executive shall not during the term of Executive’s employment or service and for the Restricted Period, directly or indirectly, hire, solicit or encourage to cease work with the Company or any of its affiliates any consultant then under contract with the Company or any of its affiliates.
5.Nondisparagement. Executive agrees that neither he nor anyone acting by, through, under or in concert with him shall disparage or otherwise communicate negative statements or opinions about the Company, Parent, or their respective board members, officers, employees or businesses. The Company agrees that neither its Board members nor officers, nor the board members or officers of Parent, shall disparage or otherwise communicate negative statements or opinions about Executive. Except as may be required by law, neither Executive, nor any member of Executive’s family, nor anyone else acting by, through, under or in concert with Executive will disclose to any individual or entity (other than Executive’s legal or tax advisors) the terms of this Agreement.
6.Rights and Remedies Upon Breach. If Executive breaches or threatens to commit a breach of any of the provisions of this Section 5 (the “Restrictive Covenants”), the Company shall have the following rights and remedies, each of which rights and remedies shall be independent of the other and severally enforceable, and all of which rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity:
a.Specific Performance. The right and remedy to have the Restrictive Covenants specifically enforced by any court having equity jurisdiction, all without the need to post a bond or any other security or to prove any amount of actual damage or that money damages would not provide an adequate remedy, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to the Company and that money damages will not provide adequate remedy to the Company; and
b.Accounting and Indemnification. The right and remedy to require Executive (A) to account for and pay over to the Company all compensation, profits, monies, accruals, increments or other benefits derived or received by Executive or any associated party deriving such benefits as a result of any such breach of the Restrictive Covenants; and (B) to indemnify the Company against any other losses, damages (including special and consequential damages), costs and expenses, including actual attorneys’ fees and court costs, which may be incurred by them and which result from or arise out of any such breach or threatened breach of the Restrictive Covenants.
(g)    Severability of Covenants/Blue Pencilling. If any court determines that any of the Restrictive Covenants, or any part thereof, is invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full effect, without regard to the invalid portions. If any court determines that any of the Restrictive Covenants, or any part
    8    
|US-DOCS\117550217.3||


thereof, are unenforceable because of the duration of such provision or the area covered thereby, such court shall have the power to reduce the duration or area of such provision and, in its reduced form, such provision shall then be enforceable and shall be enforced. Executive hereby waives any and all right to attack the validity of the Restrictive Covenants on the grounds of the breadth of their geographic scope or the length of their term.
(h)    Enforceability in Jurisdictions. The Company and Executive intend to and do hereby confer jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold the Restrictive Covenants wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the Company and Executive that such determination not bar or in any way affect the right of the Company to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.
(i)    Whistleblower Provision. Nothing herein shall be construed to prohibit Executive from communicating directly with, cooperating with, or providing information to, any government regulator, including, but not limited to, the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading Commission, or the U.S. Department of Justice. Executive acknowledges that the Company has provided Executive with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (ii) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (iii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the proprietary information to Executive’s attorney and use the proprietary information in the court proceeding, if Executive files any document containing the proprietary information under seal, and does not disclose the proprietary information, except pursuant to court order.
(j)    Definitions. For purposes of this Section 5, the term “Company” means not only Zeno Management, Inc., but also Parent as well as any company, partnership or entity which, directly or indirectly, controls, is controlled by or is under common control with Zeno Management, Inc.
6.    Insurance; Indemnification.
    (a)    Insurance. The Company shall have the right to take out life, health, accident, “key-man” or other insurance covering Executive, in the name of the Company and at the Company’s expense in any amount deemed appropriate by the Company. Executive shall assist the Company in obtaining such insurance, including, without limitation, submitting to any required examinations and providing information and data required by insurance companies.
    9    
|US-DOCS\117550217.3||


    (b)    Indemnification. Executive will be provided with indemnification against third party claims related to his work for the Company to the extent permitted by Delaware law. The Company shall provide Executive with directors and officers liability insurance coverage at least as favorable as that which the Company may maintain from time to time for other Board members and executive officers.
7.    Arbitration. Any dispute, claim or controversy based on, arising out of or relating to Executive’s employment or this Agreement shall be settled by final and binding arbitration in New York, New York, before a single neutral arbitrator in accordance with the JAMS Employment Arbitration Rules and Procedures (the “Rules”), and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. The Rules may be found online at www.jamsadr.com and will be provided to Executive upon request. If the parties are unable to agree upon an arbitrator, one shall be appointed by JAMS in accordance with its Rules. Each party shall pay the fees of its own attorneys, the expenses of its witnesses and all other expenses connected with presenting its case; provided, however, Executive and the Company agree that, to the extent permitted by law, the arbitrator may, in his or her discretion, award reasonable attorneys’ fees to the prevailing party; provided, further, that the prevailing party shall be reimbursed for such fees, costs and expenses within forty-five (45) days following any such award, but in no event later than the last day of Executive’s taxable year following the taxable year in which the fees, costs and expenses were incurred; provided, further, that the parties’ obligations pursuant to this sentence shall terminate on the tenth (10th) anniversary of the date of Executive’s termination of employment. Other costs of the arbitration, including the cost of any record or transcripts of the arbitration, JAMS administrative fees, the fee of the arbitrator, and all other fees and costs, shall be borne by the Company. This Section 7 is intended to be the exclusive method for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to Executive’s employment; provided, however, that Executive shall retain the right to file administrative charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to (a) claims for workers’ compensation, state disability insurance or unemployment insurance; (b) administrative claims brought before any state or federal governmental authority; provided, however, that any appeal from an award or from denial of an award of wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this Agreement; and (c) claims for administrative relief from the United States Equal Employment Opportunity Commission and/or any similar state agency in any applicable jurisdiction); provided, further, that Executive shall not be entitled to obtain any monetary relief through such agencies other than workers’ compensation benefits or unemployment insurance benefits. This Agreement shall not limit either party’s right to obtain any provisional remedy, including, without limitation, injunctive or similar relief, from any court of competent jurisdiction as may be necessary to protect their rights and interests pending the outcome of arbitration, including without limitation injunctive relief, in any court of competent jurisdiction. Seeking any such relief shall not be deemed to be a waiver of such party’s right to compel arbitration. Both Executive and the Company expressly waive their right to a jury trial.
8.    General Relationship. Executive shall be considered an employee of the Company within the meaning of all federal, state and local laws and regulations including, but not limited to, laws and regulations governing unemployment insurance, workers’ compensation, industrial accident, labor and taxes.
9.    Miscellaneous.
(a)    Modification; Prior Claims. This Agreement and the Proprietary Information and Inventions Agreement (and the other documents referenced therein) set forth the entire
    10    
|US-DOCS\117550217.3||


understanding of the parties with respect to the subject matter hereof, and supersede all existing agreements between them concerning such subject matter, including the Prior Agreement. This Agreement may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever.
(b)    Assignment; Assumption by Successor. The rights of the Company under this Agreement may, without the consent of Executive, be assigned by the Company, in its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly, acquires all or substantially all of the assets or business of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; provided, however, that no such assumption shall relieve the Company of its obligations hereunder.  As used in this Agreement, the “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law or otherwise.
(c)    Survival. The covenants, agreements, representations and warranties contained in or made in Sections 4, 5, 6, 7 and 9 of this Agreement shall survive Executive’s termination of employment.
(d)    ThirdParty Beneficiaries. Except as expressly set forth herein, this Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement.
(e)    Waiver. The failure of either party hereto at any time to enforce performance by the other party of any provision of this Agreement shall in no way affect such party’s rights thereafter to enforce the same, nor shall the waiver by either party of any breach of any provision hereof be deemed to be a waiver by such party of any other breach of the same or any other provision hereof.
(f)    Section Headings. The headings of the several sections in this Agreement are inserted solely for the convenience of the parties and are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof.
(g)    Notices. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by email, telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to Executive at the address listed on the Company’s personnel records and to the Company at its principal place of business, or such other address as either party may specify in writing.
    11    
|US-DOCS\117550217.3||


(h)    Severability. All Sections, clauses and covenants contained in this Agreement are severable, and in the event any of them shall be held to be invalid by any court, this Agreement shall be interpreted as if such invalid Sections, clauses or covenants were not contained herein.
(i)    Governing Law and Venue. This Agreement is to be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Except as provided in Sections 5 and 7, any suit brought hereon shall be brought in the state or federal courts sitting in New York, New York, the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by New York law.
(j)    Non-transferability of Interest. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement shall be assignable or transferable except through a testamentary disposition or by the laws of descent and distribution upon the death of Executive. Any attempted assignment, transfer, conveyance, or other disposition (other than as aforesaid) of any interest in the rights of Executive to receive any form of compensation to be made by the Company pursuant to this Agreement shall be void.
(k)    Gender. Where the context so requires, the use of the masculine gender shall include the feminine and/or neuter genders and the singular shall include the plural, and vice versa, and the word “person” shall include any corporation, firm, partnership or other form of association.
(l)    Counterparts; Facsimile or .pdf Signatures. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Agreement may be executed and delivered by facsimile or by .pdf file and upon such delivery the facsimile or .pdf signature will be deemed to have the same effect as if the original signature had been delivered to the other party.
(m)    Construction. The language in all parts of this Agreement shall in all cases be construed simply, according to its fair meaning, and not strictly for or against any of the parties hereto. Without limitation, there shall be no presumption against any party on the ground that such party was responsible for drafting this Agreement or any part thereof.
(n)    Withholding and Other Deductions. All compensation payable to Executive hereunder shall be subject to such deductions as the Company is from time to time required to make pursuant to law, governmental regulation or order.
(o)    Code Section 409A.
        (i)    This Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly, the severance payments payable under Section 4(b)(ii), (iii) and (v) shall be paid no later than the later of:
    12    
|US-DOCS\117550217.3||


(A) the fifteenth (15th) day of the third month following Executive’s first taxable year in which such amounts are no longer subject to a substantial risk of forfeiture, and (B) the fifteenth (15th) day of the third month following first taxable year of the Company in which such amounts are is no longer subject to substantial risk of forfeiture, as determined in accordance with Code Section 409A and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Agreement shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder. Each series of installment payments made under this Agreement is hereby designated as a series of “separate payments” within the meaning of Section 409A of the Code. For purposes of this Agreement, all references to Executive’s “termination of employment” shall mean Executive’s Separation from Service.
        (ii)    If Executive is a “specified employee” (as defined in Section 409A of the Code), as determined by the Company in accordance with Section 409A of the Code, on the date of Executive’s Separation from Service, to the extent that the payments or benefits under this Agreement are subject to Section 409A of the Code and the delayed payment or distribution of all or any portion of such amounts to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to this Section 9(o)(ii) shall be paid or distributed to Executive in a lump sum on the earlier of (A) the date that is six (6)-months following Executive’s Separation from Service, (B) the date of Executive’s death or (C) the earliest date as is permitted under Section 409A of the Code. Any remaining payments due under the Agreement shall be paid as otherwise provided herein.
c.To the extent applicable, this Agreement shall be interpreted in accordance with the applicable exemptions from Section 409A of the Code. If Executive and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections 409A(a)(2), (3) and (4) of the Code do not comply with Section 409A of the Code, Executive and the Company agree to amend this Agreement, or take such other actions as Executive and the Company deem reasonably necessary or appropriate, to comply with the requirements of Section 409A of the Code and the Treasury Regulations thereunder (and any applicable transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner that no payments payable under this Agreement shall be subject to an “additional tax” as defined in Section 409A(a)(1)(B) of the Code.
d.Any reimbursement of expenses or in-kind benefits payable under this Agreement shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of Executive’s taxable year following the taxable year in which Executive incurred the expenses. The amount of expenses reimbursed or in-kind benefits payable during any taxable year of Executive’s shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of Executive’s, and Executive’s right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit.
[Signature Page Follows]


    13    
|US-DOCS\117550217.3||


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above.
                    Zeno Management, Inc.

                    By:     /s/ Anthony Y. Sun, M.D.        
                        Name:     Anthony Y. Sun, M.D.        
                        Title:     President and Chief Executive Officer

                    Executive

                      /s/ Cam Gallagher                
                        Cam Gallagher
[SIGNATURE PAGE TO EMPLOYMENT AGREEMENT]
|US-DOCS\117550217.3||


Exhibit A

GENERAL RELEASE OF CLAIMS

[The language in this Release may change based on legal developments and evolving best practices; this form is provided as an example of what will be included in the final Release document.]

    This General Release of Claims (“Release”) is entered into as of this _____ day of ________, ____, between Cam Gallagher (“Executive”), and Zeno Management, Inc. (the “Company”) (collectively referred to herein as the “Parties”).

    WHEREAS, Executive and the Company are parties to that certain Employment Agreement dated as of October 1, 2020 (the “Agreement”);

    WHEREAS, the Parties agree that Executive is entitled to certain severance benefits under the Agreement, subject to Executive’s execution of this Release; and

    WHEREAS, the Company and Executive now wish to fully and finally to resolve all matters between them.

    NOW, THEREFORE, in consideration of, and subject to, the severance benefits payable to Executive pursuant to the Agreement, the adequacy of which is hereby acknowledged by Executive, and which Executive acknowledges that he would not otherwise be entitled to receive, Executive and the Company hereby agree as follows:

    1.    General Release of Claims by Executive.

        (a)    Executive, on behalf of himself and his executors, heirs, administrators, representatives and assigns, hereby agrees to release and forever discharge the Company and all predecessors, successors and their respective parent corporations, affiliates, related, and/or subsidiary entities, and all of their past and present investors, directors, shareholders, officers, general or limited partners, employees, attorneys, agents and representatives, and the employee benefit plans in which Executive is or has been a participant by virtue of his employment with or service to the Company (collectively, the “Company Releasees”), from any and all claims, debts, demands, accounts, judgments, rights, causes of action, equitable relief, damages, costs, charges, complaints, obligations, promises, agreements, controversies, suits, expenses, compensation, responsibility and liability of every kind and character whatsoever (including attorneys’ fees and costs), whether in law or equity, known or unknown, asserted or unasserted, suspected or unsuspected (collectively, “Claims”), which Executive has or may have had against such entities based on any events or circumstances arising or occurring on or prior to the date hereof or on or prior to the date hereof, arising directly or indirectly out of, relating to, or in any other way involving in any manner whatsoever Executive’s employment by or service to the Company or the termination thereof, including any and all claims arising under federal, state, or local laws relating
1

|US-DOCS\117550217.3||


to employment, including without limitation claims of wrongful discharge, breach of express or implied contract, fraud, misrepresentation, defamation, or liability in tort, and claims of any kind that may be brought in any court or administrative agency including, without limitation, claims under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. Section 2000, et seq.; the Americans with Disabilities Act, as amended, 42 U.S.C. § 12101 et seq.; the Rehabilitation Act of 1973, as amended, 29 U.S.C. § 701 et seq.; the Civil Rights Act of 1866, and the Civil Rights Act of 1991; 42 U.S.C. Section 1981, et seq.; the Age Discrimination in Employment Act, as amended, 29 U.S.C. Section 621, et seq. (the “ADEA”); the Equal Pay Act, as amended, 29 U.S.C. Section 206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, et seq.; the Family and Medical Leave Act, as amended, 29 U.S.C. § 2601 et seq.; the Fair Labor Standards Act of 1938, as amended, 29 U.S.C. § 201 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.

    Notwithstanding the generality of the foregoing, Executive does not release the following claims:

    (i)    Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law;
    
    (ii)    Claims for workers’ compensation insurance benefits under the terms of any worker’s compensation insurance policy or fund of the Company;

    (iii)    Claims pursuant to the terms and conditions of the federal law known as COBRA;
    (iv)    Claims for indemnity under the bylaws of the Company, as provided for by Delaware law or under any applicable insurance policy with respect to Executive’s liability as an employee, director or officer of the Company;

    (v)    Executive’s right to bring to the attention of the Equal Employment Opportunity Commission or any other federal, state or local government agency claims of discrimination, or from participating in an investigation or proceeding conducted by the Equal Employment Opportunity Commission or any other federal, state or local government agency; provided, however, that Executive does release his right to secure any damages for alleged discriminatory treatment;

    (vi)    Claims based on any right Executive may have to enforce the Company’s executory obligations under the Agreement;

    (vii)    Claims Executive may have to vested or earned compensation and benefits; and

    (viii)    Executive’s right to communicate or cooperate with any government agency.
    
2

|US-DOCS\117550217.3||


        (b)    EXECUTIVE ACKNOWLEDGES THAT he HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:

    “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”

BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS he MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.

[Note: Clauses (c), (d) and (e) apply only if Executive is age 40 or older at time of termination]

        (c)     Executive acknowledges that this Release was presented to him on the date indicated above and that Executive is entitled to have [twenty-one (21)][forty-five (45)] days’ time in which to consider it. Executive further acknowledges that the Company has advised him that he is waiving his rights under the ADEA, and that Executive should consult with an attorney of his choice before signing this Release, and Executive has had sufficient time to consider the terms of this Release. Executive represents and acknowledges that if Executive executes this Release before [twenty-one (21)][forty-five (45)] days have elapsed, Executive does so knowingly, voluntarily, and upon the advice and with the approval of Executive’s legal counsel (if any), and that Executive voluntarily waives any remaining consideration period.

        (d)     Executive understands that after executing this Release, Executive has the right to revoke it within seven (7) days after his execution of it. Executive understands that this Release will not become effective and enforceable unless the seven (7) day revocation period passes and Executive does not revoke the Release in writing. Executive understands that this Release may not be revoked after the seven (7) day revocation period has passed. Executive also understands that any revocation of this Release must be made in writing and delivered to the Company at its principal place of business within the seven (7) day period.

        (e)     Executive understands that this Release shall become effective, irrevocable, and binding upon Executive on the eighth (8th) day after his execution of it, so long as Executive has not revoked it within the time period and in the manner specified in clause (d) above.

        (f)    Executive further understands that Executive will not be given any severance benefits under the Agreement unless this Release is effective on or before the date that is fifty-five (55) days following the date of Executive’s termination of employment.

    2.    No Assignment. Executive represents and warrants to the Company Releasees that there has been no assignment or other transfer of any interest in any Claim that Executive may have against the Company Releasees. Executive agrees to indemnify and hold harmless the
3

|US-DOCS\117550217.3||


Company Releasees from any liability, claims, demands, damages, costs, expenses and attorneys’ fees incurred as a result of any such assignment or transfer from Executive.
3.    Severability. In the event any provision of this Release is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby.
4.    Interpretation; Construction. The headings set forth in this Release are for convenience only and shall not be used in interpreting this Agreement. This Release has been drafted by legal counsel representing the Company, but Executive has participated in the negotiation of its terms. Furthermore, Executive acknowledges that Executive has had an opportunity to review and revise the Release and have it reviewed by legal counsel, if desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Release. Either party’s failure to enforce any provision of this Release shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing each and every other provision of this Release.
5.    Governing Law and Venue. This Release will be governed by and construed in accordance with the laws of the United States of America and the State of New York applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Any suit brought hereon shall be brought in the state or federal courts sitting in New York, New York, the Parties hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by New York law.
6.    Entire Agreement. This Release and the Agreement constitute the entire agreement of the Parties in respect of the subject matter contained herein and therein and supersede all prior or simultaneous representations, discussions, negotiations and agreements, whether written or oral. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever.
7.    Counterparts. This Release may be executed in multiple counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.
[Signature Page Follows]



4

|US-DOCS\117550217.3||


    IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing Release as of the date first written above.

Executive                        Zeno Management, Inc.
            
                            By:                         
Print Name: Cam Gallagher                Print Name:                     
                            Title:                         



















[SIGNATURE PAGE TO RELEASE]

|US-DOCS\117550217.3||
EX-10.7 3 employmentagreementpin.htm EX-10.7 Document

EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between Zeno Management, Inc., a Delaware corporation (the “Company”) and a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (the “Parent”), and Alexis Pinto (“Executive”), and shall be effective as of August 31, 2020 (the “Effective Date”).
WHEREAS, the Company desires to employ Executive, and Executive desires to commence employment with the Company, on the terms and conditions set forth in this Agreement.
NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties agree as follows:
1.Definitions. As used in this Agreement, the following terms shall have the following meanings:

        (a)    “Board” means the Board of Directors of the Company.

        (b)    “Cause” means any of the following:
(i)     Executive’s unauthorized use or disclosure of confidential information or trade secrets of the Company or its affiliates or any material breach of a written agreement between Executive and the Company or any affiliate, including without limitation a material breach of any employment, confidentiality, non-compete, non-solicit or similar agreement;
(ii)     Executive’s commission of, indictment for or the entry of a plea of guilty or nolo contendere by Executive to, a felony under the laws of the United States or any state thereof or any crime involving dishonesty or moral turpitude (or any similar crime in any jurisdiction outside the United States);
(iii)     Executive’s gross negligence or willful misconduct or Executive’s willful or repeated failure or refusal to substantially perform assigned duties;
(iv)    any act of fraud, embezzlement, material misappropriation or dishonesty committed by Executive against the Company or its affiliates; or
(v)     any acts, omissions or statements by Executive which the Company reasonably determines to be materially detrimental or damaging to the reputation, operations, prospects or business relations of the Company or its affiliates;
provided, however, that prior to the determination that “Cause” under clauses (i), (iii), (iv) or (v) of this Section 1(b) has occurred, the Company shall (A) provide to Executive in writing, in reasonable detail, the reasons for the determination that such “Cause” exists, (B) afford Executive a reasonable opportunity to remedy any such breach, (C) provide Executive an opportunity to be heard prior to the final decision to terminate Executive’s employment hereunder for such “Cause” and (D) make any decision that such “Cause” exists in good faith.

|US-DOCS\116934360.3||


The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to discharge or dismiss Executive for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause.
(c)    “Change in Control” shall have the meaning ascribed to such term in the Zentalis Pharmaceuticals, Inc. 2020 Incentive Award Plan.

        (d)    “Code” means the Internal Revenue Code of 1986, as amended from time to time, and the Treasury Regulations and other interpretive guidance issued thereunder.
    (e)    “Good Reason” means the occurrence of any of the following events or conditions without Executive’s written consent:

(i)a change in Executive’s position or responsibilities that represents a substantial reduction in her position or responsibilities as in effect immediately prior thereto; the assignment to Executive of any duties or responsibilities that are materially inconsistent with such position or responsibilities; or any removal of Executive from or failure to reappoint or reelect Executive to any of such positions, except in connection with the termination of Executive’s services for Cause, as a result of her Permanent Disability or death, or by Executive other than for Good Reason;

            (ii)    a material reduction in Executive’s annual base salary;
            (iii)    the Company requiring Executive (without Executive’s consent) to be based at any place outside a ten (10)-mile radius of her then-current place of employment with the Company prior to any such relocation, except for reasonably required travel on the Company’s business; or
            (iv)    any material breach by the Company or any affiliate of its obligations to Executive under any applicable employment or services agreement between Executive and the Company or such affiliate.
    Executive must provide written notice to the Company of the occurrence of any of the foregoing events or conditions without Executive’s written consent within sixty (60) days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30) days to cure such event or condition after receipt of written notice of such event from Executive. Executive’s Separation from Service by reason of resignation from employment with the Company for Good Reason must occur within thirty (30) days following the expiration of the foregoing thirty (30) day cure period.
    (f)    “Involuntary Termination” means (i) Executive’s Separation from Service by reason of Executive’s discharge by the Company other than for Cause, or (ii) Executive’s Separation from Service by reason of Executive’s resignation of employment with the Company for Good Reason. Executive’s Separation from Service by reason of Executive’s death or discharge by the Company following Executive’s Permanent Disability shall not constitute an Involuntary Termination.
    2    
|US-DOCS\116934360.3||


    (g)    Executive’s “Permanent Disability” shall be deemed to have occurred if Executive shall become physically or mentally incapacitated or disabled or otherwise unable fully to discharge her duties hereunder for a period of ninety (90) consecutive calendar days or for one hundred twenty (120) calendar days in any one hundred eighty (180) calendar-day period. The existence of Executive’s Permanent Disability shall be determined by the Company on the advice of a physician chosen by the Company and the Company reserves the right to have Executive examined by a physician chosen by the Company at the Company’s expense.
         (h)     “Separation from Service,” with respect to Executive, means Executive’s “separation from service,” as defined in Treasury Regulation Section 1.409A-1(h).
        (i)    “Stock Awards” means all stock options, restricted stock and such other awards granted pursuant to the Company’s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof, including the Options (as defined below).    
2.    Services to Be Rendered.
    (a)    Duties and Responsibilities. Executive shall serve as Chief Legal Officer of the Company. In the performance of such duties, Executive shall report directly to, and shall be subject to the direction of, the Chief Executive Officer of the Company (the “Supervising Officer”) and to such limits upon Executive’s authority as the Supervising Officer may from time to time impose. In the event of the Supervising Officer’s unavailability or incapacity, Executive shall report directly to the Board. Executive hereby consents to serve as an officer and/or director of the Company, Parent or any subsidiary or affiliate thereof without any additional salary or compensation, if so requested by the Board or the Supervising Officer. Executive shall be employed by the Company on a full time basis. Executive shall work at the Company’s offices in New York, New York, although there is no expectation that Executive will work from the office in person unless and until the office is reopened for personnel under local guidelines and Executive and the Company agree it is safe to return. Executive will also be expected to travel to the Company’s locations as needed in connection with her duties. Executive shall be subject to and comply with the policies and procedures generally applicable to senior executives of the Company to the extent the same are not inconsistent with any term of this Agreement.
    (b)    Exclusive Services. Executive shall at all times faithfully, industriously and to the best of her ability, experience and talent perform all of the duties that may be assigned to Executive hereunder and shall devote substantially all of her productive time and efforts to the performance of such duties. Subject to the terms of the Proprietary Information and Inventions Agreement referred to in Section 5(b), this shall not preclude Executive from (i) serving on industry, trade, civic, or charitable boards or committees; or (ii) managing personal, family and other investments; provided that such activities do not interfere with her duties to the Company, as determined in good faith by the Supervising Officer or the Board.
3.Compensation and Benefits. The Company shall pay or provide, as the case may be, to Executive the compensation and other benefits and rights set forth in this Section 3.
(a)Base Salary. The Company shall pay to Executive a base salary of $400,000 per year, payable in accordance with the Company’s usual pay practices (and in any event no less frequently than monthly). Executive’s base salary shall be subject to review annually by and at the sole discretion of the Board or its designee.
(b)Annual Bonus. Executive shall participate in any annual bonus plan that the Board or its designee may approve for the senior executives of the Company. In addition to
    3    
|US-DOCS\116934360.3||


Executive’s base salary, Executive may be eligible to earn, for each fiscal year of the Company ending during the term of Executive’s employment with the Company, an annual cash performance bonus under the Company’s bonus plan, as approved from time to time by the Board. Executive’s target bonus under any such annual bonus plan shall be forty percent (40%) of Executive’s base salary actually paid for the year to which such annual bonus relates (the “Target Bonus”). Executive’s actual annual bonus will be determined on the basis of Executive’s and/or the Company’s or its affiliates’ attainment of financial or other performance criteria established by the Board or its designee in accordance with the terms and conditions of such bonus plan. Except as otherwise provided in this Agreement, Executive must be employed by the Company on the date of payment of such annual bonus in order to be eligible to receive such annual bonus. Executive hereby acknowledges and agrees that nothing contained herein confers upon Executive any right to an annual bonus in any year, and that whether the Company pays Executive an annual bonus and the amount of any such annual bonus will be determined by the Company in its sole discretion. Executive’s bonus for 2020 shall not be pro-rated to reflect the portion of the year that Executive is employed by the Company, and Executive shall be eligible for a full annual bonus for 2020.
(c)Benefits. Executive shall be entitled to participate in benefits under the Company’s benefit plans and arrangements, including, without limitation, any employee benefit plan or arrangement made available in the future by the Company to its senior executives, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and arrangements. The Company shall have the right to amend or delete any such benefit plan or arrangement made available by the Company to its senior executives and not otherwise specifically provided for herein.
(d)Expenses. The Company shall reimburse Executive for reasonable out-of-pocket business expenses incurred in connection with the performance of her duties hereunder, subject to such policies as the Company may from time to time establish, and Executive furnishing the Company with evidence in the form of receipts satisfactory to the Company substantiating the claimed expenditures.
(e)    Paid Time Off. Executive shall be entitled to such periods of paid time off (“PTO”) each year as provided from time to time under the Company’s PTO policy and as otherwise provided for senior executive officers; provided, however, that Executive shall be entitled to a minimum of twenty (20) days of PTO per year.
(f)    Initial Equity Award. As soon as practicable following the Effective Date, Executive will be granted stock options (the “Options”) to purchase 275,000 shares of the common stock of Zentalis Pharmaceuticals, Inc. (“Parent”). The Options will have an exercise price equal to the fair market value of Parent’s common stock on the date of grant. The Options will be subject to the terms and conditions of the Zentalis Pharmaceuticals, Inc. 2020 Incentive Award Plan pursuant to which they will be granted and Executive’s award agreement. The Options shall vest over a four (4)-year vesting schedule, with twenty-five percent (25%) of the Options vesting on the first anniversary of the Effective Date and the remaining Options vesting in equal monthly installments over the three (3) years thereafter.
(g)Equity and Other Benefit Plans. Executive shall be entitled to participate in any equity or other employee benefit plan that is generally available to senior executive officers of the Company. Except as otherwise provided in this Agreement, Executive’s participation in and benefits under any such plan shall be on the terms and subject to the conditions specified in the governing document of the particular plan.
    4    
|US-DOCS\116934360.3||


4.    Severance. Executive shall be entitled to receive benefits upon a Separation from Service only as set forth in this Section 4:
(a)    At-Will Employment; Termination. The Company and Executive acknowledge that Executive’s employment is and shall continue to be at-will, as defined under applicable law, and that Executive’s employment with the Company may be terminated by either party at any time for any or no reason, with or without notice. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in this Agreement. Executive’s employment under this Agreement shall be terminated immediately on the death of Executive.
(b)    Severance Upon Involuntary Termination. Subject to Sections 4(d) and 9(o) and Executive’s continued compliance with Section 5, if Executive’s employment is Involuntarily Terminated, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive may otherwise be entitled under any severance plan or program of the Company, the benefits provided below:
    (i)    the Company shall pay to Executive her fully earned but unpaid base salary, when due, through the date of Executive’s Involuntary Termination at the rate then in effect, accrued and unused PTO, plus all other benefits, if any, under any Company group retirement plan, nonqualified deferred compensation plan, equity award plan or agreement, health benefits plan or other Company group benefit plan to which Executive may be entitled pursuant to the terms of such plans or agreements at the time of Executive’s Involuntary Termination (the “Accrued Obligations”); and
    (ii)    Executive shall be entitled to receive severance pay in an amount equal to (A) Executive’s monthly base salary as in effect immediately prior to the date of Executive’s Involuntary Termination, multiplied by (B) nine (9), which amount shall be payable in a lump sum sixty (60) days following Executive’s Involuntary Termination;
    (iii)    Executive shall be entitled to receive Executive’s Target Bonus for the year in which Executive’s Involuntary Termination occurs, prorated for the portion of the year that has elapsed prior to the date of Executive’s Involuntary Termination, which amount shall be payable in a lump sum sixty (60) days following Executive’s Involuntary Termination;
    (iv)     for the period beginning on the date of Executive’s Involuntary Termination and ending on the date which is nine (9) full months following the date of Executive’s Involuntary Termination (or, if earlier, (A) the date on which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) expires or (B) the date Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment) (such period, the “COBRA Coverage Period”), if Executive and/or her eligible dependents who were covered under the Company’s health insurance plans as of the date of Executive’s Involuntary Termination elect to have COBRA coverage and are eligible for such coverage, the Company shall pay for or reimburse Executive on a monthly basis for an amount equal to (1) the monthly premium Executive and/or her covered dependents, as applicable, are required to pay for continuation coverage pursuant to COBRA for Executive and/or her eligible dependents, as applicable, who were covered under the Company’s health plans as of the date of Executive’s Involuntary Termination (calculated by reference to the premium as of the date of Executive’s Involuntary Termination) less (2) the amount Executive would have had to pay to receive group health coverage for Executive and/or her covered dependents, as applicable, based on the cost sharing levels in effect on the date of Executive’s Involuntary Termination. If any of the Company’s health benefits are self-funded as of the date of Executive’s Involuntary Termination, or if the Company cannot provide the foregoing benefits in a manner that is exempt
    5    
|US-DOCS\116934360.3||


from Section 409A (as defined below) or that is otherwise compliant with applicable law (including, without limitation, Section 2716 of the Public Health Service Act), instead of providing the payments or reimbursements as set forth above, the Company shall instead pay to Executive the foregoing monthly amount as a taxable monthly payment for the COBRA Coverage Period (or any remaining portion thereof). Executive shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums. Executive shall notify the Company immediately if Executive becomes eligible to receive the equivalent or increased healthcare coverage by means of subsequent employment or self-employment; and
    (v)     (A) in the event of Executive’s Involuntary Termination within eighteen (18) months following a Change in Control, (1) the references to nine (9) months in clauses (ii) and (iv) shall be increased to twelve (12) months, and (2) the Target Bonus payable pursuant to clause (iii) shall not be subject to proration, and (B) in the event of Executive’s Involuntary Termination at any time following a Change in Control, all of Executive’s Stock Awards will vest on an accelerated basis effective as of the date of Executive’s Involuntary Termination.
(c)    Termination for Cause, Voluntary Resignation Without Good Reason, Death or Termination for Permanent Disability. In the event of Executive’s termination of employment as a result of Executive’s discharge by the Company for Cause, Executive’s resignation without Good Reason, Executive’s death or Executive’s termination of employment following Executive’s Permanent Disability, the Company shall not have any other or further obligations to Executive under this Agreement (including any financial obligations) except that Executive shall be entitled to receive the Accrued Obligations. The foregoing shall be in addition to, and not in lieu of, any and all other rights and remedies which may be available to the Company under the circumstances, whether at law or in equity.
(d)    Release. As a condition to Executive’s receipt of any post-termination benefits pursuant to Section 4(b) above, Executive (or, in the event of Executive’s incapacity as a result of her Permanent Disability, Executive’s legal representative) shall execute and not revoke a general release of all claims in favor of the Company and its affiliates (the “Release”) in the form attached hereto as Exhibit A. In the event the Release does not become effective within the fifty-five (55) day period following the date of Executive’s Involuntary Termination, Executive shall not be entitled to the aforesaid payments and benefits.
        (e)    Exclusive Remedy. Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive’s rights to salary, severance, benefits, bonuses and other amounts hereunder (if any) accruing after the termination of Executive’s employment shall cease upon such termination. In the event of Executive’s termination of employment with the Company, Executive’s sole remedy shall be to receive the payments and benefits described in this Section 4. In addition, Executive acknowledges and agrees that she is not entitled to any reimbursement by the Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to this Section 4, including, without limitation, any excise tax imposed by Section 4999 of the Code. Any payments made to Executive under this Section 4 shall be inclusive of any amounts or benefits to which Executive may be entitled pursuant to the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor regulations thereunder, or any similar state statute.
        (f)    No Mitigation. Except as otherwise provided in Section 4(b)(iv) above, Executive shall not be required to mitigate the amount of any payment provided for in this Section 4 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section 4 be reduced by any compensation earned
    6    
|US-DOCS\116934360.3||


by Executive as the result of employment by another employer or self-employment or by retirement benefits; provided, however, that loans, advances or other amounts owed by Executive to the Company may be offset by the Company against amounts payable to Executive under this Section 4.
(g)    Return of the Company’s Property. In the event of Executive’s termination of employment for any reason, the Company shall have the right, at its option, to require Executive to vacate her offices prior to or on the effective date of separation and to cease all activities on the Company’s behalf. Upon Executive’s termination of employment in any manner, as a condition to Executive’s receipt of any severance benefits described in this Agreement, Executive shall immediately surrender to the Company all lists, books and records of, or in connection with, the Company’s business, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company. Executive shall deliver to the Company a signed statement certifying compliance with this Section 4(g) prior to the receipt of any severance benefits described in this Agreement.
5.    Certain Covenants.

1.Noncompetition. Except as may otherwise be approved by the Board, during the term of Executive’s employment, Executive shall not have any ownership interest (of record or beneficial) in, or have any interest as an employee, salesman, consultant, officer or director in, or otherwise aid or assist in any manner, any firm, corporation, partnership, proprietorship or other business that engages in any county, city or part thereof in the United States and/or any foreign country in a business which competes directly or indirectly (as determined by the Board) with the Company’s business in such county, city or part thereof, so long as the Company, or any successor in interest of the Company to the business and goodwill of the Company, remains engaged in such business in such county, city or part thereof or continues to solicit customers or potential customers therein; provided, however, that Executive may own, directly or indirectly, solely as an investment, securities of any entity which are traded on any national securities exchange if Executive (i) is not a controlling person of, or a member of a group which controls, such entity; or (ii) does not, directly or indirectly, own one percent (1%) or more of any class of securities of any such entity.
2.Confidential Information. Executive and the Company have entered into the Company’s standard proprietary information and inventions assignment agreement (the “Proprietary Information and Inventions Agreement”). Executive agrees to perform each and every obligation of Executive therein contained.
3.Solicitation of Employees. During the term of Executive’s employment or service and for one (1) year thereafter (the “Restricted Period”), Executive will not, either directly or through others, solicit or attempt to solicit any employee, independent contractor or consultant of the Company or its affiliates to terminate her relationship with the Company or its affiliates in order to become an employee, consultant or independent contractor to or for any other person or entity, or otherwise encourage or solicit any employee of the Company or its affiliates to leave the Company or such affiliates for any reason or to devote less than all of any
    7    
|US-DOCS\116934360.3||


such employee’s efforts to the affairs of the Company; provided that the foregoing shall not affect any responsibility Executive may have as an employee of the Company with respect to the bona fide hiring and firing of Company personnel.
4.Solicitation of Consultants. Executive shall not during the term of Executive’s employment or service and for the Restricted Period, directly or indirectly, hire, solicit or encourage to cease work with the Company or any of its affiliates any consultant then under contract with the Company or any of its affiliates.
5.Nondisparagement. Executive agrees that neither she nor anyone acting by, through, under or in concert with her shall disparage or otherwise communicate negative statements or opinions about the Company, Parent, or their respective board members, officers, employees or businesses. The Company agrees that neither its Board members nor officers, nor the board members or officers of Parent, shall disparage or otherwise communicate negative statements or opinions about Executive. Except as may be required by law, neither Executive, nor any member of Executive’s family, nor anyone else acting by, through, under or in concert with Executive will disclose to any individual or entity (other than Executive’s legal or tax advisors) the terms of this Agreement.
6.Rights and Remedies Upon Breach. If Executive breaches or threatens to commit a breach of any of the provisions of this Section 5 (the “Restrictive Covenants”), the Company shall have the following rights and remedies, each of which rights and remedies shall be independent of the other and severally enforceable, and all of which rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity:
a.Specific Performance. The right and remedy to have the Restrictive Covenants specifically enforced by any court having equity jurisdiction, all without the need to post a bond or any other security or to prove any amount of actual damage or that money damages would not provide an adequate remedy, it being acknowledged and agreed that any such breach or threatened breach will cause irreparable injury to the Company and that money damages will not provide adequate remedy to the Company; and
b.Accounting and Indemnification. The right and remedy to require Executive (A) to account for and pay over to the Company all compensation, profits, monies, accruals, increments or other benefits derived or received by Executive or any associated party deriving such benefits as a result of any such breach of the Restrictive Covenants; and (B) to indemnify the Company against any other losses, damages (including special and consequential damages), costs and expenses, including actual attorneys’ fees and court costs, which may be incurred by them and which result from or arise out of any such breach or threatened breach of the Restrictive Covenants.
(g)    Severability of Covenants/Blue Pencilling. If any court determines that any of the Restrictive Covenants, or any part thereof, is invalid or unenforceable, the remainder of the Restrictive Covenants shall not thereby be affected and shall be given full effect, without regard to the invalid portions. If any court determines that any of the Restrictive Covenants, or any part
    8    
|US-DOCS\116934360.3||


thereof, are unenforceable because of the duration of such provision or the area covered thereby, such court shall have the power to reduce the duration or area of such provision and, in its reduced form, such provision shall then be enforceable and shall be enforced. Executive hereby waives any and all right to attack the validity of the Restrictive Covenants on the grounds of the breadth of their geographic scope or the length of their term.
(h)    Enforceability in Jurisdictions. The Company and Executive intend to and do hereby confer jurisdiction to enforce the Restrictive Covenants upon the courts of any jurisdiction within the geographical scope of such covenants. If the courts of any one or more of such jurisdictions hold the Restrictive Covenants wholly unenforceable by reason of the breadth of such scope or otherwise, it is the intention of the Company and Executive that such determination not bar or in any way affect the right of the Company to the relief provided above in the courts of any other jurisdiction within the geographical scope of such covenants, as to breaches of such covenants in such other respective jurisdictions, such covenants as they relate to each jurisdiction being, for this purpose, severable into diverse and independent covenants.
(i)    Whistleblower Provision. Nothing herein shall be construed to prohibit Executive from communicating directly with, cooperating with, or providing information to, any government regulator, including, but not limited to, the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading Commission, or the U.S. Department of Justice. Executive acknowledges that the Company has provided Executive with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (ii) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (iii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the proprietary information to Executive’s attorney and use the proprietary information in the court proceeding, if Executive files any document containing the proprietary information under seal, and does not disclose the proprietary information, except pursuant to court order.
(j)    Definitions. For purposes of this Section 5, the term “Company” means not only Zeno Management, Inc., but also Parent as well as any company, partnership or entity which, directly or indirectly, controls, is controlled by or is under common control with Zeno Management, Inc.
6.    Insurance; Indemnification.
    (a)    Insurance. The Company shall have the right to take out life, health, accident, “key-man” or other insurance covering Executive, in the name of the Company and at the Company’s expense in any amount deemed appropriate by the Company. Executive shall assist the Company in obtaining such insurance, including, without limitation, submitting to any required examinations and providing information and data required by insurance companies.
    9    
|US-DOCS\116934360.3||


    (b)    Indemnification. Executive will be provided with indemnification against third party claims related to her work for the Company to the extent permitted by Delaware law. The Company shall provide Executive with directors and officers liability insurance coverage at least as favorable as that which the Company may maintain from time to time for other executive officers.
7.    Arbitration. Any dispute, claim or controversy based on, arising out of or relating to Executive’s employment or this Agreement shall be settled by final and binding arbitration in New York, New York, before a single neutral arbitrator in accordance with the JAMS Employment Arbitration Rules and Procedures (the “Rules”), and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. The Rules may be found online at www.jamsadr.com. If the parties are unable to agree upon an arbitrator, one shall be appointed by JAMS in accordance with its Rules. Each party shall pay the fees of its own attorneys, the expenses of its witnesses and all other expenses connected with presenting its case; provided, however, Executive and the Company agree that, to the extent permitted by law, the arbitrator may, in his or her discretion, award reasonable attorneys’ fees to the prevailing party; provided, further, that the prevailing party shall be reimbursed for such fees, costs and expenses within forty-five (45) days following any such award, but in no event later than the last day of Executive’s taxable year following the taxable year in which the fees, costs and expenses were incurred; provided, further, that the parties’ obligations pursuant to this sentence shall terminate on the tenth (10th) anniversary of the date of Executive’s termination of employment. Other costs of the arbitration, including the cost of any record or transcripts of the arbitration, JAMS administrative fees, the fee of the arbitrator, and all other fees and costs, shall be borne by the Company. This Section 7 is intended to be the exclusive method for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to Executive’s employment; provided, however, that Executive shall retain the right to file administrative charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to (a) claims for workers’ compensation, state disability insurance or unemployment insurance; (b) administrative claims brought before any state or federal governmental authority; provided, however, that any appeal from an award or from denial of an award of wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this Agreement; and (c) claims for administrative relief from the United States Equal Employment Opportunity Commission and/or any similar state agency in any applicable jurisdiction); provided, further, that Executive shall not be entitled to obtain any monetary relief through such agencies other than workers’ compensation benefits or unemployment insurance benefits. This Agreement shall not limit either party’s right to obtain any provisional remedy, including, without limitation, injunctive or similar relief, from any court of competent jurisdiction as may be necessary to protect their rights and interests pending the outcome of arbitration, including without limitation injunctive relief, in any court of competent jurisdiction. Seeking any such relief shall not be deemed to be a waiver of such party’s right to compel arbitration. Both Executive and the Company expressly waive their right to a jury trial.
8.    General Relationship. Executive shall be considered an employee of the Company within the meaning of all federal, state and local laws and regulations including, but not limited to, laws and regulations governing unemployment insurance, workers’ compensation, industrial accident, labor and taxes.
9.    Miscellaneous.
(a)    Modification; Prior Claims. This Agreement and the Proprietary Information and Inventions Agreement (and the other documents referenced therein) set forth the entire
    10    
|US-DOCS\116934360.3||


understanding of the parties with respect to the subject matter hereof, and supersede all existing agreements between them concerning such subject matter, including any offer letter between the Company and Executive. This Agreement may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever.
(b)    Assignment; Assumption by Successor. The rights of the Company under this Agreement may, without the consent of Executive, be assigned by the Company, in its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly, acquires all or substantially all of the assets or business of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; provided, however, that no such assumption shall relieve the Company of its obligations hereunder.  As used in this Agreement, the “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by operation of law or otherwise.
(c)    Survival. The covenants, agreements, representations and warranties contained in or made in Sections 4, 5, 6, 7 and 9 of this Agreement shall survive Executive’s termination of employment.
(d)    ThirdParty Beneficiaries. Except as expressly set forth herein, this Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement.
(e)    Waiver. The failure of either party hereto at any time to enforce performance by the other party of any provision of this Agreement shall in no way affect such party’s rights thereafter to enforce the same, nor shall the waiver by either party of any breach of any provision hereof be deemed to be a waiver by such party of any other breach of the same or any other provision hereof.
(f)    Section Headings. The headings of the several sections in this Agreement are inserted solely for the convenience of the parties and are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof.
(g)    Notices. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by email, telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to Executive at the address listed on the Company’s personnel records and to the Company at its principal place of business, or such other address as either party may specify in writing.
    11    
|US-DOCS\116934360.3||


(h)    Severability. All Sections, clauses and covenants contained in this Agreement are severable, and in the event any of them shall be held to be invalid by any court, this Agreement shall be interpreted as if such invalid Sections, clauses or covenants were not contained herein.
(i)    Governing Law and Venue. This Agreement is to be governed by and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Except as provided in Sections 5 and 7, any suit brought hereon shall be brought in the state or federal courts sitting in New York, New York, the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by New York law.
(j)    Non-transferability of Interest. None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement shall be assignable or transferable except through a testamentary disposition or by the laws of descent and distribution upon the death of Executive. Any attempted assignment, transfer, conveyance, or other disposition (other than as aforesaid) of any interest in the rights of Executive to receive any form of compensation to be made by the Company pursuant to this Agreement shall be void.
(k)    Gender. Where the context so requires, the use of the masculine gender shall include the feminine and/or neuter genders and the singular shall include the plural, and vice versa, and the word “person” shall include any corporation, firm, partnership or other form of association.
(l)    Counterparts; Facsimile or .pdf Signatures. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Agreement may be executed and delivered by facsimile or by .pdf file and upon such delivery the facsimile or .pdf signature will be deemed to have the same effect as if the original signature had been delivered to the other party.
(m)    Construction. The language in all parts of this Agreement shall in all cases be construed simply, according to its fair meaning, and not strictly for or against any of the parties hereto. Without limitation, there shall be no presumption against any party on the ground that such party was responsible for drafting this Agreement or any part thereof.
(n)    Withholding and Other Deductions. All compensation payable to Executive hereunder shall be subject to such deductions as the Company is from time to time required to make pursuant to law, governmental regulation or order.
(o)    Code Section 409A.
        (i)    This Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly, the severance payments payable under Sections 4(b)(ii), (iii) and (v) shall be paid no later than the later
    12    
|US-DOCS\116934360.3||


of: (A) the fifteenth (15th) day of the third month following Executive’s first taxable year in which such amounts are no longer subject to a substantial risk of forfeiture, and (B) the fifteenth (15th) day of the third month following first taxable year of the Company in which such amounts are is no longer subject to substantial risk of forfeiture, as determined in accordance with Code Section 409A and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Agreement shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder. Each series of installment payments made under this Agreement is hereby designated as a series of “separate payments” within the meaning of Section 409A of the Code. For purposes of this Agreement, all references to Executive’s “termination of employment” shall mean Executive’s Separation from Service.
        (ii)    If Executive is a “specified employee” (as defined in Section 409A of the Code), as determined by the Company in accordance with Section 409A of the Code, on the date of Executive’s Separation from Service, to the extent that the payments or benefits under this Agreement are subject to Section 409A of the Code and the delayed payment or distribution of all or any portion of such amounts to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, then such portion deferred pursuant to this Section 9(o)(ii) shall be paid or distributed to Executive in a lump sum on the earlier of (A) the date that is six (6)-months following Executive’s Separation from Service, (B) the date of Executive’s death or (C) the earliest date as is permitted under Section 409A of the Code. Any remaining payments due under the Agreement shall be paid as otherwise provided herein.
c.To the extent applicable, this Agreement shall be interpreted in accordance with the applicable exemptions from Section 409A of the Code. If Executive and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections 409A(a)(2), (3) and (4) of the Code do not comply with Section 409A of the Code, Executive and the Company agree to amend this Agreement, or take such other actions as Executive and the Company deem reasonably necessary or appropriate, to comply with the requirements of Section 409A of the Code and the Treasury Regulations thereunder (and any applicable transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner that no payments payable under this Agreement shall be subject to an “additional tax” as defined in Section 409A(a)(1)(B) of the Code.
d.Any reimbursement of expenses or in-kind benefits payable under this Agreement shall be made in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv) and shall be paid on or before the last day of Executive’s taxable year following the taxable year in which Executive incurred the expenses. The amount of expenses reimbursed or in-kind benefits payable during any taxable year of Executive’s shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of Executive’s, and Executive’s right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit.
[Signature Page Follows]


    13    
|US-DOCS\116934360.3||


IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above.
                    Zeno Management, Inc.

                    By:     /s/ Anthony Y. Sun, M.D.        
                        Name:     Anthony Y. Sun, M.D.        
                        Title:     President and Chief Executive Officer

                    Executive

                      /s/ Alexis Pinto                
                        Alexis Pinto
SIGNATURE PAGE TO EMPLOYMENT AGREEMENT
|US-DOCS\116934360.3||


Exhibit A

GENERAL RELEASE OF CLAIMS

[The language in this Release may change based on legal developments and evolving best practices; this form is provided as an example of what will be included in the final Release document.]

    This General Release of Claims (“Release”) is entered into as of this _____ day of ________, ____, between Alexis Pinto (“Executive”), and Zeno Management, Inc. (the “Company”) (collectively referred to herein as the “Parties”).

    WHEREAS, Executive and the Company are parties to that certain Employment Agreement dated as of August 31, 2020 (the “Agreement”);

    WHEREAS, the Parties agree that Executive is entitled to certain severance benefits under the Agreement, subject to Executive’s execution of this Release; and

    WHEREAS, the Company and Executive now wish to fully and finally to resolve all matters between them.

    NOW, THEREFORE, in consideration of, and subject to, the severance benefits payable to Executive pursuant to the Agreement, the adequacy of which is hereby acknowledged by Executive, and which Executive acknowledges that she would not otherwise be entitled to receive, Executive and the Company hereby agree as follows:

    1.    General Release of Claims by Executive.

        (a)    Executive, on behalf of herself and her executors, heirs, administrators, representatives and assigns, hereby agrees to release and forever discharge the Company and all predecessors, successors and their respective parent corporations, affiliates, related, and/or subsidiary entities, and all of their past and present investors, directors, shareholders, officers, general or limited partners, employees, attorneys, agents and representatives, and the employee benefit plans in which Executive is or has been a participant by virtue of her employment with or service to the Company (collectively, the “Company Releasees”), from any and all claims, debts, demands, accounts, judgments, rights, causes of action, equitable relief, damages, costs, charges, complaints, obligations, promises, agreements, controversies, suits, expenses, compensation, responsibility and liability of every kind and character whatsoever (including attorneys’ fees and costs), whether in law or equity, known or unknown, asserted or unasserted, suspected or unsuspected (collectively, “Claims”), which Executive has or may have had against such entities based on any events or circumstances arising or occurring on or prior to the date hereof or on or prior to the date hereof, arising directly or indirectly out of, relating to, or in any other way involving in any manner whatsoever Executive’s employment by or service to the Company or the termination thereof, including any and all claims arising under federal, state, or local laws relating
1

|US-DOCS\116934360.3||


to employment, including without limitation claims of wrongful discharge, breach of express or implied contract, fraud, misrepresentation, defamation, or liability in tort, and claims of any kind that may be brought in any court or administrative agency including, without limitation, claims under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. Section 2000, et seq.; the Americans with Disabilities Act, as amended, 42 U.S.C. § 12101 et seq.; the Rehabilitation Act of 1973, as amended, 29 U.S.C. § 701 et seq.; the Civil Rights Act of 1866, and the Civil Rights Act of 1991; 42 U.S.C. Section 1981, et seq.; the Age Discrimination in Employment Act, as amended, 29 U.S.C. Section 621, et seq. (the “ADEA”); the Equal Pay Act, as amended, 29 U.S.C. Section 206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, et seq.; the Family and Medical Leave Act, as amended, 29 U.S.C. § 2601 et seq.; the Fair Labor Standards Act of 1938, as amended, 29 U.S.C. § 201 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.

    Notwithstanding the generality of the foregoing, Executive does not release the following claims:

    (i)    Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law;
    
    (ii)    Claims for workers’ compensation insurance benefits under the terms of any worker’s compensation insurance policy or fund of the Company;

    (iii)    Claims pursuant to the terms and conditions of the federal law known as COBRA;
    (iv)    Claims for indemnity under the bylaws of the Company, as provided for by Delaware law or under any applicable insurance policy with respect to Executive’s liability as an employee, director or officer of the Company;

    (v)    Executive’s right to bring to the attention of the Equal Employment Opportunity Commission or any other federal, state or local government agency claims of discrimination, or from participating in an investigation or proceeding conducted by the Equal Employment Opportunity Commission or any other federal, state or local government agency; provided, however, that Executive does release her right to secure any damages for alleged discriminatory treatment;

    (vi)    Claims based on any right Executive may have to enforce the Company’s executory obligations under the Agreement;

    (vii)    Claims Executive may have to vested or earned compensation and benefits; and

    (viii)    Executive’s right to communicate or cooperate with any government agency.
    
2

|US-DOCS\116934360.3||


        (b)    EXECUTIVE ACKNOWLEDGES THAT She HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:

    “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”

BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS SHE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.

[Note: Clauses (c), (d) and (e) apply only if Executive is age 40 or older at time of termination]

        (c)     Executive acknowledges that this Release was presented to her on the date indicated above and that Executive is entitled to have [twenty-one (21)][forty-five (45)] days’ time in which to consider it. Executive further acknowledges that the Company has advised her that she is waiving her rights under the ADEA, and that Executive should consult with an attorney of her choice before signing this Release, and Executive has had sufficient time to consider the terms of this Release. Executive represents and acknowledges that if Executive executes this Release before [twenty-one (21)][forty-five (45)] days have elapsed, Executive does so knowingly, voluntarily, and upon the advice and with the approval of Executive’s legal counsel (if any), and that Executive voluntarily waives any remaining consideration period.

        (d)     Executive understands that after executing this Release, Executive has the right to revoke it within seven (7) days after her execution of it. Executive understands that this Release will not become effective and enforceable unless the seven (7) day revocation period passes and Executive does not revoke the Release in writing. Executive understands that this Release may not be revoked after the seven (7) day revocation period has passed. Executive also understands that any revocation of this Release must be made in writing and delivered to the Company at its principal place of business within the seven (7) day period.

        (e)     Executive understands that this Release shall become effective, irrevocable, and binding upon Executive on the eighth (8th) day after her execution of it, so long as Executive has not revoked it within the time period and in the manner specified in clause (d) above.

        (f)    Executive further understands that Executive will not be given any severance benefits under the Agreement unless this Release is effective on or before the date that is fifty-five (55) days following the date of Executive’s termination of employment.

    2.    No Assignment. Executive represents and warrants to the Company Releasees that there has been no assignment or other transfer of any interest in any Claim that Executive may have against the Company Releasees. Executive agrees to indemnify and hold harmless the
3

|US-DOCS\116934360.3||


Company Releasees from any liability, claims, demands, damages, costs, expenses and attorneys’ fees incurred as a result of any such assignment or transfer from Executive.
3.    Severability. In the event any provision of this Release is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the benefit contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby.
4.    Interpretation; Construction. The headings set forth in this Release are for convenience only and shall not be used in interpreting this Agreement. This Release has been drafted by legal counsel representing the Company, but Executive has participated in the negotiation of its terms. Furthermore, Executive acknowledges that Executive has had an opportunity to review and revise the Release and have it reviewed by legal counsel, if desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Release. Either party’s failure to enforce any provision of this Release shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing each and every other provision of this Release.
5.    Governing Law and Venue. This Release will be governed by and construed in accordance with the laws of the United States of America and the State of New York applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Any suit brought hereon shall be brought in the state or federal courts sitting in New York, New York, the Parties hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by New York law.
6.    Entire Agreement. This Release and the Agreement constitute the entire agreement of the Parties in respect of the subject matter contained herein and therein and supersede all prior or simultaneous representations, discussions, negotiations and agreements, whether written or oral. This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever.
7.    Counterparts. This Release may be executed in multiple counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.
(Signature Page Follows)



4

|US-DOCS\116934360.3||


    IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing Release as of the date first written above.

Executive                        Zeno Management, Inc.
            
                            By:                         
Print Name: Alexis Pinto                 Print Name:                     
                            Title:                         




















|US-DOCS\116934360.3||
EX-31.1 4 zentalis10-qq32020ex311.htm EX-31.1 Document
Exhibit 31.1
CERTIFICATION
I, Anthony Y. Sun, M.D. certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)[omitted];
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2020
By:/s/ Anthony Y. Sun, M.D.
Anthony Y. Sun, M.D.
Chief Executive Officer, President and Chairman
(principal executive officer)


EX-31.2 5 zentalis10-qq32020ex312.htm EX-31.2 Document
Exhibit 31.2
CERTIFICATION
I, Melissa B. Epperly, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)[omitted];
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2020
By:/s/ Melissa B. Epperly
Melissa B. Epperly
Chief Financial Officer
(principal financial officer)


EX-32.1 6 zentalis10-qq32020ex321.htm EX-32.1 Document
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2020
By:/s/ Anthony Y. Sun, M.D.
Anthony Y. Sun, M.D.
Chief Executive Officer, President and Chairman
(principal executive officer)


EX-32.2 7 zentalis10-qq32020ex322.htm EX-32.2 Document
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Zentalis Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2020
By:/s/ Melissa B. Epperly
Melissa B. Epperly
Chief Financial Officer
(principal financial officer)


EX-101.SCH 8 zntl-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members’/Stockholders’ Equity/(Deficit) (Statement) link:presentationLink link:calculationLink link:definitionLink 1407401 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members’/Stockholders’ Equity/(Deficit) (Parenthetical)) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Organization and Business (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Interim Unaudited Financial Statements link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Interim Unaudited Financial Statements (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Interim Unaudited Financial Statements (Tables) link:presentationLink link:calculationLink link:definitionLink 2106103 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 2307302 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Business Combinations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Business Combinations - Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Business Combinations - Rollforward of Noncontrolling Interest (Details) link:presentationLink link:calculationLink link:definitionLink 2111104 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 2312303 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Fair Value Measurement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2416409 - Disclosure - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Prepaid Expenses and Other Assets link:presentationLink link:calculationLink link:definitionLink 2318304 - Disclosure - Prepaid Expenses and Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Prepaid Expenses and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Prepaid Expenses and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2120106 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 2321305 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Property and Equipment, net - Summary (Details) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Property and Equipment, net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2124107 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 2325306 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2426413 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Convertible Preferred Units link:presentationLink link:calculationLink link:definitionLink 2328307 - Disclosure - Convertible Preferred Units (Tables) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Convertible Preferred Units - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - Convertible Preferred Units - Schedule of Units Authorized, Issued, and Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2131109 - Disclosure - Equity and Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 2332308 - Disclosure - Equity and Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2433416 - Disclosure - Equity and Share-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2434417 - Disclosure - Equity and Share-based Compensation - Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2435418 - Disclosure - Equity and Share-based Compensation - Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2436419 - Disclosure - Equity and Share-based Compensation - Fair Value Assumptions for Profit Interest Awards (Details) link:presentationLink link:calculationLink link:definitionLink 2437420 - Disclosure - Equity and Share-based Compensation - Fair Value Assumptions for Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2438421 - Disclosure - Equity and Share-based Compensation - Unrecognized Compensation Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2139110 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 2340309 - Disclosure - Commitment and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2441422 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2441422 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2442423 - Disclosure - Commitment and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2143111 - Disclosure - Net Loss Per Common Share/Class A Common Unit link:presentationLink link:calculationLink link:definitionLink 2344310 - Disclosure - Net Loss Per Common Share/Class A Common Unit (Tables) link:presentationLink link:calculationLink link:definitionLink 2445424 - Disclosure - Net Loss Per Common Share/Class A Common Unit - Calculation (Details) link:presentationLink link:calculationLink link:definitionLink 2446425 - Disclosure - Net Loss Per Common Share/Class A Common Unit - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2147112 - Disclosure - Related Party Disclosures link:presentationLink link:calculationLink link:definitionLink 2448426 - Disclosure - Related Party Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 zntl-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 zntl-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 zntl-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Awards granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Document Type Document Type Conversion of common and incentive units to common stock (in shares) Stock issued upon conversion of units (in shares) Stock Issued During Period, Shares, Conversion of Units Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Related Party [Axis] Related Party [Axis] Schedule of Assets and Liabilities of VIE Schedule of Variable Interest Entities [Table Text Block] Series A Preferred Units Series A Preferred Stock [Member] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Payables and Accruals [Abstract] The Plan 2017 Profit Interest Plan [Member] 2017 Profit Interest Plan Par value per share (in dollars per share) Temporary Equity, Par or Stated Value Per Share Class A and B common units, issuance value Common units, beginning balance Common units, ending balance Common Unit, Issuance Value Expenses from transactions with related party Related Party Transaction, Expenses from Transactions with Related Party Long-term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Category of Item Purchased [Domain] After one but within five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES, CONVERTIBLE PREFERRED UNITS AND EQUITY/(DEFICIT) Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Deferred tax liability Deferred Income Tax Liabilities, Net Preferred Stock Preferred Stock [Member] Security Exchange Name Security Exchange Name Time to liquidity (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Time to Liquidity Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Time to Liquidity EQUITY (DEFICIT) Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Common stock subject to future vesting provisions (in shares) Common Stock, Shares, Subject to Future Vesting Provisions Common Stock, Shares, Subject to Future Vesting Provisions Conversion price (in dollars per share) Temporary Equity, Redemption Price Per Share Number of executives entering restricted stock agreement Share-based Payment Arrangement, Number of Executives Entering Restricted Stock Agreement Share-based Payment Arrangement, Number of Executives Entering Restricted Stock Agreement Operating loss Operating Income (Loss) Conversion of common and incentive units to common and restricted stock Stock Issued During Period, Value, Conversion of Units Total current liabilities Liabilities, Current Prepaid expenses and other current assets Total prepaid expenses and other assets, current Prepaid Expense and Other Assets, Current Reclassification of convertible preferred units for contingent liquidation features not within the Company's control (in shares) Temporary Equity, Stock Issued During Period, Shares, Reclassification of Stock Temporary Equity, Stock Issued During Period, Shares, Reclassification of Stock Commitments and contingencies Commitments and Contingencies ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounting Policies [Abstract] Restricted stock vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Lab equipment Laboratory Equipment [Member] Laboratory Equipment Entity Address, State or Province Entity Address, State or Province Incentive units—Class B common units Class B Common Incentive Units [Member] Class B Common Incentive Units Accounts payable Accounts Payable, Current Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Shares issued (in shares) Temporary Equity, Shares Issued Accumulated deficit Retained Earnings (Accumulated Deficit) Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Prepaid Expenses and Other Assets Other Assets Disclosure [Text Block] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Class B Common Units Common Class B [Member] Options number outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Automatic conversion feature, minimum gross cash proceeds received in a public offering Temporary Equity, Automatic Conversion Feature, Gross Cash Proceeds Minimum Amount Received In A Public Offering Temporary Equity, Automatic Conversion Feature, Gross Cash Proceeds Minimum Amount Received In A Public Offering Expenses and Fees from the Issuance of Common Stock Expenses and Fees from the Issuance of Common Stock Expenses and Fees from the Issuance of Common Stock Beginning balance, in shares Ending balance, in shares Shares, Outstanding Preferred stock, value Preferred Stock, Value, Issued Real Estate, 1.2 Year Lease Term Real Estate, 1.2 Year Lease Term [Member] Real Estate, 1.2 Year Lease Term Total operating expenses Operating Expenses Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Other long-term liabilities Other Liabilities, Noncurrent Share-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Liquidation Value Temporary Equity, Liquidation Preference Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Business Acquisition [Axis] Business Acquisition [Axis] Corporate Conversion Corporate Conversion [Member] Corporate Conversion Equipment purchase and sale agreement Long-term Purchase Commitment, Amount Statement [Line Items] Statement [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Unit Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Forecast Forecast [Member] Class of Stock [Domain] Class of Stock [Domain] Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Preferred stock, shares issued (in shares) Number of shares acquired (in shares) Preferred Stock, Shares Issued US government agencies US Government Agencies Debt Securities [Member] Common units, authorized (in shares) Common Unit, Authorized Business Combinations [Abstract] Marketable Securities Marketable Securities, Policy [Policy Text Block] Net loss per share outstanding, basic and diluted (USD per share) Net loss per Class A common unit (USD per share) Earnings Per Share, Basic and Diluted Entity Small Business Entity Small Business Consolidation Consolidation, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Number of shares issued and sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Proceeds from issuance of common stock, net Proceeds from Issuance of Common Stock Amendment Flag Amendment Flag Schedule of Basic and Diluted Net Loss Per Unit Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Stock Cancelled During Period, Shares Stock Cancelled During Period, Shares Stock Cancelled During Period, Shares Share-based Compensation Expense by Type of Share-based Award Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Shares authorized to be issued under plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Profit interest award units Profit Interest Awards Profit Interest Awards [Member] Profit Interest Awards Other Other Accrued Liabilities, Current Reconciliation Of Equity Attributable to Noncontrolling Interest Reconciliation Of Noncontrolling Interest [Table Text Block] Reconciliation Of Noncontrolling Interest Cancellation of restricted stock awards Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Related Party [Domain] Related Party [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Series B Preferred Units Series B Preferred Stock [Member] Financial Instruments [Domain] Financial Instruments [Domain] Upfront lease payment Lessee, Operating Lease, Prepaid Lease Payment Lessee, Operating Lease, Prepaid Lease Payment Due from related parties Due from Related Parties Capital Addition Purchase Commitments Capital Addition Purchase Commitments [Member] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Unrecognized expense, stock options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Accrued general and administrative expenses Accrued General And Administrative Costs, Current Accrued General And Administrative Costs, Current Income Statement Location [Axis] Income Statement Location [Axis] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Summary of Prepaid Expenses and Other Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Other long-term assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] Units authorized (in shares) Temporary Equity, Shares Authorized Stock issued, value Stock Issued During Period, Value, New Issues Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Gross proceeds from issuance of convertible preferred units Proceeds From Issuance Of Redeemable Convertible Preferred Stock, Gross Proceeds From Issuance Of Redeemable Convertible Preferred Stock, Gross Total assets Assets Related Party Disclosures Related Party Transactions Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Organization and Business Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Title of 12(b) Security Title of 12(b) Security Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Weighted-average grant date fair value of options (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Common units, issued (in shares) Common Unit, Issued Number of shares converted (in shares) Conversion of Stock, Shares Issued Antidilutive Securities [Axis] Antidilutive Securities [Axis] Zentera Stock Plan Zentera Stock Plan [Member] Zentera Stock Plan Convertible preferred units, redemption value Temporary Equity, Aggregate Amount of Redemption Requirement Depreciation and amortization Depreciation, Depletion and Amortization Recently Issued Accounting Standards Adopted and Not Yet Adopted Accounting Standards Update and Change in Accounting Principle [Table Text Block] Reclassification of convertible preferred units for contingent liquidation features not within the Company's control Reclassifications of Stock to Temporary Equity, Value Reclassifications of Stock to Temporary Equity, Value Total liabilities Liabilities Cash payments to acquire interest Payments to Acquire Businesses and Interest in Affiliates Employee benefits and share-based compensation Employee Benefits and Share-based Compensation Remaining Weighted-Average Recognition Period (years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Schedule of Temporary Equity Temporary Equity [Table Text Block] Volatility (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accrued research and development expenses Accrued Research And Development Costs, Current Accrued Research And Development Costs, Current Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Fair value of available-for-sale securities in unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Commitments and Contingencies Disclosure [Abstract] Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Prepaid software licenses and maintenance Prepaid Software License And Maintenance Prepaid Software License And Maintenance Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Additional Paid-in Capital Additional Paid-in Capital [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Common stock outstanding (in shares) Common Stock, Shares, Outstanding Operating Expenses Operating Costs and Expenses [Abstract] Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development Research and Development Expense IPO IPO [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Ownership percentage Business Acquisition, Percentage of Voting Interests Acquired Subtotal Property, Plant and Equipment, Gross Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Contractual Maturities of Available-for-sale Debt Securities Investments Classified by Contractual Maturity Date [Table Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Underwriters Over-Allotment Option [Member] Preferred units authorized (in shares) Preferred Units, Authorized VIE, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Current assets Assets, Current [Abstract] Investment and other income, net Investment Income, Interest Consolidated Entities [Axis] Consolidated Entities [Axis] Master Services Agreement Master Services Agreement [Member] Master Services Agreement Comprehensive loss attributable to Zentalis Comprehensive Income (Loss), Net of Tax, Attributable to Parent The 2020 Plan 2020 Incentive Award Plan [Member] 2020 Incentive Award Plan Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Scenario [Domain] Scenario [Domain] Legal Entity [Axis] Legal Entity [Axis] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Document Period End Date Document Period End Date Property, Plant and Equipment [Abstract] Net loss Net loss Consolidated net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Total stockholders’ equity/members’ (deficit) Members’ equity value (in thousands) Members' Equity Share-based compensation Share-based Payment Arrangement, Noncash Expense Entity [Domain] Entity [Domain] Shares issued upon vesting of certain RSAs (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Cover [Abstract] Components of Available-for-sale Marketable Securities Debt Securities, Available-for-sale [Table Text Block] Debt securities fair market value Debt Securities, Trading Zentera Sublicenses Zentera Therapeutics Ltd. [Member] Zentera Therapeutics Ltd. Total equity (deficit) Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Affiliated Entity Affiliated Entity [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Common units, outstanding (in shares) Common units, beginning balance (in shares) Common units, ending balance (in shares) Common Unit, Outstanding Fair Value Disclosures [Abstract] Noncontrolling interests Members' Equity Attributable to Noncontrolling Interest Marketable securities, available-for-sale Debt securities, available-for-sale, fair value Debt Securities, Available-for-sale Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Equity Components [Axis] Equity Components [Axis] RSAs Restricted Stock [Member] Minimum Minimum [Member] Consolidated Entities [Domain] Consolidated Entities [Domain] Lease liability Operating Lease, Liability, Current Unrecognized expense, other than options Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Liquidation preference (in dollars per share) Temporary Equity, Liquidation Preference Per Share Convertible Preferred Units Temporary Equity [Text Block] Temporary Equity Non-Option equity Instruments, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Schedule of Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Fair Value Measurement Fair Value Disclosures [Text Block] Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Numerator: Earnings Per Share, Numerator [Abstract] Earnings Per Share, Numerator Entity Registrant Name Entity Registrant Name Statement of Stockholders' Equity [Abstract] Reclassification of convertible preferred units for contingent liquidation features not within the Company's control Temporary Equity, Stock Issued During Period, Value, Reclassification of Stock Temporary Equity, Stock Issued During Period, Value, Reclassification of Stock Threshold amounts (in thousands) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Threshold Amounts Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Threshold Amounts Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs Temporary Equity, Stock Issued During Period, Value, New Issues Research and development expense Research and Development Expense [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable from government grants, net Accounts Receivable, after Allowance for Credit Loss, Current Total minimum lease payments: Lessee, Operating Lease, Liability, to be Paid Ownership percentage Noncontrolling Interest, Ownership Percentage by Parent Stock issued (in dollars per share) Shares Issued, Price Per Share Reclassification of Stock to Temporary Equity, Shares Reclassification of Stock to Temporary Equity, Shares Reclassification of Stock to Temporary Equity, Shares Restricted cash, non-current Restricted Cash, Noncurrent Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Sale of Stock [Axis] Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Units used in computing net loss per Class A common unit, basic and diluted (in shares) Weighted average number of Class A common units outstanding, basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs, in shares Convertible preferred units issued (in shares) Temporary Equity, Stock Issued During Period, Shares, New Issues Temporary Equity, Stock Issued During Period, Shares, New Issues Goodwill Goodwill Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Other comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Document Transition Report Document Transition Report Other Income (Expense) Nonoperating Income (Expense) [Abstract] Common units subject to future vesting conditions (in shares) Common Unit, Outstanding, Subject to Future Vesting Conditions Common Unit, Outstanding, Subject to Future Vesting Conditions Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Other current assets Other Assets, Current Document Quarterly Report Document Quarterly Report General and administrative expense General and Administrative Expense [Member] Equity [Abstract] Total fair value of assets Assets, Fair Value Disclosure Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Real Estate, 10.7 Year Lease Term Real Estate, 10.7 Year Lease Term [Member] Real Estate, 10.7 Year Lease Term Unvested common units outstanding (in shares) Common Unit, Outstanding, Unvested Common Unit, Outstanding, Unvested Average expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Entity File Number Entity File Number Operating lease, weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Contributions from noncontrolling interest owners, net Proceeds from Noncontrolling Interests Share-based compensation expense Total share-based compensation expense Share-based Payment Arrangement, Expense Common Stock, value Common Stock, Value, Issued Gross proceeds from issuance of common stock Proceeds From Issuance Of Common Stock, Gross Proceeds From Issuance Of Common Stock, Gross Document Fiscal Year Focus Document Fiscal Year Focus Commercial paper Commercial Paper [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Category of Item Purchased [Axis] Category of Item Purchased [Axis] Entity Current Reporting Status Entity Current Reporting Status Share price (in dollars per sharee) Sale of Stock, Price Per Share Related Party Transaction [Axis] Related Party Transaction [Axis] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-sale Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Noncontrolling interests Noncontrolling interest at beginning of period Noncontrolling interest at end of period Stockholders' Equity Attributable to Noncontrolling Interest Exchange ratio Common Stock, Conversion Ratio Common Stock, Conversion Ratio Grant date fair value (USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share price (in dollars per share) Business Acquisition, Share Price Computer and office equipment Computer And Office Equipment [Member] Computer And Office Equipment Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total operating lease liabilities Operating Lease, Liability Accounts receivable Increase (Decrease) in Accounts Receivable Convertible preferred units; Redemption value of $146,944,000 at December 31, 2019 Temporary equity, beginning balance Temporary equity, ending balance Carrying Value Temporary Equity, Carrying Amount, Attributable to Parent Statement of Comprehensive Income [Abstract] Prepaid research and development expenses Prepaid Research And Development Costs Prepaid Research And Development Costs Issuance fees and expenses Issuance costs of financing Payments of Stock Issuance Costs Cash payments to acquire interest Business Combination, Consideration Transferred Total liabilities, convertible preferred units and equity (deficit) Liabilities and Equity Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Address, City or Town Entity Address, City or Town Accrued employee expenses Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Restricted Stock Award Restricted Stock Award [Member] Restricted Stock Award RSUs Restricted Stock Units (RSUs) [Member] General and administrative General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] Series C Preferred Units Series C Preferred Stock [Member] Antidilutive securities excluded from computation of earnings per unit (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Entity Ex Transition Period Entity Ex Transition Period Equity Component [Domain] Equity Component [Domain] Unrealized gain on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Other prepaid expenses Other Prepaid Expense Other Prepaid Expense Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Construction in progress Construction in Progress [Member] Entity Tax Identification Number Entity Tax Identification Number Prepaid insurance Prepaid Insurance Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Net loss attributable to Zentalis Net loss attributable to Zentalis Net Income (Loss) Attributable to Parent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Intercompany Services Agreement Intercompany Services Agreement [Member] Intercompany Services Agreement 2020 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Conversion of convertible preferred units to common stock (in shares) Conversion of convertible preferred units to common stock (in shares) Temporary Equity, Stock Issued During Period, Shares, Conversion Of Units Temporary Equity, Stock Issued During Period, Shares, Conversion Of Units Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Earnings Per Share [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Amortization of premiums on marketable securities, net Investment Income, Amortization of Premium Contributions from noncontrolling interest owners Noncontrolling Interest, Increase from Subsidiary Equity Issuance Equity and Share-based Compensation Shareholders' Equity, Share-Based Payments, And Members' Equity [Text Block] Shareholders' Equity, Share-Based Payments, And Members' Equity Document Fiscal Period Focus Document Fiscal Period Focus Total minimum lease payments on leases not yet commenced Lessee, Operating Lease, Lease Not Yet Commenced, Liability Lessee, Operating Lease, Lease Not Yet Commenced, Liability Kalyra Pharmaceuticals, Inc. Kalyra Pharmaceuticals, Inc. [Member] Kalyra Pharmaceuticals, Inc. Dividends declared Convertible Preferred Stock, Dividends Per Share, Declared Convertible Preferred Stock, Dividends Per Share, Declared Follow-On Offering Follow-On Offering [Member] Follow-On Offering Operating leases not yet commenced, term (in years) Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Operating lease right-of-use assets and liabilities, net Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net RSAs and RSUs Restricted Stock Awards And Restricted Stock Units [Member] Restricted Stock Awards And Restricted Stock Units Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Entity Filer Category Entity Filer Category Schedule of Share-based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Deferred financing costs Deferred Costs, Noncurrent Summary of Property and Equipment, net Property, Plant and Equipment [Table Text Block] Lease Contractual Term [Axis] Lease Contractual Term [Axis] US Treasury securities US Treasury Securities [Member] Stock issued (in shares) Stock Issued During Period, Shares, New Issues Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Leasehold improvements Leasehold Improvements [Member] Conversion of convertible preferred units to common stock Reclassifications of Temporary to Permanent Equity Money market funds Money Market Funds [Member] Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Class A Common Units Common Class A [Member] Supplemental disclosure of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Interest receivable Interest Receivable, Current Related Party Transactions [Abstract] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Business Combinations Business Combination Disclosure [Text Block] Schedule of Future Minimum Operating Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Stock options Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Risk free rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Number of available-for-sale securities in unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Ownership [Axis] Ownership [Axis] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Sale of Stock [Domain] Sale of Stock [Domain] Ownership [Domain] Ownership [Domain] Plan Name [Domain] Plan Name [Domain] Proceeds from the issuance of Series C convertible preferred units, net Net proceeds from issuance of convertible preferred units Proceeds from Issuance of Redeemable Convertible Preferred Stock Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Proceeds from issuance of common stock in initial public offering, net Proceeds from Issuance Initial Public Offering Additional paid-in capital Additional Paid in Capital Due within one year Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Class of Stock [Axis] Class of Stock [Axis] Income tax expense Income Tax Expense (Benefit) Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents and restricted cash reported in the Consolidated Statement of Cash Flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Accrued expenses Total accrued expenses Accrued Liabilities, Current Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Local Phone Number Local Phone Number Temporary equity beginning balance (in shares) Temporary equity ending balance (in shares) Shares outstanding (in shares) Temporary Equity, Shares Outstanding Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Denominator: Earnings Per Share, Denominator [Abstract] Earnings Per Share, Denominator Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Related Party Transaction [Domain] Related Party Transaction [Domain] Entity Emerging Growth Company Entity Emerging Growth Company In-process research and development Indefinite-lived Intangible Assets (Excluding Goodwill) Convertible Preferred Units Preferred units, as if converted to Class A common units Convertible Preferred Stock [Member] Generally expected vesting term of the option contract (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term Award Type [Axis] Award Type [Axis] Total prepaid expenses and other current assets Prepaid Expense and Other Assets Lease Contractual Term [Domain] Lease Contractual Term [Domain] Maximum Maximum [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Noncontrolling Interests Noncontrolling Interest [Member] Restricted cash Restricted Cash Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities Accumulated Deficit Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Lack of marketability discount (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Lack of Marketability Discount Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Lack of Marketability Discount Agreement term (in years) Related Party Agreement, Term Related Party Agreement, Term Interim Unaudited Financial Statements Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Amortized Cost Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Domain] Award Type [Domain] Prepaid expenses and other assets Less long-term portion Prepaid Expense and Other Assets, Noncurrent Corporate debt securities Corporate Debt Securities [Member] Trading Symbol Trading Symbol Revenue from related parties Revenue from Related Parties Percent of common stock outstanding used as threshold to calculate shares available for issuance Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Net Loss Per Common Share/Class A Common Unit Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current liabilities Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Costs incurred in connection with equity offering included in accounts payable and accrued liabilities Stock Issuance Costs Incurred But Not Yet Paid Stock Issuance Costs Incurred But Not Yet Paid Adoption and Pending Adoption of Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] EX-101.PRE 12 zntl-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 zntl-20200930_htm.xml IDEA: XBRL DOCUMENT 0001725160 2020-01-01 2020-09-30 0001725160 2020-11-05 0001725160 2020-09-30 0001725160 2019-12-31 0001725160 us-gaap:CommonClassAMember 2019-12-31 0001725160 us-gaap:CommonClassAMember 2020-09-30 0001725160 us-gaap:CommonClassBMember 2019-12-31 0001725160 us-gaap:CommonClassBMember 2020-09-30 0001725160 2020-07-01 2020-09-30 0001725160 2019-07-01 2019-09-30 0001725160 2019-01-01 2019-09-30 0001725160 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001725160 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001725160 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001725160 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001725160 us-gaap:CommonClassAMember 2020-07-01 2020-09-30 0001725160 us-gaap:CommonClassAMember 2019-07-01 2019-09-30 0001725160 us-gaap:CommonClassAMember 2020-01-01 2020-09-30 0001725160 us-gaap:CommonClassAMember 2019-01-01 2019-09-30 0001725160 2018-12-31 0001725160 2019-09-30 0001725160 us-gaap:CommonStockMember 2020-06-30 0001725160 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001725160 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001725160 us-gaap:RetainedEarningsMember 2020-06-30 0001725160 us-gaap:NoncontrollingInterestMember 2020-06-30 0001725160 2020-06-30 0001725160 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001725160 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001725160 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001725160 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0001725160 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001725160 us-gaap:CommonStockMember 2020-09-30 0001725160 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001725160 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001725160 us-gaap:RetainedEarningsMember 2020-09-30 0001725160 us-gaap:NoncontrollingInterestMember 2020-09-30 0001725160 us-gaap:ConvertiblePreferredStockMember 2019-12-31 0001725160 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2019-12-31 0001725160 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2019-12-31 0001725160 us-gaap:CommonStockMember 2019-12-31 0001725160 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001725160 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001725160 us-gaap:RetainedEarningsMember 2019-12-31 0001725160 us-gaap:NoncontrollingInterestMember 2019-12-31 0001725160 us-gaap:SeriesCPreferredStockMember 2020-09-30 0001725160 us-gaap:SeriesCPreferredStockMember 2019-09-30 0001725160 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001725160 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-01 2020-09-30 0001725160 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2020-01-01 2020-09-30 0001725160 us-gaap:IPOMember 2020-01-01 2020-09-30 0001725160 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0001725160 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001725160 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-09-30 0001725160 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001725160 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001725160 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001725160 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001725160 us-gaap:ConvertiblePreferredStockMember 2020-09-30 0001725160 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2020-09-30 0001725160 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2020-09-30 0001725160 us-gaap:ConvertiblePreferredStockMember 2019-06-30 0001725160 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-06-30 0001725160 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2019-06-30 0001725160 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2019-06-30 0001725160 us-gaap:RetainedEarningsMember 2019-06-30 0001725160 us-gaap:NoncontrollingInterestMember 2019-06-30 0001725160 2019-06-30 0001725160 us-gaap:ConvertiblePreferredStockMember 2019-07-01 2019-09-30 0001725160 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-07-01 2019-09-30 0001725160 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001725160 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001725160 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0001725160 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001725160 us-gaap:ConvertiblePreferredStockMember 2019-09-30 0001725160 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-09-30 0001725160 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2019-09-30 0001725160 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2019-09-30 0001725160 us-gaap:RetainedEarningsMember 2019-09-30 0001725160 us-gaap:NoncontrollingInterestMember 2019-09-30 0001725160 us-gaap:ConvertiblePreferredStockMember 2018-12-31 0001725160 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2018-12-31 0001725160 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2018-12-31 0001725160 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2018-12-31 0001725160 us-gaap:RetainedEarningsMember 2018-12-31 0001725160 us-gaap:NoncontrollingInterestMember 2018-12-31 0001725160 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-09-30 0001725160 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-09-30 0001725160 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001725160 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001725160 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0001725160 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001725160 2017-12-21 2017-12-21 0001725160 us-gaap:IPOMember 2020-04-02 0001725160 us-gaap:CommonStockMember us-gaap:IPOMember 2020-04-02 2020-04-02 0001725160 us-gaap:RestrictedStockMember us-gaap:IPOMember 2020-04-02 2020-04-02 0001725160 us-gaap:CommonStockMember us-gaap:IPOMember 2020-04-07 2020-04-07 0001725160 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2020-04-07 2020-04-07 0001725160 us-gaap:CommonStockMember us-gaap:IPOMember 2020-04-07 0001725160 2020-04-07 2020-04-07 0001725160 2020-05-19 2020-05-19 0001725160 us-gaap:SeriesAPreferredStockMember 2020-05-19 2020-05-19 0001725160 zntl:ZenteraTherapeuticsLtdMember 2020-09-30 0001725160 zntl:ZenteraStockPlanMember 2020-05-19 0001725160 us-gaap:RestrictedStockMember zntl:ZenteraStockPlanMember 2020-05-19 2020-05-19 0001725160 us-gaap:CommonStockMember zntl:FollowOnOfferingMember 2020-08-03 2020-08-03 0001725160 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2020-08-03 2020-08-03 0001725160 us-gaap:CommonStockMember zntl:FollowOnOfferingMember 2020-08-03 0001725160 zntl:FollowOnOfferingMember 2020-08-03 2020-08-03 0001725160 zntl:KalyraPharmaceuticalsIncMember 2017-12-21 2017-12-21 0001725160 zntl:KalyraPharmaceuticalsIncMember 2017-12-21 0001725160 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-09-30 0001725160 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-12-31 0001725160 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2020-01-01 2020-09-30 0001725160 us-gaap:CommercialPaperMember 2020-09-30 0001725160 us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001725160 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001725160 us-gaap:USTreasurySecuritiesMember 2020-09-30 0001725160 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0001725160 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0001725160 us-gaap:MoneyMarketFundsMember 2020-09-30 0001725160 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001725160 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001725160 us-gaap:MoneyMarketFundsMember 2019-12-31 0001725160 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0001725160 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0001725160 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001725160 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001725160 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001725160 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001725160 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0001725160 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0001725160 us-gaap:USTreasurySecuritiesMember 2020-09-30 0001725160 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001725160 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001725160 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001725160 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0001725160 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0001725160 us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001725160 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0001725160 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0001725160 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001725160 us-gaap:FairValueInputsLevel1Member 2020-09-30 0001725160 us-gaap:FairValueInputsLevel2Member 2020-09-30 0001725160 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001725160 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001725160 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2020-09-30 0001725160 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2020-09-30 0001725160 us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2019-12-31 0001725160 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2019-12-31 0001725160 us-gaap:CommercialPaperMember 2019-12-31 0001725160 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001725160 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001725160 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001725160 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001725160 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001725160 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001725160 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001725160 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001725160 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001725160 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001725160 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2020-09-30 0001725160 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2020-09-30 0001725160 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0001725160 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2019-12-31 0001725160 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001725160 zntl:ComputerAndOfficeEquipmentMember 2020-09-30 0001725160 zntl:ComputerAndOfficeEquipmentMember 2019-12-31 0001725160 zntl:LaboratoryEquipmentMember 2020-09-30 0001725160 zntl:LaboratoryEquipmentMember 2019-12-31 0001725160 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001725160 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001725160 us-gaap:ConstructionInProgressMember 2020-09-30 0001725160 us-gaap:ConstructionInProgressMember 2019-12-31 0001725160 us-gaap:SeriesAPreferredStockMember 2015-09-01 2015-09-30 0001725160 us-gaap:SeriesAPreferredStockMember 2015-09-30 0001725160 us-gaap:SeriesAPreferredStockMember 2016-03-31 0001725160 us-gaap:SeriesAPreferredStockMember 2016-02-01 2016-03-31 0001725160 us-gaap:SeriesBPreferredStockMember 2017-12-31 0001725160 us-gaap:SeriesBPreferredStockMember 2017-12-01 2017-12-31 0001725160 us-gaap:SeriesBPreferredStockMember 2018-08-31 0001725160 us-gaap:SeriesBPreferredStockMember 2018-01-01 2018-08-31 0001725160 us-gaap:SeriesCPreferredStockMember 2019-09-01 2019-09-30 0001725160 us-gaap:SeriesCPreferredStockMember 2020-02-29 0001725160 us-gaap:SeriesCPreferredStockMember 2020-02-01 2020-02-29 0001725160 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001725160 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001725160 us-gaap:SeriesCPreferredStockMember 2019-12-31 0001725160 2020-01-01 2020-04-02 0001725160 us-gaap:SeriesAPreferredStockMember 2020-09-30 0001725160 us-gaap:SeriesBPreferredStockMember 2020-09-30 0001725160 us-gaap:SeriesAPreferredStockMember 2017-12-31 0001725160 us-gaap:CommonClassAMember 2017-12-31 0001725160 us-gaap:CommonClassBMember 2017-12-31 0001725160 2017-12-31 0001725160 us-gaap:CommonClassAMember 2019-09-30 0001725160 us-gaap:CommonClassAMember 2019-01-01 2019-12-31 0001725160 us-gaap:CommonClassBMember 2017-12-01 2017-12-31 0001725160 us-gaap:CommonClassBMember 2019-09-30 0001725160 us-gaap:CommonStockMember zntl:CorporateConversionMember 2020-04-02 2020-04-02 0001725160 2020-04-02 0001725160 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2020-04-07 0001725160 us-gaap:IPOMember 2020-04-07 2020-04-07 0001725160 zntl:A2017ProfitInterestPlanMember us-gaap:CommonClassBMember 2017-12-21 0001725160 zntl:A2020IncentiveAwardPlanMember us-gaap:CommonStockMember 2020-04-30 0001725160 srt:MaximumMember zntl:A2020IncentiveAwardPlanMember us-gaap:CommonClassBMember 2020-04-30 0001725160 zntl:A2020IncentiveAwardPlanMember us-gaap:CommonStockMember 2020-04-01 2020-04-30 0001725160 us-gaap:CommonClassBMember 2020-01-01 2020-09-30 0001725160 us-gaap:RestrictedStockMember 2020-04-01 2020-04-30 0001725160 2020-04-01 2020-04-30 0001725160 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001725160 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001725160 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001725160 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001725160 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001725160 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001725160 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001725160 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001725160 zntl:ZenteraStockPlanMember 2020-07-01 2020-09-30 0001725160 zntl:ZenteraStockPlanMember 2020-01-01 2020-09-30 0001725160 zntl:ZenteraStockPlanMember 2019-01-01 2019-09-30 0001725160 zntl:ZenteraStockPlanMember 2019-07-01 2019-09-30 0001725160 zntl:ProfitInterestAwardsMember 2020-07-01 2020-09-30 0001725160 zntl:ProfitInterestAwardsMember 2019-07-01 2019-09-30 0001725160 zntl:ProfitInterestAwardsMember 2020-01-01 2020-09-30 0001725160 zntl:ProfitInterestAwardsMember 2019-01-01 2019-09-30 0001725160 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001725160 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001725160 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001725160 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001725160 zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember 2020-07-01 2020-09-30 0001725160 zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember 2019-07-01 2019-09-30 0001725160 zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001725160 zntl:RestrictedStockAwardsAndRestrictedStockUnitsMember 2019-01-01 2019-09-30 0001725160 zntl:ProfitInterestAwardsMember 2020-09-30 0001725160 zntl:ProfitInterestAwardsMember 2019-09-30 0001725160 srt:MinimumMember zntl:ProfitInterestAwardsMember 2019-01-01 2019-09-30 0001725160 srt:MaximumMember zntl:ProfitInterestAwardsMember 2019-01-01 2019-09-30 0001725160 us-gaap:CommonClassBMember 2019-01-01 2019-09-30 0001725160 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001725160 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001725160 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001725160 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001725160 us-gaap:EmployeeStockOptionMember 2020-09-30 0001725160 us-gaap:RestrictedStockMember 2020-09-30 0001725160 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001725160 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001725160 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001725160 zntl:RestrictedStockAwardMember 2020-09-30 0001725160 srt:ScenarioForecastMember zntl:RealEstate107YearLeaseTermMember 2020-12-31 0001725160 srt:ScenarioForecastMember zntl:RealEstate12YearLeaseTermMember 2020-12-31 0001725160 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-09-30 0001725160 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-09-30 0001725160 zntl:ClassBCommonIncentiveUnitsMember 2020-01-01 2020-09-30 0001725160 zntl:ClassBCommonIncentiveUnitsMember 2019-01-01 2019-09-30 0001725160 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001725160 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001725160 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001725160 us-gaap:RestrictedStockMember 2019-01-01 2019-09-30 0001725160 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001725160 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001725160 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember zntl:KalyraPharmaceuticalsIncMember us-gaap:SeriesBPreferredStockMember 2017-12-21 0001725160 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember zntl:KalyraPharmaceuticalsIncMember 2017-12-21 0001725160 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember zntl:KalyraPharmaceuticalsIncMember 2017-12-21 2017-12-21 0001725160 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember zntl:KalyraPharmaceuticalsIncMember 2019-01-01 2019-09-30 0001725160 zntl:MasterServicesAgreementMember srt:AffiliatedEntityMember 2019-07-01 2019-09-30 0001725160 zntl:MasterServicesAgreementMember srt:AffiliatedEntityMember 2020-07-01 2020-09-30 0001725160 zntl:MasterServicesAgreementMember srt:AffiliatedEntityMember 2020-01-01 2020-09-30 0001725160 zntl:MasterServicesAgreementMember srt:AffiliatedEntityMember 2019-01-01 2019-09-30 0001725160 zntl:IntercompanyServicesAgreementMember srt:AffiliatedEntityMember 2019-07-01 2019-09-30 0001725160 zntl:IntercompanyServicesAgreementMember srt:AffiliatedEntityMember 2020-07-01 2020-09-30 0001725160 zntl:IntercompanyServicesAgreementMember srt:AffiliatedEntityMember 2020-01-01 2020-09-30 0001725160 zntl:IntercompanyServicesAgreementMember srt:AffiliatedEntityMember 2019-01-01 2019-09-30 0001725160 zntl:IntercompanyServicesAgreementMember srt:AffiliatedEntityMember 2020-09-30 0001725160 zntl:IntercompanyServicesAgreementMember srt:AffiliatedEntityMember 2019-09-30 0001725160 us-gaap:CapitalAdditionsMember 2020-06-01 2020-06-01 shares iso4217:USD iso4217:USD shares pure zntl:executive zntl:security 0001725160 false Q3 --12-31 2020 10-Q true 2020-09-30 false 001-39263 Zentalis Pharmaceuticals, Inc. DE 82-3607803 530 Seventh Avenue, Suite 2201 New York, NY 10018 212 433-3791 Common Stock,$0.001 par value per share ZNTL NASDAQ Yes Yes Non-accelerated Filer true true false false 40613857 92552000 67246000 274884000 0 122000 140000 5178000 1505000 372736000 68891000 471000 501000 1925000 2335000 4245000 2134000 0 841000 3736000 3736000 8800000 8800000 1320000 243000 393233000 87481000 5437000 4289000 18469000 10608000 23906000 14897000 2463000 2463000 1031000 1700000 27400000 19060000 146944000 0 141706000 20000000 5601478 5601478 0 709000 3458522 2670668 2670668 0 2178000 0.001 10000000 0 0 0 0 0.001 250000000 40614453 40614453 41000 0 501522000 0 23000 0 -160531000 -82993000 341055000 -80106000 24778000 6821000 365833000 -73285000 393233000 87481000 24670000 10739000 55380000 26517000 10097000 1844000 23162000 5423000 34767000 12583000 78542000 31940000 -34767000 -12583000 -78542000 -31940000 120000 12000 368000 123000 -34647000 -12571000 -78174000 -31817000 18000 1000 18000 15000 -34665000 -12572000 -78192000 -31832000 -110000 -228000 -654000 -675000 -34555000 -34555000 -12344000 -12344000 -77538000 -77538000 -31157000 -31157000 -0.91 0 -3.21 0 0 -2.20 0 -5.56 37959000 5601000 24143000 5601000 -34665000 -12572000 -78192000 -31832000 19000 0 23000 0 -34646000 -12572000 -78169000 -31832000 -110000 -228000 -654000 -675000 -34536000 -12344000 -77515000 -31157000 -78192000 -31832000 127000 70000 15259000 405000 224000 0 -18000 -867000 5784000 833000 9049000 5155000 -169000 216000 -59468000 -25952000 304085000 0 29000000 0 97000 316000 -275182000 -316000 172482000 0 18424000 0 14228000 81883000 155899000 0 361033000 81883000 26383000 55615000 67489000 25154000 93872000 80769000 0 1412000 594000 0 92552000 80526000 1320000 243000 93872000 80769000 35878000 36000 339160000 4000 -125976000 24701000 237925000 7249000 7249000 4744000 5000 155300000 155305000 7000 19000 19000 -187000 77000 -110000 -34555000 -34555000 40615000 41000 501522000 23000 -160531000 24778000 365833000 9950000 141706000 5601000 709000 2671000 2178000 0 0 0 0 -82993000 6821000 -73285000 17.50 17.50 867000 14228000 64000 10589000 11000 172354000 172365000 18424000 18424000 329000 14930000 15259000 10817000 -155934000 15011000 15000 155919000 155934000 5601000 709000 2607000 2507000 10278000 10000 3206000 4744000 5000 155300000 155305000 7000 23000 23000 -187000 -467000 -654000 -77538000 -77538000 0 0 0 0 0 0 40615000 41000 501522000 23000 -160531000 24778000 365833000 0 0 5103000 59830000 5594000 676000 1669000 1844000 -56143000 7089000 13296000 4847000 81883000 0 5103000 59830000 5103000 59830000 59830000 278000 2000 153000 155000 -228000 -228000 -12344000 -12344000 9950000 141713000 0 0 5594000 678000 1947000 1997000 -68487000 6861000 -58951000 0 0 5103000 59830000 5594000 672000 1612000 1598000 -37330000 7536000 32306000 4847000 81883000 0 5103000 59830000 5103000 59830000 59830000 335000 6000 399000 405000 -675000 -675000 -31157000 -31157000 9950000 141713000 0 0 5594000 678000 1947000 1997000 -68487000 6861000 -58951000 Organization and Business<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zentalis Pharmaceuticals, Inc. (successor to Zentalis Pharmaceuticals, LLC) (“Zentalis”, “We” or the “Company”) is a clinical-stage pharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. To date, all of the Company’s revenue has been generated in the United States. All of the Company’s tangible assets are held in the United States.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was formed and incorporated in the state of Delaware as Zeno Pharmaceuticals, Inc. on December 23, 2014. Effective November 21, 2017, Zeno Pharma, LLC was formed by the shareholders of Zeno Pharmaceuticals, Inc. On December 21, 2017, Zeno Pharmaceuticals, Inc. became a wholly owned subsidiary of Zeno Pharma, LLC. In connection with this restructuring, the rights and preferences of the Preferred Stock of Zeno Pharmaceuticals, Inc. were exchanged for preferred units with similar rights and preferences of Zeno Pharma, LLC. As part of the restructuring, the employees, consultants and board members of Zeno Pharmaceuticals, Inc. exchanged their equity grants in Zeno Pharmaceuticals, Inc. stock for Class B common units in Zeno Pharma, LLC. Additionally, existing common stockholders of Zeno Pharmaceuticals, Inc. exchanged their common stock for Class A common units in Zeno Pharma, LLC. All exchanges were made on a one-for-one basis. The restructuring was accounted for as a common control transaction. In December 2019, the Company was renamed to Zentalis Pharmaceuticals, LLC. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the effectiveness of the registration statement pertaining to the Company’s initial public offering (“IPO”) on April 2, 2020, the Company converted from a Delaware limited liability company into a Delaware corporation, and changed its name to Zentalis Pharmaceuticals, Inc. Pursuant to the statutory corporate conversion, all of the outstanding units of Zentalis Pharmaceuticals, LLC converted into shares of common stock of Zentalis Pharmaceuticals, Inc. based upon the value of Zentalis Pharmaceuticals, Inc. at the time of the IPO with a value implied by the price of the shares of common stock sold in the IPO. Based on the IPO price of $18.00 per share, the outstanding units converted into 25,288,854 shares of common stock (including 1,160,277 shares of restricted common stock).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2020, the Company completed the IPO in which the Company issued and sold 10,557,000 shares of common stock (including 1,377,000 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a public offering price of $18.00 per share. The Company’s aggregate gross proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $190.0 million before fees and expenses of $17.6 million.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 19, 2020, the Company announced the closing of a Series A financing of Zentera Therapeutics, Ltd. (“Zentera”), a majority owned biopharmaceutical company with headquarters in Shanghai, China. Contributions from noncontrolling interest members totaled $20.0 million before issuing costs of $1.6 million. The Company holds 60.2% equity interest in Zentera for purposes of the development and commercialization of ZN-c5, ZN-d5 and ZN-c3 for the treatment or preventions of disease, other than for pain, in the People’s Republic of China, Macau, Hong Kong and Taiwan. Two of our executives entered into restricted stock purchase agreements with Zentera. The associated shares vest over four years.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2020, the Company completed a follow-on offering in which the Company issued and sold 4,743,750 shares of common stock (including 618,750 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a public offering price of $35.00 per share. The </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company’s aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $166.0 million before fees and expenses of $10.8 million. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div>Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after the date that the interim unaudited condensed consolidated financial statements for the quarter ended September 30, 2020 are issued. 1 18.00 25288854 1160277 10557000 1377000 18.00 190000000.0 17600000 20000000.0 1600000 0.602 2 P4Y 4743750 618750 35.00 166000000.0 10800000 Interim Unaudited Financial Statements <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company’s audited financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2019 included in the Company’s final prospectus for its IPO, filed pursuant to Rule 424(b) under the Securities Exchange Act of 1933, as amended, with the SEC on April 6, 2020. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of our wholly owned subsidiaries, majority-owned or controlled companies, and variable interest entity (“VIE”), Kalyra Pharmaceuticals, Inc. (“Kalyra”), for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares third parties own in Kalyra and Zentera represent an interest in their respective equity we do not control. We reflect the noncontrolling interest attributable to other owners in a separate line in our condensed consolidated statement of operations and a separate line within stockholders’ equity in our condensed consolidated balance sheet. In addition, we record a noncontrolling interest adjustment to account for equity based compensation in Zentera. This adjustment is a reclassification within stockholders’ equity from additional paid-in capital to noncontrolling interest equal to the amount of equity based compensation expense Zentera had recognized. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that we have the ability to liquidate to fund current operations. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term investments on the accompanying condensed consolidated balance sheets Marketable securities are considered available-for-sale and are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders’ deficit. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of operations. We assess whether our available-for-sale debt securities in an unrealized loss position have credit-related losses and record such losses, and any subsequent improvements as interest income, through an allowance account. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of operations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements </span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.435%"><tr><td style="width:1.0%"/><td style="width:18.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial<br/>Statements or Other<br/>Significant Matters</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In March 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This guidance makes improvements to financial instruments guidance, including the current expected credit losses guidance.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted the new guidance as of January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This standard clarifies the interaction between accounting standards related to equity securities (ASC 321), equity method investments (ASC 323), and certain derivatives (ASC 815). </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We currently do not hold equity securities, have equity method investments or derivatives. We do not believe the adoption will have a material impact on our consolidated financial position or results of operations.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. In November 2018 and April and May of 2019, the FASB issued additional guidance related to Topic 326.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The new guidance is intended to simplify aspects of the accounting for income taxes, including the elimination of certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, among other changes.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.</span></td></tr></table></div> Basis of PresentationThe accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company’s audited financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2019 included in the Company’s final prospectus for its IPO, filed pursuant to Rule 424(b) under the Securities Exchange Act of 1933, as amended, with the SEC on April 6, 2020. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments. <div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of our wholly owned subsidiaries, majority-owned or controlled companies, and variable interest entity (“VIE”), Kalyra Pharmaceuticals, Inc. (“Kalyra”), for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest</span></div>The shares third parties own in Kalyra and Zentera represent an interest in their respective equity we do not control. We reflect the noncontrolling interest attributable to other owners in a separate line in our condensed consolidated statement of operations and a separate line within stockholders’ equity in our condensed consolidated balance sheet. In addition, we record a noncontrolling interest adjustment to account for equity based compensation in Zentera. This adjustment is a reclassification within stockholders’ equity from additional paid-in capital to noncontrolling interest equal to the amount of equity based compensation expense Zentera had recognized. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities are investments with original maturities of more than ninety days from the date of purchase that we have the ability to liquidate to fund current operations. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term investments on the accompanying condensed consolidated balance sheets Marketable securities are considered available-for-sale and are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders’ deficit. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of operations. We assess whether our available-for-sale debt securities in an unrealized loss position have credit-related losses and record such losses, and any subsequent improvements as interest income, through an allowance account. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of operations.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adoption and Pending Adoption of Recent Accounting Pronouncements </span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.435%"><tr><td style="width:1.0%"/><td style="width:18.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial<br/>Statements or Other<br/>Significant Matters</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In March 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This guidance makes improvements to financial instruments guidance, including the current expected credit losses guidance.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted the new guidance as of January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This standard clarifies the interaction between accounting standards related to equity securities (ASC 321), equity method investments (ASC 323), and certain derivatives (ASC 815). </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We currently do not hold equity securities, have equity method investments or derivatives. We do not believe the adoption will have a material impact on our consolidated financial position or results of operations.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. In November 2018 and April and May of 2019, the FASB issued additional guidance related to Topic 326.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The new guidance is intended to simplify aspects of the accounting for income taxes, including the elimination of certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, among other changes.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.</span></td></tr></table></div> <div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.435%"><tr><td style="width:1.0%"/><td style="width:18.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.347%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial<br/>Statements or Other<br/>Significant Matters</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In March 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This guidance makes improvements to financial instruments guidance, including the current expected credit losses guidance.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted the new guidance as of January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This standard clarifies the interaction between accounting standards related to equity securities (ASC 321), equity method investments (ASC 323), and certain derivatives (ASC 815). </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We currently do not hold equity securities, have equity method investments or derivatives. We do not believe the adoption will have a material impact on our consolidated financial position or results of operations.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. In November 2018 and April and May of 2019, the FASB issued additional guidance related to Topic 326.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The new guidance is intended to simplify aspects of the accounting for income taxes, including the elimination of certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, among other changes.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.</span></td></tr></table></div> Business Combinations<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kalyra Pharmaceuticals, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2017, we acquired $4.5 million of Kalyra’s Series B Preferred Stock representing a 25% equity interest in Kalyra for purposes of entering the analgesics therapeutic research space. The acquisition price was paid entirely in cash.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the authoritative guidance, we concluded that Kalyra is a business consisting of inputs, employees, intellectual property and processes capable of producing outputs. Additionally, we have concluded that Kalyra is a variable interest entity, we are the primary beneficiary and have the power to direct the activities that most significantly affect Kalyra’s economic performance through common management and our board representation. Prior to the change of control, Zentalis and Kalyra transacted for the delivery of research and development services and support. The financial position and results of operations of Kalyra have been included in our consolidated financial statements from the date of the initial investment.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant with authoritative guidance, we have recorded the identifiable assets, liabilities and noncontrolling interests in the VIE at their fair value upon initial consolidation. The identified goodwill is comprised of the workforce and expected synergies from combining the entities. Total assets and liabilities of Kalyra as of September 30, 2020 and December 31, 2019 are as follows (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liabilities recognized as a result of consolidating Kalyra do not represent additional claims on our general assets. Pursuant to the authoritative guidance, the equity interest in Kalyra not owned by Zentalis is reported as a noncontrolling interest on our consolidated balance sheets.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.416%"><tr><td style="width:1.0%"/><td style="width:82.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4500000 0.25 Total assets and liabilities of Kalyra as of September 30, 2020 and December 31, 2019 are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,800 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,463 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 417000 712000 31000 21000 8800000 8800000 3736000 3736000 14000 14000 87000 391000 2463000 2463000 6635000 6821000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.416%"><tr><td style="width:1.0%"/><td style="width:82.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,821 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6821000 -186000 6635000 Fair Value MeasurementAvailable-for-sale marketable securities consisted of the following (in thousands):<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agencies</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f our available-for-sale debt securities with a fair market value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$85.3</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million were in a gross unrealized loss position </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of sixteen thousand</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, our intent to sell or the likelihood that we would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of September 30, 2020, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis. </span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.378%"><tr><td style="width:1.0%"/><td style="width:65.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,884 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:26.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agencies</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents:</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,923 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,630 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,553 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agencies</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale marketable securities:</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,752 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,675 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,762 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,437 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the nine months ended September 30, 2020. We had no instruments that were classified within Level 3 as of September 30, 2020 or December 31, 2019.</span></div> Available-for-sale marketable securities consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,840 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agencies</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table> 125748000 9000 7000 125750000 31840000 5000 3000 31842000 77523000 22000 5000 77540000 39750000 3000 1000 39752000 274861000 39000 16000 274884000 19 85300000 16000 <div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual maturities of available-for-sale debt securities are as follows (in thousands):</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:61.378%"><tr><td style="width:1.0%"/><td style="width:65.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one but within five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,884 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div> 239291000 35593000 274884000 The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:26.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,924 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agencies</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents:</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,923 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,630 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,553 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale marketable securities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agencies</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US Treasury securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available-for-sale marketable securities:</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,752 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,675 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,762 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,437 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,961 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 29924000 0 29924000 62961000 0 62961000 0 2631000 2631000 0 0 0 9999000 0 9999000 0 0 0 0 14999000 14999000 0 0 0 39923000 17630000 57553000 62961000 0 62961000 0 125750000 125750000 0 0 0 0 31842000 31842000 0 0 0 0 77540000 77540000 0 0 0 39752000 0 39752000 0 0 0 39752000 235132000 274884000 0 0 0 79675000 252762000 332437000 62961000 0 62961000 Prepaid Expenses and Other Assets<div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:70.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software licenses and maintenance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront lease payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,178 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.679%"><tr><td style="width:1.0%"/><td style="width:70.282%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid software licenses and maintenance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront lease payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,423 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,639 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less long-term portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other assets, current</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,178 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1761000 150000 320000 238000 5735000 2985000 511000 0 810000 0 286000 266000 9423000 3639000 4245000 2134000 5178000 1505000 Property and Equipment, net<div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended September 30, 2020 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approximately fifty-one thousand and twenty-five thousand, respectively. Depreciation and amortization expense for the nine months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</span> and 2019 was approximately one hundred twenty-seven thousand and seventy thousand, respectively. <div style="margin-bottom:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer and office equipment</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the three months ended September 30, 2020 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approximately fifty-one thousand and twenty-five thousand, respectively. Depreciation and amortization expense for the nine months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020</span> and 2019 was approximately one hundred twenty-seven thousand and seventy thousand, respectively. 291000 243000 360000 401000 43000 24000 6000 0 700000 668000 229000 167000 471000 501000 51000 25000 127000 70000 Accrued Expenses<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,469 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,608 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,618 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,469 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,608 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10618000 5465000 4390000 2977000 2571000 1356000 871000 781000 19000 29000 18469000 10608000 Convertible Preferred Units<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Convertible Preferred Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, Zeno Pharmaceuticals, Inc. entered into a Series A Preferred Stock Purchase Agreement (the “Series A Preferred Agreement”). Under the terms of the Series A Preferred Agreement, Zeno Pharmaceuticals, Inc. issued 1,293,104 shares of Series A convertible preferred stock at $11.60 per share for gross proceeds of $15.0 million. The net proceeds of this financing were $14.9 million after issuance costs of $0.1 million. In February and March 2016, Zeno Pharmaceuticals, Inc. issued an aggregate of 286,205 additional shares of Series A convertible preferred stock at $11.60 per share for additional gross proceeds of $3.3 million. The issuance costs of this additional financing were approximately thirty-nine thousand dollars. All Series A convertible preferred stock issued and outstanding by Zeno Pharmaceuticals, Inc. was converted into Series A convertible preferred units of Zentalis Pharmaceuticals, LLC in conjunction with the corporate restructuring and merger.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series B Convertible Preferred Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, Zentalis Pharmaceuticals, LLC entered into a Series B Preferred Unit Purchase Agreement (the “Series B Preferred Agreement”). Under the terms of the Series B Preferred Agreement, Zentalis </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceuticals, LLC issued 2,735,320 Series B preferred units at $12.43 per unit for gross proceeds of $34.0 million. The net proceeds of this financing were $32.1 million after issuance costs of $1.9 million. In January and August 2018, Zentalis Pharmaceuticals, LLC issued an aggregate of 788,419 additional shares of Series B preferred units at $12.43 per unit for additional gross proceeds of $9.8 million. The net proceeds of this additional financing were $9.5 million after issuance costs of $0.3 million.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series C Preferred Unit Issuance</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, Zentalis Pharmaceuticals, LLC entered into a Series C Preferred Unit Purchase Agreement (the “Series C Preferred Agreement”). Under the terms of the Series C Preferred Agreement, Zentalis Pharmaceuticals, LLC issued 4,847,106 units of Series C convertible preferred units at $17.50 per unit for gross proceeds of $84.8 million. The net proceeds of this financing were $81.9 million after issuance costs of $2.9 million. In February 2020, Zentalis Pharmaceuticals, LLC issued 867,194 additional units of Series C preferred units under the Series C Preferred Agreement. The units were issued for $17.50 per unit for gross proceeds of $15.2 million. The net proceeds of this financing were $14.2 million after issuance costs of $1.0 million.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no authorized, issued, and outstanding shares of convertible preferred units at September 30, 2020. As of December 31, 2019, the authorized, issued, and outstanding units of convertible preferred units were as follows (in thousands, except unit amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued<br/>and<br/>Outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A convertible preferred units</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B convertible preferred units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,523,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,523,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C convertible preferred units</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,714,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,847,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,817,348 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950,154 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,944 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,706 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2019, we reclassified the convertible preferred units from members’ equity to temporary equity because, in conjunction with the Series C convertible preferred units issuance, all units were now deemed to contain contingent liquidation features that are not solely within our control. During the year ended December 31, 2019 and prior to the conversion of convertible preferred units into common stock in conjunction with our IPO on April 2, 2020, we did not adjust the carrying values of the convertible preferred units to the deemed redemption values of such units since a liquidation event was not probable. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends are payable if and when declared by the Board of Directors. No dividends have been declared prior to the conversion of convertible preferred units into common stock in conjunction with our IPO on April 2, 2020. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Series A preferred unit, Series B preferred unit and Series C preferred unit was convertible at the option of the holder thereof, at any time after the issuance of such unit, into Class A common units at a conversion price equal to the original purchase price (subject to anti-dilution adjustments, discussed below) which was $11.60, $12.43 and $17.50 per unit, respectively. The convertible preferred units automatically converted at the then applicable conversion rate upon the closing of a firm commitment underwritten public offering of shares of a successor corporations’ common stock, at a public offering price per share of equal to or greater than the Series C original purchase price (as adjusted for any stock splits, stock dividends, combinations or other similar recapitalization) resulting in aggregate gross cash proceeds of at least $75.0 million (a “Qualified IPO”). Additionally, the convertible preferred units would have automatically converted into common stock, at the then applicable conversion rate, upon written consent of a majority of the then outstanding Series A, Series B and Series C convertible preferred units </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(voting as a separate class on an as converted to Common Unit basis). In conjunction with our IPO on April 2, 2020, which constituted a Qualified IPO, all convertible preferred units were converted into common stock. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-dilution protection</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the convertible preferred unit had proportional anti-dilution protection for unit splits, unit dividends and similar recapitalizations. Subject to certain exclusions, anti-dilution price protection for additional sales of securities by us for consideration per unit less than the applicable conversion price per unit of any series of convertible preferred stock, was on a broad-based weighted average basis.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protective rights</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the convertible preferred units had certain protective rights, including, without limitation, regarding the authorization, alteration, redemption, or sale of Class B common units; commencement of a liquidation or deemed liquidation event; entrance into a joint venture or partnership; any incurrence of indebtedness; certain transactions that exceed a certain dollar threshold; changes to our governing documents; or the declaration of any dividends. Such actions were required to be approved by a majority of the then outstanding Series A, Series B and Series C convertible preferred unit holders (voting as a single class and on an as-converted basis), as specified in the amended and restated LLC agreement. An increase or decrease in the authorized number of Directors constituting the Board or the creation of a membership interest or equity security senior to or pari passu with Series C convertible preferred units was required to be approved by a majority of the then outstanding Series C convertible preferred Units (voting as a separate class on an as converted basis).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A, Series B and Series C convertible preferred units were not redeemable except in the event of certain effected deemed liquidation events. As of immediately prior to our IPO on April 2, 2020 and December 31, 2019, we had classified convertible preferred units as temporary equity in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of our control, including liquidation, sale or transfer of control of the Company. We did not adjust the carrying value of the convertible preferred units to the deemed redemption values of such units since a liquidation event was not probable.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation preference</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of the dissolution, liquidation, merger or winding up of the Company, the holders of Series C convertible preferred units were entitled to receive, on a pro rata basis in respect of each such Series C convertible preferred unit, a preference amount of $17.50 per Series C convertible unit (as adjusted for any unit splits, dividends, combinations, recapitalizations or the like).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the payment of the Series C convertible preferred unit preferences, Series A and Series B convertible preferred units were entitled to receive, on a pro rata basis in respect of each convertible preferred unit in proportion to the relative preference amount of each preferred unit, a preference amount of $11.60 and $12.43 per unit of Series A and Series B convertible preferred units (as adjusted for any units splits, dividend, combinations, recapitalizations of the like), respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the payment of the Series C, Series A and Series B convertible preferred unit preferences, Series A, Series B and Series C convertible preferred units were entitled to receive, on an as converted to common unit pro rata basis, an amount equal to distributions made to Class A common units prior to all unit classes sharing in distributions on a pro rata basis. Thereafter, Series A, Series B and Series C convertible preferred units and Series A and Series B common units were entitled to receive the remaining assets of the Company available for distribution to its unit holders pro rata based on the number of common units held by each holder, treating for these purposes as if all units had been converted to common.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of all units other than Class B common units that were unvested were to vote together as a single class. Each holder of Series A, Series B and Series C convertible preferred units were entitled to the number of votes calculated on an as converted to Class A common unit basis.</span></div> 1293104 11.60 15000000.0 14900000 100000 286205 11.60 3300000 39000 2735320 12.43 34000000.0 32100000 1900000 788419 12.43 9800000 9500000 300000 4847106 17.50 84800000 81900000 2900000 867194 17.50 15200000 14200000 1000000.0 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no authorized, issued, and outstanding shares of convertible preferred units at September 30, 2020. As of December 31, 2019, the authorized, issued, and outstanding units of convertible preferred units were as follows (in thousands, except unit amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units<br/>Authorized</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Issued<br/>and<br/>Outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A convertible preferred units</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,226 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B convertible preferred units</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,523,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,523,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C convertible preferred units</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,714,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,847,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,817,348 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950,154 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,944 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,706 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1579309 1579309 1579309 18320000 18226000 3523739 3523739 3523739 43800000 41604000 5714300 4847106 4847106 84824000 81876000 10817348 9950154 9950154 146944000 141706000 0 11.60 12.43 17.50 75000000.0 17.50 11.60 12.43 Equity and Share-based Compensation <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Zentalis Pharmaceuticals, LLC was formed in the state of Delaware. In conjunction with a corporate restructuring, Zeno Pharmaceuticals, Inc., a Delaware Corporation formed in 2014, was acquired by the Company pursuant to a merger agreement and became a wholly owned subsidiary of the Company. Per the terms of the merger agreement, each share of Zeno Pharmaceuticals, Inc. common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive one Class A common unit and each share of Zeno Pharmaceuticals, Inc. Series A preferred stock issued and outstanding immediately prior to the effective date of the merger converted into the right to receive one Series A preferred unit. As of the effective time of the merger agreement, all outstanding options to purchase shares of Zeno Pharmaceuticals, Inc. common stock were cancelled and replaced with profit interest awards in the LLC.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the December 2017 corporate restructuring, we amended and restated the LLC agreement, and as amended, the capital units of the Company consisted of 1,638,000 authorized Series A preferred units, 3,621,000 authorized Series B preferred units, 15,000,000 authorized Class A common units and 872,620 authorized Class B common units.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class A Common Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the corporate restructuring in December 2017, 5,187,554 shares of common stock issued and outstanding and 406,831 shares of common stock subject to future vesting provisions of Zeno Pharmaceuticals, Inc. were converted into an equal number of Class A common units of Zentalis Pharmaceuticals, LLC. During the three months ended September 30, 2020 and 2019, we did not issue any Class A common units. As of September 30, 2020 and 2019, zero and 9,572 Class A common units were subject to future vesting conditions, respectively. During the year ended December 31, 2019, 7,093 Class A common units were issued and 9,572 Class A common units were subject to future vesting conditions. In September 2019, the number of authorized Class A common units was increased to 20,000,000. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class B Common Units</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the corporate restructuring in December 2017, 703,000 options exercisable into Zeno Pharmaceuticals, Inc. common stock were converted into an equal number of Class B common units of Zentalis Pharmaceuticals, LLC. In September 2019, the number of authorized Class B common units was increased to 3,458,522.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPO and Follow-on Offering</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 2, 2020 and immediately prior to the effectiveness of the Company’s IPO, Zentalis Pharmaceuticals, LLC converted from a Delaware limited liability company into a Delaware corporation pursuant to a statutory conversion, and changed its name to Zentalis Pharmaceuticals, Inc. In order to consummate the corporate conversion, a certificate of conversion was filed with the Secretary of State of the State of Delaware. All of the outstanding units of Zentalis Pharmaceuticals, LLC converted into shares of common stock of Zentalis Pharmaceuticals, Inc. based upon the value of Zentalis Pharmaceuticals, Inc. at the time of the IPO with a value implied by the price of the shares of common stock sold in the IPO. No cash or fractional shares of common stock were issued in connection with the corporate conversion. Based on the IPO price of $18.00 per share of common stock, all of the outstanding units converted into an aggregate of 25,288,854 shares of common stock (including 1,160,277 shares of restricted common stock).</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of the IPO, the board and stockholders approved the certificate of incorporation to provide for 250,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2020, the Company completed an IPO in which the Company issued and sold 10,557,000 shares of common stock (including 1,377,000 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a price of $18.00 per share. The Company’s aggregate gross proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $190.0 million before fees and expenses of $17.6 million.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2020, the Company completed a follow-on offering in which the Company issued and sold 4,743,750 shares of common stock (including 618,750 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a public offering price of $35.00 per share. The Company’s aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $166.0 million before fees and expenses of $10.8 million. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company’s 2017 Profit Interest Plan (the Plan) as approved and adopted by the Board of Directors on December 21, 2017, the Company was authorized to issue up to 3,458,522 shares of Class B common units, subject to restrictions as described in the Plan. The Plan was terminated in April 2020. In April 2020, the Company’s board of directors adopted, and the Company’s stockholders approved the 2020 Incentive Award Plan (the 2020 Plan), which became effective upon the corporate conversion. The number of common shares initially available for issuance under the 2020 Plan is the sum of (1) 5,600,000 shares of common stock; plus (2) any shares forfeited from the unvested restricted shares of our common stock issued upon conversion of unvested Class B common units (up to 1,250,000 shares); plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ending December 31, 2021 and continuing to, and including, the fiscal year ending December 31, 2030, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by our board of directors. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, the Company granted 70,000 Class B common units to employees and directors under the Plan. The weighted average fair value of incentive units granted in the nine months ended September 30, 2020 was $3.06 per unit. In April 2020, each outstanding Class B common unit was converted into a number of shares of common stock and restricted common stock based upon the IPO price. The restricted common stock issued in respect of Class B common units continues to be subject to vesting in accordance with the vesting schedule that was applicable to such Class B common units. The Company granted 1,160,277 shares of restricted common stock to employees, consultants and directors as part of the conversion. In conjunction with the IPO, the Company also granted 1,970,671 stock options, with a weighted average of $11.97 per share, to purchase shares of common stock to employees and directors who were holders of Class B common units at the time of the incentive unit conversion and in new employee grants. The weighted average fair value of the 2,794,546 stock options granted to employees and directors in the nine months ended September 30, 2020 was $15.11 per share. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share based awards was comprised of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,249 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense includes $187 and $187 of share-based compensation expense for Zentera employees for the three and nine months ended September 30, 2020, respectively, compared to $0 for the same periods in 2019. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.287%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit interest award units</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs and RSUs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,249 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,259 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Class B common unit awards was estimated using an option pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:67.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.197%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Members’ equity value (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$271,207</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$197,041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Threshold amounts (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$309,824</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$143,800</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time to liquidity (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 - 1.8</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lack of marketability discount</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8% - 26.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.88 - $3.06</span></div></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option pricing model (“Black-Scholes model) is used to estimate the fair value of each Class B common unit award on the date of grant. The members’ equity value was based on a recent enterprise valuation analysis performed. The threshold amounts are based on the discretion of the Board of Directors at the time of grant. The expected life of the Class B common unit awards granted during the period presented was determined based on an expected liquidation event under the plan. We applied the risk-free interest rate based on the U.S. Treasury yield in effect at the time of the grant consistent with the life of the award. The expected volatility was based on a peer group in the industry in which the Company does business consistent with the expected time to liquidity. The dividend yield was set at zero as the underlying security does not and is not expected to pay a dividend. The Finnerty model and the Asian Protective Put Model methods were used to estimate the discount for lack of marketability inherent to the awards.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Class B common units issued have been classified as equity awards, and share-based compensation expense is based on the grant date fair value of the award. During the nine months ended September 30, 2020 and 2019, we issued 70,000 and 91,000 Class B common units, respectively. As of September 30, 2020 and December 31, 2019, zero and approximately 1.7 million unvested Class B common units were outstanding, respectively. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes model. Due to the Company’s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company uses the “simplified method” for estimating the expected term of employee options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero. The fair value of the stock options granted during the three and nine months ended September 30, 2020 was determined with the following assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%"><tr><td style="width:1.0%"/><td style="width:44.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.6% - 78.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.6% - 78.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 - 6.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 - 6.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 0.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%"><tr><td style="width:1.0%"/><td style="width:44.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized <br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining <br/>Weighted-Average Recognition Period <br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,247 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15</span></td></tr></table></div>During the nine months ended September 30, 2020, we did not issue any shares of common stock in connection with the exercises of stock options. For the nine months ended September 30, 2020, 309,010 shares of common stock issued in conjunction with certain RSAs fully vested. Stock options, unvested RSAs, and unvested RSUs totaling approximately 2.8 million shares, 0.8 million shares, and 1.1 million shares of our common stock, respectively, were outstanding as of September 30, 2020. 1638000 3621000 15000000 872620 5187554 5187554 406831 0 0 0 9572 7093 9572 20000000 703000 3458522 0 18.00 25288854 1160277 250000000 0.001 10000000 0.001 10557000 1377000 18.00 190000000.0 17600000 4743750 618750 35.00 166000000.0 10800000 3458522 5600000 1250000 0.05 70000 3.06 1160277 1970671 11.97 2794546 15.11 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total share-based compensation expense related to share based awards was comprised of the following (in thousands):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,653 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,249 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,259 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense by type of share-based award (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.287%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit interest award units</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,814 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs and RSUs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,249 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,259 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 2180000 95000 4606000 224000 5069000 60000 10653000 181000 7249000 155000 15259000 405000 187000 187000 0 0 0 155000 329000 405000 2212000 0 3814000 0 5037000 0 11116000 0 7249000 155000 15259000 405000 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Class B common unit awards was estimated using an option pricing model with the following assumptions:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%"><tr><td style="width:1.0%"/><td style="width:67.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.197%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Members’ equity value (in thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$271,207</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$197,041</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Threshold amounts (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$309,824</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$143,800</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time to liquidity (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 - 1.8</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lack of marketability discount</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8% - 26.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.88 - $3.06</span></div></td></tr></table></div>The fair value of the stock options granted during the three and nine months ended September 30, 2020 was determined with the following assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%"><tr><td style="width:1.0%"/><td style="width:44.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.6% - 78.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.6% - 78.2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average expected term (in years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 - 6.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 - 6.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 0.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—%</span></td></tr></table> 271207000 197041000 309824000 143800000 0.015 0.015 0.750 0.750 P1Y1M6D P1Y1M6D P1Y9M18D 0.265 0.188 0.264 3.06 1.88 3.06 70000 91000 0 1700000 P10Y 0.766 0.782 0.766 0.782 P5Y8M12D P6Y P5Y8M12D P6Y 0.004 0.004 0.005 0 0 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.839%"><tr><td style="width:1.0%"/><td style="width:44.938%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.454%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrecognized <br/>Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining <br/>Weighted-Average Recognition Period <br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,247 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.15</span></td></tr></table></div> 38247000 P3Y6M14D 2492000 P2Y5M4D 17563000 P1Y1M24D 309010 2.8 800000 1100000 Commitments and Contingencies<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in various disputes, including lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any of these claims could subject us to costly legal expenses. While we do generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, or our policy limits may be inadequate to fully satisfy any damage awards or settlement. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include payments related to operating leases. Approximate annual future minimum operating lease payments as of September 30, 2020 are as follows (in thousands): </span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The weighted-average remaining lease term of our operating leases is approximately 2.0 years. As of September 30, 2020, we had entered into an additional lease for real estate that had not yet commenced with total minimum lease payments of approximately $86.5 million. This lease is expected to commence in the fourth quarter of 2021 and has a lease term of 10.7 years. Zentera, our majority-owned subsidiary, had also entered into a separate lease for real estate that had not commenced as of September 30, 2020 with total minimum lease payments of approximately $0.1 million. This lease is expected to commence in the fourth quarter of 2020 and has a lease term of 1.2 years. Approximate annual future minimum operating lease payments as of September 30, 2020 are as follows (in thousands): <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 256000 1044000 661000 187000 2148000 246000 1902000 P2Y 86500000 P10Y8M12D 100000 P1Y2M12D Net Loss Per Common Share/Class A Common Unit <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share/Class A common unit were calculated as follows (in thousands except per share and per unit amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,538)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares/Class A common units outstanding, basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per Class A common unit</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.20)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.56)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential and dilutive securities, which include outstanding stock options, unvested RSAs, unvested RSUs and preferred units, have been excluded from the computation of diluted net loss per common share/Class A common unit as the effect would be anti-dilutive. We considered the impact of presenting a separate earnings per unit calculation for Class B common units. However, as earnings and losses are only allocable to Class B common units after the applicable threshold has been met, and such thresholds have not been met for earnings per unit purposes, no losses were allocated to Class B common units.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock/Class A common unit equivalents have been excluded from the calculations of diluted net loss per common share/Class A common unit because their inclusion would be antidilutive (in thousands).</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.153%"><tr><td style="width:1.0%"/><td style="width:58.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred units, as if converted to Class A common units</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive units—Class B common units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSAs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,730 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,897 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share/Class A common unit were calculated as follows (in thousands except per share and per unit amounts):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Zentalis</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,538)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares/Class A common units outstanding, basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,959 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per Class A common unit</span></div></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.20)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.56)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -34555000 -34555000 -12344000 -12344000 -77538000 -77538000 -31157000 -31157000 37959000 5601000 24143000 5601000 -0.91 0 -3.21 0 0 -2.20 0 -5.56 <div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock/Class A common unit equivalents have been excluded from the calculations of diluted net loss per common share/Class A common unit because their inclusion would be antidilutive (in thousands).</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:71.153%"><tr><td style="width:1.0%"/><td style="width:58.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred units, as if converted to Class A common units</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incentive units—Class B common units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSAs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,730 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,897 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 0 9950000 0 1947000 2783000 0 845000 0 1102000 0 4730000 11897000 Related Party Disclosures<div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2017, we acquired 17,307,692 shares of Series B preferred stock of Kalyra for a per share price of twenty-six cents ($0.26) or approximately $4.5 million. The management team and stockholders of Kalyra are also stockholders of the Company.</span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the investment, we entered into a license agreement and a master services agreement with Kalyra. The license agreement was signed and commenced on December 31, 2014 for the exclusive rights to develop and commercialize products derived from Kalyra’s technology in the initial area of oncology. The license agreement and all rights were subsequently sold from Kalyra to Recurium IP Holdings, LLC (“Recurium IP”), an entity with common ownership to Kalyra prior to the Zentalis investment. Under the agreement, we have agreed to make payments to Recurium IP based on specific milestones and based on Recurium Equity, LLC’s equity ownership stake in us, as determined in accordance with terms of the license agreement, at the time the milestone is earned. Recurium Equity, LLC (“Recurium Equity”) is also an entity with common ownership to Kalyra prior to the Zentalis investment. In addition, the Company shall pay low to mid-single digit percentage royalties on net product sales to Recurium IP and sublicense fees on any consideration paid to us by a sublicensor. The royalty payments are also based on Recurium Equity’s then equity ownership in us, as determined in accordance with the terms of the license agreement. The license agreement will terminate upon the later of the last expiration of the patent rights or 15 years from the date of commencement.</span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Master Services Agreement was entered into in January 2015 and states that Kalyra may provide research and development services to us and that we shall reimburse such expenses on a time and materials basis based on the initial statements of work. For each of the three months ended September 30, 2020 and 2019, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we did not incur any expense with Kalyra. For the nine months ended September 30, 2020 and 2019, we incurred approximately zero and zero dollars of expense with Kalyra, respectively, that was eliminated in consolidation for research and development services provided. As of September 30, 2020 and 2019, there was no balance due </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Kalyra.</span></div><div style="margin-bottom:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an Intercompany Services Agreement with Kalyra in January 2018 which states that we may provide research and development services to Kalyra and that Kalyra shall reimburse such expenses on a time and materials basis. For each of the three months ended September 30, 2020 and 2019, we provided</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.1 million o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f research and development services to Kalyra that we eliminated in consolidation. For the nine months ended September 30, 2020 and 2019, we provided $0.3 million and $0.4 million of research and development services to Kalyra that was eliminated in consolidation, respectively. As of September 30, 2020 and 2019, $0.1 million and $0.4 million was due from Kalyra and eliminated in consolidation, respectively.</span></div>On June 1, 2020, we entered into an equipment purchase and sale agreement with Kalyra to purchase $0.4 million of equipment and related tangible assets to be used in our operations. As of September 30, 2020, there was no balance due to Kalyra for the transaction. 17307692 0.26 4500000 P15Y 0 0 0 0 100000 100000 300000 400000 100000 400000 400000 XML 14 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover - shares
9 Months Ended
Sep. 30, 2020
Nov. 05, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 001-39263  
Entity Registrant Name Zentalis Pharmaceuticals, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 82-3607803  
Entity Address, Address Line One 530 Seventh Avenue,  
Entity Address, Address Line Two Suite 2201  
Entity Address, City or Town New York,  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10018  
City Area Code 212  
Local Phone Number 433-3791  
Title of 12(b) Security Common Stock,$0.001 par value per share  
Trading Symbol ZNTL  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   40,613,857
Entity Central Index Key 0001725160  
Amendment Flag false  
Document Fiscal Period Focus Q3  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2020  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets    
Cash and cash equivalents $ 92,552 $ 67,246
Marketable securities, available-for-sale 274,884 0
Accounts receivable from government grants, net 122 140
Prepaid expenses and other current assets 5,178 1,505
Total current assets 372,736 68,891
Property and equipment, net 471 501
Operating lease right-of-use assets 1,925 2,335
Prepaid expenses and other assets 4,245 2,134
Deferred financing costs 0 841
Goodwill 3,736 3,736
In-process research and development 8,800 8,800
Restricted cash 1,320 243
Total assets 393,233 87,481
Current liabilities    
Accounts payable 5,437 4,289
Accrued expenses 18,469 10,608
Total current liabilities 23,906 14,897
Deferred tax liability 2,463 2,463
Other long-term liabilities 1,031 1,700
Total liabilities 27,400 19,060
Commitments and contingencies
Convertible preferred units; Redemption value of $146,944,000 at December 31, 2019 0 141,706
EQUITY (DEFICIT)    
Preferred stock, value 0 0
Common Stock, value 41 0
Additional paid-in capital 501,522 0
Accumulated other comprehensive income 23 0
Accumulated deficit (160,531) (82,993)
Total stockholders’ equity/members’ (deficit) 341,055 (80,106)
Noncontrolling interests 24,778 6,821
Total equity (deficit) 365,833 (73,285)
Total liabilities, convertible preferred units and equity (deficit) 393,233 87,481
Class A Common Units    
EQUITY (DEFICIT)    
Class A and B common units, issuance value 0 709
Class B Common Units    
EQUITY (DEFICIT)    
Class A and B common units, issuance value $ 0 $ 2,178
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Convertible preferred units, redemption value   $ 146,944,000
Preferred stock, par value (in dollars per share) $ 0.001  
Preferred stock, shares authorized (in shares) 10,000,000  
Preferred stock, shares issued (in shares) 0  
Preferred stock, shares outstanding (in shares) 0  
Common stock, par value (in dollars per share) $ 0.001  
Common stock, shares authorized (in shares) 250,000,000  
Common stock issued (in shares) 40,614,453  
Common stock outstanding (in shares) 40,614,453  
Class A Common Units    
Common units, authorized (in shares)   20,000,000
Common units, issued (in shares)   5,601,478
Common units, outstanding (in shares)   5,601,478
Class B Common Units    
Common units, authorized (in shares)   3,458,522
Common units, issued (in shares)   2,670,668
Common units, outstanding (in shares)   2,670,668
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Operating Expenses        
Research and development $ 24,670 $ 10,739 $ 55,380 $ 26,517
General and administrative 10,097 1,844 23,162 5,423
Total operating expenses 34,767 12,583 78,542 31,940
Operating loss (34,767) (12,583) (78,542) (31,940)
Other Income (Expense)        
Investment and other income, net 120 12 368 123
Net loss before income taxes (34,647) (12,571) (78,174) (31,817)
Income tax expense 18 1 18 15
Net loss (34,665) (12,572) (78,192) (31,832)
Net loss attributable to noncontrolling interests (110) (228) (654) (675)
Net loss attributable to Zentalis $ (34,555) $ (12,344) $ (77,538) $ (31,157)
Units used in computing net loss per Class A common unit, basic and diluted (in shares) 37,959 5,601 24,143 5,601
Common Stock        
Other Income (Expense)        
Net loss per share outstanding, basic and diluted (USD per share) $ (0.91) $ 0 $ (3.21) $ 0
Class A Common Units        
Other Income (Expense)        
Net loss per share outstanding, basic and diluted (USD per share) $ 0 $ (2.20) $ 0 $ (5.56)
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Statement of Comprehensive Income [Abstract]        
Net loss $ (34,665) $ (12,572) $ (78,192) $ (31,832)
Other comprehensive income:        
Unrealized gain on marketable securities 19 0 23 0
Total comprehensive loss (34,646) (12,572) (78,169) (31,832)
Comprehensive loss attributable to noncontrolling interests (110) (228) (654) (675)
Comprehensive loss attributable to Zentalis $ (34,536) $ (12,344) $ (77,515) $ (31,157)
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Operating Activities:    
Consolidated net loss $ (78,192) $ (31,832)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 127 70
Share-based compensation 15,259 405
Amortization of premiums on marketable securities, net 224 0
Changes in operating assets and liabilities:    
Accounts receivable 18 867
Prepaid expenses and other assets (5,784) (833)
Accounts payable and accrued liabilities 9,049 5,155
Operating lease right-of-use assets and liabilities, net (169) 216
Net cash used in operating activities (59,468) (25,952)
Investing activities:    
Purchases of marketable securities (304,085) 0
Proceeds from maturities of marketable securities 29,000 0
Purchases of property and equipment (97) (316)
Net cash used in investing activities (275,182) (316)
Financing Activities:    
Proceeds from issuance of common stock in initial public offering, net 172,482 0
Contributions from noncontrolling interest owners, net 18,424 0
Proceeds from the issuance of Series C convertible preferred units, net 14,228 81,883
Proceeds from issuance of common stock, net 155,899 0
Net cash provided by financing activities 361,033 81,883
Net increase in cash, cash equivalents and restricted cash 26,383 55,615
Cash, cash equivalents and restricted cash at beginning of period 67,489 25,154
Cash, cash equivalents and restricted cash at end of period 93,872 80,769
Supplemental disclosure of non-cash investing and financing activities:    
Right-of-use assets obtained in exchange for operating lease liabilities 0 1,412
Costs incurred in connection with equity offering included in accounts payable and accrued liabilities 594 0
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents    
Total cash, cash equivalents and restricted cash reported in the Consolidated Statement of Cash Flows $ 93,872 $ 80,769
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members’/Stockholders’ Equity/(Deficit) (Statement) - USD ($)
$ in Thousands
Total
IPO
Convertible Preferred Units
Class A Common Units
Class B Common Units
Series C Preferred Units
Preferred Stock
Convertible Preferred Units
Common Stock
Common Stock
IPO
Common Stock
Class A Common Units
Common Stock
Class B Common Units
Additional Paid-in Capital
Additional Paid-in Capital
IPO
Accumulated Other Comprehensive Income
Accumulated Deficit
Noncontrolling Interests
Temporary equity beginning balance (in shares) at Dec. 31, 2018     0                          
Temporary equity, beginning balance at Dec. 31, 2018     $ 0                          
Increase (Decrease) in Temporary Equity [Roll Forward]                                
Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs, in shares     4,847,000                          
Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs $ 0   $ 81,883                          
Reclassification of convertible preferred units for contingent liquidation features not within the Company's control (in shares)     5,103,000                          
Reclassification of convertible preferred units for contingent liquidation features not within the Company's control     $ 59,830                          
Temporary equity ending balance (in shares) at Sep. 30, 2019     9,950,000                          
Temporary equity, ending balance at Sep. 30, 2019     $ 141,713                          
Beginning balance, in shares at Dec. 31, 2018             5,103,000                  
Beginning balance at Dec. 31, 2018 32,306           $ 59,830               $ (37,330) $ 7,536
Common units, beginning balance (in shares) at Dec. 31, 2018                   5,594,000 1,612,000          
Common units, beginning balance at Dec. 31, 2018                   $ 672 $ 1,598          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Stock issued (in shares)         91,000           335,000          
Share-based compensation expense 405                 $ 6 $ 399          
Reclassification of Stock to Temporary Equity, Shares             (5,103,000)                  
Reclassification of convertible preferred units for contingent liquidation features not within the Company's control (59,830)           $ (59,830)                  
Net loss attributable to noncontrolling interests (675)                             (675)
Net loss attributable to Zentalis (31,157)                           (31,157)  
Ending balance, in shares at Sep. 30, 2019             0                  
Ending balance at Sep. 30, 2019 $ (58,951)           $ 0               (68,487) 6,861
Common units, ending balance (in shares) at Sep. 30, 2019                   5,594,000 1,947,000          
Common units, ending balance at Sep. 30, 2019                   $ 678 $ 1,997          
Temporary equity beginning balance (in shares) at Dec. 31, 2018     0                          
Temporary equity, beginning balance at Dec. 31, 2018     $ 0                          
Temporary equity ending balance (in shares) at Dec. 31, 2019 9,950,154   9,950,000     4,847,106                    
Temporary equity, ending balance at Dec. 31, 2019 $ 141,706   $ 141,706     $ 81,876                    
Beginning balance, in shares at Dec. 31, 2018             5,103,000                  
Beginning balance at Dec. 31, 2018 32,306           $ 59,830               (37,330) 7,536
Common units, beginning balance (in shares) at Dec. 31, 2018                   5,594,000 1,612,000          
Common units, beginning balance at Dec. 31, 2018                   $ 672 $ 1,598          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Stock issued (in shares)       7,093                        
Ending balance, in shares at Dec. 31, 2019               0                
Ending balance at Dec. 31, 2019 (73,285)             $ 0       $ 0   $ 0 (82,993) 6,821
Common units, ending balance (in shares) at Dec. 31, 2019       5,601,478 2,670,668         5,601,000 2,671,000          
Common units, ending balance at Dec. 31, 2019       $ 709 $ 2,178         $ 709 $ 2,178          
Temporary equity beginning balance (in shares) at Jun. 30, 2019     0                          
Temporary equity, beginning balance at Jun. 30, 2019     $ 0                          
Increase (Decrease) in Temporary Equity [Roll Forward]                                
Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs, in shares     4,847,000                          
Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs 0   $ 81,883                          
Reclassification of convertible preferred units for contingent liquidation features not within the Company's control (in shares)     5,103,000                          
Reclassification of convertible preferred units for contingent liquidation features not within the Company's control     $ 59,830                          
Temporary equity ending balance (in shares) at Sep. 30, 2019     9,950,000                          
Temporary equity, ending balance at Sep. 30, 2019     $ 141,713                          
Beginning balance, in shares at Jun. 30, 2019             5,103,000                  
Beginning balance at Jun. 30, 2019 13,296           $ 59,830               (56,143) 7,089
Common units, beginning balance (in shares) at Jun. 30, 2019                   5,594,000 1,669,000          
Common units, beginning balance at Jun. 30, 2019                   $ 676 $ 1,844          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Stock issued (in shares)       0             278,000          
Share-based compensation expense 155                 $ 2 $ 153          
Reclassification of Stock to Temporary Equity, Shares             (5,103,000)                  
Reclassification of convertible preferred units for contingent liquidation features not within the Company's control (59,830)           $ (59,830)                  
Net loss attributable to noncontrolling interests (228)                             (228)
Net loss attributable to Zentalis (12,344)                           (12,344)  
Ending balance, in shares at Sep. 30, 2019             0                  
Ending balance at Sep. 30, 2019 $ (58,951)           $ 0               (68,487) 6,861
Common units, ending balance (in shares) at Sep. 30, 2019                   5,594,000 1,947,000          
Common units, ending balance at Sep. 30, 2019                   $ 678 $ 1,997          
Temporary equity beginning balance (in shares) at Dec. 31, 2019 9,950,154   9,950,000     4,847,106                    
Temporary equity, beginning balance at Dec. 31, 2019 $ 141,706   $ 141,706     $ 81,876                    
Increase (Decrease) in Temporary Equity [Roll Forward]                                
Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs, in shares 867,000                              
Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs $ 14,228                              
Conversion of convertible preferred units to common stock (in shares)     (10,817,000)         (15,011,000)                
Conversion of convertible preferred units to common stock 155,934   $ (155,934)         $ 15       155,919        
Temporary equity ending balance (in shares) at Sep. 30, 2020     0                          
Temporary equity, ending balance at Sep. 30, 2020 0   $ 0                          
Beginning balance, in shares at Dec. 31, 2019               0                
Beginning balance at Dec. 31, 2019 (73,285)             $ 0       0   0 (82,993) 6,821
Common units, beginning balance (in shares) at Dec. 31, 2019       5,601,478 2,670,668         5,601,000 2,671,000          
Common units, beginning balance at Dec. 31, 2019       $ 709 $ 2,178         $ 709 $ 2,178          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Stock Cancelled During Period, Shares                     (64,000)          
Stock issued (in shares)         70,000     4,744,000 10,589,000              
Stock issued, value 155,305 $ 172,365           $ 5 $ 11     155,300 $ 172,354      
Contributions from noncontrolling interest owners 18,424                             18,424
Share-based compensation expense 15,259                   $ 329 14,930        
Conversion of convertible preferred units to common stock (in shares)     10,817,000         15,011,000                
Conversion of convertible preferred units to common stock 155,934   $ (155,934)         $ 15       155,919        
Conversion of common and incentive units to common stock (in shares)               (10,278,000)   (5,601,000) (2,607,000)          
Conversion of common and incentive units to common and restricted stock               $ (10)   $ (709) $ (2,507) (3,206)        
Cancellation of restricted stock awards               (7,000)                
Other comprehensive income 23                         23    
Net loss attributable to noncontrolling interests (654)                     (187)       (467)
Net loss attributable to Zentalis (77,538)                           (77,538)  
Ending balance, in shares at Sep. 30, 2020               40,615,000                
Ending balance at Sep. 30, 2020 365,833             $ 41       501,522   23 (160,531) 24,778
Common units, ending balance (in shares) at Sep. 30, 2020                   0 0          
Common units, ending balance at Sep. 30, 2020       $ 0 $ 0         $ 0 $ 0          
Temporary equity ending balance (in shares) at Sep. 30, 2020     0                          
Temporary equity, ending balance at Sep. 30, 2020 0   $ 0                          
Beginning balance, in shares at Jun. 30, 2020               35,878,000                
Beginning balance at Jun. 30, 2020 237,925             $ 36       339,160   4 (125,976) 24,701
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                
Stock issued (in shares)       0       4,744,000                
Stock issued, value 155,305             $ 5       155,300        
Share-based compensation expense 7,249                     7,249        
Cancellation of restricted stock awards               (7,000)                
Other comprehensive income 19                         19    
Net loss attributable to noncontrolling interests (110)                     (187)       77
Net loss attributable to Zentalis (34,555)                           (34,555)  
Ending balance, in shares at Sep. 30, 2020               40,615,000                
Ending balance at Sep. 30, 2020 $ 365,833             $ 41       $ 501,522   $ 23 $ (160,531) $ 24,778
Common units, ending balance (in shares) at Sep. 30, 2020                   0 0          
Common units, ending balance at Sep. 30, 2020       $ 0 $ 0         $ 0 $ 0          
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members’/Stockholders’ Equity/(Deficit) (Parenthetical)) - $ / shares
Sep. 30, 2020
Feb. 29, 2020
Sep. 30, 2019
Series C Preferred Units      
Par value per share (in dollars per share) $ 17.50 $ 17.50 $ 17.50
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Business
9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Business Organization and Business
Organization
Zentalis Pharmaceuticals, Inc. (successor to Zentalis Pharmaceuticals, LLC) (“Zentalis”, “We” or the “Company”) is a clinical-stage pharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. To date, all of the Company’s revenue has been generated in the United States. All of the Company’s tangible assets are held in the United States.
The Company was formed and incorporated in the state of Delaware as Zeno Pharmaceuticals, Inc. on December 23, 2014. Effective November 21, 2017, Zeno Pharma, LLC was formed by the shareholders of Zeno Pharmaceuticals, Inc. On December 21, 2017, Zeno Pharmaceuticals, Inc. became a wholly owned subsidiary of Zeno Pharma, LLC. In connection with this restructuring, the rights and preferences of the Preferred Stock of Zeno Pharmaceuticals, Inc. were exchanged for preferred units with similar rights and preferences of Zeno Pharma, LLC. As part of the restructuring, the employees, consultants and board members of Zeno Pharmaceuticals, Inc. exchanged their equity grants in Zeno Pharmaceuticals, Inc. stock for Class B common units in Zeno Pharma, LLC. Additionally, existing common stockholders of Zeno Pharmaceuticals, Inc. exchanged their common stock for Class A common units in Zeno Pharma, LLC. All exchanges were made on a one-for-one basis. The restructuring was accounted for as a common control transaction. In December 2019, the Company was renamed to Zentalis Pharmaceuticals, LLC.
Immediately prior to the effectiveness of the registration statement pertaining to the Company’s initial public offering (“IPO”) on April 2, 2020, the Company converted from a Delaware limited liability company into a Delaware corporation, and changed its name to Zentalis Pharmaceuticals, Inc. Pursuant to the statutory corporate conversion, all of the outstanding units of Zentalis Pharmaceuticals, LLC converted into shares of common stock of Zentalis Pharmaceuticals, Inc. based upon the value of Zentalis Pharmaceuticals, Inc. at the time of the IPO with a value implied by the price of the shares of common stock sold in the IPO. Based on the IPO price of $18.00 per share, the outstanding units converted into 25,288,854 shares of common stock (including 1,160,277 shares of restricted common stock).
On April 7, 2020, the Company completed the IPO in which the Company issued and sold 10,557,000 shares of common stock (including 1,377,000 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a public offering price of $18.00 per share. The Company’s aggregate gross proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $190.0 million before fees and expenses of $17.6 million.
On May 19, 2020, the Company announced the closing of a Series A financing of Zentera Therapeutics, Ltd. (“Zentera”), a majority owned biopharmaceutical company with headquarters in Shanghai, China. Contributions from noncontrolling interest members totaled $20.0 million before issuing costs of $1.6 million. The Company holds 60.2% equity interest in Zentera for purposes of the development and commercialization of ZN-c5, ZN-d5 and ZN-c3 for the treatment or preventions of disease, other than for pain, in the People’s Republic of China, Macau, Hong Kong and Taiwan. Two of our executives entered into restricted stock purchase agreements with Zentera. The associated shares vest over four years.

On August 3, 2020, the Company completed a follow-on offering in which the Company issued and sold 4,743,750 shares of common stock (including 618,750 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a public offering price of $35.00 per share. The
Company’s aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $166.0 million before fees and expenses of $10.8 million.
Liquidity
Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statement issuance date. The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after the date that the interim unaudited condensed consolidated financial statements for the quarter ended September 30, 2020 are issued.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Interim Unaudited Financial Statements
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Interim Unaudited Financial Statements Interim Unaudited Financial Statements
Basis of Presentation
The accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company’s audited financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2019 included in the Company’s final prospectus for its IPO, filed pursuant to Rule 424(b) under the Securities Exchange Act of 1933, as amended, with the SEC on April 6, 2020. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments.
The condensed consolidated financial statements include the accounts of our wholly owned subsidiaries, majority-owned or controlled companies, and variable interest entity (“VIE”), Kalyra Pharmaceuticals, Inc. (“Kalyra”), for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.
Noncontrolling Interest
The shares third parties own in Kalyra and Zentera represent an interest in their respective equity we do not control. We reflect the noncontrolling interest attributable to other owners in a separate line in our condensed consolidated statement of operations and a separate line within stockholders’ equity in our condensed consolidated balance sheet. In addition, we record a noncontrolling interest adjustment to account for equity based compensation in Zentera. This adjustment is a reclassification within stockholders’ equity from additional paid-in capital to noncontrolling interest equal to the amount of equity based compensation expense Zentera had recognized.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.
Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.
Marketable Securities
Marketable securities are investments with original maturities of more than ninety days from the date of purchase that we have the ability to liquidate to fund current operations. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term investments on the accompanying condensed consolidated balance sheets Marketable securities are considered available-for-sale and are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders’ deficit. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of operations. We assess whether our available-for-sale debt securities in an unrealized loss position have credit-related losses and record such losses, and any subsequent improvements as interest income, through an allowance account. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of operations.
Adoption and Pending Adoption of Recent Accounting Pronouncements
The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
Standard  Description  Effective Date  Effect on the Financial
Statements or Other
Significant Matters
In March 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial InstrumentsThis guidance makes improvements to financial instruments guidance, including the current expected credit losses guidance.January 1, 2020We have adopted the new guidance as of January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321)This standard clarifies the interaction between accounting standards related to equity securities (ASC 321), equity method investments (ASC 323), and certain derivatives (ASC 815). January 1, 2021We currently do not hold equity securities, have equity method investments or derivatives. We do not believe the adoption will have a material impact on our consolidated financial position or results of operations.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. In November 2018 and April and May of 2019, the FASB issued additional guidance related to Topic 326.The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income.January 1, 2020We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes.The new guidance is intended to simplify aspects of the accounting for income taxes, including the elimination of certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, among other changes.January 1, 2020We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Business Combinations
9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Business Combinations Business Combinations
Kalyra Pharmaceuticals, Inc.
On December 21, 2017, we acquired $4.5 million of Kalyra’s Series B Preferred Stock representing a 25% equity interest in Kalyra for purposes of entering the analgesics therapeutic research space. The acquisition price was paid entirely in cash.
In accordance with the authoritative guidance, we concluded that Kalyra is a business consisting of inputs, employees, intellectual property and processes capable of producing outputs. Additionally, we have concluded that Kalyra is a variable interest entity, we are the primary beneficiary and have the power to direct the activities that most significantly affect Kalyra’s economic performance through common management and our board representation. Prior to the change of control, Zentalis and Kalyra transacted for the delivery of research and development services and support. The financial position and results of operations of Kalyra have been included in our consolidated financial statements from the date of the initial investment.
Pursuant with authoritative guidance, we have recorded the identifiable assets, liabilities and noncontrolling interests in the VIE at their fair value upon initial consolidation. The identified goodwill is comprised of the workforce and expected synergies from combining the entities. Total assets and liabilities of Kalyra as of September 30, 2020 and December 31, 2019 are as follows (in thousands):
September 30,December 31,
 20202019
Cash and cash equivalents$417 $712 
Other current assets31 21 
In-process research and development8,800 8,800 
Goodwill3,736 3,736 
Other long-term assets14 14 
Accounts payable and accrued expenses87 391 
Deferred tax liability2,463 2,463 
Noncontrolling interests$6,635 $6,821 
The liabilities recognized as a result of consolidating Kalyra do not represent additional claims on our general assets. Pursuant to the authoritative guidance, the equity interest in Kalyra not owned by Zentalis is reported as a noncontrolling interest on our consolidated balance sheets.
The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):
September 30,
 2020
Noncontrolling interest at beginning of period$6,821 
Net loss attributable to noncontrolling interest(186)
Noncontrolling interest at end of period$6,635 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement
9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurement Fair Value MeasurementAvailable-for-sale marketable securities consisted of the following (in thousands):
September 30, 2020
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Commercial paper $125,748 $$(7)$125,750 
Corporate debt securities
31,840 (3)31,842 
US government agencies
77,523 22 (5)77,540 
US Treasury securities39,750 (1)39,752 
$274,861 $39 $(16)$274,884 
As of September 30, 2020, 19 of our available-for-sale debt securities with a fair market value of $85.3 million were in a gross unrealized loss position of sixteen thousand. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, our intent to sell or the likelihood that we would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. Based on our review of these marketable securities, we believe none of the unrealized loss is as a result of a credit loss as of September 30, 2020, because we do not intend to sell these securities and it is not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.
Contractual maturities of available-for-sale debt securities are as follows (in thousands):

September 30, 2020
Estimated Fair Value
Due within one year$239,291 
After one but within five years35,593 
$274,884 

The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
September 30, 2020December 31, 2019
Level 1Level 2Total estimated fair valueLevel 1Level 2Total estimated fair value
Cash equivalents:
Money market funds
$29,924 $— $29,924 $62,961 $— $62,961 
US government agencies
— 2,631 2,631 — — — 
US Treasury securities
9,999 — 9,999 — — — 
Corporate debt securities
— 14,999 14,999 — — — 
Total cash equivalents:
39,923 17,630 57,553 62,961 — 62,961 
Available-for-sale marketable securities:
Commercial paper
— 125,750 125,750 — — — 
Corporate debt securities
— 31,842 31,842 — — — 
US government agencies
— 77,540 77,540 — — — 
US Treasury securities
39,752 — 39,752 — — — 
Total available-for-sale marketable securities:
39,752 235,132 274,884 — — — 
Total assets measured at fair value
$79,675 $252,762 $332,437 $62,961 $— $62,961 

There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the nine months ended September 30, 2020. We had no instruments that were classified within Level 3 as of September 30, 2020 or December 31, 2019.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Prepaid Expenses and Other Assets
9 Months Ended
Sep. 30, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Other Assets Prepaid Expenses and Other Assets
Prepaid expenses and other assets consisted of the following (in thousands):
September 30,December 31,
 20202019
Prepaid insurance
$1,761 $150 
Prepaid software licenses and maintenance
320 238 
Prepaid research and development expenses
5,735 2,985 
Interest receivable511 — 
Upfront lease payment810 — 
Other prepaid expenses
286 266 
Total prepaid expenses and other current assets
9,423 3,639 
Less long-term portion
4,245 2,134 
Total prepaid expenses and other assets, current
$5,178 $1,505 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment, net
9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]  
Property and Equipment, net Property and Equipment, net
Property and equipment, net consisted of the following (in thousands):
September 30,December 31,
 20202019
Computer and office equipment
$291 $243 
Lab equipment
360 401 
Leasehold improvements
43 24 
Construction in progress
— 
Subtotal
700 668 
Accumulated depreciation and amortization
(229)(167)
Property and equipment, net
$471 $501 
Depreciation and amortization expense for the three months ended September 30, 2020 and 2019 was approximately fifty-one thousand and twenty-five thousand, respectively. Depreciation and amortization expense for the nine months ended September 30, 2020 and 2019 was approximately one hundred twenty-seven thousand and seventy thousand, respectively.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses
9 Months Ended
Sep. 30, 2020
Payables and Accruals [Abstract]  
Accrued Expenses Accrued Expenses
Accrued expenses consist of the following (in thousands):
September 30,December 31,
20202019
Accrued research and development expenses
$10,618 $5,465 
Accrued employee expenses
4,390 2,977 
Accrued general and administrative expenses
2,571 1,356 
Lease liability
871 781 
Other
19 29 
Total accrued expenses
$18,469 $10,608 
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Preferred Units
9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Convertible Preferred Units Convertible Preferred Units
Series A Convertible Preferred Units
In September 2015, Zeno Pharmaceuticals, Inc. entered into a Series A Preferred Stock Purchase Agreement (the “Series A Preferred Agreement”). Under the terms of the Series A Preferred Agreement, Zeno Pharmaceuticals, Inc. issued 1,293,104 shares of Series A convertible preferred stock at $11.60 per share for gross proceeds of $15.0 million. The net proceeds of this financing were $14.9 million after issuance costs of $0.1 million. In February and March 2016, Zeno Pharmaceuticals, Inc. issued an aggregate of 286,205 additional shares of Series A convertible preferred stock at $11.60 per share for additional gross proceeds of $3.3 million. The issuance costs of this additional financing were approximately thirty-nine thousand dollars. All Series A convertible preferred stock issued and outstanding by Zeno Pharmaceuticals, Inc. was converted into Series A convertible preferred units of Zentalis Pharmaceuticals, LLC in conjunction with the corporate restructuring and merger.
Series B Convertible Preferred Units
In December 2017, Zentalis Pharmaceuticals, LLC entered into a Series B Preferred Unit Purchase Agreement (the “Series B Preferred Agreement”). Under the terms of the Series B Preferred Agreement, Zentalis
Pharmaceuticals, LLC issued 2,735,320 Series B preferred units at $12.43 per unit for gross proceeds of $34.0 million. The net proceeds of this financing were $32.1 million after issuance costs of $1.9 million. In January and August 2018, Zentalis Pharmaceuticals, LLC issued an aggregate of 788,419 additional shares of Series B preferred units at $12.43 per unit for additional gross proceeds of $9.8 million. The net proceeds of this additional financing were $9.5 million after issuance costs of $0.3 million.
Series C Preferred Unit Issuance
In September 2019, Zentalis Pharmaceuticals, LLC entered into a Series C Preferred Unit Purchase Agreement (the “Series C Preferred Agreement”). Under the terms of the Series C Preferred Agreement, Zentalis Pharmaceuticals, LLC issued 4,847,106 units of Series C convertible preferred units at $17.50 per unit for gross proceeds of $84.8 million. The net proceeds of this financing were $81.9 million after issuance costs of $2.9 million. In February 2020, Zentalis Pharmaceuticals, LLC issued 867,194 additional units of Series C preferred units under the Series C Preferred Agreement. The units were issued for $17.50 per unit for gross proceeds of $15.2 million. The net proceeds of this financing were $14.2 million after issuance costs of $1.0 million.
There were no authorized, issued, and outstanding shares of convertible preferred units at September 30, 2020. As of December 31, 2019, the authorized, issued, and outstanding units of convertible preferred units were as follows (in thousands, except unit amounts):
December 31, 2019
SeriesUnits
Authorized
Units Issued
and
Outstanding
Liquidation
Value
Carrying
Value
Series A convertible preferred units
1,579,309 1,579,309 $18,320 $18,226 
Series B convertible preferred units
3,523,739 3,523,739 43,800 41,604 
Series C convertible preferred units
5,714,300 4,847,106 84,824 81,876 
Total
10,817,348 9,950,154 $146,944 $141,706 
During 2019, we reclassified the convertible preferred units from members’ equity to temporary equity because, in conjunction with the Series C convertible preferred units issuance, all units were now deemed to contain contingent liquidation features that are not solely within our control. During the year ended December 31, 2019 and prior to the conversion of convertible preferred units into common stock in conjunction with our IPO on April 2, 2020, we did not adjust the carrying values of the convertible preferred units to the deemed redemption values of such units since a liquidation event was not probable.

Dividends
Dividends are payable if and when declared by the Board of Directors. No dividends have been declared prior to the conversion of convertible preferred units into common stock in conjunction with our IPO on April 2, 2020.
Conversion
Each Series A preferred unit, Series B preferred unit and Series C preferred unit was convertible at the option of the holder thereof, at any time after the issuance of such unit, into Class A common units at a conversion price equal to the original purchase price (subject to anti-dilution adjustments, discussed below) which was $11.60, $12.43 and $17.50 per unit, respectively. The convertible preferred units automatically converted at the then applicable conversion rate upon the closing of a firm commitment underwritten public offering of shares of a successor corporations’ common stock, at a public offering price per share of equal to or greater than the Series C original purchase price (as adjusted for any stock splits, stock dividends, combinations or other similar recapitalization) resulting in aggregate gross cash proceeds of at least $75.0 million (a “Qualified IPO”). Additionally, the convertible preferred units would have automatically converted into common stock, at the then applicable conversion rate, upon written consent of a majority of the then outstanding Series A, Series B and Series C convertible preferred units
(voting as a separate class on an as converted to Common Unit basis). In conjunction with our IPO on April 2, 2020, which constituted a Qualified IPO, all convertible preferred units were converted into common stock.
Anti-dilution protection
The holders of the convertible preferred unit had proportional anti-dilution protection for unit splits, unit dividends and similar recapitalizations. Subject to certain exclusions, anti-dilution price protection for additional sales of securities by us for consideration per unit less than the applicable conversion price per unit of any series of convertible preferred stock, was on a broad-based weighted average basis.
Protective rights
The holders of the convertible preferred units had certain protective rights, including, without limitation, regarding the authorization, alteration, redemption, or sale of Class B common units; commencement of a liquidation or deemed liquidation event; entrance into a joint venture or partnership; any incurrence of indebtedness; certain transactions that exceed a certain dollar threshold; changes to our governing documents; or the declaration of any dividends. Such actions were required to be approved by a majority of the then outstanding Series A, Series B and Series C convertible preferred unit holders (voting as a single class and on an as-converted basis), as specified in the amended and restated LLC agreement. An increase or decrease in the authorized number of Directors constituting the Board or the creation of a membership interest or equity security senior to or pari passu with Series C convertible preferred units was required to be approved by a majority of the then outstanding Series C convertible preferred Units (voting as a separate class on an as converted basis).
Redemption
The Series A, Series B and Series C convertible preferred units were not redeemable except in the event of certain effected deemed liquidation events. As of immediately prior to our IPO on April 2, 2020 and December 31, 2019, we had classified convertible preferred units as temporary equity in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of our control, including liquidation, sale or transfer of control of the Company. We did not adjust the carrying value of the convertible preferred units to the deemed redemption values of such units since a liquidation event was not probable.
Liquidation preference
In the event of the dissolution, liquidation, merger or winding up of the Company, the holders of Series C convertible preferred units were entitled to receive, on a pro rata basis in respect of each such Series C convertible preferred unit, a preference amount of $17.50 per Series C convertible unit (as adjusted for any unit splits, dividends, combinations, recapitalizations or the like).
Subsequent to the payment of the Series C convertible preferred unit preferences, Series A and Series B convertible preferred units were entitled to receive, on a pro rata basis in respect of each convertible preferred unit in proportion to the relative preference amount of each preferred unit, a preference amount of $11.60 and $12.43 per unit of Series A and Series B convertible preferred units (as adjusted for any units splits, dividend, combinations, recapitalizations of the like), respectively.
Subsequent to the payment of the Series C, Series A and Series B convertible preferred unit preferences, Series A, Series B and Series C convertible preferred units were entitled to receive, on an as converted to common unit pro rata basis, an amount equal to distributions made to Class A common units prior to all unit classes sharing in distributions on a pro rata basis. Thereafter, Series A, Series B and Series C convertible preferred units and Series A and Series B common units were entitled to receive the remaining assets of the Company available for distribution to its unit holders pro rata based on the number of common units held by each holder, treating for these purposes as if all units had been converted to common.
Voting Rights
The holders of all units other than Class B common units that were unvested were to vote together as a single class. Each holder of Series A, Series B and Series C convertible preferred units were entitled to the number of votes calculated on an as converted to Class A common unit basis.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Equity and Share-based Compensation
9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Equity and Share-based Compensation Equity and Share-based Compensation
In November 2017, Zentalis Pharmaceuticals, LLC was formed in the state of Delaware. In conjunction with a corporate restructuring, Zeno Pharmaceuticals, Inc., a Delaware Corporation formed in 2014, was acquired by the Company pursuant to a merger agreement and became a wholly owned subsidiary of the Company. Per the terms of the merger agreement, each share of Zeno Pharmaceuticals, Inc. common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive one Class A common unit and each share of Zeno Pharmaceuticals, Inc. Series A preferred stock issued and outstanding immediately prior to the effective date of the merger converted into the right to receive one Series A preferred unit. As of the effective time of the merger agreement, all outstanding options to purchase shares of Zeno Pharmaceuticals, Inc. common stock were cancelled and replaced with profit interest awards in the LLC.
In connection with the December 2017 corporate restructuring, we amended and restated the LLC agreement, and as amended, the capital units of the Company consisted of 1,638,000 authorized Series A preferred units, 3,621,000 authorized Series B preferred units, 15,000,000 authorized Class A common units and 872,620 authorized Class B common units.
Class A Common Units
In conjunction with the corporate restructuring in December 2017, 5,187,554 shares of common stock issued and outstanding and 406,831 shares of common stock subject to future vesting provisions of Zeno Pharmaceuticals, Inc. were converted into an equal number of Class A common units of Zentalis Pharmaceuticals, LLC. During the three months ended September 30, 2020 and 2019, we did not issue any Class A common units. As of September 30, 2020 and 2019, zero and 9,572 Class A common units were subject to future vesting conditions, respectively. During the year ended December 31, 2019, 7,093 Class A common units were issued and 9,572 Class A common units were subject to future vesting conditions. In September 2019, the number of authorized Class A common units was increased to 20,000,000.
Class B Common Units
In conjunction with the corporate restructuring in December 2017, 703,000 options exercisable into Zeno Pharmaceuticals, Inc. common stock were converted into an equal number of Class B common units of Zentalis Pharmaceuticals, LLC. In September 2019, the number of authorized Class B common units was increased to 3,458,522.
IPO and Follow-on Offering
On April 2, 2020 and immediately prior to the effectiveness of the Company’s IPO, Zentalis Pharmaceuticals, LLC converted from a Delaware limited liability company into a Delaware corporation pursuant to a statutory conversion, and changed its name to Zentalis Pharmaceuticals, Inc. In order to consummate the corporate conversion, a certificate of conversion was filed with the Secretary of State of the State of Delaware. All of the outstanding units of Zentalis Pharmaceuticals, LLC converted into shares of common stock of Zentalis Pharmaceuticals, Inc. based upon the value of Zentalis Pharmaceuticals, Inc. at the time of the IPO with a value implied by the price of the shares of common stock sold in the IPO. No cash or fractional shares of common stock were issued in connection with the corporate conversion. Based on the IPO price of $18.00 per share of common stock, all of the outstanding units converted into an aggregate of 25,288,854 shares of common stock (including 1,160,277 shares of restricted common stock).
In connection with the completion of the IPO, the board and stockholders approved the certificate of incorporation to provide for 250,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share.
On April 7, 2020, the Company completed an IPO in which the Company issued and sold 10,557,000 shares of common stock (including 1,377,000 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a price of $18.00 per share. The Company’s aggregate gross proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $190.0 million before fees and expenses of $17.6 million.
On August 3, 2020, the Company completed a follow-on offering in which the Company issued and sold 4,743,750 shares of common stock (including 618,750 shares of common stock in connection with the full exercise of the underwriters’ option to purchase additional shares) at a public offering price of $35.00 per share. The Company’s aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares pursuant to the full exercise of the underwriters’ option to purchase additional shares, was $166.0 million before fees and expenses of $10.8 million.
Share-based Compensation
In the Company’s 2017 Profit Interest Plan (the Plan) as approved and adopted by the Board of Directors on December 21, 2017, the Company was authorized to issue up to 3,458,522 shares of Class B common units, subject to restrictions as described in the Plan. The Plan was terminated in April 2020. In April 2020, the Company’s board of directors adopted, and the Company’s stockholders approved the 2020 Incentive Award Plan (the 2020 Plan), which became effective upon the corporate conversion. The number of common shares initially available for issuance under the 2020 Plan is the sum of (1) 5,600,000 shares of common stock; plus (2) any shares forfeited from the unvested restricted shares of our common stock issued upon conversion of unvested Class B common units (up to 1,250,000 shares); plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ending December 31, 2021 and continuing to, and including, the fiscal year ending December 31, 2030, equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by our board of directors.
During the nine months ended September 30, 2020, the Company granted 70,000 Class B common units to employees and directors under the Plan. The weighted average fair value of incentive units granted in the nine months ended September 30, 2020 was $3.06 per unit. In April 2020, each outstanding Class B common unit was converted into a number of shares of common stock and restricted common stock based upon the IPO price. The restricted common stock issued in respect of Class B common units continues to be subject to vesting in accordance with the vesting schedule that was applicable to such Class B common units. The Company granted 1,160,277 shares of restricted common stock to employees, consultants and directors as part of the conversion. In conjunction with the IPO, the Company also granted 1,970,671 stock options, with a weighted average of $11.97 per share, to purchase shares of common stock to employees and directors who were holders of Class B common units at the time of the incentive unit conversion and in new employee grants. The weighted average fair value of the 2,794,546 stock options granted to employees and directors in the nine months ended September 30, 2020 was $15.11 per share.
Total share-based compensation expense related to share based awards was comprised of the following (in thousands):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Research and development expense
$2,180 $95 $4,606 $224 
General and administrative expense
5,069 60 10,653 181 
Total share-based compensation expense
$7,249 $155 $15,259 $405 
Total share-based compensation expense includes $187 and $187 of share-based compensation expense for Zentera employees for the three and nine months ended September 30, 2020, respectively, compared to $0 for the same periods in 2019.
Share-based compensation expense by type of share-based award (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Profit interest award units
$— $155 $329 $405 
Stock options
2,212 — 3,814 — 
RSAs and RSUs
5,037 — 11,116 — 
$7,249 $155 $15,259 $405 

The fair value of the Class B common unit awards was estimated using an option pricing model with the following assumptions:
Nine Months Ended
September 30,
20202019
Members’ equity value (in thousands)$271,207$197,041
Threshold amounts (in thousands)$309,824$143,800
Risk free rate1.5%1.5%
Volatility75.0%75.0%
Time to liquidity (in years)1.1
1.1 - 1.8
Lack of marketability discount26.5%
18.8% - 26.4%
Grant date fair value$3.06
$1.88 - $3.06
The Black-Scholes-Merton option pricing model (“Black-Scholes model) is used to estimate the fair value of each Class B common unit award on the date of grant. The members’ equity value was based on a recent enterprise valuation analysis performed. The threshold amounts are based on the discretion of the Board of Directors at the time of grant. The expected life of the Class B common unit awards granted during the period presented was determined based on an expected liquidation event under the plan. We applied the risk-free interest rate based on the U.S. Treasury yield in effect at the time of the grant consistent with the life of the award. The expected volatility was based on a peer group in the industry in which the Company does business consistent with the expected time to liquidity. The dividend yield was set at zero as the underlying security does not and is not expected to pay a dividend. The Finnerty model and the Asian Protective Put Model methods were used to estimate the discount for lack of marketability inherent to the awards.
The Class B common units issued have been classified as equity awards, and share-based compensation expense is based on the grant date fair value of the award. During the nine months ended September 30, 2020 and 2019, we issued 70,000 and 91,000 Class B common units, respectively. As of September 30, 2020 and December 31, 2019, zero and approximately 1.7 million unvested Class B common units were outstanding, respectively.
The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each option award is estimated on the date of grant using the Black-Scholes model. Due to the Company’s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected
companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company uses the “simplified method” for estimating the expected term of employee options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). The risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero. The fair value of the stock options granted during the three and nine months ended September 30, 2020 was determined with the following assumptions:
Three Months Ended
September 30, 2020
Nine Months Ended
September 30, 2020
Expected volatility
76.6% - 78.2%
76.6% - 78.2%
Average expected term (in years)
5.7 - 6.0
5.7 - 6.0
Risk-free interest rate
0.4%
0.4% - 0.5%
Expected dividend yield
—%—%

Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):
September 30, 2020
Unrecognized
Expense
Remaining
Weighted-Average Recognition Period
(years)
Stock options$38,247 3.54
RSAs$2,492 2.43
RSUs$17,563 1.15
During the nine months ended September 30, 2020, we did not issue any shares of common stock in connection with the exercises of stock options. For the nine months ended September 30, 2020, 309,010 shares of common stock issued in conjunction with certain RSAs fully vested. Stock options, unvested RSAs, and unvested RSUs totaling approximately 2.8 million shares, 0.8 million shares, and 1.1 million shares of our common stock, respectively, were outstanding as of September 30, 2020.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Commitment and Contingencies
9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Contingencies
From time to time, we may be involved in various disputes, including lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any of these claims could subject us to costly legal expenses. While we do generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage, or our policy limits may be inadequate to fully satisfy any damage awards or settlement. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. We are currently not a party to any legal proceedings.
Leases
Our commitments include payments related to operating leases. Approximate annual future minimum operating lease payments as of September 30, 2020 are as follows (in thousands):
YearOperating Leases
2020$256 
20211,044 
2022661 
2023187 
Total minimum lease payments:
2,148 
Less: imputed interest(246)
Total operating lease liabilities
1,902 
The weighted-average remaining lease term of our operating leases is approximately 2.0 years. As of September 30, 2020, we had entered into an additional lease for real estate that had not yet commenced with total minimum lease payments of approximately $86.5 million. This lease is expected to commence in the fourth quarter of 2021 and has a lease term of 10.7 years. Zentera, our majority-owned subsidiary, had also entered into a separate lease for real estate that had not commenced as of September 30, 2020 with total minimum lease payments of approximately $0.1 million. This lease is expected to commence in the fourth quarter of 2020 and has a lease term of 1.2 years.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Common Share/Class A Common Unit
9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Net Loss Per Common Share/Class A Common Unit Net Loss Per Common Share/Class A Common Unit
Basic and diluted net loss per common share/Class A common unit were calculated as follows (in thousands except per share and per unit amounts):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Numerator:
Net loss attributable to Zentalis
$(34,555)$(12,344)$(77,538)$(31,157)
Denominator:
Weighted average number of common shares/Class A common units outstanding, basic and diluted
37,959 5,601 24,143 5,601 
Net loss per common share
$(0.91)$— $(3.21)$— 
Net loss per Class A common unit
$— $(2.20)$— $(5.56)
Our potential and dilutive securities, which include outstanding stock options, unvested RSAs, unvested RSUs and preferred units, have been excluded from the computation of diluted net loss per common share/Class A common unit as the effect would be anti-dilutive. We considered the impact of presenting a separate earnings per unit calculation for Class B common units. However, as earnings and losses are only allocable to Class B common units after the applicable threshold has been met, and such thresholds have not been met for earnings per unit purposes, no losses were allocated to Class B common units.
The following common stock/Class A common unit equivalents have been excluded from the calculations of diluted net loss per common share/Class A common unit because their inclusion would be antidilutive (in thousands).
 September 30,
 20202019
Preferred units, as if converted to Class A common units
— 9,950 
Incentive units—Class B common units
— 1,947 
Outstanding stock options
2,783 — 
Unvested RSAs
845 — 
Unvested RSUs
1,102 — 
4,730 11,897 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Disclosures
9 Months Ended
Sep. 30, 2020
Related Party Transactions [Abstract]  
Related Party Disclosures Related Party Disclosures
On December 21, 2017, we acquired 17,307,692 shares of Series B preferred stock of Kalyra for a per share price of twenty-six cents ($0.26) or approximately $4.5 million. The management team and stockholders of Kalyra are also stockholders of the Company.
Prior to the investment, we entered into a license agreement and a master services agreement with Kalyra. The license agreement was signed and commenced on December 31, 2014 for the exclusive rights to develop and commercialize products derived from Kalyra’s technology in the initial area of oncology. The license agreement and all rights were subsequently sold from Kalyra to Recurium IP Holdings, LLC (“Recurium IP”), an entity with common ownership to Kalyra prior to the Zentalis investment. Under the agreement, we have agreed to make payments to Recurium IP based on specific milestones and based on Recurium Equity, LLC’s equity ownership stake in us, as determined in accordance with terms of the license agreement, at the time the milestone is earned. Recurium Equity, LLC (“Recurium Equity”) is also an entity with common ownership to Kalyra prior to the Zentalis investment. In addition, the Company shall pay low to mid-single digit percentage royalties on net product sales to Recurium IP and sublicense fees on any consideration paid to us by a sublicensor. The royalty payments are also based on Recurium Equity’s then equity ownership in us, as determined in accordance with the terms of the license agreement. The license agreement will terminate upon the later of the last expiration of the patent rights or 15 years from the date of commencement.
The Master Services Agreement was entered into in January 2015 and states that Kalyra may provide research and development services to us and that we shall reimburse such expenses on a time and materials basis based on the initial statements of work. For each of the three months ended September 30, 2020 and 2019, we did not incur any expense with Kalyra. For the nine months ended September 30, 2020 and 2019, we incurred approximately zero and zero dollars of expense with Kalyra, respectively, that was eliminated in consolidation for research and development services provided. As of September 30, 2020 and 2019, there was no balance due to Kalyra.
We entered into an Intercompany Services Agreement with Kalyra in January 2018 which states that we may provide research and development services to Kalyra and that Kalyra shall reimburse such expenses on a time and materials basis. For each of the three months ended September 30, 2020 and 2019, we provided $0.1 million of research and development services to Kalyra that we eliminated in consolidation. For the nine months ended September 30, 2020 and 2019, we provided $0.3 million and $0.4 million of research and development services to Kalyra that was eliminated in consolidation, respectively. As of September 30, 2020 and 2019, $0.1 million and $0.4 million was due from Kalyra and eliminated in consolidation, respectively.
On June 1, 2020, we entered into an equipment purchase and sale agreement with Kalyra to purchase $0.4 million of equipment and related tangible assets to be used in our operations. As of September 30, 2020, there was no balance due to Kalyra for the transaction.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Interim Unaudited Financial Statements (Policies)
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Basis of Presentation Basis of PresentationThe accompanying interim unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. The year-end condensed consolidated balance sheet data was derived from the Company’s audited financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2019 included in the Company’s final prospectus for its IPO, filed pursuant to Rule 424(b) under the Securities Exchange Act of 1933, as amended, with the SEC on April 6, 2020. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments.
Consolidation
The condensed consolidated financial statements include the accounts of our wholly owned subsidiaries, majority-owned or controlled companies, and variable interest entity (“VIE”), Kalyra Pharmaceuticals, Inc. (“Kalyra”), for which we are the primary beneficiary. All intercompany transactions and balances have been eliminated in consolidation.
Noncontrolling Interest
The shares third parties own in Kalyra and Zentera represent an interest in their respective equity we do not control. We reflect the noncontrolling interest attributable to other owners in a separate line in our condensed consolidated statement of operations and a separate line within stockholders’ equity in our condensed consolidated balance sheet. In addition, we record a noncontrolling interest adjustment to account for equity based compensation in Zentera. This adjustment is a reclassification within stockholders’ equity from additional paid-in capital to noncontrolling interest equal to the amount of equity based compensation expense Zentera had recognized.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.
Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.
Marketable Securities
Marketable Securities
Marketable securities are investments with original maturities of more than ninety days from the date of purchase that we have the ability to liquidate to fund current operations. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term investments on the accompanying condensed consolidated balance sheets Marketable securities are considered available-for-sale and are carried at fair value with unrealized gains and losses recorded in other comprehensive income (loss) and included as a separate component of stockholders’ deficit. The cost of marketable securities is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in investment and other income, net in the interim unaudited condensed consolidated statements of operations. We assess whether our available-for-sale debt securities in an unrealized loss position have credit-related losses and record such losses, and any subsequent improvements as interest income, through an allowance account. We use the specific identification method for calculating realized gains and losses on marketable securities sold. Realized gains and losses on marketable securities, if any, are included in investment and other income, net in the interim unaudited condensed consolidated statements of operations.
Adoption and Pending Adoption of Recent Accounting Pronouncements
Adoption and Pending Adoption of Recent Accounting Pronouncements
The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
Standard  Description  Effective Date  Effect on the Financial
Statements or Other
Significant Matters
In March 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial InstrumentsThis guidance makes improvements to financial instruments guidance, including the current expected credit losses guidance.January 1, 2020We have adopted the new guidance as of January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321)This standard clarifies the interaction between accounting standards related to equity securities (ASC 321), equity method investments (ASC 323), and certain derivatives (ASC 815). January 1, 2021We currently do not hold equity securities, have equity method investments or derivatives. We do not believe the adoption will have a material impact on our consolidated financial position or results of operations.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. In November 2018 and April and May of 2019, the FASB issued additional guidance related to Topic 326.The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income.January 1, 2020We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes.The new guidance is intended to simplify aspects of the accounting for income taxes, including the elimination of certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, among other changes.January 1, 2020We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Interim Unaudited Financial Statements (Tables)
9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Recently Issued Accounting Standards Adopted and Not Yet Adopted
The following table provides a brief description of recently issued accounting standards, those adopted in the current period and those not yet adopted:
Standard  Description  Effective Date  Effect on the Financial
Statements or Other
Significant Matters
In March 2020, the FASB issued ASU 2020-03, Codification Improvements to Financial InstrumentsThis guidance makes improvements to financial instruments guidance, including the current expected credit losses guidance.January 1, 2020We have adopted the new guidance as of January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321)This standard clarifies the interaction between accounting standards related to equity securities (ASC 321), equity method investments (ASC 323), and certain derivatives (ASC 815). January 1, 2021We currently do not hold equity securities, have equity method investments or derivatives. We do not believe the adoption will have a material impact on our consolidated financial position or results of operations.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. In November 2018 and April and May of 2019, the FASB issued additional guidance related to Topic 326.The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income.January 1, 2020We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes.The new guidance is intended to simplify aspects of the accounting for income taxes, including the elimination of certain exceptions to the guidance in ASC 740 related to the approach for intraperiod tax allocation, among other changes.January 1, 2020We have adopted the new guidance on January 1, 2020. The impact of the adoption was not material to the consolidated financial statements.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Business Combinations (Tables)
9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Schedule of Assets and Liabilities of VIE Total assets and liabilities of Kalyra as of September 30, 2020 and December 31, 2019 are as follows (in thousands):
September 30,December 31,
 20202019
Cash and cash equivalents$417 $712 
Other current assets31 21 
In-process research and development8,800 8,800 
Goodwill3,736 3,736 
Other long-term assets14 14 
Accounts payable and accrued expenses87 391 
Deferred tax liability2,463 2,463 
Noncontrolling interests$6,635 $6,821 
Reconciliation Of Equity Attributable to Noncontrolling Interest
The following is a reconciliation of equity (net assets) attributable to the noncontrolling interest (in thousands):
September 30,
 2020
Noncontrolling interest at beginning of period$6,821 
Net loss attributable to noncontrolling interest(186)
Noncontrolling interest at end of period$6,635 
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement (Tables)
9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Components of Available-for-sale Marketable Securities Available-for-sale marketable securities consisted of the following (in thousands):
September 30, 2020
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Commercial paper $125,748 $$(7)$125,750 
Corporate debt securities
31,840 (3)31,842 
US government agencies
77,523 22 (5)77,540 
US Treasury securities39,750 (1)39,752 
$274,861 $39 $(16)$274,884 
Contractual Maturities of Available-for-sale Debt Securities
Contractual maturities of available-for-sale debt securities are as follows (in thousands):

September 30, 2020
Estimated Fair Value
Due within one year$239,291 
After one but within five years35,593 
$274,884 
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):
September 30, 2020December 31, 2019
Level 1Level 2Total estimated fair valueLevel 1Level 2Total estimated fair value
Cash equivalents:
Money market funds
$29,924 $— $29,924 $62,961 $— $62,961 
US government agencies
— 2,631 2,631 — — — 
US Treasury securities
9,999 — 9,999 — — — 
Corporate debt securities
— 14,999 14,999 — — — 
Total cash equivalents:
39,923 17,630 57,553 62,961 — 62,961 
Available-for-sale marketable securities:
Commercial paper
— 125,750 125,750 — — — 
Corporate debt securities
— 31,842 31,842 — — — 
US government agencies
— 77,540 77,540 — — — 
US Treasury securities
39,752 — 39,752 — — — 
Total available-for-sale marketable securities:
39,752 235,132 274,884 — — — 
Total assets measured at fair value
$79,675 $252,762 $332,437 $62,961 $— $62,961 
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Prepaid Expenses and Other Assets (Tables)
9 Months Ended
Sep. 30, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Summary of Prepaid Expenses and Other Assets
Prepaid expenses and other assets consisted of the following (in thousands):
September 30,December 31,
 20202019
Prepaid insurance
$1,761 $150 
Prepaid software licenses and maintenance
320 238 
Prepaid research and development expenses
5,735 2,985 
Interest receivable511 — 
Upfront lease payment810 — 
Other prepaid expenses
286 266 
Total prepaid expenses and other current assets
9,423 3,639 
Less long-term portion
4,245 2,134 
Total prepaid expenses and other assets, current
$5,178 $1,505 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment, net (Tables)
9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment, net
Property and equipment, net consisted of the following (in thousands):
September 30,December 31,
 20202019
Computer and office equipment
$291 $243 
Lab equipment
360 401 
Leasehold improvements
43 24 
Construction in progress
— 
Subtotal
700 668 
Accumulated depreciation and amortization
(229)(167)
Property and equipment, net
$471 $501 
Depreciation and amortization expense for the three months ended September 30, 2020 and 2019 was approximately fifty-one thousand and twenty-five thousand, respectively. Depreciation and amortization expense for the nine months ended September 30, 2020 and 2019 was approximately one hundred twenty-seven thousand and seventy thousand, respectively.
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2020
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued expenses consist of the following (in thousands):
September 30,December 31,
20202019
Accrued research and development expenses
$10,618 $5,465 
Accrued employee expenses
4,390 2,977 
Accrued general and administrative expenses
2,571 1,356 
Lease liability
871 781 
Other
19 29 
Total accrued expenses
$18,469 $10,608 
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Preferred Units (Tables)
9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Schedule of Temporary Equity
There were no authorized, issued, and outstanding shares of convertible preferred units at September 30, 2020. As of December 31, 2019, the authorized, issued, and outstanding units of convertible preferred units were as follows (in thousands, except unit amounts):
December 31, 2019
SeriesUnits
Authorized
Units Issued
and
Outstanding
Liquidation
Value
Carrying
Value
Series A convertible preferred units
1,579,309 1,579,309 $18,320 $18,226 
Series B convertible preferred units
3,523,739 3,523,739 43,800 41,604 
Series C convertible preferred units
5,714,300 4,847,106 84,824 81,876 
Total
10,817,348 9,950,154 $146,944 $141,706 
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Equity and Share-based Compensation (Tables)
9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Schedule of Share-based Compensation Expense
Total share-based compensation expense related to share based awards was comprised of the following (in thousands):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Research and development expense
$2,180 $95 $4,606 $224 
General and administrative expense
5,069 60 10,653 181 
Total share-based compensation expense
$7,249 $155 $15,259 $405 
Share-based compensation expense by type of share-based award (in thousands):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Profit interest award units
$— $155 $329 $405 
Stock options
2,212 — 3,814 — 
RSAs and RSUs
5,037 — 11,116 — 
$7,249 $155 $15,259 $405 
Schedule of Valuation Assumptions
The fair value of the Class B common unit awards was estimated using an option pricing model with the following assumptions:
Nine Months Ended
September 30,
20202019
Members’ equity value (in thousands)$271,207$197,041
Threshold amounts (in thousands)$309,824$143,800
Risk free rate1.5%1.5%
Volatility75.0%75.0%
Time to liquidity (in years)1.1
1.1 - 1.8
Lack of marketability discount26.5%
18.8% - 26.4%
Grant date fair value$3.06
$1.88 - $3.06
The fair value of the stock options granted during the three and nine months ended September 30, 2020 was determined with the following assumptions:
Three Months Ended
September 30, 2020
Nine Months Ended
September 30, 2020
Expected volatility
76.6% - 78.2%
76.6% - 78.2%
Average expected term (in years)
5.7 - 6.0
5.7 - 6.0
Risk-free interest rate
0.4%
0.4% - 0.5%
Expected dividend yield
—%—%
Share-based Compensation Expense by Type of Share-based Award
Total unrecognized estimated compensation cost by type of award and the weighted average requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted):
September 30, 2020
Unrecognized
Expense
Remaining
Weighted-Average Recognition Period
(years)
Stock options$38,247 3.54
RSAs$2,492 2.43
RSUs$17,563 1.15
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Commitment and Contingencies (Tables)
9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Operating Lease Payments Approximate annual future minimum operating lease payments as of September 30, 2020 are as follows (in thousands):
YearOperating Leases
2020$256 
20211,044 
2022661 
2023187 
Total minimum lease payments:
2,148 
Less: imputed interest(246)
Total operating lease liabilities
1,902 
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Common Share/Class A Common Unit (Tables)
9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Loss Per Unit
Basic and diluted net loss per common share/Class A common unit were calculated as follows (in thousands except per share and per unit amounts):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020201920202019
Numerator:
Net loss attributable to Zentalis
$(34,555)$(12,344)$(77,538)$(31,157)
Denominator:
Weighted average number of common shares/Class A common units outstanding, basic and diluted
37,959 5,601 24,143 5,601 
Net loss per common share
$(0.91)$— $(3.21)$— 
Net loss per Class A common unit
$— $(2.20)$— $(5.56)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Unit
The following common stock/Class A common unit equivalents have been excluded from the calculations of diluted net loss per common share/Class A common unit because their inclusion would be antidilutive (in thousands).
 September 30,
 20202019
Preferred units, as if converted to Class A common units
— 9,950 
Incentive units—Class B common units
— 1,947 
Outstanding stock options
2,783 — 
Unvested RSAs
845 — 
Unvested RSUs
1,102 — 
4,730 11,897 
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Business (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 2 Months Ended 9 Months Ended
Aug. 03, 2020
USD ($)
$ / shares
shares
May 19, 2020
USD ($)
executive
Apr. 07, 2020
USD ($)
$ / shares
shares
Apr. 02, 2020
$ / shares
shares
Dec. 21, 2017
Sep. 30, 2015
USD ($)
Mar. 31, 2016
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Class of Stock [Line Items]                  
Exchange ratio         1        
Proceeds from issuance of common stock in initial public offering, net     $ 190,000         $ 172,482 $ 0
Issuance fees and expenses     17,600            
Contributions from noncontrolling interest owners   $ 20,000           $ 18,424  
Zentera Stock Plan                  
Class of Stock [Line Items]                  
Number of executives entering restricted stock agreement | executive   2              
RSAs | Zentera Stock Plan                  
Class of Stock [Line Items]                  
Restricted stock vesting period (in years)   4 years              
Zentera Sublicenses                  
Class of Stock [Line Items]                  
Ownership percentage               60.20%  
IPO                  
Class of Stock [Line Items]                  
Share price (in dollars per sharee) | $ / shares       $ 18.00          
Proceeds from issuance of common stock in initial public offering, net     190,000            
Issuance fees and expenses     $ 17,600            
Follow-On Offering                  
Class of Stock [Line Items]                  
Gross proceeds from issuance of common stock $ 166,000                
Expenses and Fees from the Issuance of Common Stock $ 10,800                
Common Stock | IPO                  
Class of Stock [Line Items]                  
Share price (in dollars per sharee) | $ / shares     $ 18.00            
Number of shares converted (in shares) | shares       25,288,854          
Number of shares issued and sold (in shares) | shares     10,557,000            
Common Stock | Underwriters                  
Class of Stock [Line Items]                  
Share price (in dollars per sharee) | $ / shares     $ 18.00            
Number of shares issued and sold (in shares) | shares 618,750   1,377,000            
Common Stock | Follow-On Offering                  
Class of Stock [Line Items]                  
Share price (in dollars per sharee) | $ / shares $ 35.00                
Number of shares issued and sold (in shares) | shares 4,743,750                
RSAs | IPO                  
Class of Stock [Line Items]                  
Number of shares converted (in shares) | shares       1,160,277          
Series A Preferred Units                  
Class of Stock [Line Items]                  
Issuance fees and expenses   $ 1,600       $ 100 $ 39    
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Business Combinations - Narrative (Details) - Kalyra Pharmaceuticals, Inc.
$ in Millions
Dec. 21, 2017
USD ($)
Variable Interest Entity [Line Items]  
Cash payments to acquire interest $ 4.5
Ownership percentage 25.00%
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Business Combinations - Assets and Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Variable Interest Entity [Line Items]      
Cash and cash equivalents $ 92,552 $ 67,246 $ 80,526
In-process research and development 8,800 8,800  
Goodwill 3,736 3,736  
Deferred tax liability 2,463 2,463  
VIE, Primary Beneficiary      
Variable Interest Entity [Line Items]      
Cash and cash equivalents 417 712  
Other current assets 31 21  
In-process research and development 8,800 8,800  
Goodwill 3,736 3,736  
Other long-term assets 14 14  
Accounts payable and accrued expenses 87 391  
Deferred tax liability 2,463 2,463  
Noncontrolling interests $ 6,635 $ 6,821  
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Business Combinations - Rollforward of Noncontrolling Interest (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Net loss attributable to noncontrolling interests $ (110) $ (228) $ (654) $ (675)
VIE, Primary Beneficiary        
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]        
Noncontrolling interest at beginning of period     6,821  
Net loss attributable to noncontrolling interests     (186)  
Noncontrolling interest at end of period $ 6,635   $ 6,635  
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 274,861  
Gross Unrealized Gains 39  
Gross Unrealized Losses (16)  
Debt securities, available-for-sale, fair value 274,884 $ 0
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 125,748  
Gross Unrealized Gains 9  
Gross Unrealized Losses (7)  
Debt securities, available-for-sale, fair value 125,750 0
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 31,840  
Gross Unrealized Gains 5  
Gross Unrealized Losses (3)  
Debt securities, available-for-sale, fair value 31,842 0
US government agencies    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 77,523  
Gross Unrealized Gains 22  
Gross Unrealized Losses (5)  
Debt securities, available-for-sale, fair value 77,540 0
US Treasury securities    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 39,750  
Gross Unrealized Gains 3  
Gross Unrealized Losses (1)  
Debt securities, available-for-sale, fair value $ 39,752 $ 0
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement - Narrative (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
security
Fair Value Disclosures [Abstract]  
Number of available-for-sale securities in unrealized loss position | security 19
Debt securities fair market value $ 85,300
Fair value of available-for-sale securities in unrealized loss position $ 16
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
Fair Value Disclosures [Abstract]  
Due within one year $ 239,291
After one but within five years 35,593
Amortized Cost $ 274,884
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents $ 57,553 $ 62,961
Marketable securities, available-for-sale 274,884 0
Total fair value of assets 332,437 62,961
Fair Value, Inputs, Level 1    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 39,923 62,961
Marketable securities, available-for-sale 39,752 0
Total fair value of assets 79,675 62,961
Fair Value, Inputs, Level 2    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 17,630 0
Marketable securities, available-for-sale 235,132 0
Total fair value of assets 252,762 0
Commercial paper    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 125,750 0
Commercial paper | Fair Value, Inputs, Level 1    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 0 0
Commercial paper | Fair Value, Inputs, Level 2    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 125,750 0
Corporate debt securities    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 31,842 0
Corporate debt securities | Fair Value, Inputs, Level 1    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 0 0
Corporate debt securities | Fair Value, Inputs, Level 2    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 31,842 0
US government agencies    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 77,540 0
US government agencies | Fair Value, Inputs, Level 1    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 0 0
US government agencies | Fair Value, Inputs, Level 2    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 77,540 0
US Treasury securities    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 39,752 0
US Treasury securities | Fair Value, Inputs, Level 1    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 39,752 0
US Treasury securities | Fair Value, Inputs, Level 2    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Marketable securities, available-for-sale 0 0
Money market funds    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 29,924 62,961
Money market funds | Fair Value, Inputs, Level 1    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 29,924 62,961
Money market funds | Fair Value, Inputs, Level 2    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 0 0
US government agencies    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 2,631 0
US government agencies | Fair Value, Inputs, Level 1    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 0 0
US government agencies | Fair Value, Inputs, Level 2    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 2,631 0
US Treasury securities    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 9,999 0
US Treasury securities | Fair Value, Inputs, Level 1    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 9,999 0
US Treasury securities | Fair Value, Inputs, Level 2    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 0 0
Corporate debt securities    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 14,999 0
Corporate debt securities | Fair Value, Inputs, Level 1    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents 0 0
Corporate debt securities | Fair Value, Inputs, Level 2    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Cash equivalents $ 14,999 $ 0
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Prepaid Expenses and Other Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid insurance $ 1,761 $ 150
Prepaid software licenses and maintenance 320 238
Prepaid research and development expenses 5,735 2,985
Interest receivable 511 0
Upfront lease payment 810 0
Other prepaid expenses 286 266
Total prepaid expenses and other current assets 9,423 3,639
Less long-term portion 4,245 2,134
Total prepaid expenses and other assets, current $ 5,178 $ 1,505
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment, net - Summary (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Subtotal $ 700 $ 668
Accumulated depreciation and amortization (229) (167)
Property and equipment, net 471 501
Computer and office equipment    
Property, Plant and Equipment [Line Items]    
Subtotal 291 243
Lab equipment    
Property, Plant and Equipment [Line Items]    
Subtotal 360 401
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Subtotal 43 24
Construction in progress    
Property, Plant and Equipment [Line Items]    
Subtotal $ 6 $ 0
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment, net - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Property, Plant and Equipment [Abstract]        
Depreciation and amortization $ 51 $ 25 $ 127 $ 70
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Payables and Accruals [Abstract]    
Accrued research and development expenses $ 10,618 $ 5,465
Accrued employee expenses 4,390 2,977
Accrued general and administrative expenses 2,571 1,356
Lease liability 871 781
Other 19 29
Total accrued expenses $ 18,469 $ 10,608
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Preferred Units - Narrative (Details) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 8 Months Ended 9 Months Ended
May 19, 2020
Apr. 07, 2020
Feb. 29, 2020
Sep. 30, 2019
Dec. 31, 2017
Sep. 30, 2015
Mar. 31, 2016
Apr. 02, 2020
Aug. 31, 2018
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Class of Stock [Line Items]                        
Convertible preferred units issued (in shares)                   867,000    
Shares issued (in shares)                       9,950,154
Net proceeds from issuance of convertible preferred units                   $ 14,228,000 $ 81,883,000  
Issuance costs of financing   $ 17,600,000                    
Dividends declared               $ 0        
Automatic conversion feature, minimum gross cash proceeds received in a public offering                   $ 75,000,000.0    
Series A Preferred Units                        
Class of Stock [Line Items]                        
Convertible preferred units issued (in shares)           1,293,104            
Par value per share (in dollars per share)           $ 11.60 $ 11.60          
Shares issued (in shares)             286,205         1,579,309
Gross proceeds from issuance of convertible preferred units           $ 15,000,000.0 $ 3,300,000          
Net proceeds from issuance of convertible preferred units           14,900,000            
Issuance costs of financing $ 1,600,000         $ 100,000 $ 39,000          
Conversion price (in dollars per share)                   $ 11.60    
Liquidation preference (in dollars per share)                   11.60    
Series B Preferred Units                        
Class of Stock [Line Items]                        
Par value per share (in dollars per share)         $ 12.43       $ 12.43      
Shares issued (in shares)         2,735,320       788,419     3,523,739
Gross proceeds from issuance of convertible preferred units         $ 34,000,000.0       $ 9,800,000      
Net proceeds from issuance of convertible preferred units         32,100,000       9,500,000      
Issuance costs of financing         $ 1,900,000       $ 300,000      
Conversion price (in dollars per share)                   12.43    
Liquidation preference (in dollars per share)                   12.43    
Series C Preferred Units                        
Class of Stock [Line Items]                        
Par value per share (in dollars per share)     $ 17.50 $ 17.50           17.50 $ 17.50  
Shares issued (in shares)     867,194 4,847,106             4,847,106 4,847,106
Gross proceeds from issuance of convertible preferred units     $ 15,200,000 $ 84,800,000                
Net proceeds from issuance of convertible preferred units     14,200,000 81,900,000                
Issuance costs of financing     $ 1,000,000.0 $ 2,900,000                
Conversion price (in dollars per share)                   17.50    
Liquidation preference (in dollars per share)                   $ 17.50    
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Preferred Units - Schedule of Units Authorized, Issued, and Outstanding (Details) - USD ($)
$ in Thousands
Sep. 30, 2020
Feb. 29, 2020
Dec. 31, 2019
Sep. 30, 2019
Aug. 31, 2018
Dec. 31, 2017
Mar. 31, 2016
Class of Stock [Line Items]              
Units authorized (in shares)     10,817,348        
Shares issued (in shares)     9,950,154        
Shares outstanding (in shares)     9,950,154        
Liquidation Value     $ 146,944        
Carrying Value $ 0   $ 141,706        
Series A Preferred Units              
Class of Stock [Line Items]              
Units authorized (in shares)     1,579,309        
Shares issued (in shares)     1,579,309       286,205
Shares outstanding (in shares)     1,579,309        
Liquidation Value     $ 18,320        
Carrying Value     $ 18,226        
Series B Preferred Units              
Class of Stock [Line Items]              
Units authorized (in shares)     3,523,739        
Shares issued (in shares)     3,523,739   788,419 2,735,320  
Shares outstanding (in shares)     3,523,739        
Liquidation Value     $ 43,800        
Carrying Value     $ 41,604        
Series C Preferred Units              
Class of Stock [Line Items]              
Units authorized (in shares)     5,714,300        
Shares issued (in shares)   867,194 4,847,106 4,847,106      
Shares outstanding (in shares)     4,847,106        
Liquidation Value     $ 84,824        
Carrying Value     $ 81,876        
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Equity and Share-based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 8 Months Ended 9 Months Ended 12 Months Ended
Aug. 03, 2020
May 19, 2020
Apr. 07, 2020
Apr. 02, 2020
Apr. 30, 2020
Dec. 31, 2017
Sep. 30, 2015
Mar. 31, 2016
Sep. 30, 2020
Sep. 30, 2019
Aug. 31, 2018
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Dec. 21, 2017
Class of Stock [Line Items]                              
Common stock issued (in shares)           5,187,554     40,614,453     40,614,453      
Common stock outstanding (in shares)           5,187,554     40,614,453     40,614,453      
Common stock subject to future vesting provisions (in shares)           406,831                  
Common stock, shares authorized (in shares)       250,000,000         250,000,000     250,000,000      
Common stock, par value (in dollars per share)       $ 0.001         $ 0.001     $ 0.001      
Preferred stock, shares authorized (in shares)       10,000,000         10,000,000     10,000,000      
Preferred stock, par value (in dollars per share)       $ 0.001         $ 0.001     $ 0.001      
Proceeds from issuance of common stock in initial public offering, net     $ 190,000                 $ 172,482 $ 0    
Issuance fees and expenses     17,600                        
Options granted (in shares)         1,970,671             2,794,546      
Weighted-average grant date fair value of options (in usd per share)         $ 11.97             $ 15.11      
Share-based compensation expense                 $ 7,249 $ 155   $ 15,259 405    
Shares issued upon vesting of certain RSAs (in shares)                       309,010      
Options number outstanding                 2.8     2.8      
IPO                              
Class of Stock [Line Items]                              
Share price (in dollars per sharee)       $ 18.00                      
Proceeds from issuance of common stock in initial public offering, net     190,000                        
Issuance fees and expenses     $ 17,600                        
Zentera Stock Plan                              
Class of Stock [Line Items]                              
Employee benefits and share-based compensation                 $ 187     $ 187      
Share-based compensation expense                   $ 0     $ 0    
Series A Preferred Units                              
Class of Stock [Line Items]                              
Preferred units authorized (in shares)           1,638,000                  
Issuance fees and expenses   $ 1,600         $ 100 $ 39              
Series B Preferred Units                              
Class of Stock [Line Items]                              
Preferred units authorized (in shares)           3,621,000                  
Issuance fees and expenses           $ 1,900         $ 300        
Class A Common Units                              
Class of Stock [Line Items]                              
Common units, authorized (in shares)           15,000,000       20,000,000     20,000,000 20,000,000  
Stock issued (in shares)                 0 0       7,093  
Common units subject to future vesting conditions (in shares)                 0 9,572   0 9,572 9,572  
Class B Common Units                              
Class of Stock [Line Items]                              
Common units, authorized (in shares)           872,620       3,458,522     3,458,522 3,458,522  
Stock issued (in shares)                       70,000 91,000    
Stock issued upon conversion of units (in shares)           703,000                  
Awards granted (in shares)                       70,000      
Grant date fair value (USD per share)                       $ 3.06      
Unvested common units outstanding (in shares)                 0     0   1,700,000  
Class B Common Units | The Plan                              
Class of Stock [Line Items]                              
Shares authorized to be issued under plan (in shares)                             3,458,522
Class B Common Units | The 2020 Plan | Maximum                              
Class of Stock [Line Items]                              
Shares authorized to be issued under plan (in shares)         1,250,000                    
Common Stock | Corporate Conversion                              
Class of Stock [Line Items]                              
Stock issued (in shares)       0                      
Common Stock | IPO                              
Class of Stock [Line Items]                              
Stock issued upon conversion of units (in shares)       25,288,854                      
Stock issued (in dollars per share)     $ 18.00                        
Number of shares issued and sold (in shares)     10,557,000                        
Share price (in dollars per sharee)     $ 18.00                        
Common Stock | Underwriters                              
Class of Stock [Line Items]                              
Number of shares issued and sold (in shares) 618,750   1,377,000                        
Share price (in dollars per sharee)     $ 18.00                        
Common Stock | The 2020 Plan                              
Class of Stock [Line Items]                              
Shares authorized to be issued under plan (in shares)         5,600,000                    
Percent of common stock outstanding used as threshold to calculate shares available for issuance         5.00%                    
RSAs | IPO                              
Class of Stock [Line Items]                              
Stock issued upon conversion of units (in shares)       1,160,277                      
RSAs                              
Class of Stock [Line Items]                              
Awards granted (in shares)         1,160,277                    
Stock options                              
Class of Stock [Line Items]                              
Share-based compensation expense                 $ 2,212 $ 0   $ 3,814 $ 0    
Generally expected vesting term of the option contract (in years)                       10 years      
RSUs                              
Class of Stock [Line Items]                              
Non-Option equity Instruments, outstanding                 1,100,000     1,100,000      
Restricted Stock Award                              
Class of Stock [Line Items]                              
Non-Option equity Instruments, outstanding                 800,000     800,000      
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Equity and Share-based Compensation - Share-based Compensation (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 7,249 $ 155 $ 15,259 $ 405
Research and development expense        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense 2,180 95 4,606 224
General and administrative expense        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 5,069 $ 60 $ 10,653 $ 181
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Equity and Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 7,249 $ 155 $ 15,259 $ 405
Profit interest award units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense 0 155 329 405
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense 2,212 0 3,814 0
RSAs and RSUs        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total share-based compensation expense $ 5,037 $ 0 $ 11,116 $ 0
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Equity and Share-based Compensation - Fair Value Assumptions for Profit Interest Awards (Details) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Members’ equity value (in thousands) $ 341,055   $ (80,106)
Profit Interest Awards      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Members’ equity value (in thousands) 271,207 $ 197,041  
Threshold amounts (in thousands) $ 309,824 $ 143,800  
Risk free rate (as a percent) 1.50% 1.50%  
Volatility (as a percent) 75.00% 75.00%  
Time to liquidity (in years) 1 year 1 month 6 days    
Lack of marketability discount (as a percent) 26.50%    
Grant date fair value (USD per share) $ 3.06    
Profit Interest Awards | Minimum      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Time to liquidity (in years)   1 year 1 month 6 days  
Lack of marketability discount (as a percent)   18.80%  
Grant date fair value (USD per share)   $ 1.88  
Profit Interest Awards | Maximum      
Fair Value Measurement Inputs and Valuation Techniques [Line Items]      
Time to liquidity (in years)   1 year 9 months 18 days  
Lack of marketability discount (as a percent)   26.40%  
Grant date fair value (USD per share)   $ 3.06  
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Equity and Share-based Compensation - Fair Value Assumptions for Stock Options (Details) - Stock options
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Risk free rate (as a percent) 0.40%  
Expected dividend yield 0.00% 0.00%
Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Volatility (as a percent) 76.60% 76.60%
Average expected term (in years) 5 years 8 months 12 days 5 years 8 months 12 days
Risk free rate (as a percent)   0.40%
Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Volatility (as a percent) 78.20% 78.20%
Average expected term (in years) 6 years 6 years
Risk free rate (as a percent)   0.50%
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Equity and Share-based Compensation - Unrecognized Compensation Cost (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2020
USD ($)
Stock options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized expense, stock options $ 38,247
Remaining Weighted-Average Recognition Period (years) 3 years 6 months 14 days
RSAs  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized expense, other than options $ 2,492
Remaining Weighted-Average Recognition Period (years) 2 years 5 months 4 days
RSUs  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized expense, other than options $ 17,563
Remaining Weighted-Average Recognition Period (years) 1 year 1 month 24 days
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Commitment and Contingencies - Future Minimum Lease Payments (Details)
$ in Thousands
Sep. 30, 2020
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2020 $ 256
2021 1,044
2022 661
2023 187
Total minimum lease payments: 2,148
Less: imputed interest (246)
Total operating lease liabilities $ 1,902
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Commitment and Contingencies - Narrative (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Sep. 30, 2020
Lessee, Lease, Description [Line Items]    
Operating lease, weighted-average remaining lease term (in years)   2 years
Real Estate, 10.7 Year Lease Term | Forecast    
Lessee, Lease, Description [Line Items]    
Total minimum lease payments on leases not yet commenced $ 86.5  
Operating leases not yet commenced, term (in years) 10 years 8 months 12 days  
Real Estate, 1.2 Year Lease Term | Forecast    
Lessee, Lease, Description [Line Items]    
Total minimum lease payments on leases not yet commenced $ 0.1  
Operating leases not yet commenced, term (in years) 1 year 2 months 12 days  
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Common Share/Class A Common Unit - Calculation (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Numerator:        
Net loss attributable to Zentalis $ (34,555) $ (12,344) $ (77,538) $ (31,157)
Denominator:        
Weighted average number of Class A common units outstanding, basic and diluted (in shares) 37,959 5,601 24,143 5,601
Common Stock        
Denominator:        
Net loss per Class A common unit (USD per share) $ (0.91) $ 0 $ (3.21) $ 0
Class A Common Units        
Denominator:        
Net loss per Class A common unit (USD per share) $ 0 $ (2.20) $ 0 $ (5.56)
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Common Share/Class A Common Unit - Antidilutive Securities (Details) - shares
shares in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per unit (in shares) 4,730 11,897
Preferred units, as if converted to Class A common units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per unit (in shares) 0 9,950
Incentive units—Class B common units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per unit (in shares) 0 1,947
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per unit (in shares) 2,783 0
RSAs    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per unit (in shares) 845 0
RSUs    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per unit (in shares) 1,102 0
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Related Party Disclosures (Details) - USD ($)
3 Months Ended 9 Months Ended
Jun. 01, 2020
Dec. 21, 2017
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Related Party Transaction [Line Items]            
Number of shares acquired (in shares)     0   0  
Capital Addition Purchase Commitments            
Related Party Transaction [Line Items]            
Equipment purchase and sale agreement $ 400,000          
Affiliated Entity | Master Services Agreement            
Related Party Transaction [Line Items]            
Expenses from transactions with related party     $ 0 $ 0 $ 0 $ 0
Affiliated Entity | Intercompany Services Agreement            
Related Party Transaction [Line Items]            
Revenue from related parties     100,000 100,000 300,000 400,000
Due from related parties     $ 100,000 $ 400,000 $ 100,000 $ 400,000
VIE, Primary Beneficiary | Kalyra Pharmaceuticals, Inc.            
Related Party Transaction [Line Items]            
Share price (in dollars per share)   $ 0.26        
Cash payments to acquire interest   $ 4,500,000        
Agreement term (in years)           15 years
VIE, Primary Beneficiary | Series B Preferred Units | Kalyra Pharmaceuticals, Inc.            
Related Party Transaction [Line Items]            
Number of shares acquired (in shares)   17,307,692        
XML 70 R9999.htm IDEA: XBRL DOCUMENT v3.20.2
Label Element Value
Restricted Cash, Noncurrent us-gaap_RestrictedCashNoncurrent $ 243,000
Restricted Cash, Noncurrent us-gaap_RestrictedCashNoncurrent $ 1,320,000
EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

#2 7?G]^P??.P4RXH9/%'B M&R]MO0BF 918L8VP%VK[$?MXMV=(Z_RE%FVG&NU!>VLB3>*X=$6YM)I..>'L\EQC MRW@)[^^HS 8-,%G"%UNCAB-CT!K8OV(K@>;-/++DSZ&BHN<^[KC39[AG\%E) M6QMX+TLL_\9'I',0F]Z+/4Y?)+S$]@"R.(0T3N,7^+(A^,SS9<_PG6*%6F,) M)\I8$\():[EE@O_&,H0^,^'CC)QR4PAE-AKA^]'*6$U7Z\<+' *5QV*S(JRKT2D6_2+I"D:?9#9$QB4ED,D" M80^2<#).W)C'P[E1E=TR2K'@Q8,TUV8L2H_+'&4V'1 N**:+VAN6>$L-IZ7V M81^"R\-)ED,:SJ8YG!$/(2S!"N2W[HY#GB3P^M4T3=)W<-U6FFXO"*0W#RW[ MY:FF23Q8=.5H_\U@.AU#.A[#E:*K]/CX(<'%ANX>*67O%\[!\)]:_@%02P,$% @ X#AI41T:1%@ P MR@8 !D !X;"]W;W)K&ULE57;;M- $/V5D4&H ME4KM.&YZ(8G4"P@DD"+*Y0'QL+''\8J]F-TQ:?AZ9M>I21$-XF6]EYDS9V9G MCZ=KZ[[Y!I'@3BOC9TE#U%ZDJ2\;U,(?VQ8-G]36:4&\=*O4MPY%%9VT2O,L MFZ1:2)/,IW%OX>93VY&2!A<.?*>U<)LK5'8]2T;)_<9[N6HH;*3S:2M6>(OT ML5TX7J4#2B4U&B^M 8?U++D<75P5P3X:?)*X]CMS")DLK?T6%F^J69(%0JBP MI( @^/,#KU&I ,0TOF\QDR%D<-R=WZ._BKES+DOA\=JJS[*B9I:<)5!A+3I% M[^WZ-6[S.0EXI54^CK#N;0N.6':>K-XZ\UI+TW_%W;8..PYGV2,.^=8AC[S[ M0)'EC2 QGSJ[!A>L&2U,8JK1F\E)$R[EEAR?2O:C^<+Q_3K:@# 5O/S>R98K M3D=@N!\./HBE0G\X38DC!?NTW*)>]:CY(ZCG\,X::CR\-!56#_U39CC0S.]I M7N5[ 6^Q/89Q=@1YEF=[\,9#VN.(-_Y'VD>P4,+0P^SAR^72D^.&^;HG5#&$ M*F*HXC'J?;N#K6%/L?]6X_VX#\#PX,=V MGMW\X05P90GU$ETL[PV6V\6HKS4/HW.XMKKMB+=#+%O7LL3?(>$IY.>C,!9C M>"N6.R?C209%-H*WR ^GL:H"J5MG?V X]<#V><'@AJO=]:^4V;'!RJ'W,(%G M3\[R4?X";KLE61(*3K,,)I,SN"S+3G=*A!0K9#DJI>A?.1,4VCJ2/_N-@SP_ M/X2#T>3T$/:5["D4IR&)$Z9[LQ<1[U@1?:BIB[6EQB&"[AL>0\/_4=18QP 3 M:[D6'D3+2=Y)%A54&ZAE39OGUN!P,=&:UDQN\[QFU1H.CE@(?8M1RM3F^#^9 M&FZA?Q']6\>G._JBT:VBBGKNLLY0+S7#[B#4E[T^_3;O5?Z=<"MI/"BLV34[ M/CU)P/7*V2_(ME&MEI98^^*TX9\-NF# Y[6U=+\( 8;?U_P74$L#!!0 ( M . X:5$G]%]!J0( + % 9 >&PO=V]R:W-H965T7#R4[I%U,@6G@KA333H+"V&H>AR0HLF;E1%4JZ62M=,DNF MWH2FTLAR'U2*,(FB?E@R+H/9Q)\M]6RBME9PB4L-9EN63.\7*-1N&L3!X>"1 M;PKK#L+9I&(;?$+[HUIJLL(6)>7"4K MI5Z<\36?!I$CA (SZQ 8+:]XBT(X(*+QM\$,VI0N\'1_0/_L:Z=:5LS@K1*_ M>&Z+:3 ,(,=R+.\8Y;-)EKM0#MO0G,;7ZJ/)G)01AU(HB2Z@)>VM:8>+SV#MV1[7QLPF8,OG D#O^$;DOA <+;B@ML]#.EF,(SA M.Q6M@9@G(WA6UB&^[Q Q'1+#44,Y&L)'3QV>J*A$O?&SPK5W*VTMJ/:T'4?S M6H5']WJ6/3"]X=* P#6%1C>#7@"ZG@^U857E-;E2EA3NMP6-5-3.@>[72MF# MX1*T0WKV#U!+ P04 " #@.&E1X+E;HP(# "Z!@ &0 'AL+W=OML( MB3<:3-^V7#^NL5&'11 'IX4/8E];MQ NYQW?XRW:C]V-IEDXLE2B16F$DJ!Q MMPA6\?4Z<_[>X9/ @SFSP66R5>J;F[RM%D'D!&&#I74,G(9[W."*2\?W( M&8PA'?#8_:BFV#<$,%0:VQ@H]26 //[S@MFQ?ST%(D MYQ^61];UP)H\P3J#]TK:VL K66'U.SXDA:/,Y"1SG5PDO,7N"M*(01(ET06^ M=$P[]7SI$WROOO?"/L*7U=9833?CZP7.;.3,/&?VE$9Z,%5/=50[N,.V4YIN M.0R1_E;"BVSN,5Z;CI>X".BU&=3W&"SO:M0(!_>1"GAO:Z7%#ZP8"&-Z-W)9 M ;T]8\D0<@^FYH1VDLJSD^[&D^[]27,+5&&+[1;U6.8K6'G@2RR/&[';B&<, M;(W_%7U@_T=PGPXWL%,-M0BZ=D)2 -4;(C$,\*$D:=X7>*MZ:"?H#"KNN\"&:_WHI!W=5Q>EQ6R2SU@:S4LCJ90D)ED M4,2LR*=PIRQO((Y8$>]] MUS2DBXH_M)9Q=6S,JZ$?_7(?NOI[KO="&FAP1]#H*I\$H(=..4RLZGQWVBI+ MOCL"=!K.K:Z&?;K!2A^M1.'K>6,I-:7EC M/+_:B@W>H_VXO=.T&O=2"EEC8Z1J0./Z>K0(+V]2IG<$GR0>S& .[,E*J4=> M_%95<2,<6MHT&D&^,U;5'3-94,NF_8HO71P& M#%GP"D/4,43.[E:1L_)G8<7\2JL#:*8F:3QQKCIN,DXVG)1[J^E4$I^=O_N\ MD_8)1%/ ?2DT7K"+!=RJFM)NA(O<3P]B5:%Y(];'R:!!U$0!2?D37KW)T[>Y+3[?RU6 MQFJZ(7^?D!GW,F,G,W[-1@).L:L0U/KUF+[[PG-\*:0GI3-(+\U6Y'@](A0: MU'L"@UXE%^X0^R]7B'TT1#.!O,EF2UT'GI+EV!>RH, M6X*Y[C&-YC@YI<9591$!XDYXV!W7,G7I#.( T@ M#+PTF4"8A?"=\3F#J1?%,_J&2>)&+TIX&0?)42I?Y%X]@7W:NK0/-;GH_G_1 MN]-J+2W(QB*EWW;B=XVTA@S]\83J#??JOP1U)9--A1@(NNI)UX6 MQOUJ>;\P+L#+^X^&PSF9]F=AZ(5A.E!S(F GH)3T4$J^&TJ?1+5K [XP](2T MCKR$G],B'_A2"ZEA3_+P^9K?5L(8N.'$UJ2!PSF$!05:U@XZ.\-8$$T722"T MY+Q3JP*Y=MOR&]B(K\9>GDSQ!ZQ7J(T+[?0M8%N96BN/;P^<1=/0BX(IG(6S MJ1?$H;M.IE057;=:[1JZ"]^R3(*9EQ&"SL*8TAT$L)3F$=9\"PE "*&?G+?# M)T550E:L?9KXP7DW/M!;S)6CDF19P:>LXHF@3.)#/W2_"QHS^%WP55O3.Z4? MT8I5*ZR0)F?;($J=KLS/SHF!5O$YO->"3@JV9)"=LXG/T">9&5&VJ^]"#I?7 MG/.U'SB3^BDKG&9^=/[-:K&GLK)IBXCC(W350P<3?TK$J1\,9AS!"Q?!'HTN ME $[Y(8+^I"KO36%W,L""5I/$BE7'8S.^\D)R*0]9-+3D/F/%X?+U$-7IH:T M"[[M+\'IM+JVLNX:C;G:-/(?DO05+$=E,E<4GT&-; L7UQD&S,&U3UPNNTQH M!H"1%$Y^XV2.L$4M%3U,1 "'4M(#8G8T/)=?:0;94[!B$;U-1VCPR%[J9PPH MTJP/]-Q!HXB-RC+U%];AL&\RX./0MR5RH\NX/JZG5&DSJH13F/A)W%90?L7B M6021'T_:4DKU<>HEZ821DKR4ZO&@CZM1;URWRH\RH:9MZ?K=OB%>M'W@5_*V MF_X@]$:2816NB37PIU05==NAM@NKMJXK7"E+/::;EM34HV8".E\K"DFW8 7] MWX3YOU!+ P04 " #@.&E1TYX'WJL" "[!0 &0 'AL+W=OSIES=G=FNM/FP9:(#IZD4'86E,Y5DS"T M68F2V3-=H:*50AO)' W--K25098W("G")(I&H61 *UP9L M+24SSTL4>C<+XF _<H?M6K0V-PIXEYQ*5Y5J!P6(6+.+) M,O7[FPW?.>[L00S>R4;K!S_XG,^"R M"@9GS#(Q^C[A"(3P1R?C3<09]2@\\ MC/?LUXUW\K)A%E=:_."Y*V?!.( <"U8+=ZMWG[#S<^[Y,BUL\X5=N_<\"2"K MK=.R Y,"R57[9T_=.1P QM$[@*0#)(WN-E&C\HHY-I\:O0/C=Q.;#QJK#9K$ M<>4OY@&@$5)T 8-;+I0MP*#=H^EL 1FA:++2@TJ;7PA6X4M>6 MSM.>3N G,O/:EFV1'R Y'_DPAG@0I:D/$QB-8A\,(1Y?P+UVI'$O[J6D"22# M.!T3I:68RZIVF -7#LFO@Y,D'9UV!*]="7$8)O'6MX4%!233; MIFU8R'2M7%M;_6S?F19M0?[;WK:U&V:V7%E*7Q T.KLX#\"TK:(=.%TUY;G1 MCHJ]"4OJKFC\!EHOM';[@4_0]^OY7U!+ P04 " #@.&E172/\Q0$$ !O M"0 &0 'AL+W=O"V:1F M6URA>:J7BF9!AY+S"H7F4H#"S=2;1S>+U)YW!_[DN--'8[ W64OY;"=?\JD7 M6D)88F8L J._%[S%LK1 1./['M/K7%K#X_$!_5=W=[K+FFF\E>4WGIMBZHT\ MR''#FM(\R-UON+^/(YC)4KM?V.W/AAYDC3:RVAL3@XJ+]I^][N/P,P;QWB!V MO%M'CN4=,VPV47('RIXF-#MP5W761(X+FY254;3+R<[,[BGOOTNM88D*;F55 M4:16!5,8W)9,ZX\?HNOPT_RP\R2X@:M'MBY1]R:!(0(6)LCVSA:ML_@=9V/X M*H4I-'P6.>:G]@$1[]C'!_:+^"+@"NL^)*$/<1B'%_"2+AJ)PTO>P?O,E.!B MVT;#A0'^GJ^U422>?R[@#SK\@<,?O,>7:BIO2@2Y@073/ ,F.!'@V0_N7\O*99HV!]'EO''#Z,XBC\Y M[OWX9.G$_EP>3ZSC?AS^ )CVT^O>!4&GG:#3GQ;T7!CNKD[/+*PP:Q0W'"G' MKUG9V#1OE*SL2U)3!MV33$8G%?>>YB]RL&WK1MD%O]EC@7KF$ MWH78R.SYK.[Q>\-?6$EZTE"0%F"-**S(CYB;XJTTB+VV]/]?E:TQ8XU&B\@5 M<$%>7)/;R:;,:9=4=!3*D\+K]2FTM4>L/+UU;,DOH9*D5LG#I]6[S&+R"@,UK';W6^VAHOSAI$_'@SAC[=J:",-LFX#%?O# M4=*=?B(^VO)Y6,TUC ;IN9TG3:A1&'=[ W^8A!!%_F@\A'/*#8Z:(#T=6]?J M-1&FEZCMA]UJ]S4Q;YOHV_'V4^0K4UM.O$OVXF1M6NI:VFH M0;MA05]$J.P!VM](:0X3ZZ#[QIK]!U!+ P04 " #@.&E15C02__0% " M' &0 'AL+W=O59(U$-SNH@WF;QCVVM:.^0KO(1EHOQ%VVILB'LHV0C) M\MH8&.1I4?V/G^I [!B0L,4 UP;XP /6@Q(;4"ZSN#5!MZA@=-BX-<&_H&! MZ[48!+5!<.B#VV(0U@9A5X.H-HBZ&@QJ@T%7 ]=Y7CFGS*!JR.BB3KK2'-$D+51\SR>%N"G9R=,N7<9'^&U?)6LS1Y4; $"'0^PF5 M<9J)#^@=ZB.QBCD5*"W0?9%*\1$NPO%O*[818"6&?0ED%&0_J2>^K";&+1-? M;)9GR"$?$7:PZC&TES\;<%G33HI$3W6M _/R6KN%A2Q%4IFK*@LO=+>[7K/8[<8?_1,*77 M3.E9IYQREE Z%VC!68Y2(39QD5#E8<+R'.1 E(Y"F:=0\FF?H-\0QNJ;^,=Q#P.GA4+04 BL%,:LD#Q]V"C9K1>@8$6BKK(,!B\A MYI*"'DC$M@7E1BD,C@*##5$^'N5&'O;,_,.&?VCE_R=5].*Z%J997%AJ(&I MHQ-4V*!!'U@I_[K)'RA7\,V.(%#IA@JW"C5/$TGG==K'2TXI-((2_8=L6\AX M<)0?V!Q;U]%[LF.E>C>[$##MJX+L[NSX[@G"[&J==+&=_6$H(=!2Q7@-H69S M]!X4Y0>-N3!I^_@%<*\RM1'5DNO:-;>);REK!@'8Q]6ZZGJG"+"6+]>N7[>E M(JS2M8HH\);P(&/<;.TP@7.&G9]LC+2:N78YNYG>VG"TJKCA*2*G!<:-K#QG MJL=":\A.6J;A',06LDG%L>K"Z >H.]V3&9N[R""H+16OMW2&^C.I)ZBB^Y@ M+8C8+HBZ*:H?\*$%?:1<[=V*9W51<6O7PWJ&O0;(QU$4^2T])M:JB+NV;,^O M'R %@9K*3<&RSAPGV"""CN^'K05#M P2NPP>9.1],:=\RU-YU+/OXVN!(Z?H MUHA6.F)OJ-XB->LINJ0FV7D@MDOD6RW^)3E^<@[<*/0/'I0FAG$N"2TYHD65 MV$7U($=>M6<1K8W$/T6F:)$D]B;O#3+EDAP_C1*_);Q:78E=7=\N4\*C#/!" MC^RFRCY%K;/$KK/U$YU]OR):&,G@!$OM:5'S[*+V!MM"/<->-;F!@\.PY:V5 M5D3/WO+-H&2 T@6:<@KEPX%4^4[:YKF60^\4C9^G5&UL?53!;MLP#/T5 MPNB %NABQTG6K7 ,+,F&%5NWH$6[P["#XC"Q4-ER);IN_GZ4[!H9D.1BB13Y MWB--*6FT>;(Y(L%KH4H[#7*BZCH,;99C(>Q 5UCRR4:;0A";9AO:RJ!8^Z1" MA7$4?0@+(0$ MH<*,'(+@Y07GJ)0#8AG/'6;04[K$_?T;^E=?.]>R$A;G6OV6:\JGP<< UK@1 MM:([W7S#KIZ)P\NTLOX+31<;!9#5EG31);."0I;M*EZ[/NPEQ,,C"7&7$'O= M+9%7N1 DTL3H!HR+9C2W\:7Z;!8G2_=3[LGPJ>0\2F>U98^U,-?%2I;"M_@IC!&N87"^0!)2V0OV?A=J9P0L<\$-R; FF0EE+^&FS 9P!K*$6ZF4@TA" M8G6.(\PZ);-627Q$R0(9(QY>0AP-KQ[N%W!^=O$_2LBU]07&?8&QAQT=@7T4 M1HJ50M9(:- 2?"E)T@[^_.!(N"$L[-\3/*.>9^1YQD=XYL+F4(D=#RQ9(,WS M]EQ+@]R4EO=01UK(3Q[279^7=#R8).'+ 1WC7L?XI(Y?38G&YK*""DW&8OAJ M':(^C1)/!E'T[E!;PKU9<]?V5IBMY)%1N&&D:' U"<"T5Z$U2%=^_%::>)C] M-N?7 XT+X/.-UO1FN(GNWZ/T'U!+ P04 " #@.&E18[1PO+$# 2#0 M&0 'AL+W=O>)C?N]/CH=I8P27<:6(V:RT(<$&CG M#"$L">%+"5%)B%Y*Z)2$3EZ9(I6\#E-FV7BHU8YHA\9H;I 7,V=C^ERZ=;^W M&I]RY-GQ[<;@'6/(1*5S+IE;#$.NR(TQ8 UAO26O")?D[[7:&$2;H6]1E@ON)Z6$VT)">$;"/637) K>D3 (@P;Z MI)T^A03IU-'IH($^??'LIW0?:UD5-*P*&N;QHC/Q'IC&>@D@,VE!@['DH[3< M/I%OGQ!)9A92\T_+/%$U3Y3/TSDSSX29=;X\B1O CPW?,@'2-BY $2K.0SDG MV(X'8;<;#OWM89WKJ+@7=N)CU+2.Z@?=<(\ZRJ939=-IS68FKS*M$GP17_]" MX^ #%@Z83HH,%[!%?\K0;6Q3EG%P '8F**U%QJZ@I+$%K6!#+'HDH6_>I26) %T M)+%72>RU2GR8?7Q'[C1W&PVY!0E+GG HU;!# M>R=UKF-Z-&PN,PWVWAZTJOS+KD'C+H+O@[2$Y9;>Z,]!_46D)P(;,"$](_!@ M\Z$_K>W+T!?Z_A+J6/C>Y&GXGUN_I%[H_4NH8V'[78&V;PO%D@LE5U?8 &G; MHDMODD1ML%5(QI[R7G6+S9)$;]"UX!%/M ::%3>8 M^&D?-6"BP;GW=&_TM-WI7VZJM.[I#:YZ"74L/SA_NJ^%/YA><3Q&"E@B+;CN8:*Z.( 7%U9E M^9%TKBP>&ULS59M3]LP M$/XK5H0TD("\-6F+VDKT!8T/H(H.]F':!S>Y-A:)'6R'PK^?[:19"VF&F";M M2VM?[KE[[O')OL&&\4>1 $CTDJ54#*U$ROS"MD640(;%. T+D/?YG*N=74>)2094$$81A]70NG0O9GWM;QP>"&S$SAKI2I:, M/>K-=3RT'$T(4HBDCH#5WS-,($UU($7CJ8IIU2DU<'>]C7YE:E>U++& "4N_ MDU@F0ZMGH1A6N$CE'=M\A:J>0,>+6"K,+]I4OHZ%HD)(EE5@Q2 CM/S'+Y4. M.P 5IQG@50#O+:!S .!7 /^C&3H5H//1#$$%,*7;9>U&N"F6>#3@;(.X]E;1 M],*H;]!*+T)UGRPD5U^)PLG1N!#*(@2:L&Q)*-:G)] 9NF.I[L(-YC%B*W3+ M:,2HY,I*Z!I=4PDX74W1\=(*.$*'H6\(*@6DL!K94-'4R M.ZHHC4M*W@%*/KI1J1*!9C2&N $_;^7\7?;9I[/OB>'7#>.;>/ZA>))%CPE+8^#B"YH]%42^HDLI M.5D6$B]30)(=;)<8.3Y_7VG:8-3F'0V7>:-3EU@]II3X>@UB%H MU>'A>G:*YISHNQZ-@<**1$2M6R0.Z]#A?W#@W9I-M_W F\]5G3]:PII0JJWJ MPLJ!$]9X>93Q@QWYPY[G-LO?JUGU_GD;3GOOB)VYO;"96+\FUO^L7$#C5J'& M_7=]&H9^\*;C_^!4DK9WWJ<,^-H,!@)%K*"RO'EJ:SU[7)HG]XU][%Y,W ;[ M5,TJY6CQ.WPYZ-Q@KKI"H!16*I5SWE7Z\G)X*#>2Y>9U7#*IWEJS3-2\!5P[ MJ.\KQN1VHQ/4$]SH%U!+ P04 " #@.&E1?L#." @$ !1$@ &0 'AL M+W=O0;5Q0%[D M9C3)G=FDO'?'9Q.VDVF2PQU'8I=EE/]\!RD[3!WL/-[XG&RV4M]P9Y.";F ! M\KZXXVKDUEY620:Y2%B..*RGS@U^._<];5#.^)K 032ND5[*DK$'/?BXFCJ> MC@A2B*5V0=7?'N:0IMJ3BN/?RJE38VK#YO6C]_?EXM5BEE3 G*7?DI7<3IV1 M@U:PIKM4?F:'OZ!:4*C]Q2P5Y2\Z5',]!\4[(5E6&:L(LB0__M,?52(:!CCH M,2"5 7FJ@5\9^.5"CY&5R[JEDLXFG!T0U[.5-WU1YJ:T5JM)3J::+L MY.P]33CZ2M,=H+^!BAT'52.)!FC.LH+EZEH@MD8W>YJD=)G"0'7.0-!43:?\ M :2^AQ80[W@B$Q#H]:VZEZ3BC7)QO[A%KU^]0:]0DJ,O6[83-%^)B2M5W!K= MC:L8WQUC)#TQ+J"X1KYWA8A'O [SN=W\%F)ECK4Y'I^:NRI;=OR=,55=2*2I=D%-2! M'9LW:E7.ZPY]6(<^M(:NF)L!CQ.:HH(6P"W]-ZI=CEZJY<-4@MK+3Q9B:4ELY! '+\4#;'00VX7P]TS ;0'T M\2CH2Z;10&P7P0N8T!:[L ?=R!BVZ]@E3!BVF>#WX!O-PZ,_SH119V'(.1': MT_IJ9^03V_7S?H$V; \\+\]SZD2>QW86$".0Q'LI%A"CB\2NB[]G 6G+X7 8 MDIX^((WCGET1G\X"TA8T0GK@C:(1NZ)=0(/*TPD->FA(C.81^QGP&6A VJ=# M59G@?#_HF-9# V+$D]C%4]'@"R]?;'X^;3,@1AU)]&(T,*)([*+X!!JTM= ? M-S??4V0CA\0NAQ?0H$/U>M"-G!&[G%W"@O;!<-#S'N0;S?/MA\)G8$&%$)T5 MYGPSZ)AV7CNW\;ZO/[:H5_&-J@5*8:ULO.NA6CL_?K\X#B0KRD\ 2R8ER\K+ M+= 5<#U!/5\S)A\'^JM"_15I]A]02P,$% @ X#AI464L"8!5 @ 5@4 M !D !X;"]W;W)K&ULI53=;YLP$/]73J@/K;06 M0I)^B2 UC:KMH574K-W#M <#1[!B,+--:*?]\3L;BK(MS1[V$GSVW>_CG'/4 M2K71!:*!EU)4>N85QM37OJ_3 DNFSV2-%9WD4I7,4*C6OJX5LLP5E<(/@^#< M+QFOO#AR>TL51[(Q@E>X5*";LF3J=8Y"MC-OY+UM//)U8>R&'TS>AZ/K7Y+N&98ZMWUF"=)%)N;/ IFWF!%80"4V,1 M&'VV>(M"6""2\;W'] 9*6[B[?D._<][)2\(TWDKQA6>FF'F7'F28LT:81]E^ MQ-Z/$YA*H=TOM%WNQ94'::.-+/MB4E#RJONRE[X/.P7A>P5A7Q ZW1V14[E@ MAL61DBTHFTUH=N&LNFH2QRM[*2NCZ)13G8GO&%?PS$2#<(],-PJIXP9.X8$I MQ6S'X'B!AG&A3^ (> 6?"]EH5F4Z\@T)L#!^VI/-.[+P';(5UF E=/#C?WM9<)T*:>UH^'J3:*/H^K\=X!@/ M'&/',7F'XZ$I$U0@ M:1"84U%P=D$8JIOB+C"R=I.32$-SZ)8%/7RH; *=YU*:M\ .X_"4QK\ 4$L# M!!0 ( . X:5%78]]Y30( X% 9 >&PO=V]R:W-H965TNZ)*^F$07/H5%[67)F[M4:>):E&*&AXU,VU5Q*9$N^"G2<,WL )\;AXU1?Z(DHL*:B-4S304!'0 MF;TYLT[62KW:X$L^]P(K""1D:!$X#5NX RDM$,GX.6!Z(Z4MW)_OT.^==_*R MY@;NE/PF"T.GNB9S*)4>>)EIU3-ML0K,39]55DSA1VY^R0DV[@NHP MO>="LQA@H_\[7@J3265-&_9]L3;.\(\C'-'($3F. MZ0<<2P+O!)9T *H&]@Y<'_+?@UPZ$'M[MFD8S<+9)/&W!\BG(_GT*/FB0-". M=]WB3D9!O>]T'/P1/6"\)R2*XUET6$<\ZHB/ZZB41O$+N-Z(V3$)!A<'%%>'H_O;U :K&=?Q:(=T?-RWIP0)M$VB_ M4 IW@;U$XQ.8_@902P,$% @ X#AI41;./63)!@ W34 !D !X;"]W M;W)K&ULS5O?;YLZ&/U7K&@/F[0ML8UM,K65ME;3 MG;1)T[KN/ES=!S=Q&C1^9$#23;I__#6$YB/8&$I:B3XT(?GL'+YCG\\?'!].)L(^_4MOGB%7J! M@AA]7R?;3,;+[&R::\S%+T\7%;X/>WRD!=^UVKQ%=/8:D1F969I?NIM?J85N MCHOF>'[+/-BY@D M7@1A(,MQ_,]G_1/H4ZZB[%\'0'H 2$N 7@O 2YFMD?JU#78RU$1:,[[O@9<] M%--\=\$$8_1LNJLGUHSB9,[Q(>H(GG> YSGA?9'I3SU(BFQD1:Z"/% Z37*G MQTWQZ1LM3&\R#=V&>]\UJR$BPO-]KP'<#)O90;,#:.8$_3W)98A6!?6[APDA M2_)M*)GQ\Y02CXH&2C/,D5Y^0,J=2.O#LQQM.K>?U4Z%"#O&ECCT+L8Y^/T# M0/_DP>^;],SGI#GXS2@'._,#O/GS#?ZY!;=@I(';C&H9^W@&!6+VA*._ZJR. M0,RY8 VPN#$W" MT']H6"4GH.ID-DXZ"6@Y<6OY2716?=MIVC/I##G&7+L\($_'I*LD$=![0D?* M)&@^>4;-)Z:66R>F):Z-3M!\XM;\RR3=)*G,%5JJV[P&WI46T&G"1\HLV/>:)= 2UD8H MNR[861LLKA2$G?HCY13TGSZCS4-=#D[%9V^3QX."X+D+P@ ^7)Q\ M>B#^GGM-?YIG37K-44M8&Z=0$3QW1="S?FW<-K;W_&@ M(GCNBC" 4Y>Z,I!U-E*7AT$!8,_H\K!NE\<9^/H\ZID2#.;*1V#0<9Y^[5>1_J M>+C+=PXJRT=JNG!0;'[Z7BLW31/"*6YRT]M:X2#6?(BU M,E@-.4@P'ZGQPFLWRG3LD?9ASF6<5+3U]E8X"#5_/U%OA(-:\ M8Z>T#VVF/V*;<+U=% $Z+3I=E,==<0O063%2GT2 7HN.O<\>W C3YYCKOP8W MEJ@V;D"JQ1 W9+ 8"E!A,5*O1(!>BXYMSC[,F5Z'C;G>CH@ J19/[HBX]%#4 M;G<C4='6V_00(-6BZZ:6Q^^=^R"U_DB=#1\DV^_8L.QS M-ZKI3F#/G%:6L!9^?)!KO^M6E:?>(O=!C/V1.AT^R+9_NM/ANVXYJ9CK?5>* M#W+M#[PK9; F^B#&_DB-#A]DVS_=Z*BZX%WSS@QKLC>M/7M3//CT1:9W09RA M4*UTF]G;HB*F^V>)]@=YLBD?Q[E-\CR)RK=K)9&PO=V]R:W-H965T M7GQDNT*;%^YR7M,=W(*^JV\DCMS.2\Y*J!03%9&P M73C7_HN5;P76XC.#HSIY)B:4C1#?S>!MOG \0P0<,FU<4/P[P HX-YZ0XT?K MU.GF-,+3YP?OKVWP&,R&*E@)_H7ENE@XJ4-RV-(]UQ_%\0VT 47&7R:XLK_D MV-@FB4.RO=*B;,5(4+*J^:?W;2).!/[TC"!H!<%C!6$K"&V@#9D-:TTU7;"YL6J,AE5F&6^UQ*\,=7IY(Z&F+">O[K$P%"A"JYQ\T 5(KD%3QM4S\ISB'QU6;Z&#.6^D?NSO^4NQM\E(>B2$%A_X5E_6Y 2_6P])/8G[N'TS2.&$5>9_,7W+2#FSX*3HFM/E(,G;/L3^68 MQJ&A.@?=N(Y.>,+ ZS$/;8(P'6>..N;H4I&MV:=VN^J7% M38?KEL8]O!&;.!X'G'6 LXN GP2VEP&@+4MAV;,]]B/,+[6=9HQ\-J":38.P MASXT"N-P-L[N>W^.#.\B_3M0BG!1[9YC@9:D%M*WOGIS2YHKTGLH=MGC< M0UN4>5<))D VMXYFH$5M#^Z-T'@-L(\%WM1 &@/\OA5"/PS,7:"[^RU_ U!+ M P04 " #@.&E1JOX^02 # !&"P &0 'AL+W=ONS!9N.:2YBDN(% SQ/ M$L1>;G!,=Q,#&J\']V03"75@3L<9VN E%@_9@LF=67D)28)33F@*&%Y/C&MX M-8.^ FB+GP3O>&,-5"HK2A_5YC:<&)9BA&,<".4"R=L6SW <*T^2QU/IU*AB M*F!S_>K]JTY>)K-"',]H_(N$(IH80P.$>(WR6-S3W3=<)C10_@(:?:PG(/3DS-P D@*?D0TYQ+*QZ:0;)1/,R@CWQ21[2.1ESB[ M!(YU#FS+MCK@LW[X' <2#A4^)?79-J5IVWC>L++9 MH^16E-Q>2M=!D"=YC 0.Y6<@6T) 4/&A22%00ID@?_5!%^?"]:#!Y\*V1P>D M.XR@YW>S'E2L![VL]\H7[Y5O%\]!BX+KPP.:;9N!!;M9>A5+KY?EC"99+C#3 M+.EZ30)D*K[HK6QRL*&TT8OEO3$MH4S/$.&T*'D7NL:F'=$J'=KRN6/\B(QB$@2<;H M%JOL>5_&=0.$SB<(7#@5N-Z9&09;ZMFUL]XB\=>^"_,,Q[!:Y;#O0^0>"Z T'__0+[[=_5H;YM$^M 7K,QY*@)\SMB&Y)R M$..UQ%B7OA2;%4-;L1$TTW//B@HY1>EE) ==S)2!?+ZF5+QNU"A5C<[3?U!+ M P04 " #@.&E1WE*=VWH" "K!@ &0 'AL+W=OK,% :B3:=M@>FBH[M8=J#F]PV%HX= M;(<"OWZVDV8MM!W:7A+[YIYS?&]N3I*5D/>J!-#HJ6)<#;U2Z_H*8Y674!%U M)FK@YLE"R(IHLY5+K&H)I'"@BN'0]\]Q12CWTL3%IC)-1*,9Y3"52#551>3S M")A8#;W 6P=NZ;+4-H#3I"9+F(&^JZ?2['#/4M *N**"(PF+H7<=7$UBF^\2 MOE-8J8TULI7,A;BWFR_%T//M@8!!KBT#,;='& -CEL@*"VJ M#FQ.4%'>WLE3UX<-0+ /$': \#4@W@.(.D#T7H6X \3O51AT %&UF8(]"GB M9D0_H*]$2F+?)#K.0!/*U(F)WLTR='QT@HX0Y>A;*1IEP"K!VIS'LN*\TQZU MVN$>[0C="*Y+A2:\@&('/CN,OSR QZ8/?3/"=3-&X4'"&=1G*/)/4>B'_H[S MC-\-#RYWE?-_ZI-_5M]J1M1/1N3XHK],QBF:,L+U]H"@G]=SI:7YS'\=D(I[ MJ=A)Q7ND,C >EU/26H?1(960FKZXP*ZY:NG.'9UUPL=T$"3X&PO M=V]R:W-H965TM%*6_D*'ZE(I#;9 MM$F;%C7M=C'MPH&38-5@9CM?_WZV(2@-E/4FL>&\YSSO,;:3/>,O(@>0Z%#0 M4DRL7,KJSK9%FD.!Q2VKH%1OUHP76*HIW]BBXH S(RJH[3E.:!>8E-8T,<\6 M?)JPK:2DA 5'8EL4F!\?@++]Q'*MTX-'LLFE?F!/DPIO8 GRN5IP-;/;+!DI MH!2$E8C#>F+=NW>S6,>;@)\$]N)LC+23%6,O>O(UFUB.!@(*J=09L/K;P0PH MU8D4QM\FI]66U,+S\2G[9^-=>5EA 3-&?Y%,YA,KME &:[RE\I'MOT#C)]#Y M4D:%^47[.C;P+)1NA61%(U8$!2GK?WQH^G F<$=O"+Q&X+U7X#<"WQBMR8RM M.99XFG"V1UQ'JVQZ8'ICU,H-*?4J+B57;XG2R>E]FO(M9.C307T7 @2ZGH/$ MA(H;]!$]+^?H^NH&72%2HJ><;04N,Y'84A765W=:SUWKV3#[_C7P+?,0KJKPJ-\@T %.!?M^O MA.3JL_HS4,)O2_BFQ.@_;>4@ /,T-Z4RV*E=4ZD](!$T_>YK9ITZ-*GU+MQ- M72=TX\3>G?>L&Q6,PJ ->H4]:K%'[\*&HJ+L"#"(6:<*S@!&_MBYH.P&>>,H MZJ<,6LK@790;*(%C:GJ+,[4YB%Y ?2P,<@==I"!R+[B[0:X?A/W<8($KPBE BCWUL8:=LW$'KQD2QVT\6M631(-D/F0/OXXFZ;1A?X'1#O'$_ M3=S2Q(,T3TSJ53U]BP-+&7=W2CP*+PE[HIS0B2\@[;-#5%]@WS'?D%(@"FNE M 9 >&PO=V]R:W-H965TPZ$XU?*GHLE(1S\RM*\.!DL.5]]&XV*:$FR ML!C2%D(698[RL(D'XR/JW/W;'Q,USQ-3EB='X>!4NR /ACZM[)HY&=98XR4A>)#0' MC,Q/!J?PVPR[):"*^"LAK\7.9U NY8G2Y_+@.CX96"4CDI*(ERE"\>^%G),T M+3,)'C]ETD%=LP3N?MYFGU:+%XMY"@MR3M._DY@O3P;^ ,1D'JY3_H.^7A&Y M(*?,%]&TJ/Z"5QEK#4"T+CC-)%@PR))\\S_\)3=B!P!Q!P!) -H'V!T + &X M+\"6 +LOP)$ 9Q_@= !<"7#[ CP)\/I2\B7 [PL()"#H"X#6MG-6WU7 NMFM M;G=6V;8;]NXWW#8<5AT?;:[%ZD*>A#P<'S/Z"E@9+_*5'ZIIJ/#B^DWR<(+\"?X'C(6EI,%CB:$ATE:?!%G M'Q\FX.B/+\.%3EPUT# MEX9% >@XQSJMZG-?5."=%L18'1TD. MBF7(2*&;X-M-?J?*7[K^R]AW/J8#\*,[M%(0@<<=W; M>@Y.S<$Q2"&6$;"A69F*;B BW463VO37)_EQ<4RIZ3_#!>F_RE8OBJ3-UJ-AC9N7J0W;X8UR>_CYO@V#/3W7Q&$'80]WZ#E2]H/,]O.Q>CZ5U1H:8>OT M_$83&?@&G43*HI#9HCY2SZ>H_62"D4X>;S21@6-:D#(H9#:HPX1_BC0/*H&6 M<3O0Y*A(.14R.]4[%%UF;BJG88"5RR"SR[Q;TV7^WLR4VR"SVTA1/S]$U)5C MH. S?GM0IH&MSQ/UB4S>4&MON']$KZE9&-?O3"KM[*UES'Y2Y8;.Y'>(/ M$]Q^$/)=#P;V_L+;<;9O>]!R]Q?5,W#6(["Y SW1N M?J$)1$;&RORPV?S>X24R<[\-F>WNWEV[RDW!QPNJK>^CQ1SFE6?5R2,":L#!#?SRGEVX/R15+]JGC\ M'U!+ P04 " #@.&E1N0P"9$0$ "5$P &0 'AL+W=O>8@UPV='--B-!E7]^[Y9,Q* MF=&"W',@RCS'_/^TM5:ZAO.9+S!*S(G\F%SS]65TV1):4X* M05D!.%E>CJ[@IUL4:T 5\8V2K=@Y!WHHCXP]Z8N[]'+D:D8D(PNI4V!U>"93 MDF4ZD^+QTR0=-34UH7;$VL.P*+4DB6&[!BD-.B/N)?9B)V -#O 2 #0$,!G@%X0P&^ M ?A# 8$!!$,!H0&$0P&1 41# ;$!5.WBU,M1K>4,2SP9<[8%7$>K;/JD:H@* MK9:0%KIWYY*KIU3AY&3*BF?")7W,"+A7;4,X)REX**@4X \P5U))2_6(+@[N),G%#TMVK\GN5=G]GNQUE^*F2\&9 MZCNQQIR(\ZYUK[,%53;M\\\3Z,8P\GPUT<\=//R&AV_E,:]* EI)Y!@)_X!$ MD@0N#/QN#D'#(1C"@>U*TTXD.(U(V! )K42^T)\E37'ULOJ&LY)TU:Y3A+LK MX8>)WU,Z:DI'UM)3S/EO/?*^NM?105VW*5DS.XR /HS M!J(X1&[00[>U/HC>6)$FX?"I:XT2VIURD"A-CKW>CSWD]A1OW1':[?&H+&:&;2[V5ZA)L%<9AF[/"QOM[ ^/F&2MT.D)"D6MZR'O M'12*6F-#=F,[5:'H<.\71-#W>A>P-3HT:/KE"3<#B7UH^1W8^'*?1P_QC[,>K326O!R&[! M Q0:'U:&76Z)C@E7 >HYTO&Y,N%_DC1?(F;_ ]02P,$% @ X#AI44$_8V,O"@ M]SD !D !X;"]W;W)K&ULQ5M[;]LX$O\J1&[O MT )M+$JB*.^E =*\FJ9.@F9S"]SA_F!L)M95#R]%)92E@].'#WA'\ M]29$DJ&D^$=$G_/&:R!-N<^R;_+-Q>+#GB,UHC&=Z#&-8RE)Z/%' M+71O\TS)V'R]EGY6&B^,N2 MQ7GY+WBN:9T],"]RGB4UL] @B=+J?_*]7H@& _0'&-R:P>TR> ,,7LW@V3[! MKQE\6P94,R!;AJ!F"&P9<,V ;1G"FB&T99C6#%-;!NBL/>=8LVR<;>UMN'8W M[/E[D&7M<&CM<;AV.;3V.5P['5I[':[=#DN_3ZHD*3/LA'!R>,"R9\ DO9 G M7Y1I6O*+Q(I2B2BWG(EO(\''#T__*"+^ DBZ +=+PNA[F9X+<)PE K-R4F;] M>W!%&",R]<&;$\I)%.=OQ:=WMR?@S2]OP2]@ G+)G(,H!7=IQ/-WXD/Q^K=E M5N1"=GXPX4)9^QWUBPN]JP MF0A0V2"+NT$6MY3G#<@[CDF>@^P!W/)L_@W\ZXOX'EQPFN3_-DCW-M*]4KH_ M)#U+$@%->2D[RO-"@-8;@3@5#KW594TE$)4"9:/U=(A@B!'R#R9/S0#MT_E. M 'T?>6W"F05ARS9_8YMO;YOH G,N(#1*'\<,]"T-[-,-&&A!V#(0;0Q$]@;F MQ?U_1'L)> 8>"EXP"IYHSJ6Y*Y8]1;)US<[7F5O)Q0S5GWW%@QU0KJMD85MT8^MT.UM?X]&IE4>MJ&9C5"TKH:.Z5V?$SFQ.Z2('#RQ+RCI MTCF556?>*A"I^!OQB,1@5=S'T5Q0B/41(/,.I)1K&\3JP4'3-5.-!W5TV/5# MMTUWI:$;\#%L].[0:/W%VMX'*N-8]/#TNVS;J:[?/JF%M8(-!T.1!E6=AZY1 MB^L5+S'ZD9&4CR;162VMI<84.P'NAHR&T,53'_G!@,:J=X#FYN'WW,#54:'MQOU>6(KHG;8UOM10082Z9NF(7#3M)H*NJT #MJN. M II;BMMZ_UEU@L5*6+UN(R084"9VK2GX>GLTUDO,8+^9\)RI X?R1'43T-Q. MK/,D+9)[$4:-QD[KF$H8A,WPWP^[:SY"U595-0/0W UG2H*BX,=[ ' M@*K*07.9*[TN^L1H/E#7](6MEMJ*U($UP3S?7CGU24#4;J&+F)26K:?2J0=[T=Q)ZKT-8UH^UILHJS%TK! M/4WI0\2K!1$!70NWD60* !T;?<<15J&B.U>X]S5; T"+QS. M>@6:KADTM\KZ8U>#E4&W"_ZDH^H276B(O*G>&D_!KF>&W3H\/FX1'IX"2 _N M8H:EH,\S0]_KP\/K-\=>X,+!\/ :@S5S<[Q5>)S7PKK;I+;GOVBHO$%-%0)[ M(W,RZ9V__46$X]^/0#7 J-Z-!H#"20_M(@ 4N'E6(Z:B.C/9POW]01!$N@G# MI8;2U M&?F;GC7,..>9V %PBQGG9Z]?$'K6]DFF"';2UU*UG"&(]'RBK+P^(Z*E M2N8Q'_:/A;#C#6O7.!4RE[NC9\(6MF.VF=\?L^!A@/951?3-.X=S[:CLC;P+ M8!R.S6JYS:F7M^\,S/)\54%]S\CW*"D2P_H@53G0+G8<2*$Q M&D'CG[3^9T@SQJ_.(@?67Z$PLCK:KQ;@3^$!MLJ8Q)OC#1B;ED+A*?)WL=2- M0^Z1&8M]X3M%_:'ST#HJ9$16>XOU.IIGNDCA$=K%R 0I!$+FQOEG%.%3U&]- M7>2&8=BX#-'63R$8&D&PKENM#E-/D/W,.5!0%9BAZJH^2GC8W+^KU"HGD5D\ M%G8G@6:R[""$![,X4$ 6F%O@UXWF3P+-D'EHF13H!6;0ZV3"G02Y9Q9Q$52& MD T48@6['"JD"<^?W@V[^&/1[P4#>#.HT,2<:.NAA0S0H+ PLYLVOB(;^ M/'DP&AJW>K;"Q58U-[E+(62P"X0,%$(&(PCYLVIXT$=)%!B:UD"!9#!R_X2R M.17[A.[I5[,O+^3A \D!7PK]EC*,A1ES$L^+6%;[]>V<)Q+%Y#X6VXV,;8[5 MM-:854+[CO-7P_ICA;K8C+KE*?)80<4**?$N6CZLT ]OL0%_;4'%FG9/],0N M'CB*P@H\L;G=DZMILE.A)-Y%/X<5AF$SAFVU_S[#_8[.O& *O_#(@5B52=5M M I-EC;M_NP LK +6P#6EA=3:I%-Z'==V!E;76JHNIMW#8D7PLZ=V"NCH+;9 M"@2Q&7'.:4H9B>.7TLZY#)KUV%>T'HE<<"Z*3^5)F92&PO=V]R:W-H965TD(02$-E7J M"]C'Y_O.-?;I;BA[X2& 0&])G/*>$0J1W9HFGX>0$'Y#,TCER8*RA BY94N3 M9PQ(H$%);-H8^V9"HM3H=[5LPOI=NA)QE,*$(;Y*$L*V=Q#33<^PC)W@,5J& M0@G,?C,XF3.[,DB6($DAY1%/$8-$S!M;MV,(*H#5^1K#AE352H1Q(G^^'45B2TB:8"F(6%PK;(>H"%-9"MRHHMY??SH M<@2"1#&_DDK/TQ&ZO+A"%RA*T5-(5URR\JXII)O*F#DO7+K+7;*/N.2@!YJ* MD*-Q&D#0@!^=QG=.X$V9GC)']BY'=_9)PBED-\C!7Y"-;=S@S_!LN-5I"N?_ MK(__V?I>,IRR81S-YQSC.]8* \9(N@1YB0@TV^ZUS(1LM7BP(2Q OW](2G0O M(.%_3CCDE@ZYVB'WB$-/5) 8\8JY>=4M>%-K:&K#G-?7O.I"7?=;MBMSM*[6 M]E#)\KQ]G5&3CNW5F,:'6BY^9]J+W2MC]T[&_@@<")N'^OL-8"WO_4QGNC'J M/1-^:<+_'/5NE0ZU/JC>.:]7*8!MM7&MWH=*G7JY#U5<'_NU:C<8L]WF:K?+ MR-LG(_\&*3 9NRHV">1C$''!B'IHSZAWIS32^1SUMO#[$X4_J.(%TZMZDUJ;:M6=K/R7"? EGI.XC*H52KRB[B4EK/80$\@ M-?F==3NT&N0C-;OI\>"=/A_\'@A;1BE',2RD*7S3D@W*\EDJWPB:Z6%A1H4< M/?0RE/,G,*4@SQ>4BMU&&2@GVOY?4$L#!!0 ( . X:5$&+ND100, *<, M 9 >&PO=V]R:W-H965TSG1!"$J)J4Z7VH=C.^;YS^0[Q M8;"G[)E'" GPEL2$#XU(B/3.-/DZ0@GDMS1%1#[94)9 (;=L:_*4(1AJ4!*; MCF5US 1B8HP&^FS!1@.Z$S$F:,$ WR4)9(<)BNE^:-C&\6")MY%0!^9HD,(M M"I!X2A=,[LR")<0)(AQ3 AC:#(VQ?3>W7070%C\QVO/2&JA45I0^J\U].#0L M%1&*T5HH"B@_7M$4Q;%BDG&\Y*1&X5,!R^LC^S>=O$QF!3F:TO@7#D4T-'H& M"-$&[F*QI/OO*$_(5WQK&G/]'^QS6\L ZQT7-,G!,H($D^P3ON6%* $D3S/ MR0%.%>!= +@YP'VO!R\'>._UX.< G;J9Y:X+-X,"C@:,[@%3UI)-+73U-5K6 M"Q/5*(%@\BF6.#&:O^RP. !(0A!$D*&OJNHAF-)$MB*'6LROEQ_-W]0:@>L9 M$A#'_$8:/P4S<'UU ZX )N QHCLNV?G %#)G\G_?Y M/WL_*X9;-(ZK^=Q+?)=:8LP8)%LD7R8"K YGK;. !WT\WD,6@M\_)"6X%RCA M?UH"\HJ /!V0=R&@1RI@#'C)W;H<%LHZM:D-,]Z.YE4OUM=1U_%DC5[+VM:- M;-\_MYDUV3A^A6E>M_*L$]-9[GZ1N]^:^X+1#1;R^R800UP J N\(UCPELIV M"O;.YY"Z6P34_2"I,UZ_5'NKHG/=HJYSW<9UJBK7;2ZJW"O2[K6F'0BZ?@8T M54FVZ=HO^/J?0U?;.MU&U@5N)SI,O M7<5V:_++8,SU3;P,GMKTM9T3H_-)%#Y=&[;[40J[M1>G;[G=JL)UJYK"=1-; M_G6J$KBS$?X!LBTF',1H(UU9MUW9BBR;BK.-H*D>^U94R"%2+R/Y2P(Q92"?;R@5 MQXUR4/PV&?T%4$L#!!0 ( . X:5&#FIUR6P0 (,1 9 >&PO=V]R M:W-H965T,)T5RYYBE<64B7,X*FZ=?12<1;FH"1VJ.L.G(2) MM#,9YVMG:C*6F8E%RL\4Z"Q)F'HZX;%<'75(YWGA7-Q&QBXXD_&2W?(+;JZ6 M9PK/G(HE% E/M9 I*+XXZAR3PRGM64!^Q[7@*[UV##:4&RGO[,EI>-1QK2(> M\[FQ% S_/?" Q[%E0AWW)6FG^DT+7#]^9O^:!X_!W##- QG_)4(3'77\#H1\ MP;+8G,O5G[P,J&_YYC+6^5]8E?>Z'9AGVLBD!*."1*3%?_98)F(-0.D6 "T! M]"7 VP+HE8#>"P#9!O!*@)=GI@@ES\.4&389*[D"9>]&-GN0)S-'8_@BM76_ M, JO"L29R9?[3)@G8&D(%Q%3_, F,81 )N@LS?+:',!7)A1%; MJ]R,,YTIC@^M+=)4*+U?A M;5$QX\D-5_JW7WQ*AK\#+TSWD,O:P_J;Y_KO-QF@X![DW+://4QZ'G'[_;'S ML)[8U[<=^"YQ!]5M&]+[E?1^J_1F?[?D9% 1#SZP,L-*Q? =*U-P]]=23H>$ MNL/-R@3#5Y4AHZ'KD>;*^)5TOU7Z980%B60< DMDEF+2=@OV7UO)'?G4>R'X M]6W$Z_FNVRQX5 D>M0H^%_H.%HIS4,Q@>AF6&99&V,EW+&.T96\/LCF4'U[#?=9NC^0'@9CQKHY"T&PI?:,!(B/%) M$V$>%AKJB3/5;*8=="2' H'$#B@80,B>VAH'H;50VLK\C[/%*/'])KI?I#,5046K\O;,,K.XM])4"!Q>M L\2" MUU]_5+O;FCFI!Q%IGT1;7E?^A9E(19(E;4'7(X/T/["UDWK"D,'/-'2P@^Z[ M#5T/(=(^A?ZOH8,=_,3O^NV&KH<.:9\Z/VKHH.1=-S3I^OX60]:[? UY'HIM6;5:?4DXSO?/+]9/R&%0? ^H M:8K/$S.F;@5N2&.^0$JW.\3^K(H=?W%BY#+? ]](@SOJ_##B+.3*WH#7%U*: MYQ/[ ]5WE\E_4$L#!!0 ( . X:5%5%/IX0 , (L, 9 >&PO=V]R M:W-H965T8\>78"[WUP"U=I,H,^)-1018X0_6SN!&ZYSZ?AR33L&8!=<4=Q*;?:8$RYY_S!=*Z2L1<819AAK P%T7]/.,4L M,TQ:QV--ZC5[&N!V>\U^:8W7QMP3B5.>_:*)2L?>T(,$YZ3,U"U??L7:("LP MYIFTO["LUP8>Q*54G-5@K8#1O/HGS[4CM@!1[P5 5 .B_P5T:T#7&EHILV:= M$T4F(\&7(,QJS68:UC<6K:VAN0GC3 D]2S5.32X>2ZI60/($9BD1^,7X)($I M9_J@2&)=_04N"15P1[(2X53JB!=F7((^13!3/'Z [_7(P3DJ0C-YJ$'5#*]F M1K[2:LV>?EPK.ZN412\HZ\(USU4JX2)/,&G!3]WX8P?>UUYJ7!6M7746.0EG M6'2@&WR&*(B"-CUOAN_(Z3:1ZUJ^[@M\6S&Y1B)+@3J[%%SE1:FD#:B9K"+X M ^,TIX\E2OC]3?/ E4(F_SA4'#4JCJR*HQ=4W%+Y '.!"((HA .BMX8"1:RU M'+8%W4T7=(Z"3PY9O496S\ES\5SH>T(?Y(0^T02U,U84L[93=.8F"CK!OX*J M8+\:MF-'O[&C[^2YICEE)7,P#1JFP0<>EV&C8NBTYXYG>HO,7#G[CXJ;:M#O M]-M#\WKD21ANNZ ,3)MQ< M\V'W_5)F#]=@V(G:<^8-P%U[-@]&Z+[BWY(V>RC[%;35KC<@=PW;/#FA^\Y_ M?5KL>T-Z[2[WM\H]AF)AJV ),2]S555^S6A3:9_:^M+?+*_*]&LB%E37;1G. M-33H#+0D456^54?QPA:/]USI4M0V4_VU@,(LT/-SSM6Z8S9HOC\F?P%02P,$ M% @ X#AI44JCY]D% P / H !D !X;"]W;W)K&ULS5;;;MI $/V5D96'1$KB"_<(D("D:J5&0E":AZH/BSW8J]B[9'>! MT*_O[MH8TL:.U$I17NR]S9DSL\?CZ>^X>)0)HH+G+&5RX"1*K6]<5X8)9D1> M\S4RO;/B(B-*3T7LRK5 $EFC+'4#SVN[&:',&?;MVE0,^WRC4LIP*D!NLHR( M_1A3OALXOG-8F-$X46;!'?;7),8YJL5Z*O3,+5$BFB&3E#,0N!HX(_]F[#>- M@3WQG>).GHS!A++D_-%,OD0#QS.,,,50&0BB7UN<8)H:),WCJ0!U2I_&\'1\ M0/]D@]?!+(G$"4\?:*22@=-U(,(5V:1JQG>?L0BH9?!"GDK[A%UQUG,@W$C% ML\)8,\@HR]_DN4C$B4'0JC ("H/ \LX=69:W1)%A7_ ="'-:HYF!#=5::W*4 MF5N9*Z%WJ;93P[NG#55[("R">4($7ID0(YCP3-^[)#9S5[!@ D,>,_KKS[T) MEPK.;U$1FLH+. /*X%O"-U(CRKZK-$7CR T+.N.<3E!!IP?WG*E$PAV+,'II M[^K0ROB"0WSCH!9PCNMK:'B7$'B!MYC?POG910ULHTQ;P\(VJV 5#Q^!KTT. M9 U>L\1K6KQ&%5Y5[D="$!:C_@X4+/OL:MWTP!K"6W(<@WZ38C( MONYZ.V4$G?H(YJ,ZF&X)T_T8*NF5A'K_H!*N$A2@$L+JI-+[2RI!LQ>\KA3? M.Y8S[WVT\H:?H!!+ZR"6-[7BGY1D_PVU+&J!@B-0\#'TXA_KIE]?./]',07T MJ63\3JO=J-#,L?;ZS7?23+T?WVH&_%PR$%1+QCWYH6B)@R"2FNM*EWW=$E6N2M2CY1?&W;@R57NMFPPT2W=RC, M ;V_XEP=)L9!V3 .?P-02P,$% @ X#AI48\N@[F1 @ R 8 !D !X M;"]W;W)K&ULC95=;]HP%(;_BA7UHI56\@&$#P6D M%E1M4BNATFX7TRY,.(!5?V3V26G__6PGC=@(93?$=GS.\[X'^R3;*_UB=@!( MW@279A+L$(MQ&)I\!X*:CBI VC<;I05%.]7;T!0:Z-H'"1XF492&@C(93#._ MMM#33)7(F82%)J84@NKW6^!J/PGBX&/AD6UWZ!;":5;0+2P!GXN%MK.PR;)F M J1A2A(-FTEP$X]O1VZ_W_"=P=XZ+=;IO-#;Q5'VW%,>G^E"5J^Y;9.)S.E! ,;9614+DF,R61R2W(G($AU^2N MQ%(#>6"2B5*0>[ %( OZ[@(,N9P#4L;-%;D@3)*GG2J-S6*R$*TT!PCS6L9M M)2,Y(6,)18=THR\DB9+H>3DGEQ=7?V<)K;'&7=*X2WS:[EEWIL7>G)F<*^,, M_KQ9&=3VB/SZA-IMJ%U/[9V@.@]M):BB4A_E+LOK-.FG6?C:@NHUJ-XY5-R& MJJ+Z!Z@XZO7:6?V&U3_'2MI8_2-6FL;MJ+1!I>=0W394>FQK.&A'#1K4X%/4 MDT+*W\-V$<-&Q/!3$?=@S)@P490(:WN5$#08 M;*,/C^C72>_$(1HU]-%_E,#V>4W=[:B+P!E=,<[0WI0V(:.CPQR/HN0?(>%! M8W(]_H'J+9/&$C8V+.H,K!%=]&PO=V]R:W-H M965T(#R"5YJ7T!=16&NVF(<&&*&R: MIGTPR;6UB.W,=BE(^_$[.R&KIC:#2? E\=MSS]WY.=O#M=)W9HEHX4'DTHR" MI;7%21B:=(F"F;8J4-+,7&G!+'7U(C2%1I9YD,C#)(IZH6!%)>:>F%M)>,"I>%* M@L;Y*'@7GTQB#_ KOG!@KEE!B:K4&[5:3-=?PN?%HBH9+MXTSJVF6$\Z.)TH(;FE?+#"9P41)R^4" M94R:W#M_/P%5&&8,F,;Z+HU7?>5=Z57,_4: [M6EB*C&N-B):J\%^S1 MU88!HO,C!J2RE$L+*54.U0EFVX1?,AU[)G>2WH\'O79W&-YO\:]?^]=_B6JV M>-)ZADY.FTGBJ(3" 2=!4L#<0(9>VQ2SJ .8/ "Y;23_Q/.<89VPHT[RST8+IA><&G(O3F9 MIF.%C@5=WL%EQZK"7V.WRM*EZ)M+>K>@=@MH?JZ4?>JXF[%^"8U_ U!+ P04 M " #@.&E10IDWWHL# ##"P &0 'AL+W=OV+>(495#TV 91 MM;)B/(-2#?G:%AN.8&) &;$]Q^G;&<34FH[-W"V?CEDN":;HE@.19QGDOZX1 M8;N)Y5K[B3N\3J6>L*?C#5RC!9+WFUNN1G;%DN ,48$9!1RM)M:5>SEW/0TP M%M\QVHG:-]"A+!E[U(//R<1R](X00;'4%%#];5&$"-%,:A\_2U*K\JF!]>\] M^T<3O IF"06*&'G B4PGUM ""5K!G,@[MON$RH!"S1E7=1:_,"' +>(@8EFFQ%ND MD",[(E"(]^_V5"'IC=EQN?WK8OO>"]OWP0VC,A5@3A.4 MM.!GW?A1!]Y6J:SRZ>WS>>UU$B[0I@=\YQQXCN>T["=Z,]P=M87S=][G?^S] M(!E^=;A\P^>_=+CR#'$H&;_L( LJLL"0!1TGE>B3"J7D>)E+N"0(2 9^("HA MP:VGIZ#L&TI=,[?3"S\(PW!L;^NBM)BYGA\$AV:S%K/!(/2'AV;S-J>N&PXJ MLX/XPRK^L#.9,T29*@"OI;-?T?4[T_E@2BA* -PJC=8(T#Q;JAK 5L#E0["6LI<0?C,)1 M0X9CJ[#ON T1CHV\P W\A@:O4!VD;%"E;-"9LGUYE"Q^[%!@6-$-_X6@HXIN M]+;[L=&5_%A"<*K+LUXT.K7*5'@8UD^NTQLU%(A&1^?;:6C4PN/WO ;/O(OG M( 6N\_R:.=T2'3]:Q<@\0AU9=FL/IOLO9'.]9T+OOPM7NNC0)"I-#D3Q>EY# MN=>)YFU$82_L-[2S:TV)>@;6IAL4*K"Z M0S5-T#-]T=[>0+[&5 ""5LJ5TQNH.L"+CK$82+8Q+=&22=5@F<]4==F(:P.U MOF),[@?:0=6W3W\#4$L#!!0 ( . X:5%VC4"W;P, .8. 9 >&PO M=V]R:W-H965TS#8%\HEYR$[ YY_"^/&#GC+=\QR8OK+F(B-*#\7&E;D $MND+'5]SQNX&:',F8[M MW%),Q[Q0*66P%$@664;$OSFD?#MQL+.;N*>;1)D)=SK.R096H![RI= CMZX2 MTPR8I)PA >N),\,?%S@T"3;B)X6MW#M'QLHCYT]F+^^:[Z9VM>FWDD$A8\_45CE4RS>J1,Y+D?X%D2'ZQIE*)+IE,<2' M^:XV7+OV=Z[G?FO!%>37*/#>(]_SO3-Z%J].QV&+G*"&$-AZP85ZEY[G[4N4 M%MHQ6@N>&09YH8A]^_D:W1+!*-N4Y"PR]/NK+HSN%&3R3XNL7BVK9V7U7B-+ M-K+@0%9T* MVLG(MJS#ORY6&7[X&[\ZA+S7TK0:SZ#Q/>\- 0WG>YW$:A/$H M'-91!_[ZM;]^J[^E7C% "&W$Z)3O$=$OZEH;8L\@E)Y6'!U\!5'Y%=CHEN<[ MJ.\_Z!+V82UKV 'LPQ.BQ\Q/(\*P[YU'/JJ]C5J]W;$(F#5F(;Y],_*Q?[,' M>?Y:R&%]Q[!+D+'7+/Q>!S!7(MHXGPG!8>_"MXWW-C;/2$>&ZDMX'$ M?E/1[Q3*9OO 01=0!B><_.$H.*9Y&G7AF\7-/H3;-Z+[U:R58+/@XWZG"#8[ M 1YT@>#@A,VHUS\&>!IT"6"SH^#V+>5^]= *L%F^\:A3 )M5'H== !B>^1_D M^<<$3Z..";I['4,&8F,;*:GU%4R5?Z/KV;I9F]D6Y6A^;IHXVXDT9ZR[&GB6Y$09@ ?7W-N=H-S WJUG;Z M'U!+ P04 " #@.&E1^/589"D$ !T$ &0 'AL+W=OV"D MHYBH)*HD%<= ?_P.*5FR&X5Q.M@/-B6=[]QY/M'CM9!?U0I D^C[?"'QRJNU1#R%3'&1 M$0GQ1>>2?IP'%F EOG!8JYTU,:$\"/'57-Q&%QW?> 0)A-JH8/CS!%-($J,) M_?A6*>W4-@UP=[W5?F.#QV >F(*I2/[FD5Y==,XZ)(*8%8F^$^O?H IH8/2% M(E'VFZPK6;]#PD)ID59@]"#E6?G+GJM$[ !H_Q5 4 &"0P&]"M [%-"O /U# M 8,*,#@4,*P PT,!HPHPLL4JLVM+,V.:3<92K(DTTJC-+&Q]+1HKPC/3BDLM M\2E'G)[<0<(T1&3!I-Z0&5=A(E0A09&3&6C&$_6!_$KNES-R\LN'L:?1I %Z M8:7^JE0?O*+^4Y%UB4]/2> '?@M\ZH;/(.R2P,+IJ 4^<\.7D'=)SW_5^O7! M<'K> K_Y?];G/VW=PR+7E0[J2@=67^^@2O\E6:98.0[^^0-%R:V&5/WK,-2K M#?6LH?XKAOXLT@>01,1$K9CI)!9^*[A$TR<\J^ZUM=*L5#NP:LT(?9I@VIYV M$^Z2V/.U7_O:=_HZ93G7+"&74<1M+A:%#%U?=]\VO,[JMT9.=VY MC&.>P1-D!92UW:TD!]7*0L&+N43W M-T]%-X?)W;3(]5KDYBURKDU+FPE.W2-\]I[@>R]ZK#WXEW+]UN /TS=_6]]^ M\ TE4#8A2]0I]G_8 M=75>0Q/TR#Q!&Z*@;J98&B(FN<2M:HDY$DG"I"(YSF9+TFTN:><=O) M1=!Z:M.S 4Q.6TKF;^BB@Q+K*EK#.M1-.X[>Q+&+.Y1.Q)Y MC%"_.T(=LCSBEA=:Y/:$]2 TGM?L<@4L FD$\'DLA-Y>F$-;_4?#Y#]02P,$ M% @ X#AI45Y,OO#B 0 TP0 !D !X;"]W;W)K&ULK91=;],P%(;_BN5KF--D&VA*(M$ @E0U8EQB=SD)+%FQ\$^:<:_ MQW;24%C;"\1-[&.?Y\UY_96.VCS:%@#)DY*=S6B+V-\Q9LL6%+=7NH?.S=3: M*(XN- VSO0%>!4A)%D?1+5-<=#1/P]C&Y*D>4(H.-H;802EN?JY!ZC&C*WH8 MV(JF13_ \K3G#=P#?NTWQD5L4:F$@LX*W1$#=4;?K.Z*Q.>'A /^0?U]\.Z\[+B%0LMO MHL(VHZ\IJ:#F@\2M'C_ [.?&ZY5:VO EXY0;N^1RL*C5#+L*E.BFEC_-ZW $ M),D9()Z!^"]@=0Y(9B"L')LJ"[;>HW&S MPG&8?^([D"E#)^4'6#ECZ\O8.PEN*_$$6$Q@? 9\X'* /S'F2E[JCI>ZXZ!S M?49G"Q:-*!$J4G#;OB!?=%<.QIPN:GU9;+ O&\[[[[]%O>9%Q6)2O V*_JKL M\_@ZB:(H9?L3MI+%5O(_;5T6^Q=;R3-;J\2]",]\L:,CYZ_[9VX:T5DBH79D M=/7JAA(S7:$I0-V'X[33Z,YTZ+;NU0'C$]Q\K34> G^PEW8ZD@O)D-*F++RZ MDAAEM=G$J!?Z_L)CB'"81+QA=TS5(!4-5S&<]RY@AV]9#(/%1P@L[E9D.(:/ MY^]_-T+=O -V//MP=N8_7MSL^\^[P 7T7H3.#X!>^OXTV 2GX(O#X*^QI]!7 M!Z%?(4^!/^V"!]#.1L]=61+E@@\W-X/6H#6E404YT:. M)$5I1B4JSP25$DQ/,H(*P5&G8;O#330VQ90^F*_:KWR'W>:C._/-C?%^J@6Y MJ<58P_#'-,L>8\,W<4%%UD)];?1Q>&>;(L/W$N>D[>PV[P5,T8-I.JHJNOE" M2<$9MH<_.&$2H>T^4 I)GG0V4RJI=F )P1I+1=*QYX]$U1*W:EM.;3ZM.3Q! MS?_V.1>88XGH6+2N_6-^RF]6/+OZ7Y*[7Y5]P2]J=._/8Q0(U M.;L^?HVN(SHZD9Y[?X^:A)T6H?<"TXK%\*=IZNB0%*P:0A7ASBI)EF'^K%/0 M>(56NM7?X>OU&-8?20$3;8T.P6BP^0"X99K>] M9!:GK\[F4Y= MM14-=Z_-3F@XLC&VX1YV[=W4[:S@M=L*X1LUS6:S^;3A4B?OWNZOM;33>,=X M47EI-!2&@ELI'MR?XV&7W4LGUU))_V.1=-M*)*R16C;R4=2+9)8PMS4/'XV5 MCT9[KE:5-4HMDK0_<"NLE]6SXE6 _,+7KBOQ?'W- 621S&=PP8VTSG=G=-?G MP'@OX.1^K_7F7"HO[!GWXE]KVIW4=^$R\!33Z#&Z..Q_^R">V/\31K/9R$J< MF:IMA/9]'*U0 5"[K=RYA&G>B$5R:NZ%#<\#-[BH^V?S !5%RIY(.& OZ@Z/ M$D770CM1,]AR1LD:.&KV#U=<5X)%D!D"F1T0\FL60>8(9'X0R%7 @;]&D 4" M61P0U<"[">X/@O:'%N]"@#-FP&\W;6H;PG4L-_8[D*@0R[L9G6#\^H\7< M!PUJNED#8'="#(=*AM@RYUQ:=LM5*]AGP5UK0X_H8SK,+BFQ7I96[+BLV8?O MN]!87/<27OFML.R]JKX0"LIYI646"S7H1"J>,E#HSZ3KE(F=(TQ8(8I)2-6"FJ^ M0;*887+)B.6"8\;I8H:.88@M\Z*@V2L8GBKA_HHI,]^ E!+ P04 M" #@.&E1\R"+>>D! 2(@ &@ 'AL+U]R96QS+W=O )/[F/!00D5#B]B %28/D<269Q#)[HE"$8Y%08/F M5-;8\O5??;+&GK^D75NVW2%OMGV>'/>[0UXTFU+ZAQ#RAT.@O#SQG-X_SGS,GKJ4]_F=BM5MME>NJ6'_MT*+\, M#I_=\)XW*95F\MH.ZU0633CNKJ=SN!SDYCRYF3R_+9KA^4V:4#M((4CK!QD$ M6?T@AR"O'Q0A*-8/FD'0K'[0+03=U@^Z@Z"[^D'W$'1?/TBF*..4(&F$-8'6 M@EP+@=>"8 N!V()D"X'9@F@+@=J"; N!VX)P"X'<@G0+@=V"> N!WHIZ*X'> MBGHK@=XZ>MDFT%M1;R706U%O)=!;46\ET%M1;R706U%O)=!;46\ET%M1;R70 MVU!O(]#;4&\CT-M0;R/0VT:;)01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$ M>AOJ;01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'K[:+.;0&]'O9U ;T>]G4!O1[V= M0&]'O9U ;T>]G4#OB'I' KTCZAT)](ZH=R30.Z+>D4#OB'I' KWCZ&,E@=X1 M]8X$>D?4._ZGWKF<=BE?>[[7^/S_I+J<[TW7QU^6WR='[%QP#O +R.,74$L# M!!0 ( . X:5&R:$G8U0$ +\A 3 6T-O;G1E;G1?5'EP97-=+GAM M;,W:74^#,!0&X+^R<&M&UZ_Y$>>->JM>^ .+HS#9M4T7%ED5H[M@+!05M2;DUE&71I;6MR:F1[]BSA1K MLR(F9K,Y*VP7J8O3V-?(KBYO:&DV39S<[M+K4-MND7EJ0C:YWD_LLQ:9<:ZI M"Q/3.-MVY9>4Z5M"GE8. MW7W6_*^+FGR8'R\,VV: MQ78-"_&EH9"/E_BF1[MG"=3AHHHMDV^+WHRGAS3#M/^RH_. M'\J,!::9#]ZZD$[,T^%Q[T?2KYZZ5(A\K,<_\2,QE3[Z^Z@_[9+*7V:G[7VV M?CV<1V##[?@]_GS&'_4/[$. ]"%!^E @?6B0/N8@?9R"]'$&TL&UL4$L! A0#% @ X#AI M4>)E5$AO!0 JQ8 !@ ("!#@@ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ X#AI4&PO=V]R:W-H965T&UL M4$L! A0#% @ X#AI46ZPF*"3#@ @&$ !@ ("!$2@ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ X#AI M43KYS1F)"P ?A\ !D ("!B4$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ X#AI4>E05HT( P P08 M !D ("!N%D 'AL+W=O\" #2!@ &0 @('W7 M>&PO=V]R:W-H965T0IT MG ( *P% 9 " @1U@ !X;"]W;W)K&UL4$L! A0#% @ X#AI48F?%@9;# 32H !D M ("!\&( 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ X#AI486PAJN:! - L !D ("!(X0 'AL+W=O M&PO=V]R:W-H965T 9 " @1^/ M !X;"]W;W)K&UL4$L! A0#% @ X#AI4:JN M0D]'!0 70T !D ("!<)H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ X#AI495O:M$4 P LP8 !D M ("!B:@ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ X#AI4>"Y6Z," P N@8 !D ("! MZ[$ 'AL+W=O&PO=V]R:W-H965TJP( +L% 9 M " @5BZ !X;"]W;W)K&UL4$L! A0#% M @ X#AI45TC_,4!! ;PD !D ("!.KT 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ X#AI46.T<+RQ M P $@T !D ("!#,H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ X#AI464L"8!5 @ 5@4 !D M ("!>M4 'AL+W=O4T" .!0 &0 @($&V >&PO=V]R M:W-H965T&UL M4$L! A0#% @ X#AI44B,<2!( P !PH !D ("!BN$ M 'AL+W=O&PO=V]R:W-H965T4IW;>@( *L& 9 M " @6#H !X;"]W;W)K&UL4$L! A0#% @ MX#AI4= 8:CBT @ I0< !D ("!$>L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ X#AI44$_8V,O"@ M]SD !D ("!>/@ 'AL+W=O&UL4$L! A0#% @ X#AI48.:G7);! @Q$ !D M ("!I D! 'AL+W=O$ # "+# &0 @($V#@$ >&PO=V]R:W-H M965T&UL4$L! M A0#% @ X#AI48\N@[F1 @ R 8 !D ("!Z10! 'AL M+W=O@" M 5"0 &0 @(&Q%P$ >&PO=V]R:W-H965TBP, ,,+ 9 " M@= : 0!X;"]W;W)K&UL4$L! A0#% @ X#AI M47:-0+=O P Y@X !D ("!DAX! 'AL+W=O&PO=V]R:W-H965T3+[PX@$ -,$ 9 " @9@F 0!X;"]W;W)K M&UL4$L! A0#% @ X#AI4:$GKQY2 @ 7 P M T ( !L2@! 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ X#AI4?,@BWGI 0 $B( !H M ( !QC ! 'AL+U]R96QS+W=O XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 276 324 1 false 60 0 false 6 false false R1.htm 0001001 - Document - Cover Sheet http://www.zentalis.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members???/Stockholders??? Equity/(Deficit) (Statement) Sheet http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members???/Stockholders??? Equity/(Deficit) (Statement) Statements 7 false false R8.htm 1407401 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members???/Stockholders??? Equity/(Deficit) (Parenthetical)) Sheet http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitParenthetical Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members???/Stockholders??? Equity/(Deficit) (Parenthetical)) Statements 8 false false R9.htm 2101101 - Disclosure - Organization and Business Sheet http://www.zentalis.com/role/OrganizationandBusiness Organization and Business Notes 9 false false R10.htm 2103102 - Disclosure - Interim Unaudited Financial Statements Sheet http://www.zentalis.com/role/InterimUnauditedFinancialStatements Interim Unaudited Financial Statements Notes 10 false false R11.htm 2106103 - Disclosure - Business Combinations Sheet http://www.zentalis.com/role/BusinessCombinations Business Combinations Notes 11 false false R12.htm 2111104 - Disclosure - Fair Value Measurement Sheet http://www.zentalis.com/role/FairValueMeasurement Fair Value Measurement Notes 12 false false R13.htm 2117105 - Disclosure - Prepaid Expenses and Other Assets Sheet http://www.zentalis.com/role/PrepaidExpensesandOtherAssets Prepaid Expenses and Other Assets Notes 13 false false R14.htm 2120106 - Disclosure - Property and Equipment, net Sheet http://www.zentalis.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 14 false false R15.htm 2124107 - Disclosure - Accrued Expenses Sheet http://www.zentalis.com/role/AccruedExpenses Accrued Expenses Notes 15 false false R16.htm 2127108 - Disclosure - Convertible Preferred Units Sheet http://www.zentalis.com/role/ConvertiblePreferredUnits Convertible Preferred Units Notes 16 false false R17.htm 2131109 - Disclosure - Equity and Share-based Compensation Sheet http://www.zentalis.com/role/EquityandSharebasedCompensation Equity and Share-based Compensation Notes 17 false false R18.htm 2139110 - Disclosure - Commitment and Contingencies Sheet http://www.zentalis.com/role/CommitmentandContingencies Commitment and Contingencies Notes 18 false false R19.htm 2143111 - Disclosure - Net Loss Per Common Share/Class??A Common Unit Sheet http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnit Net Loss Per Common Share/Class??A Common Unit Notes 19 false false R20.htm 2147112 - Disclosure - Related Party Disclosures Sheet http://www.zentalis.com/role/RelatedPartyDisclosures Related Party Disclosures Notes 20 false false R21.htm 2204201 - Disclosure - Interim Unaudited Financial Statements (Policies) Sheet http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies Interim Unaudited Financial Statements (Policies) Policies 21 false false R22.htm 2305301 - Disclosure - Interim Unaudited Financial Statements (Tables) Sheet http://www.zentalis.com/role/InterimUnauditedFinancialStatementsTables Interim Unaudited Financial Statements (Tables) Tables http://www.zentalis.com/role/InterimUnauditedFinancialStatements 22 false false R23.htm 2307302 - Disclosure - Business Combinations (Tables) Sheet http://www.zentalis.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.zentalis.com/role/BusinessCombinations 23 false false R24.htm 2312303 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.zentalis.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.zentalis.com/role/FairValueMeasurement 24 false false R25.htm 2318304 - Disclosure - Prepaid Expenses and Other Assets (Tables) Sheet http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables Prepaid Expenses and Other Assets (Tables) Tables http://www.zentalis.com/role/PrepaidExpensesandOtherAssets 25 false false R26.htm 2321305 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.zentalis.com/role/PropertyandEquipmentnetTables Property and Equipment, net (Tables) Tables http://www.zentalis.com/role/PropertyandEquipmentnet 26 false false R27.htm 2325306 - Disclosure - Accrued Expenses (Tables) Sheet http://www.zentalis.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://www.zentalis.com/role/AccruedExpenses 27 false false R28.htm 2328307 - Disclosure - Convertible Preferred Units (Tables) Sheet http://www.zentalis.com/role/ConvertiblePreferredUnitsTables Convertible Preferred Units (Tables) Tables http://www.zentalis.com/role/ConvertiblePreferredUnits 28 false false R29.htm 2332308 - Disclosure - Equity and Share-based Compensation (Tables) Sheet http://www.zentalis.com/role/EquityandSharebasedCompensationTables Equity and Share-based Compensation (Tables) Tables http://www.zentalis.com/role/EquityandSharebasedCompensation 29 false false R30.htm 2340309 - Disclosure - Commitment and Contingencies (Tables) Sheet http://www.zentalis.com/role/CommitmentandContingenciesTables Commitment and Contingencies (Tables) Tables http://www.zentalis.com/role/CommitmentandContingencies 30 false false R31.htm 2344310 - Disclosure - Net Loss Per Common Share/Class??A Common Unit (Tables) Sheet http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitTables Net Loss Per Common Share/Class??A Common Unit (Tables) Tables http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnit 31 false false R32.htm 2402402 - Disclosure - Organization and Business (Details) Sheet http://www.zentalis.com/role/OrganizationandBusinessDetails Organization and Business (Details) Details http://www.zentalis.com/role/OrganizationandBusiness 32 false false R33.htm 2408403 - Disclosure - Business Combinations - Narrative (Details) Sheet http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails Business Combinations - Narrative (Details) Details 33 false false R34.htm 2409404 - Disclosure - Business Combinations - Assets and Liabilities (Details) Sheet http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails Business Combinations - Assets and Liabilities (Details) Details 34 false false R35.htm 2410405 - Disclosure - Business Combinations - Rollforward of Noncontrolling Interest (Details) Sheet http://www.zentalis.com/role/BusinessCombinationsRollforwardofNoncontrollingInterestDetails Business Combinations - Rollforward of Noncontrolling Interest (Details) Details 35 false false R36.htm 2413406 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details) Sheet http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details) Details 36 false false R37.htm 2414407 - Disclosure - Fair Value Measurement - Narrative (Details) Sheet http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails Fair Value Measurement - Narrative (Details) Details 37 false false R38.htm 2415408 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details) Sheet http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details) Details 38 false false R39.htm 2416409 - Disclosure - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) Sheet http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) Details 39 false false R40.htm 2419410 - Disclosure - Prepaid Expenses and Other Assets (Details) Sheet http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails Prepaid Expenses and Other Assets (Details) Details http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables 40 false false R41.htm 2422411 - Disclosure - Property and Equipment, net - Summary (Details) Sheet http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails Property and Equipment, net - Summary (Details) Details 41 false false R42.htm 2423412 - Disclosure - Property and Equipment, net - Narrative (Details) Sheet http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails Property and Equipment, net - Narrative (Details) Details 42 false false R43.htm 2426413 - Disclosure - Accrued Expenses (Details) Sheet http://www.zentalis.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://www.zentalis.com/role/AccruedExpensesTables 43 false false R44.htm 2429414 - Disclosure - Convertible Preferred Units - Narrative (Details) Sheet http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails Convertible Preferred Units - Narrative (Details) Details 44 false false R45.htm 2430415 - Disclosure - Convertible Preferred Units - Schedule of Units Authorized, Issued, and Outstanding (Details) Sheet http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails Convertible Preferred Units - Schedule of Units Authorized, Issued, and Outstanding (Details) Details 45 false false R46.htm 2433416 - Disclosure - Equity and Share-based Compensation - Narrative (Details) Sheet http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails Equity and Share-based Compensation - Narrative (Details) Details 46 false false R47.htm 2434417 - Disclosure - Equity and Share-based Compensation - Share-based Compensation (Details) Sheet http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationDetails Equity and Share-based Compensation - Share-based Compensation (Details) Details 47 false false R48.htm 2435418 - Disclosure - Equity and Share-based Compensation - Share-based Compensation Expense (Details) Sheet http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationExpenseDetails Equity and Share-based Compensation - Share-based Compensation Expense (Details) Details 48 false false R49.htm 2436419 - Disclosure - Equity and Share-based Compensation - Fair Value Assumptions for Profit Interest Awards (Details) Sheet http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails Equity and Share-based Compensation - Fair Value Assumptions for Profit Interest Awards (Details) Details 49 false false R50.htm 2437420 - Disclosure - Equity and Share-based Compensation - Fair Value Assumptions for Stock Options (Details) Sheet http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails Equity and Share-based Compensation - Fair Value Assumptions for Stock Options (Details) Details 50 false false R51.htm 2438421 - Disclosure - Equity and Share-based Compensation - Unrecognized Compensation Cost (Details) Sheet http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails Equity and Share-based Compensation - Unrecognized Compensation Cost (Details) Details 51 false false R52.htm 2441422 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details) Sheet http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails Commitment and Contingencies - Future Minimum Lease Payments (Details) Details 52 false false R53.htm 2442423 - Disclosure - Commitment and Contingencies - Narrative (Details) Sheet http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails Commitment and Contingencies - Narrative (Details) Details 53 false false R54.htm 2445424 - Disclosure - Net Loss Per Common Share/Class??A Common Unit - Calculation (Details) Sheet http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails Net Loss Per Common Share/Class??A Common Unit - Calculation (Details) Details 54 false false R55.htm 2446425 - Disclosure - Net Loss Per Common Share/Class??A Common Unit - Antidilutive Securities (Details) Sheet http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails Net Loss Per Common Share/Class??A Common Unit - Antidilutive Securities (Details) Details 55 false false R56.htm 2448426 - Disclosure - Related Party Disclosures (Details) Sheet http://www.zentalis.com/role/RelatedPartyDisclosuresDetails Related Party Disclosures (Details) Details http://www.zentalis.com/role/RelatedPartyDisclosures 56 false false R9999.htm Uncategorized Items - zntl-20200930.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - zntl-20200930.htm Cover 57 false false All Reports Book All Reports zntl-20200930.htm employmentagreementgal.htm employmentagreementpin.htm zentalis10-qq32020ex311.htm zentalis10-qq32020ex312.htm zentalis10-qq32020ex321.htm zentalis10-qq32020ex322.htm zntl-20200930.xsd zntl-20200930_cal.xml zntl-20200930_def.xml zntl-20200930_lab.xml zntl-20200930_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "zntl-20200930.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 276, "dts": { "calculationLink": { "local": [ "zntl-20200930_cal.xml" ] }, "definitionLink": { "local": [ "zntl-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "zntl-20200930.htm" ] }, "labelLink": { "local": [ "zntl-20200930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "zntl-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "zntl-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 413, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 5 }, "keyCustom": 35, "keyStandard": 289, "memberCustom": 17, "memberStandard": 34, "nsprefix": "zntl", "nsuri": "http://www.zentalis.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.zentalis.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Interim Unaudited Financial Statements", "role": "http://www.zentalis.com/role/InterimUnauditedFinancialStatements", "shortName": "Interim Unaudited Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106103 - Disclosure - Business Combinations", "role": "http://www.zentalis.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - Fair Value Measurement", "role": "http://www.zentalis.com/role/FairValueMeasurement", "shortName": "Fair Value Measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Prepaid Expenses and Other Assets", "role": "http://www.zentalis.com/role/PrepaidExpensesandOtherAssets", "shortName": "Prepaid Expenses and Other Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120106 - Disclosure - Property and Equipment, net", "role": "http://www.zentalis.com/role/PropertyandEquipmentnet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124107 - Disclosure - Accrued Expenses", "role": "http://www.zentalis.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "zntl:TemporaryEquityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Convertible Preferred Units", "role": "http://www.zentalis.com/role/ConvertiblePreferredUnits", "shortName": "Convertible Preferred Units", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "zntl:TemporaryEquityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "zntl:ShareholdersEquityShareBasedPaymentsAndMembersEquityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131109 - Disclosure - Equity and Share-based Compensation", "role": "http://www.zentalis.com/role/EquityandSharebasedCompensation", "shortName": "Equity and Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "zntl:ShareholdersEquityShareBasedPaymentsAndMembersEquityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139110 - Disclosure - Commitment and Contingencies", "role": "http://www.zentalis.com/role/CommitmentandContingencies", "shortName": "Commitment and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143111 - Disclosure - Net Loss Per Common Share/Class\u00a0A Common Unit", "role": "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnit", "shortName": "Net Loss Per Common Share/Class\u00a0A Common Unit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147112 - Disclosure - Related Party Disclosures", "role": "http://www.zentalis.com/role/RelatedPartyDisclosures", "shortName": "Related Party Disclosures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Interim Unaudited Financial Statements (Policies)", "role": "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies", "shortName": "Interim Unaudited Financial Statements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Interim Unaudited Financial Statements (Tables)", "role": "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsTables", "shortName": "Interim Unaudited Financial Statements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307302 - Disclosure - Business Combinations (Tables)", "role": "http://www.zentalis.com/role/BusinessCombinationsTables", "shortName": "Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312303 - Disclosure - Fair Value Measurement (Tables)", "role": "http://www.zentalis.com/role/FairValueMeasurementTables", "shortName": "Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318304 - Disclosure - Prepaid Expenses and Other Assets (Tables)", "role": "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables", "shortName": "Prepaid Expenses and Other Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321305 - Disclosure - Property and Equipment, net (Tables)", "role": "http://www.zentalis.com/role/PropertyandEquipmentnetTables", "shortName": "Property and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325306 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.zentalis.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328307 - Disclosure - Convertible Preferred Units (Tables)", "role": "http://www.zentalis.com/role/ConvertiblePreferredUnitsTables", "shortName": "Convertible Preferred Units (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332308 - Disclosure - Equity and Share-based Compensation (Tables)", "role": "http://www.zentalis.com/role/EquityandSharebasedCompensationTables", "shortName": "Equity and Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i450b8d9070c54398b658d16f1bd50b70_I20191231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i450b8d9070c54398b658d16f1bd50b70_I20191231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityAggregateAmountOfRedemptionRequirement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340309 - Disclosure - Commitment and Contingencies (Tables)", "role": "http://www.zentalis.com/role/CommitmentandContingenciesTables", "shortName": "Commitment and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2344310 - Disclosure - Net Loss Per Common Share/Class\u00a0A Common Unit (Tables)", "role": "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitTables", "shortName": "Net Loss Per Common Share/Class\u00a0A Common Unit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "ic77031da53f1433ea8eca6d76999fada_D20171221-20171221", "decimals": "INF", "first": true, "lang": "en-US", "name": "zntl:CommonStockConversionRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Organization and Business (Details)", "role": "http://www.zentalis.com/role/OrganizationandBusinessDetails", "shortName": "Organization and Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "ic77031da53f1433ea8eca6d76999fada_D20171221-20171221", "decimals": "INF", "first": true, "lang": "en-US", "name": "zntl:CommonStockConversionRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i21c07697a1844b3b93f0ba0f9653c232_D20171221-20171221", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Business Combinations - Narrative (Details)", "role": "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails", "shortName": "Business Combinations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i21c07697a1844b3b93f0ba0f9653c232_D20171221-20171221", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Business Combinations - Assets and Liabilities (Details)", "role": "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "shortName": "Business Combinations - Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i58d265ba4bcd480ab89ba00486fb66ed_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i978aaa2b4b32484d9802f131593c1320_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Business Combinations - Rollforward of Noncontrolling Interest (Details)", "role": "http://www.zentalis.com/role/BusinessCombinationsRollforwardofNoncontrollingInterestDetails", "shortName": "Business Combinations - Rollforward of Noncontrolling Interest (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "zntl:ReconciliationOfNoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i783cd72901b6441fa219564414652bae_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)", "role": "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails", "shortName": "Fair Value Measurement - Components of Available-for-sale Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414407 - Disclosure - Fair Value Measurement - Narrative (Details)", "role": "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails", "shortName": "Fair Value Measurement - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)", "role": "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails", "shortName": "Fair Value Measurement - Contractual Maturities of Available-for-sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416409 - Disclosure - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)", "role": "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails", "shortName": "Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i978aaa2b4b32484d9802f131593c1320_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i978aaa2b4b32484d9802f131593c1320_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Prepaid Expenses and Other Assets (Details)", "role": "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails", "shortName": "Prepaid Expenses and Other Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Property and Equipment, net - Summary (Details)", "role": "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails", "shortName": "Property and Equipment, net - Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i978aaa2b4b32484d9802f131593c1320_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Property and Equipment, net - Narrative (Details)", "role": "http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails", "shortName": "Property and Equipment, net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "zntl:AccruedResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426413 - Disclosure - Accrued Expenses (Details)", "role": "http://www.zentalis.com/role/AccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "zntl:AccruedResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "zntl:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Convertible Preferred Units - Narrative (Details)", "role": "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails", "shortName": "Convertible Preferred Units - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i2cf28591a0ca4eda8110eadf859071e4_D20200101-20200402", "decimals": "INF", "lang": "en-US", "name": "zntl:ConvertiblePreferredStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i450b8d9070c54398b658d16f1bd50b70_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - Convertible Preferred Units - Schedule of Units Authorized, Issued, and Outstanding (Details)", "role": "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails", "shortName": "Convertible Preferred Units - Schedule of Units Authorized, Issued, and Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i450b8d9070c54398b658d16f1bd50b70_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i480821ab68b149969a9c102150218a11_I20171231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433416 - Disclosure - Equity and Share-based Compensation - Narrative (Details)", "role": "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "shortName": "Equity and Share-based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i480821ab68b149969a9c102150218a11_I20171231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i978aaa2b4b32484d9802f131593c1320_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434417 - Disclosure - Equity and Share-based Compensation - Share-based Compensation (Details)", "role": "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationDetails", "shortName": "Equity and Share-based Compensation - Share-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "idedb8bfe7c674a99a9016bfa63c1e06c_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i978aaa2b4b32484d9802f131593c1320_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435418 - Disclosure - Equity and Share-based Compensation - Share-based Compensation Expense (Details)", "role": "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationExpenseDetails", "shortName": "Equity and Share-based Compensation - Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i0b87906470a6447ea2bd9852abb70f54_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:MembersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436419 - Disclosure - Equity and Share-based Compensation - Fair Value Assumptions for Profit Interest Awards (Details)", "role": "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "shortName": "Equity and Share-based Compensation - Fair Value Assumptions for Profit Interest Awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "iba606b5c3c82483ca001c55ec814463e_I20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MembersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i978aaa2b4b32484d9802f131593c1320_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i978aaa2b4b32484d9802f131593c1320_D20200701-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i4e99cecda7c2411e8922db7719ee0924_D20200701-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437420 - Disclosure - Equity and Share-based Compensation - Fair Value Assumptions for Stock Options (Details)", "role": "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails", "shortName": "Equity and Share-based Compensation - Fair Value Assumptions for Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i4e99cecda7c2411e8922db7719ee0924_D20200701-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i53910a065ebc4cf8a2fc4422bba821a5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438421 - Disclosure - Equity and Share-based Compensation - Unrecognized Compensation Cost (Details)", "role": "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails", "shortName": "Equity and Share-based Compensation - Unrecognized Compensation Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i53910a065ebc4cf8a2fc4422bba821a5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441422 - Disclosure - Commitment and Contingencies - Future Minimum Lease Payments (Details)", "role": "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails", "shortName": "Commitment and Contingencies - Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442423 - Disclosure - Commitment and Contingencies - Narrative (Details)", "role": "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails", "shortName": "Commitment and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "us-gaap:NetIncomeLoss", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i978aaa2b4b32484d9802f131593c1320_D20200701-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445424 - Disclosure - Net Loss Per Common Share/Class\u00a0A Common Unit - Calculation (Details)", "role": "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails", "shortName": "Net Loss Per Common Share/Class\u00a0A Common Unit - Calculation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446425 - Disclosure - Net Loss Per Common Share/Class\u00a0A Common Unit - Antidilutive Securities (Details)", "role": "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails", "shortName": "Net Loss Per Common Share/Class\u00a0A Common Unit - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if0049aa4870a4f92baa1ef21210045b5_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448426 - Disclosure - Related Party Disclosures (Details)", "role": "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails", "shortName": "Related Party Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i8142fc4af1704d7a8417ee60826744bd_D20200601-20200601", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i73efad84697542c18375983e75c375b1_I20181231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members\u2019/Stockholders\u2019 Equity/(Deficit) (Statement)", "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "shortName": "Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members\u2019/Stockholders\u2019 Equity/(Deficit) (Statement)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i86eccb45ffe740df9997eed0d2ce06e1_D20190101-20190930", "decimals": "-3", "lang": "en-US", "name": "zntl:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "i64514b6eae2c4040bd9750809c731adc_I20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1407401 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members\u2019/Stockholders\u2019 Equity/(Deficit) (Parenthetical))", "role": "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitParenthetical", "shortName": "Condensed Consolidated Statements of Changes in Convertible Preferred Units and Members\u2019/Stockholders\u2019 Equity/(Deficit) (Parenthetical))", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Business", "role": "http://www.zentalis.com/role/OrganizationandBusiness", "shortName": "Organization and Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "if6343e0ddb3d41aabc495be876466adb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "ib5b6d97a72744aff9db25bb064656464_I20190930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - zntl-20200930.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - zntl-20200930.htm", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "zntl-20200930.htm", "contextRef": "ib5b6d97a72744aff9db25bb064656464_I20190930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 60, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r428" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r432" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r431" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r427" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.zentalis.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r216", "r319", "r320", "r322", "r424" ], "lang": { "en-US": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r274", "r275", "r283", "r284", "r424" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails", "http://www.zentalis.com/role/BusinessCombinationsRollforwardofNoncontrollingInterestDetails", "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r274", "r275", "r283", "r284" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails", "http://www.zentalis.com/role/BusinessCombinationsRollforwardofNoncontrollingInterestDetails", "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r219", "r222", "r332", "r333", "r334", "r335", "r336", "r337", "r356", "r410", "r411" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r219", "r222", "r332", "r333", "r334", "r335", "r336", "r337", "r356", "r410", "r411" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r208", "r219", "r222", "r332", "r333", "r334", "r335", "r336", "r337", "r356", "r410", "r411" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r208", "r219", "r222", "r332", "r333", "r334", "r335", "r336", "r337", "r356", "r410", "r411" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r190", "r220", "r325" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r379", "r402" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r19", "r143", "r144" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable from government grants, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.zentalis.com/role/AccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/AccruedExpensesDetails", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r28", "r182" ], "calculation": { "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r45", "r46", "r47", "r396", "r416", "r417" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_MembersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r44", "r47", "r48", "r91", "r92", "r93", "r282", "r412", "r413" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r20", "r248" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_MembersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r91", "r92", "r93", "r245", "r246", "r247" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r223", "r225", "r251", "r252" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r225", "r242", "r250" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total share-based compensation expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per unit (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r86", "r135", "r137", "r141", "r162", "r274", "r283", "r301", "r374", "r394" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r6", "r41", "r86", "r162", "r274", "r283", "r301" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r295" ], "calculation": { "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total fair value of assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r150" ], "calculation": { "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r151" ], "calculation": { "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r148", "r169" ], "calculation": { "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r152", "r153", "r390" ], "calculation": { "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "After one but within five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": { "auth_ref": [ "r152", "r154", "r391" ], "calculation": { "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r145", "r149", "r169", "r377" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Marketable securities, available-for-sale", "verboseLabel": "Debt securities, available-for-sale, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails", "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r226", "r244" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationExpenseDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r218", "r221" ], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails", "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r218", "r221", "r262", "r263" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails", "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Ownership percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r264", "r265", "r266" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Cash payments to acquire interest" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalAdditionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contractual obligation to increase property, plant and equipment either through construction or future purchases.", "label": "Capital Addition Purchase Commitments [Member]", "terseLabel": "Capital Addition Purchase Commitments" } } }, "localname": "CapitalAdditionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r26", "r79" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r74", "r79", "r83" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash reported in the Consolidated Statement of Cash Flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r74", "r302" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r85", "r86", "r105", "r106", "r107", "r109", "r111", "r120", "r122", "r123", "r162", "r301" ], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails", "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails", "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails", "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails", "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r36", "r189", "r380", "r401" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r186", "r187", "r188", "r191" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Class\u00a0A Common\u00a0Units" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Class\u00a0B Common\u00a0Units" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r91", "r92" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r198" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_MembersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock, value" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitAuthorized": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum number of common units of ownership permitted to be issued by a limited liability company (LLC).", "label": "Common Unit, Authorized", "terseLabel": "Common units, authorized (in shares)" } } }, "localname": "CommonUnitAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonUnitIssuanceValue": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_MembersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).", "label": "Common Unit, Issuance Value", "periodEndLabel": "Common units, ending balance", "periodStartLabel": "Common units, beginning balance", "terseLabel": "Class A and B common units, issuance value" } } }, "localname": "CommonUnitIssuanceValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssued": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Number of common units issued of limited liability company (LLC).", "label": "Common Unit, Issued", "terseLabel": "Common units, issued (in shares)" } } }, "localname": "CommonUnitIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonUnitOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC).", "label": "Common Unit, Outstanding", "periodEndLabel": "Common units, ending balance (in shares)", "periodStartLabel": "Common units, beginning balance (in shares)", "terseLabel": "Common units, outstanding (in shares)" } } }, "localname": "CommonUnitOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51", "r53", "r54", "r59", "r385", "r407" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to Zentalis" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r51", "r53", "r58", "r271", "r272", "r292", "r384", "r406" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive loss attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r51", "r53", "r57", "r270", "r292", "r383", "r405" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r84", "r276" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r80", "r81", "r82" ], "lang": { "en-US": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued", "terseLabel": "Number of shares converted (in shares)" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Preferred units, as if converted to Class\u00a0A common units", "verboseLabel": "Convertible Preferred\u00a0Units" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r209", "r217", "r418" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails", "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Components of Available-for-sale Marketable Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r159", "r170", "r175" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "terseLabel": "Fair value of available-for-sale securities in unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r160", "r171" ], "lang": { "en-US": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of available-for-sale securities in unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r14", "r373", "r393" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred Costs, Noncurrent", "terseLabel": "Deferred financing costs" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Summary of Prepaid Expenses and Other Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r254", "r255" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r77", "r133" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.zentalis.com/role/PropertyandEquipmentnetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r226", "r244" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Share-based Compensation Expense by Type of Share-based Award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r89", "r320", "r378", "r403" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Due from related parties" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r110" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share outstanding, basic and diluted (USD per share)", "verboseLabel": "Net loss per Class A common unit (USD per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareDilutedLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r112", "r113", "r114", "r116" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Common Share/Class\u00a0A Common Unit" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnit" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-based Compensation", "terseLabel": "Employee benefits and share-based compensation" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.zentalis.com/role/AccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued employee expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Remaining Weighted-Average Recognition Period (years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r243" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized expense, other than options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r243" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized expense, stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationExpenseDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r91", "r92", "r93", "r95", "r101", "r103", "r119", "r163", "r198", "r205", "r245", "r246", "r247", "r257", "r258", "r303", "r304", "r305", "r306", "r307", "r308", "r412", "r413", "r414" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r298", "r300" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r217", "r296", "r329", "r330", "r331" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r209", "r210", "r215", "r217", "r296", "r329" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r209", "r210", "r215", "r217", "r296", "r330" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r217", "r329", "r330", "r331" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r156", "r157", "r164", "r165", "r166", "r167", "r168", "r172", "r173", "r174", "r175", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails", "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r178", "r179", "r372" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r155", "r158", "r388", "r389" ], "calculation": { "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due within one year" } } }, "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementContractualMaturitiesofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r55", "r135", "r136", "r139", "r140", "r142", "r370", "r381", "r386", "r408" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r87", "r102", "r103", "r134", "r256", "r259", "r260", "r409" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r76" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r76" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r76" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r180" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "In-process\u00a0research and development" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable, Current", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeAmortizationOfPremium": { "auth_ref": [ "r64" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization of purchase premium on nonoperating securities.", "label": "Investment Income, Amortization of Premium", "terseLabel": "Amortization of premiums on marketable securities, net" } } }, "localname": "InvestmentIncomeAmortizationOfPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r63", "r132" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Investment and other income, net" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Contractual Maturities of Available-for-sale Debt Securities" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Operating leases not yet commenced, term (in years)" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Operating Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r315" ], "calculation": { "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments:" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r315" ], "calculation": { "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r315" ], "calculation": { "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r315" ], "calculation": { "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r315" ], "calculation": { "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r315" ], "calculation": { "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r32", "r86", "r138", "r162", "r275", "r283", "r284", "r301" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r86", "r162", "r301", "r376", "r399" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, convertible preferred units and equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, CONVERTIBLE\u00a0PREFERRED\u00a0UNITS\u00a0AND\u00a0EQUITY/(DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r34", "r86", "r162", "r275", "r283", "r284", "r301" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LimitedLiabilityCompanyLLCMembersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "EQUITY (DEFICIT)" } } }, "localname": "LimitedLiabilityCompanyLLCMembersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r119", "r205" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of ownership interest in a limited liability company (LLC), including portions attributable to both the parent and noncontrolling interests.", "label": "Limited Liability Company (LLC) Members' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total equity (deficit)" } } }, "localname": "LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Equipment purchase and sale agreement" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MembersEquity": { "auth_ref": [ "r120", "r121", "r122", "r123", "r205" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity.", "label": "Members' Equity", "terseLabel": "Members\u2019 equity value (in thousands)", "totalLabel": "Total stockholders\u2019 equity/members\u2019 (deficit)" } } }, "localname": "MembersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MembersEquityAttributableToNoncontrollingInterest": { "auth_ref": [ "r205" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LimitedLiabilityCompanyLlcMembersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of ownership interest in limited liability company (LLC) directly or indirectly attributable to noncontrolling interests.", "label": "Members' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MembersEquityAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r39", "r86", "r162", "r301", "r375", "r398" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "periodEndLabel": "Noncontrolling interest at end of period", "periodStartLabel": "Noncontrolling interest at beginning of period", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "http://www.zentalis.com/role/BusinessCombinationsRollforwardofNoncontrollingInterestDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInMinorityInterestRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]" } } }, "localname": "MovementInMinorityInterestRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsRollforwardofNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r74", "r75", "r78" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r49", "r52", "r56", "r78", "r86", "r94", "r97", "r98", "r99", "r100", "r102", "r103", "r108", "r135", "r136", "r139", "r140", "r142", "r162", "r301", "r382", "r404" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss attributable to Zentalis", "totalLabel": "Net loss attributable to Zentalis" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r49", "r52", "r102", "r103", "r278", "r291" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net loss attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsRollforwardofNoncontrollingInterestDetails", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Adoption and Pending Adoption of Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of\u00a0non-cash\u00a0investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r206", "r273", "r280" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Contributions from noncontrolling interest owners" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r91", "r92", "r93", "r205", "r268" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Operating Expenses" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r135", "r136", "r139", "r140", "r142" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r310" ], "calculation": { "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r310" ], "calculation": { "http://www.zentalis.com/role/AccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r309" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease\u00a0right-of-use\u00a0assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r314", "r316" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating lease, weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r90", "r104", "r131", "r293" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Organization and Business" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r10", "r33" ], "calculation": { "http://www.zentalis.com/role/AccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Other Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Assets" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PrepaidExpensesandOtherAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r42", "r43", "r45" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrealized gain on marketable securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r50", "r53", "r270", "r271", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Underwriters" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance fees and expenses", "verboseLabel": "Issuance costs of financing" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r65", "r67", "r147" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesAndInterestInAffiliates": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a controlling interest in another entity or an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Payments to Acquire Businesses and Interest in Affiliates", "terseLabel": "Cash payments to acquire interest" } } }, "localname": "PaymentsToAcquireBusinessesAndInterestInAffiliates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r69" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r226", "r244" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)", "verboseLabel": "Number of shares acquired (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_MembersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredUnitsAuthorized": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "The number of preferred units authorized to be issued.", "label": "Preferred Units, Authorized", "terseLabel": "Preferred units authorized (in shares)" } } }, "localname": "PreferredUnitsAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r24", "r25" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "verboseLabel": "Total prepaid expenses and other assets, current" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": { "auth_ref": [ "r14", "r373", "r393" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails_1": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Noncurrent", "terseLabel": "Prepaid expenses and other assets", "verboseLabel": "Less long-term portion" } } }, "localname": "PrepaidExpenseAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r3", "r5", "r176", "r177" ], "calculation": { "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r70" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from issuance of common stock in initial public offering, net" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r70" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "auth_ref": [ "r70" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock", "terseLabel": "Proceeds from the issuance of Series C convertible preferred units, net", "verboseLabel": "Net proceeds from issuance of convertible preferred units" } } }, "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r65", "r66", "r147" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturities of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r71" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Proceeds from Noncontrolling Interests", "terseLabel": "Contributions from noncontrolling interest owners, net" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r49", "r52", "r73", "r86", "r94", "r102", "r103", "r135", "r136", "r139", "r140", "r142", "r162", "r270", "r277", "r279", "r291", "r292", "r301", "r386" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Consolidated net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r28", "r183" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r185", "r421", "r422", "r423" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r27", "r181" ], "calculation": { "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Subtotal" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r183", "r400" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r183" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r181" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": { "auth_ref": [ "r195", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.", "label": "Reclassifications of Temporary to Permanent Equity", "terseLabel": "Conversion of convertible preferred units to common stock" } } }, "localname": "ReclassificationsOfTemporaryToPermanentEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r216", "r319", "r320" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r216", "r319", "r320", "r322" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r319" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Expenses from transactions with related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r216", "r319", "r322", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r317", "r318", "r320", "r323", "r324" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Disclosures" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosures" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r253", "r425" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r83", "r371", "r395" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r7", "r14", "r83", "r420" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash,\u00a0non-current" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "RSAs" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r205", "r248", "r397", "r415", "r417" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_MembersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r91", "r92", "r93", "r95", "r101", "r103", "r163", "r245", "r246", "r247", "r257", "r258", "r412", "r414" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r61", "r419" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r313", "r316" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued and sold (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Share price (in dollars per sharee)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Unit" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Basic and Diluted Net Loss Per Unit" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "auth_ref": [ "r105", "r106", "r109", "r111", "r115" ], "lang": { "en-US": { "role": { "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r225", "r241", "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r295", "r296" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r96", "r99", "r117", "r118" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "terseLabel": "Recently Issued Accounting Standards Adopted and Not Yet Adopted" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r28", "r183" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r88", "r321", "r322" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r226", "r244" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationExpenseDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r37", "r85", "r120", "r122", "r193", "r196", "r197", "r199", "r200", "r201", "r202", "r203", "r204", "r205" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails", "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r274", "r275", "r283", "r284", "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails", "http://www.zentalis.com/role/BusinessCombinationsRollforwardofNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "auth_ref": [ "r285", "r286", "r287", "r288", "r289" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities of VIE" } } }, "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Units" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails", "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Units" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails", "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Units" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails", "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r76" ], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Restricted stock vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Awards granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date fair value (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free rate (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationExpenseDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r230", "r232" ], "lang": { "en-US": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "terseLabel": "Non-Option equity Instruments, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized to be issued under plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value of options (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r231", "r244" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Options number outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r224", "r229" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationExpenseDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationUnrecognizedCompensationCostDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r236", "r249" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Average expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Stock issued (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, in shares", "periodStartLabel": "Beginning balance, in shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Interim Unaudited Financial Statements" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/InterimUnauditedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r16", "r17", "r18", "r85", "r86", "r105", "r106", "r107", "r109", "r111", "r120", "r122", "r123", "r162", "r198", "r301" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails", "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails", "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r38", "r91", "r92", "r93", "r95", "r101", "r103", "r119", "r163", "r198", "r205", "r245", "r246", "r247", "r257", "r258", "r303", "r304", "r305", "r306", "r307", "r308", "r412", "r413", "r414" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r91", "r92", "r93", "r119", "r357" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitParenthetical", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r17", "r18", "r198", "r199", "r205" ], "lang": { "en-US": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "negatedLabel": "Conversion of common and incentive units to common stock (in shares)", "terseLabel": "Stock issued upon conversion of units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r198", "r205" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Stock issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r17", "r18", "r198", "r205" ], "lang": { "en-US": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedTerseLabel": "Cancellation of restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r198", "r205" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Shares issued upon vesting of certain RSAs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r38", "r198", "r205" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Value, Conversion of Units", "negatedTerseLabel": "Conversion of common and incentive units to common and restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r17", "r18", "r198", "r205" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Stock issued, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r86", "r91", "r92", "r93", "r95", "r101", "r162", "r163", "r205", "r245", "r246", "r247", "r257", "r258", "r268", "r269", "r290", "r301", "r303", "r304", "r308", "r413", "r414" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity.", "label": "Temporary Equity, Aggregate Amount of Redemption Requirement", "terseLabel": "Convertible preferred units, redemption value" } } }, "localname": "TemporaryEquityAggregateAmountOfRedemptionRequirement", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Temporary equity, ending balance", "periodStartLabel": "Temporary equity, beginning balance", "terseLabel": "Carrying Value", "verboseLabel": "Convertible preferred units; Redemption value of $146,944,000 at December\u00a031, 2019" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference", "terseLabel": "Liquidation Value" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLiquidationPreferencePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference Per Share", "terseLabel": "Liquidation preference (in dollars per share)" } } }, "localname": "TemporaryEquityLiquidationPreferencePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r11", "r194" ], "lang": { "en-US": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Par value per share (in dollars per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitParenthetical", "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r11", "r194" ], "lang": { "en-US": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Conversion price (in dollars per share)" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Units authorized (in shares)" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Shares issued (in shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails", "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Temporary equity ending balance (in shares)", "periodStartLabel": "Temporary equity beginning balance (in shares)", "terseLabel": "Shares outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/ConvertiblePreferredUnitsScheduleofUnitsAuthorizedIssuedandOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r11", "r194" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "terseLabel": "Schedule of Temporary Equity" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradingSecuritiesDebt": { "auth_ref": [ "r145", "r146" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Trading", "terseLabel": "Debt securities fair market value" } } }, "localname": "TradingSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r156", "r157", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails", "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r209", "r387" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "US government agencies" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails", "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r209", "r217", "r387" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "US Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/FairValueMeasurementComponentsofAvailableforsaleMarketableSecuritiesDetails", "http://www.zentalis.com/role/FairValueMeasurementFairValueofAssetsMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r129", "r130" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/InterimUnauditedFinancialStatementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails", "http://www.zentalis.com/role/BusinessCombinationsRollforwardofNoncontrollingInterestDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r274", "r275", "r283", "r284", "r285" ], "lang": { "en-US": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "VIE, Primary Beneficiary" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsAssetsandLiabilitiesDetails", "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails", "http://www.zentalis.com/role/BusinessCombinationsRollforwardofNoncontrollingInterestDetails", "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Units used in computing net loss per Class A common unit, basic and diluted (in shares)", "verboseLabel": "Weighted average number of Class A common units outstanding, basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails" ], "xbrltype": "sharesItemType" }, "zntl_A2017ProfitInterestPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2017 Profit Interest Plan", "label": "2017 Profit Interest Plan [Member]", "terseLabel": "The Plan" } } }, "localname": "A2017ProfitInterestPlanMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "zntl_A2020IncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2020 Incentive Award Plan", "label": "2020 Incentive Award Plan [Member]", "terseLabel": "The 2020 Plan" } } }, "localname": "A2020IncentiveAwardPlanMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "zntl_AccruedGeneralAndAdministrativeCostsCurrent": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/AccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued General And Administrative Costs, Current", "label": "Accrued General And Administrative Costs, Current", "terseLabel": "Accrued general and administrative expenses" } } }, "localname": "AccruedGeneralAndAdministrativeCostsCurrent", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "zntl_AccruedResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/AccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Research And Development Costs, Current", "label": "Accrued Research And Development Costs, Current", "terseLabel": "Accrued research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentCostsCurrent", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "zntl_ClassBCommonIncentiveUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class B Common Incentive Units", "label": "Class B Common Incentive Units [Member]", "terseLabel": "Incentive units\u2014Class\u00a0B common units" } } }, "localname": "ClassBCommonIncentiveUnitsMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "zntl_CommonStockConversionRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Conversion Ratio", "label": "Common Stock, Conversion Ratio", "terseLabel": "Exchange ratio" } } }, "localname": "CommonStockConversionRatio", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "pureItemType" }, "zntl_CommonStockSharesSubjectToFutureVestingProvisions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Shares, Subject to Future Vesting Provisions", "label": "Common Stock, Shares, Subject to Future Vesting Provisions", "terseLabel": "Common stock subject to future vesting provisions (in shares)" } } }, "localname": "CommonStockSharesSubjectToFutureVestingProvisions", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "zntl_CommonUnitOutstandingSubjectToFutureVestingConditions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Unit, Outstanding, Subject to Future Vesting Conditions", "label": "Common Unit, Outstanding, Subject to Future Vesting Conditions", "terseLabel": "Common units subject to future vesting conditions (in shares)" } } }, "localname": "CommonUnitOutstandingSubjectToFutureVestingConditions", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "zntl_CommonUnitOutstandingUnvested": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Unit, Outstanding, Unvested", "label": "Common Unit, Outstanding, Unvested", "terseLabel": "Unvested common units outstanding (in shares)" } } }, "localname": "CommonUnitOutstandingUnvested", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "zntl_ComputerAndOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Computer And Office Equipment", "label": "Computer And Office Equipment [Member]", "terseLabel": "Computer and office equipment" } } }, "localname": "ComputerAndOfficeEquipmentMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "domainItemType" }, "zntl_ConvertiblePreferredStockDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Preferred Stock, Dividends Per Share, Declared", "label": "Convertible Preferred Stock, Dividends Per Share, Declared", "terseLabel": "Dividends declared" } } }, "localname": "ConvertiblePreferredStockDividendsPerShareDeclared", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "zntl_CorporateConversionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporate Conversion", "label": "Corporate Conversion [Member]", "terseLabel": "Corporate Conversion" } } }, "localname": "CorporateConversionMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "zntl_EarningsPerShareDenominatorAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings Per Share, Denominator", "label": "Earnings Per Share, Denominator [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "EarningsPerShareDenominatorAbstract", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails" ], "xbrltype": "stringItemType" }, "zntl_EarningsPerShareNumeratorAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings Per Share, Numerator", "label": "Earnings Per Share, Numerator [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "EarningsPerShareNumeratorAbstract", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/NetLossPerCommonShareClassACommonUnitCalculationDetails" ], "xbrltype": "stringItemType" }, "zntl_ExpensesAndFeesFromTheIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Expenses and Fees from the Issuance of Common Stock", "label": "Expenses and Fees from the Issuance of Common Stock", "terseLabel": "Expenses and Fees from the Issuance of Common Stock" } } }, "localname": "ExpensesAndFeesFromTheIssuanceOfCommonStock", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "monetaryItemType" }, "zntl_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Follow-On Offering", "label": "Follow-On Offering [Member]", "terseLabel": "Follow-On Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "zntl_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net", "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets And Liabilities, Net", "terseLabel": "Operating lease right-of-use assets and liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "zntl_IntercompanyServicesAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intercompany Services Agreement", "label": "Intercompany Services Agreement [Member]", "terseLabel": "Intercompany Services Agreement" } } }, "localname": "IntercompanyServicesAgreementMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "zntl_KalyraPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Kalyra Pharmaceuticals, Inc.", "label": "Kalyra Pharmaceuticals, Inc. [Member]", "terseLabel": "Kalyra Pharmaceuticals, Inc." } } }, "localname": "KalyraPharmaceuticalsIncMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsNarrativeDetails", "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "zntl_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Laboratory Equipment", "label": "Laboratory Equipment [Member]", "terseLabel": "Lab equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/PropertyandEquipmentnetSummaryDetails" ], "xbrltype": "domainItemType" }, "zntl_LesseeOperatingLeaseLeaseNotYetCommencedLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Liability", "terseLabel": "Total minimum lease payments on leases not yet commenced" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedLiability", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "zntl_LesseeOperatingLeasePrepaidLeasePayment": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Prepaid Lease Payment", "label": "Lessee, Operating Lease, Prepaid Lease Payment", "terseLabel": "Upfront lease payment" } } }, "localname": "LesseeOperatingLeasePrepaidLeasePayment", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "zntl_MasterServicesAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Master Services Agreement", "label": "Master Services Agreement [Member]", "terseLabel": "Master Services Agreement" } } }, "localname": "MasterServicesAgreementMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "domainItemType" }, "zntl_OtherPrepaidExpense": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other Prepaid Expense", "label": "Other Prepaid Expense", "terseLabel": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpense", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "zntl_PrepaidResearchAndDevelopmentCosts": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid Research And Development Costs", "label": "Prepaid Research And Development Costs", "terseLabel": "Prepaid research and development expenses" } } }, "localname": "PrepaidResearchAndDevelopmentCosts", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "zntl_PrepaidSoftwareLicenseAndMaintenance": { "auth_ref": [], "calculation": { "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid Software License And Maintenance", "label": "Prepaid Software License And Maintenance", "terseLabel": "Prepaid software licenses and maintenance" } } }, "localname": "PrepaidSoftwareLicenseAndMaintenance", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/PrepaidExpensesandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "zntl_ProceedsFromIssuanceOfCommonStockGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Issuance Of Common Stock, Gross", "label": "Proceeds From Issuance Of Common Stock, Gross", "terseLabel": "Gross proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStockGross", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "monetaryItemType" }, "zntl_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Issuance Of Redeemable Convertible Preferred Stock, Gross", "label": "Proceeds From Issuance Of Redeemable Convertible Preferred Stock, Gross", "verboseLabel": "Gross proceeds from issuance of convertible preferred units" } } }, "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockGross", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "zntl_ProfitInterestAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Profit Interest Awards", "label": "Profit Interest Awards [Member]", "terseLabel": "Profit Interest Awards", "verboseLabel": "Profit interest award units" } } }, "localname": "ProfitInterestAwardsMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails", "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "zntl_RealEstate107YearLeaseTermMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate, 10.7 Year Lease Term", "label": "Real Estate, 10.7 Year Lease Term [Member]", "terseLabel": "Real Estate, 10.7 Year Lease Term" } } }, "localname": "RealEstate107YearLeaseTermMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "zntl_RealEstate12YearLeaseTermMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real Estate, 1.2 Year Lease Term", "label": "Real Estate, 1.2 Year Lease Term [Member]", "terseLabel": "Real Estate, 1.2 Year Lease Term" } } }, "localname": "RealEstate12YearLeaseTermMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CommitmentandContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "zntl_ReclassificationOfStockToTemporaryEquityShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reclassification of Stock to Temporary Equity, Shares", "label": "Reclassification of Stock to Temporary Equity, Shares", "negatedTerseLabel": "Reclassification of Stock to Temporary Equity, Shares" } } }, "localname": "ReclassificationOfStockToTemporaryEquityShares", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "sharesItemType" }, "zntl_ReclassificationsOfStockToTemporaryEquityValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reclassifications of Stock to Temporary Equity, Value", "label": "Reclassifications of Stock to Temporary Equity, Value", "negatedTerseLabel": "Reclassification of convertible preferred units for contingent liquidation features not within the Company's control" } } }, "localname": "ReclassificationsOfStockToTemporaryEquityValue", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "zntl_ReconciliationOfNoncontrollingInterestTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation Of Noncontrolling Interest", "label": "Reconciliation Of Noncontrolling Interest [Table Text Block]", "terseLabel": "Reconciliation Of Equity Attributable to Noncontrolling Interest" } } }, "localname": "ReconciliationOfNoncontrollingInterestTableTextBlock", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "zntl_RelatedPartyAgreementTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Related Party Agreement, Term", "label": "Related Party Agreement, Term", "terseLabel": "Agreement term (in years)" } } }, "localname": "RelatedPartyAgreementTerm", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/RelatedPartyDisclosuresDetails" ], "xbrltype": "durationItemType" }, "zntl_RestrictedStockAwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Stock Award", "label": "Restricted Stock Award [Member]", "terseLabel": "Restricted Stock Award" } } }, "localname": "RestrictedStockAwardMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "zntl_RestrictedStockAwardsAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Stock Awards And Restricted Stock Units", "label": "Restricted Stock Awards And Restricted Stock Units [Member]", "terseLabel": "RSAs and RSUs" } } }, "localname": "RestrictedStockAwardsAndRestrictedStockUnitsMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Generally Expected Term", "terseLabel": "Generally expected vesting term of the option contract (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsGenerallyExpectedTerm", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Lack of Marketability Discount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Lack of Marketability Discount", "terseLabel": "Lack of marketability discount (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails" ], "xbrltype": "percentItemType" }, "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsThresholdAmounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Threshold Amounts", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Threshold Amounts", "terseLabel": "Threshold amounts (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsThresholdAmounts", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails" ], "xbrltype": "monetaryItemType" }, "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsTimeToLiquidity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Time to Liquidity", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Time to Liquidity", "terseLabel": "Time to liquidity (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsTimeToLiquidity", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationFairValueAssumptionsforProfitInterestAwardsDetails" ], "xbrltype": "durationItemType" }, "zntl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized, Percent Threshold Used To Calculate Increase", "terseLabel": "Percent of common stock outstanding used as threshold to calculate shares available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPercentThresholdUsedToCalculateIncrease", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "zntl_ShareBasedPaymentArrangementNumberOfExecutivesEnteringRestrictedStockAgreement": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Payment Arrangement, Number of Executives Entering Restricted Stock Agreement", "label": "Share-based Payment Arrangement, Number of Executives Entering Restricted Stock Agreement", "terseLabel": "Number of executives entering restricted stock agreement" } } }, "localname": "ShareBasedPaymentArrangementNumberOfExecutivesEnteringRestrictedStockAgreement", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "integerItemType" }, "zntl_ShareholdersEquityShareBasedPaymentsAndMembersEquityTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shareholders' Equity, Share-Based Payments, And Members' Equity", "label": "Shareholders' Equity, Share-Based Payments, And Members' Equity [Text Block]", "terseLabel": "Equity and Share-based Compensation" } } }, "localname": "ShareholdersEquityShareBasedPaymentsAndMembersEquityTextBlock", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensation" ], "xbrltype": "textBlockItemType" }, "zntl_StockCancelledDuringPeriodShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Cancelled During Period, Shares", "label": "Stock Cancelled During Period, Shares", "negatedTerseLabel": "Stock Cancelled During Period, Shares" } } }, "localname": "StockCancelledDuringPeriodShares", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "sharesItemType" }, "zntl_StockIssuanceCostsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock Issuance Costs Incurred But Not Yet Paid", "label": "Stock Issuance Costs Incurred But Not Yet Paid", "terseLabel": "Costs incurred in connection with equity offering included in accounts payable and accrued liabilities" } } }, "localname": "StockIssuanceCostsIncurredButNotYetPaid", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "zntl_TemporaryEquityAutomaticConversionFeatureGrossCashProceedsMinimumAmountReceivedInAPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Automatic Conversion Feature, Gross Cash Proceeds Minimum Amount Received In A Public Offering", "label": "Temporary Equity, Automatic Conversion Feature, Gross Cash Proceeds Minimum Amount Received In A Public Offering", "terseLabel": "Automatic conversion feature, minimum gross cash proceeds received in a public offering" } } }, "localname": "TemporaryEquityAutomaticConversionFeatureGrossCashProceedsMinimumAmountReceivedInAPublicOffering", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "zntl_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Stock Issued During Period, Shares, Conversion Of Units", "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion Of Units", "negatedTerseLabel": "Conversion of convertible preferred units to common stock (in shares)", "terseLabel": "Conversion of convertible preferred units to common stock (in shares)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "sharesItemType" }, "zntl_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues", "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Series C convertible preferred units at $17.50 per unit net of issuance costs, in shares", "verboseLabel": "Convertible preferred units issued (in shares)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement", "http://www.zentalis.com/role/ConvertiblePreferredUnitsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "zntl_TemporaryEquityStockIssuedDuringPeriodSharesReclassificationOfStock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Stock Issued During Period, Shares, Reclassification of Stock", "label": "Temporary Equity, Stock Issued During Period, Shares, Reclassification of Stock", "terseLabel": "Reclassification of convertible preferred units for contingent liquidation features not within the Company's control (in shares)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesReclassificationOfStock", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "sharesItemType" }, "zntl_TemporaryEquityStockIssuedDuringPeriodValueReclassificationOfStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Stock Issued During Period, Value, Reclassification of Stock", "label": "Temporary Equity, Stock Issued During Period, Value, Reclassification of Stock", "terseLabel": "Reclassification of convertible preferred units for contingent liquidation features not within the Company's control" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueReclassificationOfStock", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredUnitsandMembersStockholdersEquityDeficitStatement" ], "xbrltype": "monetaryItemType" }, "zntl_TemporaryEquityTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Temporary Equity", "label": "Temporary Equity [Text Block]", "terseLabel": "Convertible Preferred Units" } } }, "localname": "TemporaryEquityTextBlock", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/ConvertiblePreferredUnits" ], "xbrltype": "textBlockItemType" }, "zntl_ZenteraStockPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zentera Stock Plan", "label": "Zentera Stock Plan [Member]", "terseLabel": "Zentera Stock Plan" } } }, "localname": "ZenteraStockPlanMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/EquityandSharebasedCompensationNarrativeDetails", "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" }, "zntl_ZenteraTherapeuticsLtdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zentera Therapeutics Ltd.", "label": "Zentera Therapeutics Ltd. [Member]", "terseLabel": "Zentera Sublicenses" } } }, "localname": "ZenteraTherapeuticsLtdMember", "nsuri": "http://www.zentalis.com/20200930", "presentation": [ "http://www.zentalis.com/role/OrganizationandBusinessDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70258-108054" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269825-111563" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90193-114008" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r426": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r427": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r428": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r429": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r430": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r431": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r432": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" } }, "version": "2.1" } ZIP 77 0001725160-20-000034-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001725160-20-000034-xbrl.zip M4$L#!!0 ( . X:5$(W:-%,U< $IN @ : 96UP;&]Y;65N=&%G_9+T3(-."1[CX=@0&[.=<&!]#; MI\^7'2HIB\JV2JK6 .;\^KNF'*12#>"A5'3MV.&VH2J5RERY<@W/>M8O_^?X M_.CJCP\GP:@:I\&'WU^_.ST*?GCRXX\?GQ[]^./QU7'PV]7[=\&SG=V]X*J( MLE)7.L^B],7?R(0SW[,/)$ M/G643^X*?3VJ@OW=_=W@8UY\TC<1_[[25:I^->/\\B/_^Y[^Q\_T.=^_668PRO(I^,\ MS8N?_K%+__L9?_-D&(UU>O?3_[W28U4&9^HVN,C'4?9_PQ(6\DFI"CWD#Y;Z M?]5/>T_A&?3/6W[H,Q@GU9DRDSC8AP?_\Q][+W9_7O[/7W[$(OK"^PEM!/^H4I^K)U&JK[.?8EA\5?SPM9=B MO[44+UM+P9MP\O[#N_,_WI^<706';R].3O!OS?==XDWYO9Z\W-EOOMF?=5GI MX1W_2&<)O"B]_3=_U_:V\[M>_79Z&72]<+!5C709_/,?K_;WW79_HRG2B#_I M"I8H7F*##J\+I?A\?M-IS5TY6IF]G[<#6"625E W.JOR8' 71%D2#%1UJU06 M_(_*\N!]E$77-.4P.,WBG3"(@F.51K=1H8(X+R9Y$:$&Q%57_5STHWP\B;*[ M7BPYKF\4W([R-+T+\ML,EKZL!Z5.=%3 #X:XZ/A>9?!A%!7C*%9UI>,H+7GU M>[S*'T @^B'7(:WR430.WD9I&EV/5!%L]7+-3CZK&/;W1O5GV&)G?@RF5!^6=N>Q7L(??SNY.#F\# ,4 M!M&S)$96L@.\)R9146EX*MPQU2@"(U<55:2SX!#NE014('[C0I456;Y'>5;6 M:87FK[TNIZ3QC1H4-:K,_>>]E\9:0;U@& MI:J"85[ 5S1^"BYW*PR/5C.+BL%7\6-81*> >- HEPW5 %#,& RF]+D.-7/S_6)=S;69VJ M:/J]^R_-0B4J%H/_IQH6J,#O_?#KL1KJC(5]E=IM)P@.RZ NR9]I'326(Q8; MO%KXH+*U,XK@Q#=_/591!O]=(& M@3KH%">1GE]_&12_?I61ON.R[N\^(,*R M%6W/_D"_[F=ZO]=Y5"0KDMM][U8FH2M)$&E*J"*/X18"P[LHC;Z4"V?VO;&1 MR4Z9'*R73!Y%H,;Z(Y-H/8D 6AWY17?OP<[3YXLOW[W=5ZNX?6D!MO1V,$MD MK)V(J[3W\F>X=+*HKD9Y 0_ V+T*P.)/=!FG>5F# P1K!Q;-4.-;:3!W= ;V MX%@,H2*HBBA18";&A:K:)QU_K^>7"H4PT>4HD_P5_ ]^'58+1!H:)XA-^+ M@MM"5Y7*V%(B6]6$\SR7#,S3UA/(;S-/0&LM3FO<+[)T\[H*4CT&X:4)1YU/ MA@&<@1PV7E=78"!G>?8$3.F)PO'Q'V4.1T%7^/02!D^CPDV:_9/'+%SWDBYT M0719LMF,NY/HN*+-!3$B 8+=A']R"#$*)JF*\&_7M4XKVM]5:;?NU\_@R63B MH_M?K%3/8=#;G8PJQ_CV4*4YB#,9N+2T:71KC^7O8.C"&;^L_*-(H0O\=:'@ M8_+#N(")PF;=Y.D-'B70!Z,\4R7OR!CLZ#2HZF*BJQI._Y892LZ"^3;]\,^Z MT"5N.HE 7:$?-3V;[2\[-DOY0RL^-?!L,BJL&C5^.!^M__3<4OLY<);$DTF13Y M!/YE;D;OS) 2K' ?&D?D\//L(KY6;VT9 M*,,@EWN$-!=I M+=R$LKFDMR,=-\);(.Y1F6?1(,4@&KK.\'@*C@V4W3_^'6HMSYD7CZ)J< M[9Q&@X-4LPT!$YE(( @F!7M>3L#-H4D-$/F@X-P6*N4/+#2(:'>_^LZN9!_G M15E@F6Y [Z_450V_M27QP+49Y;?J1A6K71K*;4PHVB\2;PX+ZS/ZO;B;Y. 9 M)XLMC3C%GY4!>!YA0'<=_@>.-8R'IYN.@2Z#2\5VP!XXM<$(\R%Q7!>%B96: M8\*QK:W#[4 $!R?E#CE8%N@KP$F@X*P]X31IN.A".;+XXY+LS!DO5-:@++K> M2GW6)>J%CSHI$6\I^83R9Y4=5@R]SA) M02LD=6T,X.'L9,-"1>Q?? MFVE_'Y323&W@XYZFO[*O,C* M5Q;,5XOD\KF$2O:?_?S[Y9/C\Z/+?_[C8/_GO;V7SY_O@IVS\Y1_R7]V(:/X MSU'A8D+7Z@GNQZOA3.6VJPT3U\E'H>+ 2P8,Z\T2BX[]UO U7 M]B<5<$;,/&J)DXQJXCK/R0ZN1@_.7"UG2J'@K&ACKBC*5:CKG+PVF]L0C9KE ME7'+0/1A Q7&2L0K*,$ BMD89:#FM.TB:BT&&X>==VO(6 <2-AZ#1R-82!-) M0KO-4WI#&2C'KY!MAY^SUET(9I3LYXQ/>"\S0+6.*C>D82?@DN9X#YG[QL^A MD-L.NU6!ZD/_"H1.+@?O6L!_D_P\7$;Z*B"DP[;BM0DF,P!N%&77=.,?P6>+ M/.T!!*&=>I.$&_C-<:$'X.219XUN" @6I_/4(G I1 0>D]1:PM7O 7X*ID-5X*":4&]@Y>O0@1 MU1 )'FI8Y..@PO@?F@#PW]#&[*_0;*Z+.QCDNC8.,OZ2];S&9\"51 ?@NM9) MA'$OT/FU2OAZ(3/A&U_>*P1-S!1?M3;B2^_Q%@VM"W*1^J"MG12+LTGAU&%G M8C! \69SPP-!F4121ZA54E9H67#NYQZ0B_O*XU=0V(VA#U[LO#A899(R"F)[ MO4^OK?%7Q3J=( 1K -8FPS'1Z"\4J(N2-BSR8]GP"XR.XW=A9+0#YXX5D7O M,,U C\&:1(L6 ^+LX*#JJ7*.PZ*T<'R-J%(O\*@S I>5 ME07GD>TP;\8V),SQS7%^@T'+H6]CHQ:&#YBP/T4FHLD$W(**1U0IOJV?/C(' MHO%XL$_4YUA-*D'!91+ L2A"WWCVIV"W$<3C1H/'X$QKOB_PK>J4O SW)W5 M]8R!BO&H=24?G ./HTE!SY.N@IXHXV.&3@F<1O=$4A'3#V6_*$KS3/F^=OMP M+KS""+A)":D.YWJIRU!,08E]WBO9V4R7KVQ#A<9?8UFS#4@S*;P4BHHHD37I;E881+9$[9[*_/5X;R" !?7M5D, MT$%Y+-E/,0>&9$78U"J_'CIJ172C4E-3($/:US(94F/!+&O-/EKIF8\]:(/5 MP 2:!W[#C44-GP]@C<2_;EBH'&>G[TPFX,Q1!LL3!0S &W/MGB@\DA,[DT=; M&[(0P1.,8<(VU6?\0[A(85%-KL0NVW"16VHB^5_FEM(G0=&7^C,JBA>[VT$2 MW97=SZ>-I.?M!,'5TO%_+R8:(9)(YXE$X0M\YE/S3 S#HT?B'M-XJX!2);I82N9UN?947B]<37F_5N>&O=MQ>+#IM3Y_. M.6TKN7"4/V).6,= MQ@,OI.FON:QZVPILAL(DQ(; *_TUG^]?D0L!V,&(@20PFL LWZC/X(W01CT &Y5<#)DAS$=E252(=\%? MQ&#@",:AX, M3!2^"%[T=NO3 DOR/TU+AI]^Y7WZ"1K%UAZ^(FN:DB?L&]SK MS \<*)2A^0VURA&,*+D1MR.21=>@&^)1#HY5^RMMMQB34\6-*CU,E=EBMZWJ MA9*EY.5KBF/_QZ#S^JOV(Y4Q7/)I+IIX09':'A#9U&A! MN%\8JIDVTTP 3CR3<'%I<^3G.-C-":?&9^@%^$0X)OE'+7K)LA[\*181U971 M!PW! 3U^I)7ON9T/AW#XVK/K,>W?TC M"G?+G!;' M4XO&B*#.Y,2I)N(GN2L0Y2S@AL^3__\>SESQ2[Z#S583HV("*IEA3C?6H N3T@%==7&N[HWT=#PS M8L+&WKE(]X0(@.2^G!1YK)(:S?%KE:F"M\ !+$C2,\34*/.@*6( >36XGPE6 M/$+BQU#)+(6*B;ZI1E7@/E2&@: "87DW866:)N0%\*"@X&1Q\:T7#_L6TF! >4X(X( MR:? Q_Z9,_0.1OBC*$IUZU&CXC-,,[UC23(X. MNE!#1<%]&$V[.-=SD.*03[)+2-D"W1:R'Q.+%%++K@/"<-*NP(H3&UL8Q!JD MBJX*#.N#V8=J:)!3D((O/**C,94$E"@<8[<$'!"6 C5H&@8L;HT2+5!=Q-[E MONE-A6+X%#$OZCJ_P6(T MW"KL#6,IW+S1^WGN5PS_9^/4E"2X,"7)Y9H!V0;Q5.U+LG7UAAS M:F3 M1G6];W&(O236X-_N8II=;-U/ 64CMP[H!R6U >$+LM5>@Q,ZU-6JG0H?.\XZ?!)1 MO$7,H%!"=6 GEDK,_K!I[M-OVZ_'QN! 7I)^1#+5U:S"6-=/OZU3O$I"EVB[ M-X*ZO[- 5%_C3E]2X*V7PMD0OLBO?T,+X_]]^FPWA)FAAQ39 BB^20@I 91541W3F& M%QNE=]N=>$I_KEU1K$+=:%@]KNR#$:5AG@3UP)Y1A )#^@U7EF"#GGC0$@* MJF]-L!2OG6/V MGJJMM&O+! N\>!V,/(V41J:&M!IW?2JAN\>[T0W#,)P37M=&\^,VE-0D8+[YC M@G.8MNK>42]MUR6;';S']!NX?[!7UEA2D4@BF<6:*9C9SO-/0%QHJH<-L-_> M(-7EJ",_U] B,^[ESE9G)NSK))N6C*J=D:G6HJ=-&*^K4U.K#G1^2I!"WU*W M"T:!685I:==( T/G/F_K**J4O%'37^I*OD;QIRR_355R+:DK2A1*X!W)'E![ MV?YE7D.SH2K:J7W[(SQ]VPE,2X:'G$[4E*LXE6;(_J[08G;&,A@ MJJ-Q7O/R=&NB#JEM+3A,B>@OFJ;.8GX]NI!?]AHTO=^ '3RTF+X'=MB^<%2N MD*+FOB[-:IWM_1DFV$!Q/B3E1%/+(K/.\QQK@C\B&%32%46!A"^4_?':[(0= M?79"KZ>.4HVQ"*/A1@*S"SDL&'#"CA350]<5UCVW3C!FS,C-;YF!83M=3W + MOJW:>7.K_D-?]].7;BAU#]8CJ _XBJO09D:LSH78Z? D+3&HTXY(CLAL5JFJ ME$BC50O;R0DN+%?P75+3U6)6P2Y>LDTMWPE4\ MJW;GIB4:I&0\J(NRD8CV"6"(CN9)/GPRR>-/Z#F83AA2F(0&@:EIZ^:1:R7@ MN^K0&L=<6.H,#*=L'(YN )RU&ML=%I(2+2S# UC)DQ M@A@JX 3"-I9(Y84I[Q;!A^,DK,S@<1IIK/6CA0'U@["AQWP 59\.X!HB]S^@ M5XS/0A1QS^(\+2.#CR259I;LTL#4Z>3EPV&PU4LO_<-5/Y#.%&"BH$=4>G?T ME Z;;;#!F[ ^E,!NI\=*+19:)H.!WI8;Z,R"NLB>KLUJF3-W/>;,!0HB"M"R M'M<,6I5:\'V/C8ID6)(KWQ@NM,H[<=B?._'9SN[3!48IUR:B3CFGX(UXO-2= M8-6FZOW<7G)*^75L?+';225IU@T\MW7$.N#<5H5.)R0>'$!T/-CV)82O$[>B MY<%;A[(9D)<8HPMWMDJ7/ ]8G$0S*24H2\IJY'%M8I-DJM.$:H1B3N9VJ%AS M",BSA07G_;H'+O$60 >JWX?21*R="$\H7C.+$2C/4JKJFHWN>#:?=W\#^_M> ML+]G&]C?!O:WWK;9NM5M'U9//F+JZ\2B"MB-ZPDA7BN>G(63SX'EA" MEU[1CP\'QVHAF :L0N@3RXAEY.KPTNC6RT7>"YAAT"&VIR%E%Z5/ -I#=X:< MF[QTV^*N0# 71TDY3\)]O#E?PHRV6*2^ "9BGUK:D MQMRZ(;T*F%]7D$_)C%ELW8""[S9FY"%_QUG&7@KZK=>,=EQIOOS MUN?;TN^M%GVV7IK'FIO![VC ]9"-$_%@7NV>F(ME\&PK86Z!@ZU\NZF3? )^ M4C!2^ZL=@,16[(4-?KX9*LLM"Y;275EIGSZZW68R=3A.M:HM],$NNS6@+4ZJ MB69S#J<_M.0@"43,15A-L3Q)/$N&DR+PN=E2=! BJ M*5C%,Q(QR[._:MA>"BTDIO:U<='P!R4PXYBO&L1783!245J-/#&4C_ ,F[-H MQG*Z3X=_)MJ$7;;"U\O\MVBX>%$ENW&/W>@O8/%09.'<=8_H0VID?LN@1ZI@ M9FN8)8,KGFZ/[DQA-D/H%)Y'_.S681<]M%09-#&Z"SKDY0]336$PKM-*P^W* M]O36ZVU,"Z38&F=O?SN4P#$=3S6WF,<#/6,^WUK4J*75 MJLS+>8V*EA2JZ87T04&&$H@I:#;X.RI:-Y0Y&(1J=M$)<3C$).)% M\+/]69FG.J%S<3[.] .W.LZP=-W >Y9%A.P'K][&%?2F?EYHS-S/P$81^>O M+P[[8&>((B%#CRXBLV%..3+W>MF)OR?V)C!A;YCDAEG3,$I#.'HT76,D<^4@8=#ND0^[>U07KI%2<9P-J$W.<-A_W^)"8#T_ []/U M>/;RFA5TJVL*U40'AO0ZKI5@;B?;4(YV 7RWC=<&/WN?[9V:P/VW^\LW>2N. M4DRG2U29"*((*1[>9TF+&2CR*Z\I][8KY97 MMALP=[F7V&YN:RF7QT/M0(XO.XUU9NQC8Y/ )O3H=X= MUG1M?L&J$P.7;E:*QE'&S%[<(% @Q=+\S4Z"S$W0>IDJ+!9%?8:;H#*Y<TH-B"TM^5@]@B. W M7D*3L <#!!5M5E8J(BXO?EEC4)E<1$,#253%S_)'@_RF4X.9D45$-WG_E>?] MGV_R_IN\_P,R78 M]VX8,[O]-,8L=(LI?'F35OK@TMRP=?36WJOMZ?!*%!R-L-P1'W0$ORSRE 6Q M$58T(3A?IN,4NQP:^E$?^> A7#F.N$1PKP5O: PN5@@> (P*/'Q)FOB0N4L@ MS+@=31.]ACE<\7Y#O+L8(EC[&PD9PAQZ : MKF$TG [I*?\)R*<46O4,@^K$%!4F>3VH3 ZS\25DW76",X:7]>:#:TQO[@G@ M?:<5\D]:(WMK.0UK0OO\SH,\B8"3TC;L!NAFB;3>;&]_9276EW!RL'8\JOZY M]WJR_LN>KPNOF>I'N8V]CJEA<&SZG+:'ZELO2]=C98Y.K/PL3Z-W+-E88.[4 MZ8ROSNGS:M=U?K/:VZ[UG=-9]C[3OV^SV2YW%L\U15Y<,U]LG5D7_%>7C6_B M2#IA=0&6"]CS*U9DAZB,;$U4-WN-\X4(EZKKPM+4FZH!N;3,]2@HF"G5WP>:T646Q,&-"U M4#?Y)S3GI P.?4_<)GIYM%:0RX""E632M$GQB-BRP?KU/=%/ZRN)-B/I4TX@ M45H\$E(NM [+GE8CGWP>Z8&N@I4F==M6"?Y-=A:\ '@.&]/42MMY2>*UTIIC M-Y$G0SJ>SY\3S,,DY;\0'K 49I]<%[Q52X2%VHBY7_GY#4A#OOEMU9TMOG?4 M0JWX=NMZC>7Z_5R@4?.=[/7NQ9Y1DJP^XX50^EVSP-ZFO)#:N=X).8I(B:6H MG,$HQ6Q2<\(78MVA_R\89PM3] M3B-!/F*RDORX%;OR6]%OLQ&\S@IGL78R( M6_2N9Z[/1>B+VTV*@>I0R4VOFOG#+_!OIAE>I[]-C(1D[GK4S2W;NU,%(,]E M7.B!5Y5C+8V=!A.NKW3FDD#"HS1KQW8)42-5U^6,470K^JQT8!P<'SGI)L,CHT*N:8BJV6=Z7 M'<1W?LR!%S/1"'#N$=<_ )?^,2\^P6,/$U38[#]3O]:JD"S#&8;<=6R!8&&P M?Q#\OG.Y<[3CRE_V]W;W @6RK_[:"6UH_QC+KRL3UG\'5BJF9TT_]I(3%\+# M93HO2D,F\+7@$L0_P7K\ZD[5=[^5#EX\Y%(:]NQ2@K>8=R>=Y<%[4 W7W[%( MJW.=EZ#(\+TG@I!.>5 -.\K'#XWY%54'A:S)836XD:;4*&J)4JE/!"+U"$-, MV-?.&"M="IG([(>Y\[_PN?@B21VSHB+DB%\S([5#&^S#RK$/+S;8APWV88TN MMK911K6!UBSSM!NIG09)4M&1.">5=N?7_1D#YWO2R=WS\ON^;'*=V_"]R.3N MN3+?E4MNQL*0(Y+F,$2(S40ICN\J/:TI?=MV$5H9 3&F\^$0,84MAR6ZCA!& M:$Z"Y$DFT,VD%TE!H\,%4EQP_RS^9'"KV/BDIV1HMZ M.^Q>+&'O#EO9V8F(-:',LVL!(3:B6QKO?R(-U B:B;%Y&1V;LL+T.ZEV')#" M;+/F&WJA/T,^6')Q"-=#R#0ZR!:;*Y>H%/XQO5:!]!:GP 7M<@P#@C[D_B=- MOH^F_@=-U2PU_:+-OG^PA&@[T3[M!>J0-,WSOO$D+M#=1[#7$>'M0#%&V8I[ M=RS7?V;^CGZMJQCK=$&9!.YBS/*,X3:572'ZT/Y7HF:(# MLMWA_/99X7T;V'7'X!R8Z1:NS'*D)]Q8'J&J6]PZ(>=>7:PB$:"$R6ZZH^R7 M[5?PQLTL3V^(N2-5CI$R!GN[@-\:X42$@9>:K(#-@>T8S)#NQ3&92ADL; DS M=;,38*H8X[C%Q$*',2HNKT'4!*#\%0Q.KV6=$MOO@BXXE5TCLYIY0(PN!MR- ML1 /$SA6Z@!,CO_WC$"=EQ7!)+Q*.LFNP,YF/%#!=![ND9Q$8*E3I;Q]>L<7 MOOT7%XFU>V/1MF_/;EAJ'Z(S4Q$P^UU@:_( #8-6.PZ7+ZAC,/=*MD3L_K90 M(W*MVB>C*7 -M@/!G=O$5%Q?4*R7.7W#9K9@X?W^EQ/D+UF:UQ/G[G<3YI*EO0>]TG^/0 ME BQ5M09@M-9%9\,\4/:#T74<(%M_AK=G= H+UOJL^QU"/X MU3F6\4QRP^0!8:U"2KAX. KD-O%!#\9J/%"$!HND;MBH*/I.*5AXGAV?'>1< ML/PT!J S>PU@@> EE&LUNO+V\?)R"FF?'L;TNWN,7=QE88[-I?VW, MIJ,\&V*?)=*OIQEU@NJ% >75MC=N*3)3%%UA>.LT'4R'[ #;)"$^.[$;(KJ] M[>LQ1#+#^ P7U)3HF')BWV&Z5X^97*!'/WAO=]IZNU/W=M;K7>6N=K7#M0B8 MW+0AX\(E(A"""^+.@\\W3&)C +B>J0L=^C56)T_71IUA_2JK]TREC]I)_E:(CF]OU1[9>WO5=FU7%N">J80N6Y>K MMEK6X^RH$ BS:AAHS@"Q:(';O/C4:3,)0US+_N#PO36/*J3/9U20,8V6'^Q> MKF%_S\OSM3DO9XC2*!$UFSP#N9UFX8XF/SC.M.$N\G4=<0GU6 ?&%LWT1F'H 98/M-( MLGR("@HP\XG4A;E.B+<)$T@2\2UM%@[^9NXCKGF1=(PJV_V@.E8"3\UK?UA: M&#=R)IJA\>C ^PAUDI4Y?^5U\=L0-;.K?N$!5\Z%]HWLMT*SQUZ,?%HIL@"& MOCRHM+RG4+3<6Z312/-2F6HNU)M@B""5JW7?@BVOY=.LRG%<_.@SXC)UF1?E MME7P8N^T.D,M1#>LB97P8FVTW@4767)AF%!H$.CM=8%!S55#$AND;S0C5A$@ MT0H.'K.16!=$-P*3Z3TS_H3W*XRT;&4/L-9,"71 M^)!,":\Z^8'/3KS\P_\84P +Q/+ M.H7?C#-;"=_3HS]='K%U*! 8M-+YE22UP6SG>1>8G6@C76DP@1292 /$F^YE MXLB($'A#Q+G.N:G\YGX!K";Q+E#A?Q<'@VB*J"SS6!//*+>^I2]:UDO'I-]D M?)@ZQ\/9>L^>+21=M4NB95MGE')9)0:.3JER^[EIK@3S*89K)?[9 MRY]?IS52B&,S)T36K=Y7)W,6]-M$"&M,1]^ +)&:J;.&@<_E M-(CH350Q=W0OSEP) _% 2=I$3 CK"%S#-S-N\&7:GAJ3B/EZC48U$Q.J]O+K M+L$FX[SRC/.K3<9YDW'N)U5#MQ*V:A/!VPUEB4 >\G8,K7M=V+P@]XBS).J& M"1TVQ/9D$J49VN*(HFK'>B;Y+1N;3$/3>DK!XTT_C=C7L;R#F+R8P 9=\+#] M04N5DS'EE7NUAO8V/F\C@2(J_S:"?Y0-&F&VL]%\1K[,3S1KTNJZFJ^L3>$P M M:SQ";O48R3RIA7N@BN%;9(GX#1%I1Q/E%F>5.57?N?PZOB,?(+L]DU6C.S MZ\2(%QM>()__Y<5)5IT^OVK%)IR@8Y%4)A1\29#D1O+!=1G"Z?2#/?@A.2QS MI)PX#O'7=.9M141C((\&U4D[EHFPO'N]8<2[0#-I>DS,6WDU&?0E_SEE,,K3 M9,Y<;^'W5#[>T'L.Y#=U0ND1]E1ZU%R:.J&QC5Z<&@BPT;214/XR:$Y MA&AB>7ZII ["!YX:X5I:A?986\YNO-U/;?D1MJQ*U2 E$^"#N;)7K"7/0R0?2"!()Y<&Q!9?W%M'T_K")"631GB$-I&&Q4A(")+5Y+$:XB6';Z5P M:0H%OSN,*TJH8>WA+*;'D8+[(RXTJN>4\6"QOM'X5W@N*AG.U.$[O5$)4=C# M9ZC(FFLA,=\!CZ-6H^ T"A88+D.*QFQX$3:8]BT-##!4*=Q^")\1*\?G3&%[(K+35MMFWKC/'=BH9BI J]_C+O%YI> M-(WF;C15*EEYO![4GVMF$QQC@V'=!V_I#5[.K ^G $#!\] ACGM9#2=ZHP=0 M'VF2B4)!"RF[-AFP[2@!J&,Z< IP@PT^6%FP-)E!F/L#61.=TOV$#/"_0^+V[F;SH M&\'6@GX7IQG<^6CW<1JW']EXT_WB<8K(3%KZJ&_WS+*RLV(Q\6-R77R7%-2) M/G&2/M5#,/&Y%S'!+8C+(C0WT"=U]P3F9/2NM5>U>5>.RS?:"-J.8%DTGBKJ MHFAWPV=S%34,6;"M4QFV)>U9B?4+[#"TVIMV;$<1C[!D^<_%2N*!,0K)O+:O ML+ +1UD/X!^F7GV.3(2-'>)NWYNLRZB*&D![?PUQDGI>H.- M =$LDV/$H@5KRM0>J4_TW!94K@MWQ!#B^ M66^'7*\[X=";+FGQ4\JBHWF3Y+M#A.I@\$IGI&3GK4:TOW]PL)*3?WM[N_-G M-"ZCI-@!'V656\: \_;-V^QY@@ 1=+!463ED!]Z\E*TD')JIB:,J'?X&YJ[L MWH:$_;#'';S.''$7) 5T CM.)^+%:'/12D \ 5_V0 M2#\ M4.YYANN;C\# 7'7>ZF-@/R?=$(SU(3VQR>^$K\>@!E=*[;M L%9,[;N[4FK? M!6NS6FI?69K9]*%\*QR)58?/&\D;@_9-&^U3X&7R+DJQ#M;[400[@71P\3Z"]=!HL/ M:4N+4_&V.3 3]W#F76'AU'0QE4&R(6>6:;'^[+GA?H[N2@]?8DN?2*PY&:41 MAB=-C= %%,(* N&BDX6MVKN;'46?Z400=6:SBWOC5_ YY/-?@LP6VQ%U\.O MB3Y>#IMS\Y7/#5M/1@$[,N%RNJTU&B"$(A)\O&7^%+L:+XE1L+6W^Q7?Z.7. MPM EKO)TQ!Q#!T^>$=3B!ALHQ5$JT0)T(7D#J@=1CGS9VF_#4^CE9JZQ[Y"4\[]@O2F6$3VG+15V+%?APANVG)C/&('L\2N#] M=4D_O#$Z3[1?^UMYT6X+YE6^4LVKO14&:'A,)YJN?,#&2RX)1)@[NR(#)>:0 M::$^5M4H3P1H5>;IC;D8S"PD("C/L:Z*A ZY.I8G2HT_[@PPTI0'>VT>7;#B M'J&.C8^P\1&^[))HIUX1;RCI7YML1H1>^Z#&HZBX%HN*"135)U-F8(BK6VAE MD/@L)ITH'8/@9RW.$"XXH7,4ZPEJ30G.>,-XP-.F)IK&/0=;T;8YHW@",5(/ MFMG@X36 F9U MKX9QQ!HT3F&;D_13>CQU.-MU3DPGBC2F1@W$R\M!1]O 'B/76A; M(\69>8O9CQ@+N9TXL[>J:5,A$3O3=-@8"MXKV&KK*'6D6_-A6LB8E<6&[L>< M4UZ"T.@PDZ>9:45XK*B9PIY_$;-PP80J*974#=(]TPVP1.5F71J8'+6K0.W8 M[?A,OX+_!F;:C>32S$G#PE^" =6(.\G>-^1%P'3LJT1YPVFUG:46'W&C$292J6[OVI<9,3D9@5<(-^V4&(U>7X"J[_J6YY_09W$ M6SC%:%!>>$U:>D,\W:B9U)R97= [0-P0K!60]@ XQ-!4M\D%#H++U6U8-24T M9U0524&N!661G=]A@QP?V:TNP_E^! AN7=+)\."X:300,K4J^KP$(?N;]:[.H!%(I$G%@;(EO^'0L/I/2)'9>6$ M'0W[S-S;]^V#&&R9;S:+7!'<. 3EG,6&JD=GVXB:HIP9YZ5PL$)M6,56#W5_ M6"IF@W7_&V'=>V8>D)JEWK1BTOEYDZZ&464]^!/_.<:6AX0Y858R).JJL4V4 M0K9D)%C\K$LNA#J'FB.W4UJL\OU^$BW-*SYF-.;T M$=$-X;U!\%7A]Z"1;@L$U63,^U671=DP]20@[RZ00ZP(4/FY$C L_BJHRQ[CEX[5">E<] ML< *.;0-F=D&@7_7XXGA@;BL8XQMY"OM(.\33+=[SG6G-@E!YK/"=QV*D,X5 MO;Z#[]J60$+PARPE3$*1#57%0%X?C":%?MQ(+L06B:15PU7"4*6G'=-X2.V+)"+;,M'D:_I3"A:^R32NX M8+)NBH6=^'!&' F'0Q%6)LLG0$37^+HE*^+^EUB$"J*:28<.L MS6HST-_(6.14MTFRIUJU6PL+MMQ#:*&Q0R^V$_!-=5@BYT["1\,_+ R9 MZ5NQ2-]81WCQ,9[81$270NPF6?H$^69,-Y"&1L5& &A6&K7GIQ99_2$U"0Y2 M1MKPZ[/6*UUSD7*.TD/V$2:$L^1-#;7\>.VS>,WLL\NZN-$W4=H# \QGWK3. M3]CP) R]P6U4%'B3ZCX8Q\JX.V%D^A1EB0C"R@Y-B_O7N1/<*%L*$0QZ MVH4*'JU4JS63ZH\4(NF!@AY&.A4J2A] 0<)+A/'6U_2IM">N@YSQ@G/ORX*W M]MCV9VAFKEKQV*)G@05*COA3B+/-Z8W^%O>%M>SY!GX +/1#(,[;X)-5NIFPR%R 1LMY-H/>;Q'<;AF1]%@[G]3Q!^\ZCL%#^5(IF+% MB5M_(INLP0ZTSU-$=5?P6,0/M'ARX3X!*TQ3 4TKKDV6?Z&\:X/%VOW4KT)@ M^$$H@"N4;YTX*E6ZM&)C2Y':H!;W?R?A7[?.6V=$5;UJF4?R#2'-MF$Q%!N_ MZG<6;0;6)1;:-CFT/T]4JKFM2V1J)R6-(T\2%<^-L**2 I#8]#QAAFVBV!X8 MNPI;X?& &(6%+[CAS0=2 <83H_2 VQ)FA$I#A)V&.X X 4S.!:GM;#Z$&*QC MI2>5'8,'P;Y?*9B0*H7MFU#L=AC%!$!47,5DL,1,.& 9S$TYCPQ+]SN,415Y MIN/&-_F)&)35-_1,;)%HT_N6 ^;4N.WLG2=R&U*]'B -]C9(@PW28+W- MAG7K'.4W[%RU[0"WB8D+$G-7;:AM7'.>1CRQPW"V_7="@=TSF.R&86RF5GKL M[B[J#,'.H>F/Z7-8*G)P)W*%LEYA^#&:0Z1Y>B(-, MC]>@7K32P*R#";8 *OV^:[!L]1BW3Y0 N_65^-@3 M3,?Z/&$RN$GMF=++[O:6,&=Q9<;-JB7JKZXKUQT<51%,'<3Q1OH<40>5LC0E M1083X:!C, LK)<@M^FCUU;IU,#G+8;'1&QPV.G"?2N79RKN;939DY;!<7D?" MG!W,&P884=K:5+*9(L-)=$<::8I4IN-Z9F@7?=RPA RE,Y^TY+$$ N"3@Q:@ MVOB"J4/%92. U%U#6R:JC TD/L$B8CVH*^NT$PV+BKA;HWTW"8L@ G0\87/! MH.Y".[.0E< =U_ZXOE#>;+:\6DP? K!M@G2FR##PN14>L,ZLVTG5M[I!+;/R M-[E.'J]6^+1F6N$M,92N^/!_Q.O+7/DXV:#,37Q0F'B\7L_CJ(QKXCR]5MQ\ M2S),")U6PMN#-?R9\L$QR)*K"OE.:8M6D$.WIEK\J5$F:5V8MEYT_Q&C4FB_ M>HL<0X)WX@NU"?(Q8[&W8%&?!@C:ZAAD.7KHP($.R&-NN?9X#TNZ9H?E")N) M@%<'&U=R,/6-#='"#NY,DF%PB=<*]:GLER=@^(9)TSO"X:Q&\G16\>[EPL#D M.!D^1H%P.)/VVW2_V<"X ?F;-BMX,^IKI+;VN++,6%5^S8A@/B3DB.BJ)HHW M5P-.>=5H8>7#C DAL[:_,_!OVAPF$4+ -E['TN!8@OVD-Z:VLS3;V7Y)M.A- M1QS& 7->FWU]RI/+&GAC(+IWH!I)!?%UO*3ZXSWOX[4[[R[3N?+3C$8F7%78 M4 '/+M%"%U4'LXU#7-#YBC"XU, :@8A/N!X W7YA>,/LR3#2A2EUYY.+WB?W M)IZ!W4&N2Q.SLPRXEPVH"2_5$%=2'=O@NB.7>N,?_V M-BJI3 LK^=%JQ\DE131DFJ I,CLSK(T;/-I#EJW9(4-1&>5I8O*ZS/IXK!(^ M=ZN^1@_ICNKP,AL)38N2][*>4MI7Y>:B,6\D+>1=6[&RH\N)7S4RQD9KOF]% MQ-@-SC;''4&VY)'?CAZU\Q0+>-:WYMPCW]:;->;9[<+BZ:7Y1 M!\C^4.5TO]HLJ9C9RVIVQF$ZBMX&2)GV2$.Y6S""6Q3,9-=0%YX:\&7 U:@E M' /WKF.\FQT8#*/RPMI:6N7#NL8.N#781C!**' 28K6[V7:Z:(+PK2R?Y@NO MR/87',P&XK!ZB,/^!N*P@3CTDTQAQG5\N,VNLX9U%'+VY]5HV_0A( I.:E\W MSO&WKO' =)'.4!?8[*ZS&0$7,5([UU(@JT&:9U@R[*G8R*\3#@I=?L(Y@)(> M*HT>.'LU6Z\?.N>.&;:*C6=/F&Z1CCDOG'$)MPO7+W6G:Z<,#%LU>(6-4) D M[\*C%J/&?61D7]>:A]%E61NN'2GV#*X:?5EBD"-"ER:@FBJ,WC.*(O"$E\%OB M_#%';(8U,>!N]KA9-@!,.7B#R=VZ@.M2=;CU8^$7R;'Y)+SOQO;T;,=9QN/IWX^3:/0&%$A5"G";0WCH-F-+3KC0W/ M9PG)=EL9M-)O'8=NMLUI\I$SVT+,D()VQR:OS8><*PRX&K[7SN-%2*S%=K$- M!B=@:MXA #NRO14;R55A931AGKPP/VWH8'@2:^;&[ECVVUF*P#KB5*&:<%52 MA%E,V%GT T9Z0%R.S7QOTT"'-]N*MK?VM^'J0;AY8R3^!98[/]<(.EFA, YB8GB:!=Q7XL^G.P M]6+["5V$Y=S;>Z:\F.MVMJA)4KP(MHZVO6E1-Z.*6L7JTBL2F%[ M97!LG@Z!$_54G/QG#542)+G@Q::^WW$!+&S/ES.OUY0=@H 9C$CZQ10NLCEO MG=38M>:[\ZBQ47-/)D0?29C UAH06(75L*SJ;$/*/K73]G4V(I-/M@CW"6W# M:!IFOM[&*R-5W!JSN#'$;"K.LWRL8Y>A;&5"INQG)QFV0FX:H8S&PGB@K^N\ MYB QIV5H*?0R=SK-P#[ :T\7T7G@Z]" ]@P]S(S@TLSNQ9ZWE1G3!L]OQ43K MX!P9LV:V58."O(>78>.0IF$4H$EB:UBCO8[N&P7;,C5-] M_5:'OI7$+0WE\/*22 *6+#5KI MVN8[6ULXY_F"]A"$X*(9<)1D>F*6>K_Y8-ORTEC:#8X+3U^D^B_TV4V62GV. M1U%V[8+H4F#/DU]>&W@''\&7JNB!5RF<3P=[/UM 4/ !<_=ON$ 5?O5T.K"Z MQ!LN<)P[ HSW6;FE1MFD [Y;.N#I)AWP[=(!*)PZ^<\?],O!7KR_?_!*1Z\&!WO[R=.7+_[][(='E4(XZ$DLKMM8.CT+/IY>G9U<7@8? M?SNY.#E_TZJG0=B=!?ZU0TNV:(DB!QRO=TQ-T2"_>;B=>=#:EQ4NTGT#EO?] M^S.P M<>G/X#"K1CD8I'_L!)=U%@;O=XYGMI19^II\@*[_?JMVL+]"@9GUYUDT5BQ* MLSZQV:A>_'F%*93Y._6A4"7UH2+?\FB$;>6G)S@W[J# M?(\_7/)RS<(EWUZTEHL7GWPF+$EP./.T/2Q@NVS8]^N][],%[PL*;VY5^LG9 MR<7AN^#BY-W)X>5)/K^TOQ-:1*7#,STVER56E9 MLYUS4D#3U??=F>H^XOU[C:-HBV%#N=1IL];*EC,RS!RUEM@7&J!BD M2#VN+'SXW_@_DRC_M_ROKUV3<&ZK;9EDFC4V;-^>2N"49[Y*&63(0&>$/MC: M](5:XA!OP1-3[I&9WC'.7\I_&7IJJH9[N9 ?.#?7AX6 M7L[%?18NRTJ W$=N/O1,X1)OM6[Q]5L?XR,(@RV_!92N1%2H8UM39%7Y/SAJW:RU4"9XA M=]?F)MG-CMH;;=^]]F?G'\/@"C?@S?G%"74L1@(@G;B^CJ:!N1']-NG %(BT M44W4K$QJG"9N[:#^JJ/XSO%^N9I*U[N"2]B\ILM$!MQ"Y'H?%VI;XM[#[KH( M,76U.L@'YBD!X;&<=^'YM+E>]Q#*9&X$JU.P]F;FU_OI4\Z.*_B2MV*2H8VL MW2LSM17-++[U= DVJ5>C*!WBGH]@QU7*#:_P"N=+/2_*$)2 QO]$"7*&EA6( M$/W8[UQZ8QIH$3,O?:?!MXW*AL6+KJ^\0"5*K>!'47&MIBY 8F\#[TYQ3]\R M=/U]+3.I+HC?C#U"-,O1X/9H1''*PZ%.L6**IHML+DGH4YXBLX!.-%98D6+4 MJFP0,O)3)E')H QY7^Q1H$I>!.[4SC.$5U%(U*7P7SD#-N!OUW+ X'G$]D9U MNLQL&MI"9WQN!>-DZHX:Q-K ;VN5';FJ^::YAK"A#_=#ZRCBA6>/HI*I%;FY MF<8N0!GU,K[1154K%H+2*X7GTA1<)J$W;[44:CCD_6]N;31,A?D MWG'-F/M779%?P/ -X@4-^2->>1;V<(4;0O)US3X0GFAW^-%.\P[NYNA=Z67I M4YA4Y@6\\S*E6>S;L8LO#3M YKG/"-Y/>0P7%7'UVU?\&P!;%I7[[-.4]J96 M8IY9N:X@EO4 I/396,>>S/8D^R?R=HKSUQQ,C $4>78]K%-G%(=>)V5IJDZZ M!FO=56)["J$A$=5P=<&%[1N+> 4G"MY0_D[FI[E^,>F?8WVR%W?:/!$ MR;0)#F.J)-X[>/&,:'V(:P'OZ&?[P>\[ESM'.[9$&@[H;E]SMFJE4?2>+DJI M_EII1,'@9E1P.(8A8O2OI M:F]$L-*%&+'-\)UB]]_)I4_KV#V9*W\N-[&UD[R&RUWGCOGKQPL69NN_D M@ST>8_HNWCMXM;>YBS?"^)"[^%KA!1P7VCJV+6!%^T+>/VB+WXO]C?1MI.\> MN:4>PW".3[Y3*X0E$#AT0$_^JJ,T^ !^X1(G<7_WQ58B7_;9BL77XXI6_-<; MZ1Q[)!XM!;J8SPU,[KW@:.?-SH5WPC>NWN: /^1Z>4/CDV'S7B4:0YWO%,:B M.X39M[1=^M28V_LO-O;VG$1U/U>F3X*HB^!=-,@+[/&=)5&1>*;UTU=+NWW[ M&S':F@E?*V76,:/G\FYEW08/MW#"F-;G9)RC MW>9QTNB6-?@C7_Q'_GKS6J-XPG6;%Y]48=%.#?'J$"-7MN$$""201[$0DQFC M3'*0- *6#+&5;+-CTS>5N;^',EF\X]U:@-%M&5/'V\B) '<(Y,;(-K#2CLY? M7QPN5RNU'JOYV+4<$KDOH080(3/.\.YP)WQP1Q"MYC$E6]V2/PRYJ?NQ@D]B MU:( (GF,5E.'*3U F7#!5G>7?#DDB;!,B#_A -&$MF,,=)<^V:B3APO.;+F9 MPT@_**2/.14?5=ASPU;LF<"NEVDYGV"KI9H$#_9MK,O2LVL8Z-@$$#K\H.N[ M;$!!#F&4--([A$HB'+2%I%<6-"DP>P$E,VXSCY4B\QBU8DW 7&GQ]6W?H'D' M]LNA,V=^M<00_5R;47Z+8-O5+DVK%)?<->.J8<6%/:,EAEX4MTMFR#YW?DA3 M=ZYCEB]LW^S1OGV9O MU!QK!G9E#%=[++=VG.<314UFR73%0SIUA7^=P&-?5NYO4)6Q)+?P_M12;,HR M-F497Z&&>C!;,?WWR='O5Z?_.@D.C_Z_L_./[TZ.WYY_'5XA]<)OAY?! MZY.3L^#P^%^GER?'R,YY>'8GYV M222>A^].WYQ?G)T>!D>G_SI]%QR='Y\$ER='5_")8._YL_TP^/C;Z=%O_+UC M>"H\[,WYNW?G'R\WK RK;E(UJ\L9@16'UZ=7)P>OGOW1W#XY@U, $3>>^SER=75.Z)[ M=E)_?/*Z\5+P#7JG'<&<_"D,(&]N;D MOS]PAY\/(0?@UXX^R.X.'W[V]4EZJ3WAW_P9A'ES>]GQ[B'H#H^GKQ[ MA_^EG]!WSJ]HTZX.KWZ_.J%-/#I__QZTS[O#CZ!U3L^.3C^\.R%M=7D*V@R4 MV0GM^GT,K#5@&KXG6).XA\_R2KI\((<*%>9OQ=B..)%VQ&J; J_@ 6;PAQXV M61J0(_C9+D5.4XK3@JT+LZ8@G2OVW=#B+KJYX^U@9IN5>;1)#7+F6PJG4S6E ML$QJVQ2>:L:Q+CQF?C]LFB8%$_-8U\C))$&I;N'G=T_R3 5;^WO;M*7T"^S" M=O=DB%_>>O:L>G8>-,W8%RSD8"J%[J43^$2OQ<64/ M4D87&U;G'U#$2*%V9>)BTS23QA.C%,[S] YFC2%:ZBH8@QC[_<+E5>C]$Y7"N$)]W"#. LV%@*)" M9YA)2Y$1BBLL!G4)LEJ69M>G7V=S?A]T?M7#SF]CKTTC]^9A"0-=L(# 26$- M/= ,#:0+P(TNMP&]QRC8>O5-7-V7.PM#79B*FXXX8FCIR;,=7'\0V@JK+F2K M,:?"6;IJM,H$'1^ F9HOQ/LXS?'PE2W5ZE1/XJE4,D+0,A&]@%LG/Q86( 16 MZ*'FYALQ.0KL(E#SW0W;X7U/X7!Q"L&:PU-GT7W$N[B":XW:D3"<2U$DN[O, M.]DH3/;R8^R!V(W6B6![LPR&>FA-Q>?/Y39V&%[[^4ZSSF>"0K(8"X+8Z/-N ML=A?,X[6LSPX)&;-59.RS_.C;J,"SDE5MLT22[MHO<]".3;*+!?24#I%&/J@ M8UK!4.60L6,XB*;V+:5E(:(D;OL VT2N(9;KG$;3.K,$I0*T&W*!(/)XPEC% MV%JHFXR;R;@]W63<-AFW)93%M *PE*<6/QIZK*="=]IF*S7\HARLZ60!!8>G MIF8P&,U"Y"J&GD1S$+ED4\58Y4+SL3?; M)5E7+ NKFR%=;*?B1]UP#^X[!E.77>XYM=O#2@D$UJ)_YT<(.@]RML* X1D;\ MV$A?C4W-T%AT\17MUXVYD2.*+PH1=8ANRT QY+:B,D\7(C:-;G@NTBR \>?" M.(T4A&AL4A!X/TJ JAOM5HJD(+75UR0$&;][:1 M8>NETF.]P:T5GA1HV?#I;.0(K(UOO%!;;3*HJU8XQ&'X75O13%WGE8Y<.(6] M533"W[!'/@9_N-&"9"H=,YT# OV:>_!^#FQKV!IFS,=T5B,83!8].@:ZDD]V MO&N(>9]$E;H0?1#R\1W2!.EE\F(,GR]J[J<:>\)D%3.=?!?CC<8#?5TSG21N M)5\8TK0G:3@JM >D56 =[YI[*_4U=EEU0[:[LEV:W"@:RL8)AI%.ZZ*!4YY_ MS[DYB-MURY2P\N;&X*+\4-$PN.R8(1=N\*U*R\*O1TO+03>RPGA"^/K$>$I%_]YRT?3'0 >*+ID@-C)JH(?IQK 3H16$)ZK&Q]^P%5TFI%ZP1 M*C+4!JPR6CUEC(JEH=C YC=C34]YN3+/HG'#U Y0(/ >,-*@)&1ER/9A2:G. MK"Q;W/U1#7M1@$R2,-D=1VOV$>B@%VNF@TXR)*X)>M&JLJU\C'IPV0%2.[JJ M*[9+%$_>]E8Q"L<<(Q \4WXKOS%=Z+C%'RD6L!R&(2H_X=Q9,F&M5K7C",'LI'FX(=G_OEK-D5JU1?#),YRFHX8)B%/P$1_ M&LZFN2=A9ES&)AF#@S=:TR9 MT3IE1 A!-'/FYP#GR.IWRB_,@=)>PC2B"KV5#PB+?6,:3WX7[.NW_-K?+EWT M[&^1+L*%U\E__J!?#O;B_?V#5^#/EB/]Y[-3C8VT^>OGSQ[[W= M'S8YIF^=X3\]PV*3LY/+RX"Z+)^_"06(@V%NH<( ?4L1(+!$!AC.;_DRT8VG MUAOL:\[2L[XBH3.&NB@K:\PPG.=KZP_97%$(N$PK4M,>#N5^>)UO_>?_J"P/ MWD<9'"ENP72:Q0MOP>^YGE\']K3(?.OKF\XS\E8E,JOG3%[^S]=W4F+43SN] M#QI@G8[##[]^*.!6"L[ ;#>U8]$X> O74G0]0NZ^/HKR+,N]CW-=#/N]ANW/()MUVPS2JT$ZXG7S M1_F>WY+[Y/FKG>?K'[S<7=+(P%CTZ=NSPZO?+TZ"#X=O3Y!>15A+NL/1CS&\ M^>,@3^[@/Z-JG/[Z_P-02P,$% @ X#AI4<81"0P%5P 66L" !H !E M;7!L;WEM96YT86=R965M96YT<&EN+FAT;>U]:5/<2+;V]_=7Z/:\=RY$"!HP M7NB>F0@,N)O[VN >GQ[ODRHI"PJVRJI6@N8^^O?L^4BE50L7DK@FIAPVU"5 M2F6>/'F6YSSG;_]Q>'IP\?O[HV!23=/@_6^OWQX?!#]L_/CCAV<'/_YX>'$8 M_'KQ[FVPN[FU'5P445;J2N=9E/[XX]')#\$/DZJ:_?3CC]?7UYO7SS;SXO+' MB[,?<:C='],\+]5F4B4__.-O^!/X4T7)/_[/W_YC8R,XS.-ZJK(JB L552H) MZE)GE\&'1)4?@XT-^=1!/KLI].6D"G:V=K:"#WGQ45]%_/M*5ZGZAQGG;S_R MO__V(SWD;Z,\N?G'WQ)]%>CD[S_HK9U7KW9?O=Q[OJ>2W;WM%Z]V7XZ2YR^V MHF1[]Z4:[?Q[&R;Y(WRR/Z&UX1_1$Z-47V8_Q?!45<@#S:!QGN;%3W_9 MHO_]C+_9&$=3G=[\]%\7>JK*X$1=!V?Y-,K^*RQAFS=*5>@Q?[#4_ZMX*O3/ M:UD2&"?5F3)+Q.MR].[]V]/?WQV=7 3[OYP='>'?FN][AS?E]]IXN;G3?+,_ MZK+2XYO&\GJ+^_7>=;?S72]^/3X/NEXX6*LFN@S^^I=7.SM;/YO7_TI3I!%_ MTA4L47R'#=J_+)3B(_-5I[5PY6AEMG]>#V"52%I! ^BLRH/131!E23!2U;52 M6? OE>7!NRB++FG*87"Y&EZ$^37&2Q]68]*G>BH@!^,<='QO&^22'7U2,6SOE1K.JI63*$U! P1J/%8Q MSBV(2I3+_?H2]'_P;#MDP7_# MG34M::PXSQ(RBLN@5%4PS@OXBL9/P=FWM^V3W8"3TP]A<(&[\.;T["C$-X<5 M@>M$R:T,)Q<7;%I7=90&LR*?ZA(>/X%+GS];13!HPCLXBXI*PV\C7#<\]V.X MIO+K\J]_>?[JYZ>ZA-N;RU,13>]BYZ59J$3%8E;]5,,"%?B]'_YQJ,8Z8V%? MIE;;#(+]$EQ&LAI;!XWEB,4&74H^J'RI3"(X\V.=QN3T)4DB#0E M5)&'< O%55Z41E_*A=-_;ZQDLE,F1X]+)@\B4&/#D4FTGD0 K8[\K+MW;_/9 M\]LOW^VM5\NX?6D!UO1ZT"1$DNHS3 MO*P+A6L'%LU8XUMI,'=T!O;@5 RA(JB**%%@)L:%JMHG'7^OX:?1>*Q3#7Y# MB3_!7\#WX=5@M%&AHGB"WP,'OM!5I3*VE,A6-4$39]RB>=IZ O['/@&MM3BM M<;_(TLWK*DCU%(27)AQU/AD&< 9RV'A=78&!G.79!IC2,X7CXS_*'(Z"KO#I M)0R>1H6;-,C6WL_!4Q:N>TD7NB"Z+-ELQMU)=%S1YH(8D0#!;L(_.5 3!;-4 M1?BWRUJG%>WOLK1;]^MG\&0R\17:D$O5CRC&*.%9I#N),!BXM;1I= MVV/Y&QBZ<,;/*_\HEO@O_'6AX&/RP[B B<)F7>7I%1XET >3/%,E[\@4[.@T MJ.IBIJL:3O^:&4K.@ODV_?"/NM E;CJ)0%VA'S4_F_7/.S9W\H>6?&KN=6PN MB[PL@TQ=PMN0!P]+?*W3=%RG 9PG]-#KF!30_'?-Y^"7A9IQ,FHX?SE%2:N(%%UZ$\Q4@:H=?-02EA"^E-3HN3[YG;GJM:_H:L%E'@?C(JK! MHU?3D?K?_TW%+[.7"6Q)-)L5^0S^96Y&[\R0$JQP'QI'-KJ,=%96BZ],7GY/ M#S[!*^6J_VC(%I1AD,L]0IJ+M!9N0ME37ZDH5RUV: M:A)5(,P:#3*6>'-86)_1[\7=) ?/.%EL:<0I_JP,P/,( [KK\#]PK&$\/-UT M#'09G"NV [;!J0TFF 2)X[HH3*S4'!..;:WMKP[V.AS4O_ ![Y#\QG\WRHJK! MEKG!21:@E)(;MH9P\%^]&JXQW"5>A]7?2JU@[701]^5 &G&\RC[K!,N >7>4Y&1C7I#^_X MP)-9SK";GUA57JE>*,HHKZI\^M.6^THT O^KKN:_LB@R](4/UJO;SM5S"?7L M[/[\V_G&X>G!^5__LK?S\_;VB[UGN\]>;&T^XU_RGUWX&?YS4KB8UJ7:0'GZ MN!&-8?]_BM+KZ*;\8<@ GWN9(#CA)5D@%Q0=*M1E3MZ.S0F()LKRRK@SL.1P M-A7&&,2:+L%PB-F(8V37_)TOZB &VX"=7FL 6,<+SC0&72:PD"8"@_:.IRS& M,E".7R&;"#]GK:(0S \YJCV?\%YFA.H0555(P\[ E<>R-V%W:K@ MR*%? OI$E*JG3O'?I!H>G!7LCM$.0$#H[*S%CR8(R_"<291=TDUY )\M\G0 M*?MVRDH25>!OQH4>@7-$'BF:[R!8G 93MT%W"#8!?\-H'0R[?XUWY_LTRNZ> M9;BO;OJ.,@_)HQ%ZSCSDR8 2#RB]QX@$1-OM#$S\K,9+(:&0^O;>JQE[C,^!*H@-P6>LD MPG@1Z/Q:)7R]D 7X<,5\IP.R1+!!K_BJ1R.^]!Z_H U]1J[%$+2UDV)QTB@, M.>Y,J 4HWFQN>. ADX#I"%%*J@7Z,:0ST%*Q)M&@QD,R^*ZJ>*N?X)4H+QY7)+VVX\R)3'&WNGS5BH[V GOODS)X)%93[W6D=7^BP:42&F=P7BRB+$/0X2@J55!&:53$E*EC,*\(Y;V]Y: MWX!U4D$1);HNSZ* P5MS']P3'D-R8F?R9$';MZ;6@RF66I@8O#% L[R" M135Q=KMLX]OL7A,J_#R[ESX):K[4G^#67GNQM1XDT4W9_7S:2'K>9A!OKT.0LXGB767S@D&#L@;-ZG%NG'ED7#.TZ+:!9Z[JT]5#7B MD#[-=!/C[W:Z]55>+%Y/>+WO[5BMC1^7;WV,4*8ZJ[ @\,*9WL/QLQ&S^< S M,O\UETEH7TQ-\U_<"DS2ZB_Y?/_4WF+3M,[LPS5%QRJ@"V30K)W+X4[__+<[ M'2N70?%R(K"8/>*U2#%\HVSH%Y/J%[<)];-G"_3%D@X:S6GGJSS\RZS'*C\] MB/STX[R#+WOOX'EU-LA;N4O'#N%*M@7;G"1'VY@,:(-6"K0?-#2?CO,I6(23 MFQ(3E"DCI2E[R='*:!;%6(< 7^<["9T\^CO=RM>Z1#^0/+]QC=]I0 +PWI8( M:1/4XQOU&;P1VJA[8*.2BR$SA/FH+(D*\2[XBWD&H\(X%!RXAHG"%\&+7F]] M6G /_J=IR?#3K[Q/;Z!1;.WA"[*F*3K+OL&]+MB10VLQ9K9APW $(TJNQ.V( M9-$U7,3Q) ?'JOV5MEN,T>_B2I4>:,-LL=M6]2FRS[_#(ZK.N IX%"K[#%3$ M<.(K"U518/_7JZPF_1C?0>JF'J-SF>HI-/J)K&C,;F NP@\DA>)-].K_LO56 M$E6R(T M*M $A5_2S/*9I,X,J Z)?.@WQ*+B0=OH%8++(LKP,[.Z*.N(TXI=2M@?G8;" MF'A%E[+@AFA #,)S=8$-L3+.0B#)!0/D>#3!5]0S&%)]4D6,U[> ^?PB1)S/ M*;]7L.:=KI$"SW-]\\[^0=^)&J[9NC,H#HC!N:9;BZL"SDVX'V3ZM0(%3.6& MR1+7](=_W"/,.5RQ[%7F_=0/PY200_8&4$&=M8 .2V8R:;M&9&RC:7$PT6H< MO%6741J)((H:_@8SB-.44_7) 2&M1)3L@(L#-= M@$&8:XJ^Y>O0;".3I>\,4T04R.&M&D6E+CM&N,Z+CWW! UXP"L&@:/T.'PV] MOT4IOO7EA)SG (.<>75N'FUL=H\CR4),\ST!'P O"TF4NHLQ0)6/+4U MF,9IXU.8V,EA'1&NC%4C])5,I0)?0"A*2@ADE5*1;9.7KAV$84(T7>&X9306 ML%U5%XTD$,\Z2DL"V_#;<41. "T]-K_!Q1!,,5,J88^V#<5S8;7NW?4N#F;& M@]V^<5FL&1&!R*O.BCQ628UNPB4L4D&!/P_/0<Y\=U"/!41)P[3@CCZ!EUBBO!EK?V"&&Z+: M1(&57-U)D6FB<:G11<_K,KTQ=SQ*ZTB5%IHJUTM(I[;0% FFCV+$N')T$VEJ M3H$$N$EOX8TW4HZ,HH&73 K$V)-"JNC>7193>*-6-LM:=Z)3P; M5*QID4@>>)8H':C78"J,P2U:LNKW 86L>F81F>LG,.F4J;? MME^/]<5(7I)^1#+512ULM."SKVNZ++.,.%H?C*#N;-XBJJ]QI\_)AQJD<#:$ M+_)+(O!:_K\P6@@SPVLLN%%1$>*7Z [$E'8,;\R5DFU(FO.22Z)WIH)_5-WH MBJVA $M*G-UM\+G(91J3/YF1@XSXNBF\V"2]6>]$M/ES[?(U"G6E8?6XV -& ME"82XB>6.5*=Z!(Y%SVLJO5?\: E!,%37QGPO MU9 M#=B@W*_0DDM'2SY;H257:,G'A-I8>+OZT6R)*"B8LY9X')@%&5/@4!G7&.Y4 MT'MH+;0#_N;044F]B M+ 5425F*[AWULC:=N8IY9DOZ#=BLV UE*IDI9+++8LTDF^P;^B<@+C055@:J MQ'"5+B<=Z9F&Y=%CRWN0XW7LF:LBG9FEFD2##K6Z2T[8_P]>U:]OL09KYMATV2<.[39-+H%H]IK1W)0R;+RXF>7ME%;DC;P<])6]TTBO M/[2\? !.Z([0PBV15/:^\9SE1AIW>OS/$?'_8Z];.G M=]1&#A>81?P1@6^2 MTBL*Y,>A_(0'Q@P[6D*$7OL'I1IC$=; C03V(W(Z,'""HTA4(5Q76 G<4D68 MUJ$89\L'#ML998()\+7;3NW:>RST+S'ZTA5EE\%U!CT(7W$URTQ"T[D0FQUA M-,O%Y]0\\I$Q@4RJ*N4QV=Y]9>ZX%C1#U+GNXD5$NQY+_8R]A5$!\DWUM5,8 MRXQG)8\IGG7$=2W+CF7-2S1(R714%V4C6^I3HA ]RT8^WICE\4=T@0QINY3J MH&5CJKRZJ9M:6>*NRJS&,1=B*(,4*1N'HQO89W3O\5F8?1Y8D+ME9/"1I&+%DGTSF#J=O'P\'FACX_<7IT.(,G"D MC'P?4&7NCI[38?T&&[P)ZT/):G6ZWD18WS(9#(1T!3JYK5)PH&NSW%X76UZO MBUL41!2@93VM&5?[ITX'LZ=N+NY]>SQ78K'V$@@2H,C M+CFDXLNEWHW?;5D%-E@N<_2W2P/H8+*%!@58L]%]V :BCY2M.FW4K XX32'5 MIX.P'3"^4Q?Q!+-#.R^?$S['5=8*@&R*?3=X<<>W\?\/U%2CZI4AK#@'?4P! M,HDP4P%Z52K**W)T>6W:G3V=#O5S'70&1'_ MO/'P^5J\ODQ-]1G-'QH5X;8EW,W<$6[XUB[31>/8&O#6:["Y<$4X]RM%$?N\ M+H*UW?4-,HKQ-ZA,RGBBDCI5H00.R(;8&.-$;?YTY_E_KIMW->.;[\N*CG51 M8F%3!E\L2L&VS2LJFT4IU#32U%:C/2!R==,>"S(MP-Z#\"YW#&UU'LVY<0GF[TDCVN33*:0)$VHQN:[LX7-;U8XNF^%H]M=X>A6 M.+I'752S>RL[S;!<[7,,+6%69M@WH,'SN/MB1DG@/I;;/$N)$J&_7F9W1*XM/HV@./W0M):^"\MA,N :Z49DQAA#A5:@RH^($GV(408*G[[;S[W,V:R=D#=O]B8UXW_'*2MO1?VN3L;%9U9M;WT^PR\< M>-//QT8H8&_ X#>\4P9(>H]%/UXAO=Q@9;"[EC!7T-Y:OMX3ES$*1F@XM$/\ MVO+YL,',VZ.RW+)@4?N%E?;YH]M].HE)ERF6L M!\%EK%%'$BB@44MR/5%9D-18^#PI#/6.#7K.RUW/ 31UG(5P&&6NCUZ(:/:B MEMADG=787.K]Q6D( E$S5V:SHIHDGB3"29%Y76S6/$-.'5VPBN?2D2S/, [( MH87$$%$T+AK^H 1F'#EF@QLSQ$[U:37QQ% ^PC-LSJ(9R^D^'?Z9:'-Z6KH- M#^'88NKD1144QSUV8[BIFWV1A5/7-VH(204V9T% OS?H]NN' MH:E[L/F7M?VN3BPF:-\HK+JE 6?^,/44!M,ZK33)V;Y8&UO/92# M*Y.V+^N7U@=I/9W!.9W.];5:U&^E9S)WZV[XY 3MLR5M?H']7"IC!FPMT9F M*JTFB&%]KGRN10IPW;SMOL_="TOR'P"&05=!W]' MU>N&RESJV(]9B!LBAA*O@(]US,H\U0D=BM-IID=PVE[7"1Z],W#:LICJ(_&[ M^W$EK>"?-UK!#Q/3<'#Z^FQ_"-8'=^E39/[AU60WS&E&[L52=I91$KTB&+97 MS$+'W*<8NZ%R2#1H8V1;C*G&AEN&,4\]V9ZCDEE>YIISIN,-]Z/U8,U#&+.S M-MQ-!9F5=WU/\QW")C<=>;_XF#+$9E\3A:4)9/Y?3\"I4&;G5+( ?RQ^B\[* MVCG;5)EA> COK4JX+;AI(L/+:D6(*[%:E9XD(.8C8=#MIHZYFV=740OE##RK M4)M(Y+Q!N M&_SL?;9W;@+WW^[/W^2U.$HQR2ZQ9N)PI((;0Q\I"_L9SUAG,JFUG76_)MH# M(>9UFK"032*[\IYZ8V];7MENP,+EOL-V:@) MP$%WK\ENSS8Z*CEL5HMZ=US3M?D9JTXDF;I)^!%'&9-OIBRZ@)&\-;-8$,"KN+;#>PPN?IQAH*TSC%4/?@XQ:5BA=-;%CB MRW:MOM?8\U5O0#"@L(5NM0"YNU6+0H;F&\Y"J0S;>J[/1UBBX&""? _XH /X M99&GH?4LK"5,B4\;JY%!L(P^Q4[C)1.,HXQ2?,F>)B^0 )3@, M_FDW[8SXSO@#'^16^ 49X,\$=71HFMVWAQI:CV77X6O!0:O\5,/8OQ'HKH=K MMTY[ONI:)K=H:+QUG?]6X:WO==?Z=CS(K/A]IK\H^]"U4UU&$BHS*>(21 FU M=*X+_JO+%3=-J$[0ES,-:32/GL\-@Q%7JIBX2^&T;PMTI*\%?.A,.>\.\)F M0TL.Y+ V86#PB@X&(5SR1"N/K;J1886C]J9_B%\DXJ^EBQ?%NHC!,*HP%%B& MEL(.WA6-9[)B! KQ=,FTDT>F,,_@.@2#8;R2:#-C/O$3\JYB"2J14B'FN!PH)\C1IXD>Z2I8:G*Q;97@WV1G@R17 MI7@0Z/MZIK>X3ERG.S;EO6O/GQ/6P"2'/S--?2=$.24+\%8M$;1HXS!^7>)7 M*-_]ZK=5=]:R[ZKJ=9[5DF^WKM>X6V.X,S1JOI&]WKW8/06SZA->""7%P"0- M"/8V11O5YN5FR-$L"E=&90^O(W,Z+O")Q;K#\EY!X%H G5\V032YPB(I M,.@1\H&A2_?O.N-KR=[%4+7%EGKF^D+\N-2ZD&*@PBV*OU7-/-9G^#?SA/'S MWR:"8S)WO>XQ+=N[4P4@;79]&R7L)R+'@/E)FUT:WHZQ MM[?GS)<$:V#VO:(>9D3M<[_L((T(F)QXL1.-!.=>\ZP'P*8_Y,5'>.Q^@AJ; M'6CJ%UX5$NX^P=BOCBTB*0QV]H+?-L\W#S9==<;.]M9VH&"SU9^;H8TQ'V+! M8F7BRV_!3,6H_R4FR-G[].@P32-?6&0L4@=G"ULUPI]@/GYQK^J;7TM[+QYR M*XT'=BO!6RRZE$[RX!WHALMO6$/4N*-,^Y4 U#R@>R3/D5E0^_ M,*Z;)%,:%(5S>A2U1*G41X(R>GP6)I]A9XR%&(5,I/]A[OS?^EQ\D:2.65$1 MA,$OZ9#2EA4J8>FHA!=J-U$Z#PZ?HR."22KOQ MR]*,@?,M65WO>?E]6U+7SFWX5IRN]UR9;TKIVK,PY(FD.0P!UFER18%\5XAH M3>GKMHO02@F(,9V/QPA5:3DLT66$Z!0[FG%9;C7ROQ+CYK.[+,V39&S;$<:V M@=WM.[?%B:NZR%HA;Y?[*_*9*I:6F=WY IG9-@_&?.*RV6TDQ P;NK5,H1IR M!(,L\>81O8IB-,@IN4FD;J4K(,-#+G.V45D382T=H0ZYK+F$;:ASBFO%+M^? M[RH#>BM$GM99-): MK*'0X(.I+CF EG\T253LI592MI6]C%8'C+![L:2)1MA*S\Y$K F\F%T*&JX1 MWM)X_Q.GG4:>RA@;*-.Q*2O,OY-JQP$ISM8WW]"+_1ENO)*K%!B8+]/HX )L MKERB4GW5L58!M9M+.'!!NQS#@* /N9]:DXZBJ?]!4S4+'C]KL^\?+"%62;1/ M!P%T)4WS?&C,8K?H[@/8ZXA07* 8HVS)+;3NU@9N\8YW."GSHB3._6,T#[:_ M$<_Y'?JRW=*5[23/*$Y3Z25R\^S,97KFV&ILMUF_'6=XWX:XW3$XAV:ZABNS MG.@9*#X8#@&0:]S!*.?>GZPB$:&$V6ZZH^R7[5?PQLTLC6R(R2-53I'1!%NL M@=\:X42$()9ZG8'-@5V1S)#NQ3&;2BDL[,PV=[,38JJ8XKC%S.)),2HNKT$% M\J#\%0Q.KV6=$MMVBBXXE5TB\9=Y0(PN!MR-L?#BXH@&D&Z2_+]E&M&@YQ7A M)+R2+LFNP,YF/%#!3!/ND9Q$8*E3I;Q]>L,7OOT7UQZT>VW2MJ_/I:GF+ %\ MI$#3^]\%MB8/T#!H=<5R^8(Z!G.O9$O$[F\+-B+7JGTRF@*78#L0B+;-F\1 M_U)6/+'3O->\ U?IR)#GDKI[@5$ 6C"?$NLP?"/'7GX(IG,_KCCGN=3^-;=< M=DON7[.SU/XUMZS-)6$(NR0V3!X0(^)1J;. H MD-O$!SV8JNF(O#N$CE$!JU%1]!WJF@G_Y-GQV<'B?\N28A Z_6L "P0OX5'O M;_\G81.FH"C-R\[C)WT[50\7=5H"^YZ0+*[?"(O@8NAAL/ M-]\PA)Z"WW4<\6B6?(.-'FK2*VZ&>*QMMPM,O"VJ"08 MY;ACA>[T[JDR^07O8V2Y>9]K9BD"GF^BKL!78^H59M=FSQ$_N +,+!TP\W(% MF%D!9AYJ$RW)!&*/4=27N[''2(!1NHH-;+37;E'%#JY%^Y&[W^2_<)'3B$F7 M6*,)%P65MEW;%?V_9PJAR];E[EVLXW//R_-&MBA,]R 5T F/@=6W&0L.NCB(9(%&>EN;%,"TPK XC<0JL#2Q]\GH(-Y MWZ8ECDU=ZTP3X"93EQ$?50-Z8%#=3&<<>QIAW4PCN\(M8D-VAY0NS'U"S$&8 M.9)0;VG3;_ W1UQ;V_!+ MKXO?'J>95O4K#KAF+K1O9+\5FCWV@N/S6I$E,/3E0:7E/86BY=\B@4::E\J4 M<:'B!$L$R42M_Q:L>:V(^FK&E.M6PXO!T^I8="NLX9&8"2\> MC=H[X_)*K@@3\@Q"N[TN,*JY;"QB@W:,9L0J CL4P\%C?A,\F!@LD$\8K]W4 M"Z(17;J6T@Z7Q5[<\T<0#%WN+5Q+I MPDNRG8+GQI9S!)JCECV81@"3C6F)#?KPCD^X&^5,/]7,+>PR;?Z8K]^G<7OK MU=(47S0@Q;?YXM4M+I)4I*.O0'FHY?4--0KOPB"CG8S=6$IQW\-I:(1F;;V< M!J\$L"X(7X4G4OHY_0'^5IGH6&J=X2R8&FA\2*:$T1M9GB., "1!(Y8KV?$; MB9T2*LPK628-'%=H+G [0\M8.@7SY,;T.!0F:Y]B&>.N";*65Z:ZW4,'>T7H MB2M"-_A@DZ(WEX"[)' I^(=DW,1$#:B+@K#AW"T$UN-F#O!K>E*V)BT) #?G MYH2#=EKW,\DJ!W_F1P,Z\XL/_'Y,B"X3Q#J&WTPS6_H^T*,_7P^QMB^8%[3. M^94DI\&LN7D7>IVZL[I:8$(E,G4&B#?=R\2*$2'2AK@XG5-3^)@[Q^-^O6?/%G)WVB71LJT] MM5M6B8RK7<=7GP2-]"MH+A\:(#K/2:JO/RO60*/#9%%"?<%E5Z7%*&/47 M555>@/8HQ2\*QDH(-%@KTR!ADZX.!JF+PL(MI_1Q,65XF8@D&I>Y0+\4M7;7 MPG4IP$6K>7O@=E4H]HTPAMS$5:+X%+RU$K_[\N?7:8WDU=A&"*%TR_?1G)5A MP<*ENY47R9Q%^38AP1KST%<@2Z1FZJQAX'/]#$)X$U4L'-T+,-/0(Z:#I'R) MF!#6$;B$;V;<6LJTX30F4:$N,78D&M5,3$C"RR^[!*M4\])3S:]6J>95JGF8 MW S=2MBJ341K-Y0E(GC(VS'LX'5A$X+;_YIH'J)OI2INYBQ!EWPL/U!RXV3,<>5>[6&]C8^;R-S M(BK_.H)_E WB8+:ST7Q&ALR/-&O2ZKI:K*Q-I3 BU+/$9NU1C)/*F%>Z""X5 MMNR>@=$6E'$^4V9Y4Y5=^I_#J^(I,@JSV35Y9&;7D1$O-KQ /O_;BY,L.V]^ MT8I-.$''JJA,./>2(,F-Y(/K,H;3Z0=[\$-R6!9(.;$:5M3GJT:LBK@7C8$\ MXE,G[5@7PO+N=241[P+-I/DQ,5_E%6'0E_SGE,$D3Y,%<[V&WU.]>$/O.73? MW FE1]A3Z7%Q:>JHPS9>Q3CT+GIB']"-[(Q2 MV/X:5_/=,/Z48N/D@#8F2V&]4- ;FNBOD6714'QR: ZQF5B/7RHI?/ 1IT:X M[JQ"!ZPM^_L]#U-;?H MJU(U2LD$>&^N["5KR9,<#\"E$,LZ"P'#.!6U(N" M-1-.N[-,,167XFE%G".#!/^*?Y(77O,KOT*',TDWP24:4ER:(ZR8 M3-MNF4='X%ZBMB#F49H;^[?(OHEI2E.#QGI'JNP.,-]9EK85%'T8?YB3_?*F MKFKLC7M11#0Q_^-BAM WFMR=_XVG(59-Z(G/^FHQB*Z:J71:R@<0",3)I0&Q MN51,VD?3^L(D)9-&.(0V-$P?T1%QK5<\I L%A?:?PK/!>5#&?J\)W>J(1(Z^$S5%7-Q8^8[X#'42[/ M0,T$(E'SM=57JF7:M!$7+(,NJ&2-&X9&YGDA/XWV)\U17WN20T 5+6"*G%(D M$E4T99VV%S?KSX#*Y2D^@1C-0@H^J2:)>A*5-2EQV+8KG:?6(R 4"K5G>@0K M&;'@1-JCU+2\+\%8IUS8'>&CREI['X(GQ$KQ^=-RW2'L#L^PC,^O42H) 7,; MJ49Q*SZ@]$8?4S@<\_K2TF&>ZMAMR>(=:*)V'11'2&PZ%Z>+4,A*";Y"?^\0..W[E_R8FB,6K=TN#C.X,Y'NX_3 MN,/(QIM^%T]31'IYZ*.AW3-WE9TEBXD?D^LBN*2@3O21D_2I'H.)SUUP"6Y! MY!6AN8$^JIL-F)/1N]9>U>9=.2[?:!QH>X!ET72NFHNBW0V?S972,&3!A*<$ MMI4@$#MAFB^PP]!J;]JQ'=4[0HOE/Q=+B$?&*"3SVK["K6TWRGH$_S ]D[FF M37#RZE-D(FSL$'?[WF1=1E74 -C[:XB3U(LJ;%:IUF^5:MU;I5I7J=:G>)^. M'MU].B3CJU6--/(ZNY!1KYNSM=@^\/$*@S:4/I.A4Q=R7UQN0TMT1>&0#H3QNC0XB"(EI:"E]3\W%\&VY";@P(Y:"9,I$GZ@&] M?&0>T'XQTE4QA!.'CWT8*N1&( MI3N[3+&&H:XP_FR^*KG8&%EDF\F&_]Y_=RZD3S0E;U>"LSJ5[,M[C(DFE%@9 M9+T8[21-=PAM:#G(^T>=7/*^LY."JA2A[7@"')VLMT.NE9U0Y,T7L/@)9-'( MO$GRW3$">$J]]*S*)8Q;/&XG[0Q;M:^UC\#E"O@S1_EH+,0:U/GF80'_N,E@P M0UM:G(JWK6N97H;3Q JK?.8K?PSL"IF=3 ?PW>>&F1A<;0\,8>MT2*PY^H)O]'+S MUC@;KO)\>!<]WXU=P@5<87N?.$K%V44/B#>@>A OQN>M_3H1HI,8=, M@^^IJB9Y(JB@,D^OS,5@9B'1*WF.=54DSL6EG#Q1:DMQ8U!\II;5:T+H?.U[ M>.HK'V'E(WS>)='.$R(X3G*5-C.*<++V08TG47$I%A73_*F/!A-OZ)5;T%J0 M^"PFG2C];.!G+8(+KHZ@ (QK R: MV=R&S4)[;G0/#LU\[)>+6_VV@0U(Q-IH?6YY1#'00E0VZH4V)3T&:9<%>>E> M#<-@-6B7P0<>-\M@Z1J!/.F4S: M?;2._D3F!B\@?#I#X"[CUAV8OMUOJP3MD$:%G$/1209?,9NE8$FB.^8KIO75 M87RM"Y7@$BBPU/*HLK^."B\TQ MN/3>8O8CQD)NYWWLK6J:*4C$SK3$-8:"]PJV-#A*'4/48DP1TCMEL>&F,>>4 MER T.LRD&7JM"(^Z,U/8D2YBRBB84"5U?;K!$&=ZU96HW*Q+ Y.CI@JH';L= MG_E7\-_ 3+N1&^F=-"S\.1A0C;B3['U#7@3YQ;Y*Q"73A:O;[MX5>F3JOP8\ M[G7>H!-M1XG5)\Q(E*F49?NKQA4QS,15P 7R=5']RTE3$[+ZU=#2U+> ^G^! M4XP&Y9G72F0P],B- C_-B<5;&.[%#4%@NY#8XQ!C4XHE%S@(+I=B88F/<')1 M"1\%N6ZIX>O\#AOD^,AN=1DN]B- <.N23H:''4VCD3!_5=&G.]"&+V@-/6R2 MB[U'=FC>Z3)6:1IE*J\'VBOZL1='#0ZT?IM(Y(G%K+'E_YYZPA^0H[)T=HF& M?6;N[?MVZPO6S#>;%9F(Q!N#[!J&/ &35IIZ-YO%;#.-(@[F6 %B7*7M^!4VU;&R&K0\8-)E3(QG2&X:,^5DV*UK@;6HA]TJ8(M2EFN>/$ M$T)EZ7+3:KC.\76,B2,ML.*/WF $/)Y$R(TT5<4E-W'QJ*OZ*J>CF&K@2DYM M(XIIA(=>15PT?"C*:?'U-026F+)"-;,M'D:_I3" M6U]EG5;PELFZ*19VXN.>,!,.AR*L3!)0<(JN>W-+5B0Z4&)!)8AJ)MTFS+6! M/Q9<$ M=I::$[AE;9:;H-OQ<@)&QB*GNDT./M6JW1]7H.<>@ MM(7JQS8!OJOT2^6,2 M/AK^86%$S=!*(8;&H,&+C^'&IJ%7"DF9)/$3Y$XQG2T:&A5)[='J-&K/SSRR M^D.:#1RDC+3ABF>M5[I&&>4"I8=,&DQN9HF(&FKYZ=IG\2.SS\[KXDI?1>D M##"?1=+Z1F'#DS"E^M=14>!-S@4JF,QC=4+@?R;T$O1$G? MWYM/]LNQ*FD]U'T@D$]7F)-')LP76+#[U[\\V_KY/8'O7U.^.-91H9=6Q^92 M3*9AHS,F7;R2-7?8EDE+:Q93YXW08ZF63*OCH821Z5.41"*$*SLT+1Y;YTYP MMV>I4S#@:M<^\L'.XQNO DV&9:;S7/(!6RT0VL_Y.D>Q?$C.XH&DO^K(B[<9=\I M>"@G,A4K3MS&$IE1#;2@?9XB*LN"QR*\H,7Y"O<)6&&:ZFM:86^R_ OE71LL MUNZG?I$"HQ-"P6.A?.O$T8+2I14;6XK4!O5I_YZ$_[%UD3HAVN5ERSQ22P@! MM V+H=CX1<%]I!!8MEAHV[#/_CQ1J>86)9$IK90LCSQ)5#PW=8I*"D!BX^Z$ MV:*)+GID["ILZ\8#8A06ON"&-Q](!3=/[,@C;K&7$6@- 7@:[@"B## Y%Z1I ML_D08F..E9Y5=@P>!'M8I6!"JA2V;T:QVW$4$SY1<9&3@1HS'X%EXS;5/C(L MW>\P1E7DF8X;W^0G8E!67]$SL>6W9(L0 GFI2XYA\U3 +*B+S(Z+^Z7@ TG( M,^AY+69=U['RV3P8K.UEG#A4"D<>;6G0,CBNJ0!LT]/QLFCC:];SE@3HU;J-YX(KM]GPV+H@^CWZG;3G8CZ>M0(G9P9W*-LEIK> &63^18ABR_8Q M4F*4NQ?B(-/3-:@?6\>;7RR ^VUT3=+T3Y75R^\9W\Q?ER*\[-"9/O")%WGL M(4(CT+KXD-RS _YA&-;\&C:J_2F:I6&\ MUD#FYR;SWRZDE:9;I? 2]Q#0^9ZW!-B\!H0&_F6Y]1)L9U/Z/<1@V>HI;I\H M 7;K*_&Q9YB.]6G$9'"3VC.5F=VM&F'.XLI,FT5-U"M<5Z[3-:HBF#J(XY7T M[*%N(&5I*HX,)L)!QV 65DJ0)_/)ZJO'UHWC)(?%1F]PW.@F?2R%:4OOU)79 MD)7#K%3X^,JWP"_%O+OGP?\#KRUSY.-F@S$U\4(AZO+[%TZB, M:V+TO%3<2$HR3(BL5D+K@R7^F?+!,<@!JPKY3FEK6I AMJ92_;E19FE=F!95 M=/\1X5)HOWJ-%$2"=^(+M0GR,6.QMV!1GP8(VNI^8RE\Z,"!#LAC;A_V= ]+ M^L@.RP$VQ@"O#C:NY&#J&QNBA1WJY."Q/P+#IDJ9W=+I9/1UQ M<7?LO5P8F!PGP\Q-.N58#_IC;GM M+,UVME\2+7K3W85QP)S79E^?\N2R!MX8B.X=J49207P=+ZG^=,_[]-&==Y?I M7/II1B,3KBIL#H!GEUBCBZJ#^,8A+NA\11A<:F"-0,1G7 ^ ;K\0P&'V9!SI MPE3"\\E%[Y/[;$N6&5/!0CSGXF4M5Q=O] [F#?+8G1V8Y<1';4#)_JB"NI#. MU061>#O7F']['954Q86%_FBUX^22(AHSB] N8[R;'1@,H_)"ZEI:Y<.ZQL2X@]VUT3JB44+!DQ#KW=6Z M4T8SQ&]E^3R?./YS!6U8/K1A9P5M6$$;ALFQT*UM\[%!S^VOL^^L84&%O/UY M-5DW?0J(HI-ZL4US_*UK3#!?I3/6!79NZVQ6P%6,U)NT%,QJD.89U@Q[.C;R M"X6#0I8*,4)-$[\ZC'J L=6=F7M>9A=%G6AHM'JCV#BT;?%I?QO1OFX<[3 M/%3HEQD4HYUPT3EA^P0TNA?.GI*C*-O2+@E\2Y@E/<;>II3"Z.0(T*5)J2:* MPS<,XXB\(27R6^+\,4ELAC5!X&YVN3XCH*]+O5=>RU6[0IQ4=K.VRZ1ZR]TZ MRE#G!SGG5\(ODV-RSOG?E>WHV8[]QN.QGT_3*#-&4@A5BG!;0TAH=F.-COC8 MG.\^&5EOZX)6^JWCS/7;G"8?V=LUHD<*V@V=O"X@+ M;3 X 9/S!@'8D>T^7%W+;]HB9)\2)8.UCWID7-CBIJ>ZI+KTA@?G%;FG2? M6H1,I>NX%=5U@M(91Z4K=':3H6\#OMK=>+4T#QIM+C)XT^$=W7FZ^ MH'7XX@8(U1PXY)KZI#CX7!J![16HXS9?EJ]VK4)VP*M.7=ATWN>89EQP 0,( MAKW+^?A6A\")>B8^_FY#E01)+GBQN>]W7 "W=N_+F==KS@Y!P Q&)/UB"A?9 M7+1.:NHZ]]UXS-FHN6G+ M.J\Y2,QI&5H*?9<[G69@'^!UKXOH//!U:$![AAZF)[C4VYO7<[8R8]K@^:V8 MAQU\(V/6]%LU*,C;>!DVSMD34*[=_/S)-U*NW6W-FLH5%X'O1VEI:,37=9=% M/VOCH\:>RW?2758V#'U'6_%VG$4K#MN;*! ;S\ L0I' TK1&>1_;-0RV8VZ< MZLMW0O2M).YX*(>7ET02L&Q)-M;*:PRY:-F2NC"@WW;L8'[VCB)":N4K]VS0 M2I][9\M("AXC[G[-UR@"K]Z-A]@ MO<,;WN(X=P0:[[-R=QIEE1;X9FF!9ZNTP-=+"Z!PZN3O/^BMG5>O=E^]W'N^ MIY+=O>T7KW9?CI+G+[:B9'OWI1KM_'OWAR>52M@;2"RNVU@Z/@D^'%^<')V? M!Q]^/3H[.GW3JJ=!V)T%_K5#2[9HB2(''*YW3$W1*+]ZN)VYU]J7)2[2?0.6 M]_USF1B%OCG]2X&W\B[*X."Q(WJ4X+W.JOQ;K;8?!SM;.UH!/O9W_$,25 M+-R5R"X6612E]Z9W!>.143:[:S<0+RQ"ZXJFYVI0E ]B]F!I\T W1A?X_6S$ M]&/G! [1:OMNW[[.)M9!EE^#QU8B$50PKJF9*_R>?#7NT%JH$AQ#[K?-;;.; M/;97VKY[[4]./X3!!6[ F].S(VI2C)P_.G&M'$U+5\J^=%&<(_-?XG2I GM*Q A.C'?K?2 M*],TB]AXZ3L-CFU4-BQ>='_E!6I1:O\^B8I+-7<#$F,;N'>*^_B6H>OI:]E( M=4&<9NP2HEV.%K=''8I3'H]UBE52-%TD<$E"G^84R01THK&JBA2C5F6#A)&? M,HM*!F+(^V)? E7R(G!W=IXAO(I"JS64VT] 6 M-^-S*Q@G4S?4%-8&?ENK[ A5S3?-/81-?+@'6D?A+CQ[$I5,I\@-S31V_LFH M?_&5+JI:B1!XY>]EI3,=513@^ _:FYAA>*,8V)'#&F(,9:R0A"I/VM8&C1(N"P/1HJF(%'X MX;RD[]"AHW_#9H,C@#_T^IB'F$28@L70ZD],K0N02*VD@X*M 5"$I;PG;' Y MA8YPD.G3\2WA+#HR=45,HE2"0QSZ,"EX!9! S%.4.6F(-4Y34#F0.1[B> 1C M93N:P%O!@EY/E/!>F"[5$*H?ZEE]PYAT9')N7_5 M%3D&#-H@+M"0/^*59&'?5K@A)%_7[/W@B7:'(^TT[^AF@=Z5_I4^;4EE7L [ M+W.:Q;X=^_C2I -DGGN+X/V4QW!1$3^_?<7O ,YR6XG/#DUI>VXE%IF5CQ7$ M\C@ *4,VUK$/LSW)_HF\GN/Y-0<3@P!%GEV.Z]09Q:'7/5D:J9.NP?IVE=@^ M0FA(1#5<77!A^\8B7L&)@C>4OY/Y::Y?3/KGV)&+[D\["=09="%3&$%HP[TF M/[:5%Y$0.'^ 0@=@L\8W[G7#CO<-S;-8 Q$2.OCG\;$M;-=7&CQ1,FV"_9BJ MA[?W7NP2E0_Q*^ =O;L3_+9YOGFP:VM[8&N]DH$!RV" M9VK",L=W@M5[+Y\UI6]GKU?Z7JYD;R5[#Y&]SAOWU8L7+L[4?2?O;?,8\W?Q M]MZK[=5=O!+&A]S%EPHOX+C0UK%M(2O:%_+.7EO\7NRLI&\E???(+0T8AW-X M](W:']P!@D,'].C/.DJ#]^ 7WN$D[FR]6$ODRSY!L?AZ7,6*_WHCW6(/Q*.E M0!=SN(')O1T<;+[9//-.^,K56QWPAUPO;VA\,FS>J41CJ/.MPEATAS#[EK9+ MGQIS>^?%RMY>D*@>YLH,21!U$;R-1GF!?;VS)"H2S[1^]NK.;M_.2@Q7JO A M$GADP -GJA*B6*Q%R*?4\Q M[L:"=F<"CAP3/L1+V3<:F0E'*V76,:/G\FYEW48/MX#"F-;G9)RCVN9QTNB: M-?@37_PG_GJ+VJ%XPG6=%Q]58=%.#?'J$"-7M^$$""201[$0DYY19CE(&@%+ MQM@^MMFDZ:O*W/>A3&[?\6XMP.BVC.GB;>1$@#L$OS_;O5BSU M.%;SJ6LY)&^_@QI A,PTP[O#G?#1#4&TFL>4;'5+_C#F1NZ'"CZ)98L"B.0Q M6HTE9]=N#VFJ+KEGFCD[ M>0%27ZBHXC:%*X7Z>0KU5O.L@4GG_7(;:C'MB/S,8,=BU;SO&H72N'5>K457 MP?7*XO[\';UU2[OW#V\<+OY049$1S-;SF"*O7I73/]S=/#;Q?$_CX+]@_]W.Z_ M/7YS>G9RO!\<'/_S^&UP<'IX%)P?'5S )X+MY[L[8?#AU^.#7_E[A_!8>-B; MT[=O3S^OA*>S?R>E%G0N/*LH3B M<7!V='A\<7H6P/_Y:\1(68EO_G^/PB.#X) M?@6I@U_]>G0&PO=/^)L,?''\CGAC19AA4/RIF1F**\XA#([?T/ GP>O?8:QW M,A9(X>EO;P]!U.$4O-N_.#H[WG_[]O=@_\T;F "(O/?8\Z.+B[=$]>RD_O#H M=>.EX!OT3IL".OO.I?CU$6[(_H?],]JC\_WCPX8F" .G@Y#$!O;FZ'_>GQV= MG\,>?-B''X->./D].#O^Y=>+\^#\5]RDWWFWB/7FMY-#W$30'1^.WK[%_])/ MZ$NG%[1K%_L7OUTG+Y[!^KG[?X'4#O')P?'[]\>D;HZ/P9U!MKLB+;] M/B;6(^ :OB=GL@BPJ5YJ_%V(0XD2;$:IU"K^ #9O"''C=Y&I E M>'>+8J,(*?7.F2^[8[ M!BF8^G6DJ8C=1JD:X8K#H_VPZYW+"7%/X;3JM#(NF25P,$0C\237E,&D/K7( M&\.X![<#K=:J-%7D#2AK3"QH:A6-B^&O02,#Z@_66!I;*"NT-7,KU#B8TC^O M;(J'3/R!NRF=^=)H5B*VJA4>+'/*[,&"(-G$%7AB6145&O^!\ZUG(H:X<3$+ MGM^TOADT)=Y1_A=//!%!+( M+%A[NP\ M:)JQ+UA(PU0*XTLG]HE>B^LI>1:H(PN-JW./J6,P4)HQ\Y")K,A=IHB+3=-, M&D^,4CC/\SN8-89HJ:M@BFRQ7IMP>15Z_T2E,*[0'S>XLT!S(::HT!DFTU(D MA>(BBU%=@JR6I=GU^==9G=\'G5_UL//;V&O3O[UY6,) %RP@<%)80X\THP/I M G"CRVU [S$)UEY]%6?WY>:MT2[,QLT''3&ZM+&[B>L/0EMAX85L-:95.%%7 M39:9H^,#T*OY0KR/TQP/7]E2K4[U))Y*)2,$+1/1"[AU\F,A D)LA1YK[K\1 MDZ? /@+UW%T1'M[W%(YOSR)8>WCN++J/>!=7<*E1.Q*,\TXTR>XN\TXVVO_V M\F/X@=B-UHM@>[,,QGIL3<7GS^4V=C!>^_E.L\XG@T*^&(N#6.GS;K'8>60T MK2=YL$_DFLLF9E_D1UU'!9R3JFR;)99YT;J?A7*$E%DNO*%TBC#V0<>T@J'* M,=SV ;:Y7,,MUSF-IG5F.4H%:S?F&D&D\H2QBJFU4%=) M-Y-T>[9*NJV2;G=0%O,*P+*>6@AIZ!&?"N-IF[#44(QRL*:3"!0+D9LFMWP7*1? $/0A70:60C1 MV*0HN#1BD@EBOPJ\KF6B,[10*T'LIM$U+C<:B;FY)_\(FL*.&&)R^> 7'.C&4Q=V+Z6*@=ERS2N(]1&3U MTV(2%?IFO_4P1-72KE2%:-]J,MPA]2?QA:XN.:"@S7O;R+#U4NFQ MWN#6"D\*M&SX=#9R!-;&-UZH+3@9U54K'.)@_*ZS:*8N\TI'+IS"WBH:X6_8 M(Y^"/]SH0C*7CIG/ 8%^S3V$/P>V-6P-D^9C/JL1#":+'AT#7"2I%< ME.@8WBZAV)Y-H/K%=;]EU+#C'.N#N(T?\\5:8^&\DI@?'1KZSCQ#21 M6I6%B0?3J,:.$)B3/]QK.!/')GR@B9.BA38TKV%%Q.8+E)899Y MS]#[F]]_3CJ_&.@ 4493I 9&3=08_3C!&."+PA+44V/OV0NNDFHO6"-49*@- M6&6TVLH8%4M#L8'-;\::GO)R99Y%TX:I':! X#U@I$%)R,KP[<.24JE96;;H M^Z,:]J( F21ALCN.UNP3T$$O'ID..LJ0NR881+O*MO(QZL%E!TCMZ*JNV"Y1 M/'G;7L4H''.,0/!,!:[\QG2BXS9_I%C ,U@3+<5S$N#@T=Q6] 8[840$GDA M$:(6(,:1)1O6:ETSCAS(1IJ#'Y[YYZ_9%ZE58@R3.,EI.F*8A#P!$_UI.)OF MGG!Y&EF1<8&)D5V!9PPO M8_(LS)S#P/1S8.Q>.Q+!A@%Z-H6^Q!Z?Y&%)+S(#][OD8\??]90*8L^,UBDC M@@BBF;,X![A 5I>57Z 57CN'*405>BKO$1/[AOM.KM\G+_[ U.77_-IWER?: M_2[R1+CP.OG[#WIKY]6KW5 M^F&57/K:J?WC$ZPS.3DZ/P^HQ?+IFU 0.!C?%AH,4+04^@$39(1Q_)83$UUY M^KS!O.9,/.LD$BQCK(NRLE8,XWB^M/Z0S16%@,OT[7-,M/0> .5^0)VO_>>_ M5)8'[Z(,CA2W7SK.XENOOV^YGE\&[W2;W3;4-UUDW2U+9);/EWSW/U_?2''1 M, WT(6B QW0 $['79V/U4?0+7XCW\.+_OZ_;BD)=;_#J\8S>W MZJOC]+B.S1"4RUW^I Z'+&,K$?L2HM@+JMW)HEX-^ZV&'@5P4^7M:4<$?1WER _^95-/T'_\?4$L#!!0 ( . X:5%]A.C( MW0< -XF ; >F5N=&%L:7,Q,"UQ<3,R,#(P97@S,3$N:'1M[5IK;^,V M%OV^OX)-L&D"^/W(P\X$R"0I&J"=F:9>#+I?%I1T91&11)6D['A__1Z2\B-. MW$GA:<8--A\<2WQ=WGMX[B'I\^^N/UZ-?OMTPQ*3I>S3O][_='O%]NK-YN?N M5;-Y/;IF/XY^_HGU&JTV&RF>:V&$S'G:;-Y\V&-[B3'%H-F<3J>-:;Q?G]@T^B4<7_SC_KEYGUS(L,\H-"Q5Q0Q$KMSWG3/Y\WW2#G@8QF%^>1 MF# 1O=L3 77.^J=G8:\?4"\,.(_"4^J?],ZZW6,>=$_^TX:1353W;;29I?1N M+Q-Y/2$[_N"D4YCA5$0F&;1;K7_N/:IGZ,'4>2K&^'@_5K+,HWIE M?>S^AJ\UEZN;N]'M#[=7EZ/;CQ_8X]FL1HBK,8)D9(%VQ5_O^-ZSQM[6V&5N M$IG/V&\-]FN9U]C/C>L&"TD9$<^82;@YV.^?#E\ZCV'!HPCKH9Y2C$%.\<9% M3.01HC6HVS??:*[MQGP2KS_ZFEM:C;YUPRU+^(28HHF@*9C$)$*S7TJN .MT MQNZHD,HPF;,?I,I8NU7_A:IK[#8/&XC6V5N( M5F?GHO6>:\0(T8A7BLD,!&BDK_>D0DXA:!(+%8Y BRQIF6$/@&V&E;45L.FY,4^L?2MX MZ^TK 42H84X;5FA\!&1 ";!\#-0YCP M?$SL$K1T5Z:HT>[R>KM_2-Z*=C_R3T=N^'6@H8;-OENHFUY_A\!SR(]V!3W' MC;.V]<,U: ;$60(MI3M 4)[A:.@QW"<;=G_7"P?]8>6GEFK)O/NL,WX^MPAWSM.>-F MPM/2+2R[ BB.H3+$A'*(WZ=J89&07D 4_O%Y >$( PVQR+67*8$LS68+7D)E M?%&;K :+ORR;63!7=X[\R'L"]CBXV0'> N2B'8*<7][7/II/46$W;Y7&<"7/ M0D_8,ZC<:U^+!&9CNR*)?5^>TI%Z9!B6RL9^A>>?Z363VN"]/>%"7QK;>_:[ M/Q=@AQN:Q Q-FIKM2O#H;G)[3OMEC0O%W8=>:L2KA=)$3F(.]!3Y!*R\P?7 M,H=XFV%W>4]IM0E=JU_;VD5; KUSLD- [[\=,>\.J:+Y*JDM>>2JZ%=1RRRTCE^=76<2_09>;R,?U!4@@D5XYY(P'[7">'P#,X6%N. MQW\K_N:+D'XO!N%2I\2O[?IE_2=Z=F\[.%/X6X2E#[7>HSW,8C--2T MH+:-Z Q$*HQK HA)A<7A-("& -!E!H# 2VXR54IY]A1F2]K;+:3MCGP'TGR" MOT0>CQ6(HX:XDZ,[(,>=D^$G7]7A?[B/% 77X)4((V1V< #QI[/T.(B#7 F M92_14EYH&LR_#)$)BI3/!B)W_G>-AA.;/R \JJLY('5YY]AH^7M' W-,-.^_ M*FZXHJ:)GI;U3ANML].-Q:U&>V/9'W7;;70ZQU^]UUZ_T3UY6;=-YPCO#'A5 M%SQ_M]?=^^(-9A7^0:=X8(LU[_UM$;$> Q]:?]_[;2N/_87. "!?GQ$=[-_/'JN(KSM7?P>^,?3?8L('^SWPG?L\V&\? MMX;/W3 _V"Z+%G*+8RK?;]%%1I4O/!?QM#P>9=?3?+')O/E!;,.A+?W_R M6MQZE0B*VF5N=&%L:7,Q,"UQ<3,R,#(P97@S,3(N:'1M[5I9;^,X M$G[?7\%QL)D$\"%?Z?CH -U)&A-@IKLG\**Q^[*@I))%A!(U)&6W]]=O%2E? M<3SM1?KP!)L'1R*+9+'JXU=%4N.?;CY<3_[Y\9:E-I/LXS_>_GIWS6J-5NM3 M][K5NIGLV@S2::YT98H7(N6ZW;]S562ZTMAJW6?#YOSKM-I:>M MR7V+NNJUI%(&FK&-:U=C*L%?X/'5W\8_-1KL1D5E!KEED09N(6:E$?F4?8K! M/+!&HY*Z5L5"BVEJ62?H!.R3T@]BQGV]%5;"U;*?<B)HV$9T(NAC]/1 :&O8J8G]2)'#4NUVAW2]_9R*4%C6;3<[XQ;)+R>[,^6-J41H5M#' M-I?KV_O)W;N[ZS>3NP_OV?9L-EW']12]9U6![8K''OGZRO:>5/:NSGX#*8SA M[&V3W18%:+FHLPBT%C0:8P*'L>X3AH2$ASC$DNH[.& M#2KY05-M-Y>3^/ZC/S)+T.R3&>Y8RF? -,P$S)%A;"H,^[WDVI(7V#T42ENF MZ=IKVK8H4JY IC!H[ 1;D=@1PBP$6J%R22\0? <3?Z-%@6HS(XI'31",<@ M@4AHC#XHEF-SU"0&S>:IB%)F2OI9MY^#AJH3FD FC,0P11%O+FR*$S0%1$Y! MZA=I0J@8ISG#9C$+%YMF>"D0[/YU( @L$3DZF?"R=FH=\8?B6*TWZD6>()UP M2I+P.9)EC'TB<#8\6$?0":*@ OU.D"4H2[G&9 4'\VAHA'WLLJ\Z2902!1"( M"M'BAC-.GXB;E"52S.L='=XF M6\XY/;GLM%^-3(6H*D<@BE!)(O#US)P[S]TQKL%A!'TN0@GD2P8(S!#C5DHM M2"Q#AB26I/=8F$@J4V([XDZMI =+H54$,18;=H;8B '!Y@%P^SE*>3X%]@9I MZ;Z4*-'N\D:[?P9>BW8_]F_G;OC'0$,)BK[/R&ZZ%T<$GC-^?BSHN6@.VF2' M&S"8I:.W7*SYLH?K% 8C7IK#FU \"@%A48WD(YPJ-7: M#$3QI$12D'N^J&$ M=DUCFU2H0>(#0K$*<6NLU"N:I$J!E(:Z&"5%[':%I@R-B 77@B8@?"!VY)Q3 M3Z6AX.@6C'&1U%$7;CM1(=P/ND8%)GPB*B4GQL5I.276019;^)"]F6G@4P@D MB*2([2%^!@D>%X[#(\)QMT=V.#T9M$>4GEDR\Z [>C&VCH[(UIXS;F=YHD"&+W"C M%KB[? !9;4(?R=>?;:)G OVHDOG^RTGFW2%5O%PE]35/$6UN(G5-682U@]U> MWTVY5MIQ3+NLTIY?2<858)>9B\?P)T$A5%P[YHT%ZN<(9""NN:(,*4QK7A M4@"#\=^4&>(#C>0F4T64)P]A7E1X/[[L_0U&\40C;=31[>#(#H'CSC@KA-5] M$!3Y3,D94"3,^;0ZJM45/T)62+4 K)VGRC,BW\(OXNVKI G-O2C8FEVG1Z2^ M[7=?5GG^:ASJJR\A*E36JFQXX5K1Z0RL;M$0S:#I!DWRPL!P^3#".%!(OAB* MW)G?-1K-*'I@VE'=RR%0US>1S<#?1EI4Q\;+_JOJIJMJV7BWKG?9# :7>ZN# M9GMOW9]UVVUV.A=?O==>O]E]=5BW+6<(;PRTJBEX_KK6K7WQ^K)R_[!3?&;M MI>N]O0D1CWW@7>MO@7\,%]S@\G(!E+U'L&LAW[O?TI'T1C':OE[>,\=SE$#"73CS+ MLL_IHR)*%YL+M#8=##(R\U_,;R_<3<]@ST,_//E>O'J="DC8NU7J\,'OU_;& M^F/1^^P;9X:NQZ&@;R.B ]0IM$#[%73!OC*EVC;EC[#2^1/!T2V^EDNU-OQ[ M2)ZW^6U8H?R7<4-_TS&#O5^+56EAL&["0R2VTNXVV:O$UJ__ULU]=7?U7U!+ M P04 " #@.&E1=C%^AB % #O$P &P 'IE;G1A;&ES,3 M<7$S,C R M,&5X,S(Q+FAT;=U8;4_;2!#^?K]B&G04I/@]0$A2I#1)5:264.*JU_MRVGC7 M\0K;ZUNO";E??[-K!P@TO>A:]2U"%O;LRSSS/#LS]N#9>#H*/UY.(%%9"I?O M7[XY'T'+HXDXL6M!*EBI[C+)=+ M>QG80BZ<\,K12W6<5(B2V531UME /\$K(_3LM\$SRX*QB*J,Y0HBR8AB%*J2 MYPOX0%EY#9;5C!J)8B7Y(E'@N[X+'X2\YC>DMBNN4G:V7F?@U/<#QVPRF NZ M.AM0?@.'UW-*M4K9 MBU;&O_>B5^H_I)3E?0\U_V]M3%.L5MED90O\I[Q%JVQ0&R->4ZBZX44 M54ZM2*1"]O9B\^LW=Z[Y]?44*R893U>]YR'/6 D7; E7(B/Y\W:)H;=*)GE< M#RSY/PQ=0:_,[;)Q$]=)><[6;GN^]G5RF_ Y5Q#XMC=P]/@UV">0'T"),*Q, M_FA81I.K\/S5^6@8GD\O4*]7L_?#BQ#"Z2:PGPF2UX7W]LP>V3";C PL+SAR MVS":[T#$<.?Z#>25L)E0F1&(E8I'I&T;,-Y'MEP MH!?9W^OZOML?B:P@^?U#B(4T>Q3HL:# , 849JQ0+)LS"0%*R*1-4D+, M4[3=>35C424QD2-\DE.8W$8)R1<,\VV6\;+4"/!/CZ28G"%ADJ&K#WVIT:Q= M06-6&HI)E19 !)>!>VOM[WO%)OU$V>D2H*'3>?SBZ&:/U@=L91XF< MDYR5UO0V92L81DI;M#[::">JK:?I@7-6&E.V@NM<+!'M@NWO'77[.^NH()1B M";)2%B/'1X^497G=[R:M ^]PC>+;;[\9EV,[Z.@XA!CR1M!QE:*Z(]1FJO5T MIS')_JZX9+HXEYJ9LCD:7G! #@&EZQT=T,,[HN\5>:?&AFWO-.@@E:=]K=5? M@4[_AZ23YYA/,F(XPDRF",ZD^-30L^::<)W*"LE*36M;FTF: DY#9TB*I)<% M\ERVS:R8YR2/]'-0;'%6EM2H$)B^S9[E60I/E[*U,;R#P._83;NMG M#;O8"LJS_U+-7"@ELMZQF:7(/&5W15-(RJ0NF"DI2M9;_].GO"Q2LNKQW(38 M3.K?Z!R(V;LIPRC&^Y[1=NN^4:$[BJ[7;\RV,3F*/K5UNK9[VMUJ=FUOJ^US MRP:V[Q]_]54[1W9PLMNRC@E$'0R,:HFDOV@%K4M#'\/P/M[G9-^::ZZ27'[PUPE(E_!1VS:J[P-;^VQO1&.'>7M:O"M MG52QP]"MT6[2F*F.!49/I)R"#MM/QL./&?8OR%6[OKQ]JRPV2CB+L07#=DSQ M&P;3..;8V;?A$HLVU_755/!1@IT ;O:_7T:_(AZS8H_KMZAHE_:KD!R;D@*[ M$G8'4]0P#S^1JHVB'%/?'^#A4 !L M !Z96YT86QI#,R,BYH=&W=6&U/VT@0_GZ_8AIT%*3X M/20A29%"$E2DEE#BJM?[$Y2QQF=U: V5ZKH.,YRN;27@V59,.31(J.Y@DA0HF@,"\GR&7R*J;P$RZIBQ$FPV5^"[O@N?N+AD M5Z2T*Z92>K3VTW/*^YYC%NE->;PZZL7L"EC\IL8: 9UZON<>'I!VH]T,2$1: M;K,Q;37\)")Q])>'03HXO)PCU2JE;VH9RZTYU>MW6GZANDL6JWG'<]W?:QOC M%+U6%DG9+.^8:-&:<,16F:OH M>LZF3$'@VW[/T>/78!] O@,EPK12\:-A&8PNPM.3TT$_/!V?H5XO)A_[9R&$ MXTU@/Q,DKPT?[8D]L&$R&AA87G#@UJ$_@?YP?!Z.AK\&SC6Z0[<)XQ,(WXY@ MTK\X[I^-)M;XCW>CS] ?A-KBNZZ_%69&Q SWI>(%NL5U#6R6QPBYX[>*^YOO MVX-K?!'<:0X1SW,:Z?((2Z;FH.84/BR(0"K2%5S0@@L%:#SA(@//M3X 3^!/ MC!M)DW ^)R(C$5TH%I%4UN$TCVS8TTYV=]J^[W8'/"M(OC)W7G(8CR KI0ER?'!/69;7?C%I[7G[:Q3/O_QF M7IIVT-!Y"#'EE:"318KJCE";J=;3C<8$_7O!!-6'L]3,R&IK>,$>V0>4KG>P M%^_?$'VKR!LU5FQ[AT$#J3SL:JW^"G3Z/R2=+,=ZDA'#$58R17!FC$\-/6NN M"=.EK!!4:EKKVDS2%' :!D-2)%T6R+.LFUD)RTD>Z>?H,#:-HZDW.&J1EJK@ M6+S,FG*MA*K*V5N9WD#@-^P'W);/*G:Q%11'7U/-E"O%LT[3S%)DFM*;0Y.+ MF I]8*:DD+2S_J<;,UFD9-5AN4FQF=2]TC40JW=U#*,8;WM&VRW[1H7AJ'CM MOS+;QN2H^*&MT;;=P_96LVM[6VW_Y3:P?;_YS;TV#NR@]3BWCDE$F0S,JD32 MW]2"VE>[E8K^CE]<@[>FOLRW5L1]#DIJRW[]9?;[$#>'.8K@C%^51_-A>3+? MZ\6KC'W'9* @G[_H&=D?KS9/XV^+M>QWMU+_$H!W=QJMKC17W=:XW?<4NSQ) MX-B&45'HEG C&4_=#J[.2>UIF7V*CZI0FO.WP&SSE,6@T_R3\?:+T_2$ZOG8 M]\SGJJN#.:,)G-ST&.,D8?@2\K_?CY^M__O.W9_QV&'ZK3)Z1#B%8)B_ A-X MVZ[QS52^1);VOW XFLWGF%;K#K^/Z?/N?L4K>/D-LR-HBJWG%=WZ7:]J"]W; M*62*A6VA'D[9&L3&M?PJ:;Z/'OT+4$L#!!0 ( . X:5'8Q5]Z3R # $[1 M'@ 1 >FYT;"TR,#(P,#DS,"YH=&WLO6EW4\>V-OK]_ I=GWO/FXR!H/J& M)+S# TEEVY.(UT=. MN8A/XG/*>?#.6FZ%$91$+X1TB5,JM/??46OML[-\SDI]TO/B;'#MQ#-?=JI3BVZGZ$*>DV>#TG7[J5<> MN0'.V3-&\-4(:S,UOLFPW]YW[OCB1LGU?763T8%G>7+:A+8Y'5_RN3OH7'OP M9YQTURGZ3T/OJ#J?6$XNWK+?$XSJV]\43^7/1F=<#NNNF+0\D7K[KU3E0S^J#5T\MOC9C-T;SQ6"NGYX/>]>_.#W"C=<8#P@0#U\H7M^'O87'RV\K+7G> M_-+>/3_&%PKUM]]6!G V>%9Q][,7__5?__7KH!ATX$5FM?:8HWY]5O_XZ[/Z MUKX7SU_\&HN35G]PWH'?5F+1/^ZX\^?=7A?P!8JSY_E$*.N/18S0K3[B\4W4 M%&41ZN>?#;8A_;92),4%!Q*CYU%0YWP05GHP6@FE7/1_O:I>A>*0+[F\ZX[R MHZ%XOM;%]SM_B<,I76>]&^'L/W"^TBHBWCKR/\_]J][)6[9]LL3C M&WNX=;CV>8-M%GN[G^3&YT]DZ]4?9QMOMHO-5W_0O0][GS=VU\@F^W>QP=;Y M6[[9V?O<.]OXO'FX=[0FMW8WY.:K?;*Q^_NGO<,_R.:'UT<;G]?.-E_%8N]P ML]BDAKQE'\_W/@2U\?GUX<;1AMS;W>QL?7A/-]^\/]UZ]>EL\_ G[WW^>.K M@V*3K8F--WLG\Q]>'VP_7ZT^9AP/?8'UWS)SY+=C_N'N,Y^!YL^W!S=QN?]P?Y>+A]L/=A[7SO M\/7AYN'&Z<:'/]CFYT]RZ[4Y?;N[-MC8(6=O=U?_ IQ4"I#:@477%M[[MG&: MM$.TCOC@K51TY05!(F@FJ4*>N$;/R9.WEFB\^FSPW/=Z'7#=Y#I9EBX)OXI6 M)V;+\[KC]I<$_Q;!SZX2/#&TIT!MFW+#VT($W;8V0!L2X?U[\37^UE]2]UO4/;]*79HB0QS%VMPPAM0UKFT" M0)NKD(A!=&4\7WGQ!Y^J&$<$AT=XQX/HSJ\2_>6P+"]HO@>N7.O&5WCNDN;? MHOGGJS0/0CM&F6XKJR0"9Q;:EAK1!AY,-)%H#6KE!67/.)V91&?J+N7Y7K0E MU^29*Z^]Y6T:I&@+1T@;3;1K@U?1NZC <[?R(L__%Z1]=AV#E:C@4=H"]&^! MCAFP/N]7R!V)WZK@^/,! L;?5OK%T7$G(]GJMX,R\\8UE/CTK!_Q%L^NWZ-^ M_N5#1^_0[PW+ZEN%N)^/&*[FB7_"<.,;004%Q]^*F+^G LI6]4)PJR_Q$CJ^[/';QFO'*J;;-R>4CZB/C M[^.'/+LV4>/[#+M%/6G] X>3>C$-1^#ZPQ)>C!Y?'1S?8GQL_#W?XU8ZF$#1 M5@C/6=""F608,=12[@P%3;CZ:SV_/J5$SL'TUY[9H)Y1BI,O+VXT.O*=,SJL MN/GZE(T>(#SL[[A2A&&S D<='Q */ MUB&_45#J^-37O:.$.15QU?K&_WZ[-;[ M7TS9Q6O,BBZ!!P@*_2 7DG#H[")Q$B1C)*-@J)N>;"X 72:H,32S6MED)%<1 MI<18Y5GR^!M50JO(%DU>?F^(O"2/$F,E)!N(T!#1M4390$A@':AHQ:+)RX/2 MY>0?E3H9Z%Y,>BQ.$&J$#DR'E.>-VM&\X8?YFS=4:?>=MWSJA.9-:!J3I""3 M5")J;M%')3X"ZD02J'"C>:/S/6_W]$\G.&^6"Z^"31*G1"#B\E([ZXD B?X0 MY6D&>A6M=III(5Q*-GHFO2=* M*(G_US,P+\&):U'J264/:! &A9HY)23Z,L+I0),S@2.$\D*.LSJJ 8*\]O

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�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

-U M=4:F_#T_JGJ^"$5^B.2>@C+ECQE "G! $&"8<2)W%SB,Y3J\6N.%WI[B1!]& MZ^FV)W=3>"NBM^BKM*L-H=ZFX$I@'*]:.TP:?^V?E8#G-U'&QGZ/^C8M^U/= MC&K&]^AY:+/W/3HP+D^QA4JDR-F[C2*2NL)O=<6[VS;?B:H4VAR%49 R* "* ME7-6H@H[Q0$'&$9A%@L69FDZ7_('E1CCWB 2ST0(K2F0U5/@2)11SACD0M[D M!E;1L+G\"):*J^L$J^H0K_/;0UO<,.C.:/3T6,?^8(R5SD 91[7@7BWYMD!Z MD[YE?XSZJ_N9A\P-P+LI"K6E03SDE&0Q M2 3) /3E'X@F%%#!I=F3A#Q-$A.SY[B+J5D]]ZH/C];"#:]+=P)+7=>,:Q!R M[DG1B4QKQ'.2Y^! =4<9#=I>7BMWP8&6/5D*#I\<'&GVC'/6)#.]6;*[]2,O MZJK5[5>*4SG5$Y@"%N $P#B$@/B9G/$A8\@/.4*Q5D2*09]3.TAL1/9XFQE8 MV2PK)?:6%W EOW&$VD7T2<)"2E-I9L9<_B%4!'$D8A!2#G&0P(B&T5R2/EF] M$O[=OEV3\//Y<:CQG[7C87\@],C:,KB.V;O]KAMQ*S@K@9O"]0XHW0 @RX&& M%[L=.^Y0%X<388C:KPZXKSJX$3MC;];7^U\X5<5@G7G41JAR,J_?%%SE291Y-'] OKVY:V#TZFOPB#PW=IP&5Q;C3QL(]U5C35\9C=4%K'NO9:RT<]X M=U$64=F[@++9[O"RY&+]UU0>]3Y;LNO3*PHD&U#]B&?TEK&R<8I2"-_5@2!8E53NL$1!&* M<1I1+*A1(9C]YJ?=?O[Z__VI80F ?,+UY/QP&QU.]%LQ)V-EIG:TFRM_O M8=QL]R>U.TI9?_JI@;?.])&SS8+?B<_%ZEGN_5Y4G>VU) 1EM..I3>]6VEE5ZGV]3;/\7&=L MKV0V3=BJ.P::U\8.D'5^"'@-J.87Q(8(6;T;UNU[W&MA0T2.;H1-WQ]H6%"Z MVE1VRN?5(E>6BNF:>;:!"*Z6;Q?0B&%87UO.]C;O(7M3Z:,&]_,;( MJ=BK/]I MNH0()ACPD@4!]*LAJE[$&YJB_B7 MP[B+;31S):]QJBXG ZJYVK_2,#GF0 LIF.JL[-OXW$K%">1E[\%]$AG:3\GW MCY&KO0=9:UG;^_H8<-$I>6Y5J"_M96LG-5F"?>S3*(8I(,)/ $QX HA*1H$$ M20(>R9]B_<2+9[N9&C'+YCW>BFAPY70>1XU[/ROH..;#G8S=C=&EI,LF0!G< MN%D!;*1[M%/ 6;H,NPA#[Q77^;?'N[BZJ,'>==3EI\T34+^7=O7ZY88Q.>:E MJH/'[XHJ-8,4?DY@F,2J@CBJ$_) *.F/0H!A&HI4<3M?BS3/_\3"H/P7RLMZE**;]K8IDUO<,T W#4L*IMH.J:.2E3O MC=?D>]KA6HD[Q,2Z"*!))BV+0(Z5.*L74%O)L31QZ<^%=:F1$5-?:>JSG^E* M]Z6K#MM+N?U51_>M$SKT(Q[Q- T$P1 )!C )$6JLAAA@M*8(Z-BMZ>[F1K? MME)ZS[68AO?[IZ$TNK.X J!Q[BM*KY'0@WJ-*XHSVIZYGCCW MM)7)?[-D\B?%9I?N->?EN[RDBY6J5G[/?ZS?+"J_749X@D(!_#!B ,8H X1B M4E4,"S.&F1#\"G;0E6."]*&$;J-<#'T$AP[&('YQ ?'(!%3Y#[20=VMB[]3P M?E>*>)4F]J]4AV+ID,BT17E-IC/%ZP(5&C=G)0-H[8]=^VG/190AFB48(!I* M/L28@2P(*& QPV&6L RK6/7!:3^[?4V-\VK9O+P.6#"._-%!5X_@+&'FF,1. M!'S4 -:2.DO=>0H.A_DZ][I[S22=I_2^D)GSY"O#..,+7^-\R=E[7"SSY4,I M>6KSM%FH'#GON,AIOI;4$<6N9+/10SC#/, R#U:#&#*J.28A ,2);[\ MOR 6B58Z7ZW>IL8QG82"2MKZ\+Q0,H.5 )OV)T-R:_2CKD<\UK!TS#D[&"M! M9]Z7%D(I;)W*P4$^PCY0G&0F/-GAZ^0H[-/];+;"WI<&0!AR M=4CLA^JX.(E %B<(I'&$Y>8',9H:U8SO[VYJ['*0W:0\2F]BR"C]6&M2BC4$ M77-*!R?W1S=ZL%AEE?X>QZ45+>V/>$7OK8&QY[A\5/^O]E[?\4+%J>[\MM4O M;I9L_P>=)[=Q(32,4,Q9!C(:"0"CV <(XP@0X@<1]?U,A&91ZC:DFAI-*3%G MGOK3ZT@[ZV8\KWZIV.OP9YT7#"/?K8RO'N>-/FJ.J='2@#D)*[**M=5@?2N" MC1O6;Q/+HP0 5AL?F-Z5R]6#[]NGVXJ2C>-]^6[#/\E%Y?X/OOC.?ULMUX_E M//8C/TXS!B+$$@!IE +,569"BI /8YK@S*QP\$!!ID;E\ML/#+/"#AT"/>H= M UC';%NK,/..-KE;/68JF3CAWF=I[,^\OW%<>'=+B^6VK@71:J[:H;*,F]'V M2L2.\MY>V][P!$RK9>WIU48&I1@QE!&0X#@$, R$)#V*@*2\U!=1$)"4FN9= MVN]B:IRVY]9:BUO_J]^E4!=031/R*IAWG1:W507J73VMM.IW30 MR^A9E$YK>2IYTIDG1XX%OZM*!99WFW6YEN:^Y*:Z-M%<6D-Q3/T0\!1R -* M 48A!BS"C)$ BB SREA7E8I>';7!7$8,VD^^B#S$020R%4B0V$& M4)1D@@DNDM3H:-2J=%-;'%KE5$9=I5Y;R:BYGE ';5U/TU9)3U+45DVOTG-H M1*R-89.3S'-R$^4$?CSX;FLU.KJ^C M<+-9KY[D$D9W1;H^U*G[_U*LRE*=\'XN5I1S5OZ6+_.GS=/-D_*GEN+Q_#MG MM\N;SQNRR.F=$%6MTWE"0YBQR =AP.0>0Z@87,A\D!)"8(I5)(C6$C**M%-; M4K8*-G47RDXMA9GW5.OD/2AE/:IN;IX;=;VB4='+EQ[VGBLM):G5:@[/U&__ M^^A?;R8WZH[7GV,7[]TGT*F(^*']!"J-ZTN[5F>O4=JKM?9:M;U;N17R:LV] MNPE^"<,+.KSJ%_%JU1Y>ZB?H8MBX9PUDL"$,)(%$F .19"+),((!1@ 5& M+ JYT+9%##J>FEFQYVNHA/?45U859&KE5QN@YLK M+B/R8AHK/Z.<':\D$\' M8H-EU1'4(ZV0-B$W6^0&X-:[7IFT-][2,T#+O55DR/M7W)1UCU;G/@EHB!F1 MNU!* /2I#TB:9L!7YYA!%L" P'F=VO?K&A=K@_NN;C\FL^*P-W<3XPU_R)*&PGGG;4-L!]U9[P'*6L$S$":!IIISW5?1RR@E(@T3"RBD.!&N ?;]D MH\':]N60;2K)'"!J<),W%*,Q;N+V;]$LWYZ=4MSZ[==>)^/?7IW2\>3MT\D' M!U?:KBMZ5BQ<'4O.!TK 7(\N7?8?*VQ:6Y(;.<@Z$'![1+,&EM@B^ Y M9H=+N W)EGD)0(,-KD4@1]K4#OX0S7:PFL#T[EHOM3'>3E53F[W=J>X[5Z97 M:#?!\PC1B/F"@Y!&TJQ*LP @+/=1&>,)(QG!$>7S]6J-%WIFU5$/1I2Z[.8-'=!(Q>3_PU/A'"HMY/D!]M.7B?AP:&. M9Y,<'#UX16(#Y?=7\$?97OZ=WR[IZHE_7)7E)[Z^$_?X1UT"1OZ\4(3RCM?_ MW56^]1,804: P%32 $PAR'@F0(#\"/EQ HDPRZQRM4A3,\7J&'_:5G-93,UPG MU?CI&ZR@>#+%@YV6KXF JS;%GW%Q5U0E)EBU/Y;]5F=DI;;B.I8J\J[R5:+!2Y*5=VP M/L8V3,&I,P1ZY&D96,?LV+U,G'E28%52IA:Y/AA3507KD!/;D79:$-D/O>OO M]A5B\;1P.!VJ?$A:QB&8@31$&D"8IP%%&@!^&<0IA MC$.B5;CO\MK.^<+IZ6%:MU!=/!!$:X&GQEO=F%':C2UM#K$,BS6X'FX]"IS2(#HF MTIO/MV]GIR-_=Y&:,Z_=GWABI;:\9>4BW>IDL03$2,!;K17A6N9QBTJ,- )' MU2?&ZG?8.O2NN5]6GW[9B)/_-V=-CM*;)3N9SM'P>.S*7B9$*ZTF%5>4*MO> M5AFY&:S5F1TE=-U+5.K@O,P2OC;9XUJ11B4'2_@=SGU;S5JI0/,QE_]A%;/4 M7B5<5?M-1,BC5 0@(10!&.$8($P8B"G$&?'CB(;7E*(YV>G43+V.D/4)SE6U M:$[CK,>3MM%S3(;' 6I=*'V:/Y7SP.J9Q%W>1MU39EL:F\S^__6#49W7[CZ\<5\WY7*GJ5 MCIHN5MICI$=:-I%W3%CC@F[,;KI(VF2VBWV.RFJZ"!PRFO9[P]CLS::4+97E M#:VW9"K?TX^\G$.2I#Q,$(AA$@*(0PPR['. PD#X,(Y(9%;8]$P_4^.N5DRO M(Z?!1*/R016F*]!WHSW8S-3[8 M"MI)2V'@[7T>SGX>L >2!8WR&N,6?!\K (=X*8".YPAM]6&;N[Q=AZ'5\ M/__V>"[O%S78IB M:HRRE?"*LY\30.J1QG7P.*8)0V3,,Q&<5=YJ*H+C7L;-17!6RZ-D!.>?O#:7 M]U!7HG#@^ =MF-,18^1E"Q M0LP!Q!0"0@("?)$&)*0L3 .CRBCV19PJV6=<*ECI[JI;UC M5E6.96AV:VL?@2:WO>K0NN9&JZ-:J3E2PFO;@^$FZ[4U*5\I];5ME,_GO[;> MD]E:4Q9K*0Q?XB)??5@5G.)RW1RC0!QCZ$,*$$]$%=;S;O6$\^4\"'D2ASP *(9R0Y@A)J4??H*E M$8A1:G3@=-S%U"9Q?34ME^A*1N_W6DK#'>$))/6LINOP<7WT;@B->63>6>VM M!N(=]S)NW-U9+8_"[,X_>>613V5KSD481AB%(?!CK(Y[)%9(!')V!RA,F)SV M26(TN_>;G]K,[AQH5/(-/>6IL3,\X3%&9+S3G0M@##_8V=/9R:%.WRU M.L4YFI?KG.)%6QVJ_D@-'&+V8;ML2P\"8X3I.0 '(UOZ2.]KS>==@Z-9S$$! &.8L $DPPH( :81Q20S(^(SV(L MI+GRG1=D-2[/K;U[^LY%Q<5C?D#WQ)[B1W(Q#M$'7 M8Q074#KF%XGB3F:O%=I34G?O@^P=A [%RB;]:/<]*AF9(G)(3<;O7Y-Q35WF MWFS6CZM"Q;'.H8@(0[ZZ((DC #,5_P!C'PC&(4$)\7UL=M1ZHI.I$5 3([21 M0I8S#V_E'&[2G(16\^SU2L!\,^[A_P\7?^5J=>NX6S<^K14Y?YB$/$>3,!S!-4P!#E !$N !Q M)F+LAR$DF5'BOO-=36V=VTG:L0C-%K8>7/4HPPY:C@GC)% SKY;3^[WYKQ,? MJV.2.T< M<:/R&[9;&K<#H,?Z%D%U3/VG\DF\V7[3C;SN\D.< <9E>HC#+E\U.\09_2\E MASCWFMD2P'@^?[]J*Y+*4-V"2^JJS!7[*:'F7V8*I[I&D'*>=' MFQTQQ]GMZ2!C]]"SI[^1#S\O:WY\"*KQSC#F."QJ*Q((E1+G;#_J?&+]N5%E M!^_XMI?;'_[?.2]DDX\O3>A]3HSDE9U,;;RMIQ7&?;OXZ,%K1;#3T",X9QHX9[CIXC1EM$$PV*F\O8Z_&6540=<]4^ MF+<=,+MU56T&.&AB8S?.X5*G(X<[:&)P'/6@^Z+YU=F-9#6FF.W# C_,B8AI MD D!PCA+5=YD=4*F*J6FUE!M M[@'>'!95[A3_+M^\[)YIBH/?J-O0G07%11)#P2#@,2$ )EDB*9P(P#)*.$X1 MAM3H%-^R?).S@CO5UKM*>>]_J+]S56+O7O:ZO7UKGJVT,K.);8^TGJW\BN/G M>&'I%*@^&)R]@>RJIT:S^V"C8CV:3DUL1\-@M?RU91''+8?M!M^C\MB.NAEX M(G))@G,"[%\\=T+X4X$XBE@(J%#A1G+E -@/,Y 0Q)D?QPPAL[,2VQ).N\(NQ/LJ:IRRO.7:N-R4:JT7O8G'"*\=%L@AG M8V#US,:ZD..>YKC"^.B5EWTZ:0\N,L31&)0$)I M!&#@RQF0^A0$C#/FIY0F?JP7@/6\/M[9UV4=]DZ] M-!X?MF>Y6S_RXH;28J-JW6.2+ZK4%F\W12&_DCFA# D6TV)K4_R7ZOE6JHDWWAHB>K G0 1 M!CE. H SQ &,$9%[.1\"%A.601:EF.E;6T,DF!K![.O@W8DV>.YFO2YRLJES M0JU7WKYRVW75P @9-& :MISK87#,8,N1V$DLU%[-"Q9 MDM? UFMC#FIX/.OS&KWW[-*K&AI:S4FV40=G'=_^?I&]%3E=-VG6*T/YPZH0 M/%?)HP*"0\)C++?WRO\P11 @GPN0)"*,D9#6;9P:>-%<+]%$76R:Z_5MW=9B MJT,=J5"?PQBFEA M^7!#U_GW:E,QASQ+LC -0(B5JXL?9P"+. $DY#YG+&&I(//U:HT7>K2JW[61 M6;\5P-TD5M[:5(KN;ZW8ZE+P MYV\URK]X6^&]F\LP&W.A.6(VN<^@]U&YSAR50VX;T,+0/(MOY1:FP(O;)>,_ M_A_^,J=9G/(X3$!&57)=2 G(,&(@X=2'E"8B"+72*IWM86H'#DUBP49*KQ+3 MDW*:IEL\!+*?^ M4!NBS[A8MUD:HA!%F/,$A)P& '(D0);0%& 5=(X"1A)HE";MN(NI3>A&0J\2 M<6 FC!- ZMD0U\'C_&3/"!EC<^"\\C:7_1.]C+J\G]?R?+Z^=U)PO,Q M7_+;-7\JYSR..(LC 5)*5%Z)* $(HP3X(N8P@3Q.83ATMI_J<-ISOR.Q][N2 MV:N$OH(+3H)NS@S70CDJ3QBC>!5O]$'CBD5.]OEJG-*'0!_#]+XW\&"9%W*/ M\6:_4&?CIY.1@$5I% ,A30@ &42 I&D ?!8D@;0Z)-50(T?L\WU-C65J4;TW MWJZB[#=]!SP=<#6/=^U YOK\]ABM^HS6?B%,#4"L'K[V=#?NZ>IEO8^.3S5> M&48:%0_)1LN;)9.]?,]IOGRX$Q_R)5[27.UURG5179V6*FZM//VKQNKFPD]2 M1#"(,N7I2PD"*&-9Y21!HBB#U.:SD-\V*^AGU4F@%P&KZ2%.=C1NDH<^78]2-?0^/+#^&G[.UWAQPUA>%?-N MSI,X8P1&00S2F L 8Q\#Y*<,JV8WF?9\J-: M\%2ZW7Q=VCYI@,M !S<&[7#XS5\FNG>QJW\%JOMD0NC9" MI*C>3M:9M]4%B%4!2JF-_)D>Y,;D,Q0WF[1D+,.HA#44H4,J&]S.,))[__2\ M6+UP7I^G\=/)33ZMEM]Y*>VO.H+\7G%']_=*F$^K]=_X6@7V/"R5@-5=R=US M1<=S01*>\# $*$H# $64 B3_#6*:(8@83V)B= \ZBM13L]2^+8NMG!ZO$QO. MFLB:52VR&<>.,_9ZQ#RY$75]X7LJ)=4NA]#,V^K:ANG4.LPJ8I>_77LO?.WM M]*RX?V,SL2#6U M=:B2U=L)ZREI#9<>.\-EQ>:W/PB3V CLU/).#MC,(Y5NGE1NM'V"&=8C;AXT M!9O2CL(,2\-MAF'C0T/R90?*VKD3*I+KPV+U1WE#RG6!J6[*H[XF)C1EMV)6 M]>94)&(EJ?=[*ZM-_SX-2.Q&5_?T-W+\]&7-CR.D-=X97.'RF1?KE\_R4UC? M+)G*T?-<)PA5[BDW/_)R3C(68A^F@"1Q* V.& ,3J@ZU&+92@=,\Q@%(<4 MMM3%Q7)IRXO=CEW<4A>'$^4MM5\=X)_69&[["U_R B]D^S?L*5_FBM36\@M1 M.[%M9L$@CJ. TA P1!*5R98!++($D#CVTXADE-%8VT?-H..IL5";C/"AEKTJ MVH;WI&^/W$SRW9J,1#\KN<37,36UT#9B>U)N;U_PZDQ+(_GC=0 ;.+,Y GHD MAS9[@)OYM U K=>OS:2]\7S;!FBYY]\VY/UA!NCMDJZ>^-;"_:A&3Z6J5S90 MA"AD-(,@2Q@%D,0,$%]D@&4P3DF:9G%J5"*DIZ^I47TMJK?;D[7"#C(X^T#6 M,S0M0>>8Q0>C9FQ@:N!AT[#LZVY4@U)#[T-#4N>5P4EO=M76ZWQA=YMUN99V M4;Y\F/L!C87O8R!\"*79&$DB\2611#'%64P%SH0PS(#3T]W4&*1-^E*)7 =J MMFGVO([8YL6"--'OYQ7[F#JF%DTXK:;4T4#F^OPZ?9V,G6Q'0^$3F7=TWK)J MG#31D"&$/$XH!CR6.U+(DP @Q D@*N-JC"G*J)$O;F]O4Z.7GJ5V4)QJ/]17 M&2F3BR2] CM;AHJ[\-#^#J=@K/0'<.J]-(Q/3H4-M;4+7AH/F_+=AO^-X^+^ MC]4\"5.<0&FW^)3[ /HD SBF 8BC("0H22*!C!C&L/^I<8[\XD(S5C$%7(]G M',+H^@3^7!CA5OQ94U7R,\[9S%,:>%(%>WPT$#N;#&4JPJB<-1"?0Q8;VHS5 M3,I-9'LWS>GVZCSAA(9>[^MZ=JC@!3-(T17(?&:OH3LP MAK$JAQISF,8B8-#HP/M:@:9&D5\W3T^X>%$.2FW>@_?-A6=U&=K4;*O4,8P, MOW;H]'ATS %QS*JM*MMKNITVVZP4LZ-1\79*F52=,H]5MP2TU;#V:V4:-P+> M$H)'P?*VVAUA"RY'G\_3*$OE\I$"IH)E(0Z(VH0G(!7<3PDD&"&M:X3!$DR- MA>7G'3G@.]B(FT(YR:VX4N*5-N-=_%YM.UX),=T->1>CJ[;D>PU=4_ZX MHE%5NJYQ,.()2I(P)<"/@@1 2<8 DS0!C 9$^"'GE!F5$3C9R]08J[9 %LK] M5';WY.$!%N)I./5XZFJ0''-1UT*KHCJIFPK'9Q"P7]CXL*-7J&=\1M?398S/ M/3S0J5\.[BEX5N'BIJV+7G@LWF_7CJE"[H7D2"DQ$R('/E<^[6J(S+B+@$PB1B!%*H-'5 MWX7^IC:3JS3\'M[*9^ZFI NTWD2W")_CN;^5M*FWOO52VDEK,5>U'BQ6TT]? MZ'+^7.QHIRS4B5R5LR'I6YWX@MGG#^I:\JW*G54L58QZ_NEEJK< M(_,(,Q)R"$'B4\E>L"H0GPJ >,:#0%I7:13/90-DI16D?)TT)E.Q*Y.[&5EG M]WENM*KSE.>-7NHVG^[TD4^U-\L;_5IL-L:PGQ!''A?7)T3M4"A-O%85[TYX M.V6\CC:'-=]F=<*F\0;'(#!ZO$$:*5;:]6"915#;@; ^ P2)",! _@T%&08I$B+%-.$^AT9)PJMFC0SM$5)_ M5^D?!]T%-C#I6=#FRCOF_@O^<>;Y]/84M)H0KVYYW(QV>]H+^:]4Y@P\EK@K[> M#'>$J6,:.%L<_,!)TX5[Y@#$1J@9_OI.EP-PT:PD;M&5LBS6NY2$7RE?XB)? M59?F-!882>L ()%@ !,8 .3'# 0(H9 G<8QPHD-69WN8&B6ULAGY&YS'KY]N MK*#B^DY $Q!MQKBH= \OR'<[G"#_=<@'YQL?9=9?U*V=VY[S9;E:Y*SZ1U6UXT[(#4;9;F_?;,I\R*$I50G]U>2!? MICDO=XLGH;X@&/N )7&@HIW^$H3D/E\O^#QA#/F$9LIU5<6( MR[UO%J<$\(BE24I]GA"HF\#KL/&I\7TEE.*'(/R9_-*63GC13\EUA%X_.5^+ MB6,N-87#*+W6.;VO2*9UU.1HJ;/.*=--E'7VF8$.9O21L\V"WXDF3V@;QJ*( M0)U1[RR$,(X$X6$ 0DY\ &-" 289!PQCF-)0L!@:V8#Z74]M@K>2JX^Z37[[ MWBA;\P#X]0PT-Z ZWVD>X]F1VVETL3E@5OW0]'L?UQG-&)4CCS3S%@8RV,GR M8)W:=F]>=H\TL7E5S;"F$-A?Y(/K\G99>\S])\\?'E55L>^\P ^\^N4[N5O? MNJC,(U\2G4 8"*RVPB*$ *5,_HV0- [#A)!(RY)Y)?FGQJ6MP #7$GL/2F1/ M6K'<$\K#J_+D5>5&'$1A&$8S]P6@2]W0_ ]?LWRE-V=6] M6Y]2I?DY6<*R6ZNR5,X1"@5/?B&M]W*+A-= 43_B*3 Z'H06UY/7&4>KB]+( M*HR[LKW.^!PMCZ\DQD#7[RHOKPKDJGW,YSB2NW>&SJME?]9*?GD3G22;M=M!_,PPED"PP@0I*Z M"8T!B;,$\#C.1!8+/TN9V23OZVYJ4_[3YHE("U,:GO4<;QV;KYOXO8#KTH M M&)V30BNH0G$_S[Y]CM !Q2YC]/8X,G_H:'_,)EIO#70_7:YSEB\VJL;0KM#K M^Q]TL6&<*8]89?ALZJN)._$>%\M\^5!*>Z:V>UY.-U#Y5F2<\ PF!$1Q',DM M>*SJ64;RGY3!+!$0A[&6;\H(LDZ-U;J2=HHZ#TJRX7*(]:AP(@/GF$<'CIFY M\Z][-*UZ%#L4=UPW9?>X'_D^C]#E@,B]_RUWN7('6RU&*D'+;US98',.19AQ MRD%"4G70&G&0L40R?Q*36&XW4QQHI6WLZ6-J/-U(65M-GI+3(#[K#(S]G&H) M',=<>(R+]WLMI.;BU0>006#:]4"-%'!F\"&9Q8[U(] ;$W;FU?%BO?IEWXOA MNO"HE8Q1-P\/!7_ :W[SI'QQZA"QI^J@[XO*'E!4)X+S@ CH$T9 F"*HG#!3 M@.3_ ()<)#&, DT:O$J*J1'EV_/AQC.OV&HP)"',L%'2LUR=8^^8AX]34VU5 M\&H=U)Y_IX774<-9SBHS%!UFLM(4Y#7S6YEA=2'KE6%C0TLRR/E-\[J$%W]> M\-:#\6DEYW_M SG'/$S3(,& )S@#,)9$F6$:@9 EF*8)5'EHS,HN7.YT:I38 ME;DN+-\1UK26@@;F>HQG&TG'!-<5=^9M!:X=NG7P'%#G0!\@N[4,-/H=N5Z! M/A+'-0D,WKW69_(3_Z/C/UVLEO*OM.*Z4F6Y>527N>7MLOM,OJ2YE*H3>1$B MP5**8D RR@",< *RE&"0A0&E,:4H3,T9I\;JVW/EZU7E M^*H44MX[W9"95J61W$!M8N[&5=2*A*_D3FH3W?,NIU9[&7".*4EJ@&<^TA&/A)P"*: ;C%," $[FQCR(@TI#A),0B0FB^K QL=J]Y MS&DF@A9)9#5)' GBE.SWE+B07\P3JT+]7HVH\@Y.U";W8(/ R\WL-APR;'.S0>INO>8?+ )@:61]L% M7,Q)2K&?I"G@H&1@29^F/MC]ZH96 M9Z-M8#97QNFMNF[BY5I:IT+(#J6I5( M9<@HH;:Y"%,[!JC203\W:JAU#M>*R,UC+;QAO2#S,=$C![=(.^:0SQU\&_&] MG?S5EKW5H-JT;W6P6*1H,'Y62QF92S%NP:/!*!V511K>TC V?/_TO%B]YK!?=( M(WDU$\M.>!SM2&]&A/K#H<=_3D!V3'M;?-]T\3T7IFB/ZXRQLDEQ^IV/RFS& MF!P2FGD#U_'85UY\SRD_W<U/J_7?^%KN%%N#NF^9/Q MY+L W*IX;JUT&V:NM*SN$U_XVMLI.FL_"G7\W%'6_LHP[ABY6%Y&TN!5UJAQ M1^?<0C>R%%8<8 ]2'7$8X\3/"$C]0%GZH0!(X 0DJKXA@2'Q$Z/CCM[>IF;= M=Y,A'1[>7^6_.BB?E#7H')/Y(5).G06T0''H7OJ:F:&T=+_@+CJ-_$_;Y!@W M9;FIG55+E<6-2GK\ZVHAFUE(6;_@-9\SZD<)\J$J!)8"Z..@#D 2,87&,E;S(8;3UFG-@8CF@L#TS2U*G7V-%\ MYK6Z>YU/1&D_@9Q,YD,UB3Q,!F+_8^1>,A\':_F6!G0]P&&LR9'XA9=-TK$:CD'_ N$.6<<"2?+5M0FWEK&2/6ZZBEW]IX/EK&&NZY9YF_/= S2]VG\CMI M 6/EJOJ1RT6G]2]Y^;9D>5GY)7/V_@>5C]9!=?,D)CC$*0(HHQ3 *$: 0'4J M0H0(LX"C)(Y;+V&];<@@.;1FT[ZKL./%0*GQ9R]7^2KDE!KF #)L2/1V"NY@ M'LF5K))?95EM-/ J%6;;'-TO,Z^KAE?KT<0!6_0^NP9'JWYJ@P09UZ/M&JR. M?-^N:FQHM"]9=Q++?,?Y0IT:?5@57_&"?UL6'"_4Z?3'55E^7I75J?0\]$E" M0LZ GX8A@'Y$ (Y1!C@+:91&H8@CH[2D0X28FJG\82^)-FYU &)5@%)JX96[ MC%(JL_96*6]1%7IOU#*-&QXP>GILZGI,').I$K^3Q&OFW1R-B&+3[2 H-;S/ MEP9A0+#QJB;YYV?N-$F@>9]+4#UD* MXA"IZI\\DD1*0A!DS$]YYD,_S8;%)!M(,34F[=[,G:^X.U/'H/N_KN^B#+,K M#ALXS;-KU\/A^C3:U4A<$3<\ $DWX<$F@KQ2%/ K,X'^PYI;'@:_'R]#2-N M TU5T;Q=2>8;4JX+*8)!4G?M-B2/#9M7VAN5V^;Q9EQ_5D5O09&1$ 4U9&C*0P)0!F(4(8,X( MH F*<:8D7H NYPC MU)B"-#"Q23A]W8U*+QIZ'Y*)SBL#[DP_%_P9Y^SK2JS_P 7_F%-UXR?IZC>L MSH"76.HS3X7(&*0$()%PN9'Q$ MHI:Z7K6?=H(;7.=I(:]Q26H;3\<$TT+9RNLU E>7=[^Y0]+@3M0VHB-=AUZ- MK-D]J E*O5>@6@V-=_MIHM?>Q:?1BU=:>3=ER=?E;QPK$Y+=+;^H\[!"FI=5 MR?)ORQ4I>?%=[=:JY4(YG4N[M37E[6OJ M_:YT]2IE#4^V;'\*AD;L^ ,\HN$[XM@.-YGMCH 3,]N2B*]CFMO%]ZPY;[F; M@76F&*NN2?#BLUS!;I=O\7.^QHMF?YM%(>0ARP *DAC *).6/R,8)&%*19 & MB%&CW*J]O4V-\W?">DI:D"^]1E[#.D^]$.NQKS7@''/I>9A0A)(,^,(7 8D EF$&* X$H'\ M(PC"X/JJ<[L.)T9%[+5(N;YP'0"2^<5J'PA6+U!/ M=C3N16F?KD<7HKT/#]VZ_->F7#?IUMK=$?_$U[=+NGKBR@GL?J42'7XN5M]S MQMF;EV\EEV;/UA/WADIRJGW)6J^#)$U0*@0#1,0$P!BF -,L!D*2!TU#2"@U MJXWK0,BI\4]'1Y7JL&BU])9\77O!RI^JOU.5=7)35E$&WFKK#H^W&O[9=&?E MX O0W9"][K@ZW\?M#>E604]JZ-4J>C\K)7]1OZZRB;:**J^QG[_5@_Q+)^AA MIZ\3GQ:7 V)W#^E SI&WGNZ0/MZQ.NQKN!?;:MDI^'ZW69>J'(OL;$["*"5A M&H L#D( <9J #&(.4NX3(1 E!!D=F/5U-K5EH);5*RO[:K63T_M9LGV57M,T MX5LOU)IFJ24 75NG-7:5G+,Z"X3O\=PD1V[Y^9_L;W;7ODN:G//DN MOC.,2+84587&WBS9^R;H?FN*!(1!BI(0, *).C*+0288!#!B$20L2$*!3-CD M8H]3HY2=]?#>*"&!/L1Z+&(5.,=4LL.L$K;R4VK%=6)Y:8-CDU4N=SHJM6AC M<,@O^B\.(YF=G?1!"EU[(F]D=TV_RL^?BU7!Z^?N\0]>OO\A.Y9]Y$MCWK;L@ST2'F$0;-*W2W%')?X1<#]<,L;HGN;FB7[Y4RF+3.R[P=8CZZMP>:8 M[QC,*4IH@7R3 )Y'< M\XJ0 !1&&,B_Q'%*<,"H;\(7VY:GQ@U2,$.;;XN1IH4V1'/7]M3G.P: M6C5:MHV/:V([N ]\'1[&(JO<+CM[21U>+1] M#(?3D^U.=Z][L'VL]\5S[1.O#&.1MN)=50"OSL'SN!CWZ<0*N8R:ZN7M[Z]VLUT5.-NLJ)GJ] M4ND"U5&M@Y@_4X2L^FYJ=SZN0Z8I)D=>EL8-#'5&4-43*V_.*B @%[GRV%17 M6,K588,7O^&U"A1Z>2=E.2BXAZ*80\H#Y8HOB2S.(I"E4028'V _E!P7!4;. M4-<(,S5NZPCM-5(K/VNY>3E.C^P=I% V=3>X8@AU_0G&&1CG#@-;-;R='LH[ M_L1HO7A*%Z=5%VW :M<%X IY1K[COQZYXTM\"VT.=@DK5 F"=[S^[^VRR5_T MC@M>%+QU09,V:[4:U'DJYK[(1$8$!D(0"F ( R!_(*W))$EA*/\7^-BL?LHP M0;2F^*@%5-KT6VW1K&HSMJI,3%R);.S1-61\=,G5&>:C^6%5@GL_MRK\HJ+) MVC%HQ*^&H+;R;_J'8(BGU14(6G:B&B+)V/Y15Z!UPO7IFM8&^NE_EPTM%JN* MK>^J$H;-IHXDF 5)S(#/XA H!R: ?!^"5+8C:,80Y$9)U,[V-#5[\]M2PO>' M7)UD7X8>^6?!U.,O*Q YIB@E(]@*Z=52.M@+7\3"JL/]V<[&=;2_I/.1@_W% M%X:>X#>4\VV9K[LW]QD5-(BY#X(T%@!F<00(X1&@',9A0F+D)T;%KL]U-#5. MV,KI;92@5CPDSH*L>YI_/73.S_%;U"H99T[\(B[A8/?@_DQ?(Q_9]VM\?%A_ MX?EA)/%77.1U K_Z^O#]21)K_.CG4/@V'3;XXZ&%4/CBMW>%\/_/40,>"ZL2D MJ=.]C9)/?0P9\2$0F9![FCC(0)9$ LCY[6>"$,8C(^?,D[U,;78WX@TZPST- MHZ83P+7@N+[PK^2;>2T^3K(Y]6%@]4K_9$?C7M_WZ7IT5=_[\+77\O5=_S;^ M.PX9XZ&J HU)"&#@R[^)* ,HYD+^+HLC;C3MSW4TM9F_D[-SE5.'Z,]4(KNA M5^8'\)I>AP\';;2K[L:+:N8DPKT?!S=WTP=]O=*]\VF-S]\IGWG>C![*8CU_ MNUJ6TGQCZA:UVD>H/&H_\G*.@R#B*8E @$D*8)9D !.4@#CF491E+&215J+= MODZF1@M=.;U64+G\25$U$^WV0MI/![: X0#YK\/Y MW]O^*'-?1\-VWFL].Z RX&^XE-/I*R^^YU2V]E!PKDBE.2'C<8 2'B+ HA0! MF+ 09+[B@"",&$K]!.O5%+WU7[]-X8'$I_Z$'] MB:_OQ#W^,<]B/PI2B@%-H2]I4ZCC41P!(=D30Q\E049,TJ;U]&7$H".D/=N/ MN*@2H.&#R('_K2;5(C<\;^G#6V^;90E%Y^;5<I\(M;_XR@ K[49!)9N3PRK;O?D#%TR%FK5A7S[- M, UB$!*>2"M-J"R-) 141"0(&(T%TTJV=;FKJ5EI]X_<4_)6@9$&-D8_GAJ6 MF364''-(!5!-VZG9NG MRI&P5.[&5.Z\W^6J^,"2?9';\'G&(P)%D( LXP& C$4 <1(#$:<\$11G/M;: M((\F\=08O)718XV0WDO.%^?]X5YIG/7LRDF-GN.5I5($$*6)U]76ZZBK N"Z MSS4JUP0Z\W;%F+V.WC-O^TVTJGM*=WOV[&C#9-,J=B_TJ+;U:&-P:*&/U_&5 MON95OBZYE;LKOJ[5B6_5]V=>5-+- PQ##C-?+CP!!3!%!&1$KD,,!A%*>)JE MJ1CD>=[;[=16CYU'=9.Q[QD7WO>*490?.ELM%K@H53ZMVB=]J$MZ_UCH+0[V M$7;,\#MPFVQ^4F;Y*7NUU UQ?U8GEDIP!Q[L6D Y\6?O[_EUO-NUT#CKZZ[W MMOFE\5=IN.,B7WU;EI(*J\CFM@8T1C$+:0B8GX4 "E4>BZET?X(3$?E)D$9: M#NZ]O4R-D%I!#6L\]R-Y^;+8"CZN#49M:(RNB"^J?NT=\?D.1KLDOJAC]Y;X M\L-FLYSQ?/Z1/^!%[5M>N2^D6$1Q' M XD3-:.0#'"001%DH H00QR'5F=LG MVI[:C*[$:R(GC/P_3N'6/Y.O1,/Q_#4!0GL&]ZB\F[=E.W%+3O_TL/K^JWRK MGK?R+X=3]E2+HTS4'E7:Z=GWR,#=0KU!*>]73;+*LYGHYCQ+:%R%:]"$RQT# M9( $$00Q8T+.9YCX$37+Z:'?N=9G/&X>#]G0(R[KQ$G/C=R5!RAOA3;<*^B/ MA.9^P2ZZ(^T9&J'5-60CMG>0OG*VG[_2XK[!&#"K>P?]WL?=/QBC""$"DHA,R^'TL.&IV19* M-D\)YRGI],V*/; NVQ1#(7#,%9K:&]D2IU2]PI#8:VXT*^*4$ET3XN3OS:?< MN^;R]#.7NP7V?LE4]K$Y\E%*288 3KGYC: M)&R%]&HII87+J@1]^M/Q-)"7Y^75\#B>H,;(&$W57NVOF+.GVQUM\O:JU9W% M_0]:3C5O&)9XL9T)?:6]V=&=!"QJHS-*DO37"634QD [5;JE $?9OLC7'ZO* M"D*PD%$?D!A),Q)"'^ DCD'JQTE$11;Q)#1QOMTU;;2&C5ABV+B*0@N5H EF MRG$%^2&6%G<" 49^!B#S14AY1F%&YM]Y058&92@&@-7M8L)PQ8F?T"0C *$8 M AA ##).!(@(1XC1C,6I4?*>@5_6V'%PRVMQTUY]!J#A>)E1W\R!#[;\YV+# M5+V@SZNB]GTY\,1V7@KZ&"K+:T[;^MB+RX%6)U:1PR>&+1>UGV&I5J'UBYS7 MA"2<"I 1)N=U',8@@P(!B+(X#I*0!R@S63'V6I_:HG&O^J@=)QY7"PE9^<__ MA,(@_=?J"'3]\NM3+7W[TY]9E4UH;>A$L8\P$;Z@$ M &9-K.?LGY<;4IIKYJF2MR'5(]4!P/EF%<;N?[% MJR6S1XTG%;;)COL=C$J0)W4[Y,C3#]GTI)YS@3"$@9S#J3(;F32&,$PX"-.4 M\4@$ L=&29%/=S.U:=UU::4=.6TX+5_E:3RA:7W2[7?G9#FK3"-\I);I' MOB=_/W!!5F;[;5EN.'NW*>3FLCY&KNL[?Y%[S")7CNG58Y7[>ET9,V%IEOH4 M@3CC1!5V\4'&H;+!!0]BX?#X-I<4))YM09>K4)SZ]06D9]Y.SUJA_0V MC,AR_=/KL+1J7PR39%S[XRJTCNR3ZUH;X':R4B4C]"['CIZ?T/RIY+)ZV756 MVVO<*?;:&\^?XI0:>PX5)Q\8MC"KBHN[@HO;DHP?5L57O#@LDAAC!AD/ A"G MF &(&0($\@ D40PCN9U&D5Z,Q)#.I[8(JQW):EDY#YZN9?D;+O[.ZZ/UH14M MC09';^EU!;ECPC@H##H[!;C+"I5#8+.YMAKU/^J*.@29PW5T4!O#^.Z^P.H* M;->;ZGN>T)2%$,O=1: .!H,D <1/);O1D" :$Q;$6BEI>GN9&H-5AO1E:GD=5CI:OQ&IM^&H'M$4PO C:9Y'1'HU)&KZZ'W-#_\(#D M5"J+&R_P_:/\XYEOUCDM/ZY9DQ7(#R"G!!+@$Q@#"*, 8"8($ QG.$ P9%P_ M-U5?3U,C@T96[^N&+'):U8HU2+74BVD_!5A%RC$-M"!UY?2DH'\:DIZJ%S.# M[%2VL!LI.=59#"TEI]*!HSQ^\?/FXH'N7MEL'H\:_J.M>=+_:=R[:5AK F(<,2<8-!(< $H0!#@@# M:8J2J/+G0\+$A\6AK-/TB&G<- :ZN[@<6CW;;R(#YGCI:+3TMFIZC9[>SQ\_ MOOW%._ KF82WW@@C8].R=2GNJ/;Q"+@?6MEC=#EL[=D=H[_%Y>/-LOJ/DD9N M4=7IV^F?-F94)"W'\.1-^9P&Y#9).FKY!F5A6T@=TBS5MHTSWIU M(X1D]6T=EK:@<$A03!.*@/ S7WE70) E3"7ERVB6^C!+L98#U/DNIL9Y.RF; MS##Z^:[.8-A/7':0<4Q'1Z!8+*Y\&8!K\UV=:7VT9%?]VG4S75UX].I! M8W7S>*'+<3> >OH?;>(T7QM<-^AIM?RVS-=WFW6YEO:KW.3-@P2%R,\("+)$ MVA!<(DL2GX$PYC1-:>!3:L0O)WN9&JO40GH;*64Y\U8[08?[6YY&-T1QG,K_ M!TF&5%B?_'0)$Q3XD?"Q8*$@-)P_UTYG:URL1\+XL,>QD";\(5\N%?]". M@-9;(J^&SO5&OD9,"3CS.B):K65U'@'+5:Q.=#1V_:KSNIZH7-7S\+ 5;ILR M_UU>TL6JW,AOQ3 335\3$_IP.Z4L.H(ZR3ZC@XC-#[FWOU&_9QW-#S]KK7Z3T4D>@@")(#N M7^FT7>/X?)PYOM1$S_FAP-76E%+*EI0^SGKZ#R IB;I1 4R6151QTXG2>R] M0"[<]EX;Y RG::&RC&=>VFJ=+1C;O._@Q&U:FQD8U1O>$7[=G<'K+45_?.>2G3%J3?4?X SQ,*)X/YAP]],D,\CD"D.[P"H@P$0CP/,4 M 8/R5.="Y!@5(8SGV_#8B*Z1N[!J1+WRHZ#[,.;S[H>"F\(NP3C(H68 9W8) M1C7F(.40:J%$)K0,T_?JHR>&4?\Z"-,^U0LW5>QVAZ!M[Q[Q&X+Z0+GGD<*!.*3\S!Q;OM0<>44$0.AY+@^SOFK\L?6CW/]+UYQY=N!VJU*4;TAJ^F M\LU+M1Z]F_'5JLQ7F1!>F)R) C!)*,!:8B R+>R/FALI%4W#-D:#+1C;F+)Q MP*7+;5S8U>.Z24HW;EP-QGI;I72E&0CW]<]%]8_)[WK]8Z'JC*_ TYOPKO3C MOEX[J&<2?(6^"4]T[XIOU!SW8".&36_OBM%19GOG!W75!^'K4FFI6A/LDFO+ M.D0L+W!FYX2V5PHG R)S0&6J@: $:R8YH3@H/:^UM;'Q9KTB;N0;AY1U\@/8 MD^%BP=8SFP4CUD%TPP.)N-H:;0T.+*'AX?NQ4H;/3==&")="&W5@%H8DI5H@ M4*0LMTMY[F9BVJ[LA<@8UYBPL)3>DZV,C2N'Y\<#4D/?/ D0)/ MO+@V+PCZB9MM-O1* ;$G?#T?Z7KJXO 0UM^G\^GC\V/]?D*!4\-I!C!%&F"# M.1!*2< 9*3)#:2XSXANYNO?DL7W0M7'^8:K[.+5_QU=YW_>!0&57Y%#4D]Y> M&X&Z_]#! D]/^M*,-SU]0?BGU]34+R-7W>9*)0J9IUH)C5( ";&#+)<("((0 MH!CFA<0RDX+Y?H?GFQG;1[E79&!C:H<2RBW 7OYPX\#5\U?<$:F@;_HR$-=^ MX"TM#/:U7_:R^>E[7-UMKGW_I)?<*4V64::[=,'GY=*5"G5B.2Z$SLEG.($P M5@":%PB@+%52(DHE#=KT;&]N;+Q0&IG,-E:&3<0O(.LW(X^'5\_$L#5T$U2^ MM?4FJ:V--TGW0R7F;/U"BX-.V_V\/YR_>][5C47>/3[-%B]:?]'+GU.I3\M\ M?UK,G:JM5J5RYJH4.VC^_FZQ6G]:K/]+KS]KN?@^G_Y#J]V3JIONUS_T\NL/ M/K\O0^%7$P1A5J3N;#]3U/XGLP3%, )09S"#A4PSYK5P>'5/QL9]W^;+K>V) MKD3R;Y*%LSI96[.3165W&"F^WHOBQ[?_%-W?]]F11^F$RO^- O*[7YM3H\H; M2_D6 GO=.GG1ZV2'PDUR^[AXCCD4O'J'Q1QE7L^900>P5^^SP['Q]0WJJ'VI M'Y\62[Y\J3;A/T[M'ZHTYL&^E=H.[%)OCODF#!+)H-1 (6U'2B48X(I2P RC M4A&)M0P*_@UI?&R#6\/8Y&EK;9D3HQ:S&5^N$CM=JO)C M-C@OK$;U#J"^F> MQY&MV5L)I";L.]-W<0D1U3<[0!95E#.D_6&U.CL@49'90]#]K926,7 MFB,FI ",\AQ@D7/ A"# LAC&!&(*M1>7M;8R-M*Z

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